paclitaxel has been researched along with Benign Neoplasms in 1678 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (0.36) | 18.7374 |
| 1990's | 223 (13.29) | 18.2507 |
| 2000's | 439 (26.16) | 29.6817 |
| 2010's | 733 (43.68) | 24.3611 |
| 2020's | 277 (16.51) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, JY; Chang, YL; Chen, CP; Chen, CT; Chen, LT; Hsieh, HP; Kuo, CC; Lee, SJ; Liou, JP; Pan, WY | 1 |
| Annable, T; Ayral-Kaloustian, S; Beyer, C; Birnberg, G; Cheung, K; Cole, D; Discafani, C; Greenberger, LM; Hernandez, R; Kaplan, J; Khafizova, G; Krishnamurthy, G; Loganzo, F; Musto, S; Niu, C; Norton, E; Suayan, R; Tang, Z; Williamson, R; Yamashita, A; Yang, X; Zask, A | 1 |
| Fang, X; Shao, L; Wang, S; Zhang, H | 1 |
| Jeong, IH; Lee, S; Oh, S; Shin, WS; Wang, Q | 1 |
| Aspland, SE; Ballatore, C; Castellino, AJ; Castillo, R; Desharnais, J; Eustaquio, T; Goelet, P; Guo, Z; Li, Q; Nelson, D; Newman, MJ; Sun, C | 1 |
| Chen, S; James, DA; Koya, K; Li, H; Sun, L; Wu, Y; Xia, Z; Ying, W | 1 |
| Chang, MY; Chen, ST; Liu, DZ; Reddy, PV; Sinchaikul, S | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Cai, SX; Drewe, J; Kasibhatla, S; Litvak, J; Sendzik, M; Shelton, E; Spencer, JR; Sperandio, D; Tseng, B; Yee, RM | 1 |
| James, DA; Koya, K; Li, H; Liang, G; Sun, L; Wu, Y; Xia, Z; Ying, W | 1 |
| Chen, GY; Fong, WF; Globisch, C; Hu, YJ; Shen, XL; Tse, AK; Wiese, M; Yu, ZL; Zhu, GY | 1 |
| Cai, S; Han, H; Jiang, J; Jiang, W; Jiang, X; Larrick, JW; Li, L; Tian, Z; Wang, Y; Wright, SC; Xiao, Y; Zhang, Z | 1 |
| Abrams, MT; Breslin, MJ; Buser, CA; Coleman, PJ; Cox, CD; Davide, JP; Diehl, RE; Fernandez-Metzler, C; Fraley, ME; Garbaccio, RM; Hamilton, K; Hartman, GD; Huber, HE; Kohl, NE; Kuo, LC; Li, C; Lobell, RB; Mahan, E; Prueksaritanont, T; Schaber, MD; Slaughter, DE; South, VJ; Tao, W; Torrent, M; Walsh, ES; Whitman, DB; Yan, Y | 1 |
| Chen, H; Cheng, MS; Liao, N; Nie, H; Wang, J; Wang, QH; Yang, YH | 1 |
| Ayral-Kaloustian, S; Beyer, C; Discafani, C; Hernandez, R; Lucas, J; Nguyen, T; Zhang, N | 1 |
| Chang, CY; Chang, JY; Chiang, YK; Coumar, MS; Hsieh, HP; Kuo, CC; Lai, MJ; Liou, JP; Reddy, GR; Tan, UK; Wu, SY; Yeh, JY | 1 |
| Chen, YT; Chou, TC; Dong, H; Kapuriya, K; Kapuriya, N; Lee, TC; Lee, WC; Naliapara, Y; Su, TL; Tsai, TH; Zhang, X | 1 |
| Bonesi, M; Conforti, F; Deguin, B; Loizzo, MR; Menichini, F; Tillequin, F; Tundis, R | 1 |
| Chou, TC; Dong, H; Kakadiya, R; Kapuriya, K; Kapuriya, N; Lee, PC; Lee, TC; Shah, A; Su, TL; Zhang, X | 1 |
| Agrawal, SK; Rani, R; Roy, P; Saxena, AK; Singh, J; Sondhi, SM | 1 |
| Chen, X; Guan, Y; Lei, P; Zheng, D; Zhou, L; Zhou, W | 1 |
| Bastow, KF; Chen, HY; Goto, M; Lee, KH; Lin, JC; Morris-Natschke, SL; Nakagawa-Goto, K; Wu, PC; Yang, PC; Yang, SC; Yu, SL | 1 |
| Chaniyara, R; Chou, TC; Dong, H; Kakadiya, R; Lee, PC; Lee, TC; Marvania, B; Shah, A; Su, TL; Suman, S | 1 |
| Beck, WT; Bleeker, NP; Das, SG; Doshi, JM; Hermanson, DL; Srinivasan, B; Tang, R; Xing, C | 1 |
| Gangjee, A; Hamel, E; Mooberry, SL; Westbrook, C; Zhao, Y | 1 |
| Cao, R; Chen, Z; Fan, W; Guo, L; Ma, Q; Shi, B; Song, H; Sun, J | 1 |
| Fu, WZ; He, HL; Huang, LH; Liu, HM; Wang, YG; Xu, G; Zhang, XH; Zheng, YF | 1 |
| Cikotiene, I; Díaz-Rodríguez, E; Domínguez-Kelly, R; Freire, R; León, LG; Padrón, JM; Pandiella, A; Ríos-Luci, C | 1 |
| Balzarini, J; Baraldi, PG; Basso, G; Bortolozzi, R; Brancale, A; Fu, XH; Hamel, E; Kimatrai Salvador, M; Li, J; Lopez Cara, C; Romagnoli, R; Viola, G; Zhang, SZ | 1 |
| Bane, S; Hu, H; Kingston, DG; Mukherjee, K; Slebodnick, C; Snyder, JP; Zhao, J | 1 |
| Bastow, KF; Lee, KH; Morris-Natschke, SL; Ohkoshi, E; Wada, K | 1 |
| Choi, DL; Choi, HW; Choo, DJ; Chung, KS; Huh, G; Kang, HB; Kim, J; Lee, JY; Lee, KT; Park, JY; Rim, HK; Seo, JH | 1 |
| Chen, Y; Cheng, M; Lai, CY; Lee, KH; Liu, HR; Liu, HS; Morris-Natschke, SL; Qian, K; Wu, PC; Xia, P; Xia, Y; Yang, ZY | 1 |
| Kalivendi, SV; Kamal, A; Kumar, GB; Reddy, MK; Reddy, VS; Shaik, TB; Srikanth, YV | 1 |
| Cai, BC; Chen, JW; Chen, Y; Fan, NB; Li, X; Wang, Y; Xu, SS | 1 |
| Ahn, JS; Asami, Y; He, L; Jang, JH; Kim, BY; Kim, JW; Moon, DO; Muroi, M; Oh, H; Osada, H; Soung, NK | 1 |
| Han, J; He, WJ; Ji, CJ; Tan, NH; Zeng, GZ; Zhang, YM | 1 |
| Cao, D; Chen, J; Chen, L; Han, X; Lei, K; Liang, X; Ma, L; Peng, A; Peng, F; Qiu, J; Ran, Y; Sang, Y; Tang, M; Wang, G; Wen, J; Wu, W; Xiang, M; Yang, Z; Ye, H; Zhang, R | 1 |
| Akula, B; Bharathi, EV; Billa, VK; Cosenza, SC; Gallo, JM; Lv, H; Mallireddigari, MR; Padgaonkar, A; Pallela, VR; Reddy, EP; Reddy, MV; Subbaiah, DR | 1 |
| Cao, D; Chen, J; Chen, L; Han, X; He, L; Liu, J; Ma, L; Peng, A; Peng, F; Sang, Y; Wang, G; Wei, Y; Wu, W; Xiang, M; Yang, Z | 1 |
| Chang, CY; Chang, JY; Chang, YT; Kuo, CC; Lai, MJ; Lee, HY; Liou, JP; Liu, YM; Mehndiratta, S; Nien, CY; Pan, SL; Su, MC; Wu, JS; Wu, SY | 1 |
| Alfonsi, R; Bai, R; Bolognesi, A; Brancale, A; Coluccia, A; Di Marcotullio, L; Dondio, G; Famiglini, V; Gulino, A; Hamel, E; La Regina, G; Lavia, P; Mazzoccoli, C; Mercurio, C; Miele, A; Nalli, M; Novellino, E; Passacantilli, S; Pelliccia, S; Rensen, WM; Ruggieri, V; Silvestri, R; Sisinni, L; Varasi, M; Vultaggio, S | 1 |
| Aksenov, AV; Aksenov, NA; Aksenova, IV; Brenner, AJ; Bryan, BA; Cavazos, DA; Correa, J; De Carvalho, A; Frolova, LV; Johnston, RK; Kiss, R; Kornienko, A; Lefranc, F; Magedov, IV; Mathieu, V; Nguyen, G; Pendleton, AL; Reisenauer, MR; Rogelj, S; Rubin, M; Smirnov, AN | 1 |
| Chen, M; Hu, Y; Liu, T; Ma, X; Song, P; Xu, L; Zhou, Y | 1 |
| Capuano, B; DeBono, A; Scammells, PJ | 1 |
| Fournier, E; Grisoni, S; Guilbaud, N; Heudré Le Baliner, Q; Liéby-Muller, F; Marion, F | 1 |
| Chow, LM; Duan, LX; Hu, X; Jiang, T; Li, XM; Liu, T; Liu, Z; Wan, SB; Wang, BC; Wong, IL; Yuan, J; Zhang, XY | 1 |
| Alfonsi, R; Bai, R; Bigogno, C; Brancale, A; Caraglia, M; Coluccia, A; Da Pozzo, E; Di Marcotullio, L; Dondio, G; Famiglini, V; Gulino, A; Hamel, E; La Regina, G; Lavia, P; Marinelli, L; Martini, C; Mazzoccoli, C; Mercurio, C; Miele, A; Monti, L; Nalli, M; Novellino, E; Passacantilli, S; Pelliccia, S; Porto, S; Ricci, B; Ruggieri, V; Santoni, A; Silvestri, R; Soriani, A; Varasi, M; Verrico, A; Vultaggio, S | 1 |
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Lee, H; Srivastava, V | 1 |
| Chennamaneni, S; Gan, C; Lama, R; Su, B; Zhong, B | 1 |
| Cui, JR; Ge, ZM; Li, RD; Li, RT; Li, YB; Liu, P; Sun, SQ; Wang, X; Yan, X; Zhou, DM | 1 |
| Bahulayan, AK; Kabeer, FA; Madhusoodhanan, AR; Nair, MS; Prakasan, N; Prathapan, R; Rajalekshmi, DS; Varughese, S | 1 |
| Chen, C; Liu, J; Tang, J; Wu, F | 1 |
| Fu, ZD; Huang, JT; Ji, TF; Li, DZ; Li, XY; Lin, JP; Liu, HY; Pan, XD; Song, HX; Wang, CY; Zhang, QZ; Zhang, YL | 1 |
| Crawford, E; Curry, W; Gupton, JT; Harrison, A; Hoerrner, M; Huff, E; Juekun, W; Kellogg, GE; Kimmel, M; Lescalleet, K; Lounsbury, K; Mooberry, SL; Moore-Stoll, V; Obaidullah, AJ; Ortolani, J; Patteson, J; Rohena, CC; Shimozono, A; Sikorski, JA; Telang, N; Yeudall, S | 1 |
| Cui, MT; Goto, M; Hamel, E; Hsu, PL; Jiang, L; Lee, KH; Li, L; Morris-Natschke, SL; Wei, L; Xie, L; Yuan, SJ; Zhang, Q | 1 |
| Boger, DL; Brody, DM; Brütsch, MM; Carney, DW; Cross, RM; Dong, H; Duncan, KK; Lukesh, JC; Radakovic, A; Shukla, V; Yang, S | 1 |
| Han, HW; Lin, HY; Lu, GH; Qi, JL; Sun, WX; Tang, CY; Wang, XM; Yang, YH; Yang, YS | 1 |
| Jing, Y; Ojima, I; Wang, C; Wang, X | 1 |
| Bao, K; Guan, Q; Guo, H; Liu, S; Wang, J; Wang, L; Wu, Y; Yan, P; Zhai, M; Zhang, J; Zhang, W | 1 |
| Dymock, BW; Kitagawa, M; Lee, KH; Lee, SH; Liao, PJ; See, CS; Wong, J | 1 |
| Ding, N; Gao, D; Li, Y; Ren, S; Wang, J; Wang, Y; Zhang, M | 1 |
| Chen, K; Fan, J; Ma, X; Qin, YJ; Zhang, YL; Zhu, HL | 1 |
| Attanzio, A; Barraja, P; Carbone, A; Cascioferro, S; Cirrincione, G; Diana, P; Montalbano, A; Parrino, B; Spanò, V; Tesoriere, L; Ullo, S | 1 |
| Dybdal-Hargreaves, NF; Gangjee, A; Gentile, T; Hamel, E; Mooberry, SL; Pavana, RK; Risinger, AL; Shah, K | 1 |
| Bi, Y; Li, W; Ma, C; Shuai, W; Sun, H; Xu, F; Xu, J; Xu, S; Yao, H; Zhu, Z | 1 |
| Kumar, CG; Raju, RR; Reddy, KT; Sreenivasulu, R; Sujitha, P | 1 |
| Abdel-Maksoud, MS; Ali, EMH; Oh, CH | 1 |
| Xu, Z; Zhang, L | 1 |
| Chein, RJ; Chen, JJW; Cheng, TR; Chou, TH; Chung, WC; Hong, TM; Lee, TC; Lin, MS; Tsai, ML; Weng, CW; Wong, CH; Yang, PC; Yang, SC | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Bao, JX; Fu, JY; Han, HW; Lin, HY; Lu, GH; Lu, YT; Qi, JL; Sun, WX; Wang, MY; Wang, XM; Wang, YS; Wen, ZL; Yang, MK; Yang, YH | 1 |
| Emami, SA; Taleghani, A; Tayarani-Najaran, Z | 1 |
| Li, W; Li, X; Lu, L; Shuai, W; Xu, F; Xu, J; Xu, S; Yang, L; Yao, H; Zhu, H; Zhu, Z | 1 |
| Cheng, J; Liang, Y; Tang, H; Wang, Y | 1 |
| Duan, Y; Li, W; Liu, J; Liu, Y; Qin, S; Sun, H; Xu, J; Xu, S; Yang, X; Zhu, H; Zhu, Z | 1 |
| Ji, A; Li, L; Li, X; Liu, J; Liu, Z; Lou, H; Qian, L; Qiao, Y; Sun, Y; Wang, X; Xu, Y; Zhao, X | 1 |
| Chen, ZS; Li, W; Liu, Y; Shuai, W; Tan, Y; Xu, J; Xu, S; Yang, DH; Yang, L; Yao, H; Zheng, T; Zhu, H; Zhu, Z | 1 |
| Bai, P; Chen, L; Fu, S; Han, K; He, W; Li, J; Li, Y; Liu, J; Liu, Y; Shi, M; Tang, M; Xie, L; Yan, W; Yang, J; Yang, Z; Ye, H; Zhang, C; Zhu, Z | 1 |
| Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F | 1 |
| Li, X; Lin, H; OuYang, F; Pang, Y; Yan, J; Zhang, W; Zhou, J | 1 |
| Kim, YM; Lee, SW; Lee, YJ; Nam, SH | 1 |
| Blouw, B; Colombo, M; D'Incalci, M; Davoli, E; Frapolli, R; Fuso Nerini, I; Kang, DW; Meroni, M; Minoli, L; Morosi, L; Panini, N; Porcu, L; Ubezio, P; Zucchetti, M | 1 |
| Atrafi, F; Boix, O; Bruns, I; Chawla, SP; Diamond, JR; Eder, JP; Genvresse, I; Gutierrez, M; Langer, S; Lolkema, MP; LoRusso, PM; Mathijssen, RHJ; Rajagopalan, P; Sankhala, K; Subbiah, V; Tolcher, AW; Verweij, J | 1 |
| Bertagnolli, M; Dickler, MN; Espin-Garcia, O; Etheridge, AS; Innocenti, F; Jiang, C; Kindler, HL; Lenz, HJ; Lin, D; Liu, G; Owzar, K; Quintanilha, JCF; Ratain, MJ; Sibley, AB; Venook, A; Wang, J; Xu, W | 1 |
| Huang, J; Li, T; Wang, H; Wang, M | 1 |
| Du, J; Fan, J; Huang, H; Liu, B; Ma, H; Peng, X; Shao, K; Shi, C; Sun, W; Wang, L; Yao, Q; Zhang, Z; Zhou, X | 1 |
| Jing, X; Lu, S; Pei, Q; Wang, J; Xia, R; Xie, Z | 1 |
| Carter, BW; Colen, R; Fu, S; Gong, J; Hong, DS; Janku, F; Karp, DD; McQuinn, L; Meric-Bernstam, F; Milton, DR; Naing, A; Piha-Paul, SA; Shah, J; Stephen, BA; Sulovic, S; Thein, KZ; Tsimberidou, A; Yap, TA | 1 |
| Huang, J; Wang, L; Wu, J; Yuan, Q; Zhao, W | 1 |
| Cao, X; Chen, Q; Du, Y; Ge, P; Liu, Y; Luo, S; Song, H; Su, Z; Zhao, X; Zhu, X | 1 |
| Bēma, D; Bērziņš, J; Buiķis, I; Freivalds, T; Harju, L; Miķelsone, I; Patetko, L; Simsone, Z | 1 |
| Deng, L; Li, Y; Wang, R; Xu, H; Zhang, S | 1 |
| Dao, TP; Doan, P; Doan, VD; Nguyen, BT; Nguyen, DT; Nguyen, VT; Plavskii, V; Tran, NQ | 1 |
| Endo, A; Endo, M; Hirose, T; Kashio-Yokota, Y; Mori, T; Ohba, K; Sato, S; Takahashi, K; Watanabe, F; Watanabe, T | 1 |
| Ao, H; Fu, J; Guo, Y; Han, M; Li, H; Lu, L; Wang, X; Wang, Y | 1 |
| Bissoli, NS; Bonela, LAS; Gonçalves, WL; Gouvea, SA; Menezes, BC; Oliveira, KG; Sartorio, CL; Thebit, MM | 1 |
| Garg, R; Gayen, JR; Katekar, R; Singh, P; Verma, S | 1 |
| Chen, X; Huang, C; Jin, S; Liang, H; Yuan, Y; Zhang, B; Zhang, W; Zhang, X; Zhao, J | 1 |
| Abd-Alhaseeb, MM; Mahmoud, MA; Okda, TM; Omran, GA | 1 |
| Chen, J; Gao, X; Hong, Z; Liang, X; Lin, Y; Liu, X; Mi, X; Miao, J; Nie, W; Qian, Z; Ran, M; Wang, B; Yang, T; Yu, T | 1 |
| Chowdhury, M; Kumar Das, P | 1 |
| Pradhan, A; Sahoo, SK; Singh, D; Singh, P; Srivastava, R | 1 |
| Chen, Q; Liu, G; Liu, S; Wang, Y; Xu, S | 1 |
| Ando, Y; Kiyota, N; Minami, H; Mitsuma, A; Morita, S; Toyoda, M | 1 |
| Biswas, G; Dalal, A; Ghosh, SS; Prasad, NK; Shome, R | 1 |
| Lou, ZP; Ma, FY; Najafi, M; Yu, DL | 1 |
| Chen, H; Wang, F; Wang, L; Zhang, X | 1 |
| Cao, X; Dang, J; Epstein, AL; Feng, M; Gunes, EG; Querfeld, C; Rosen, ST; Sun, Z; Wang, J; Wang, Y; Zhang, W; Zhong, X | 1 |
| Bo, H; Chen, D; Guo, S; Qiao, A; Rong, Y; Shen, H; Shen, J; Tang, X; Wang, J; Zhao, Z | 1 |
| Achariyapota, V; Chitkumarn, P; Rahong, T | 1 |
| Fan, W; Geng, Y; Li, Z; Liu, Y; Piao, Y; Shao, S; Shen, Y; Sun, R; Tang, J; Tang, Y; Wang, G; Wei, Q; Xiang, J; Xie, T; Xu, L; Zhou, Q; Zhou, Z | 1 |
| Bloomquist, C; DeSimone, J; Foley, H; Hagan, CT; Kim, I; Knape, NM; Mecham, S; Wagner, KT; Wang, AZ; Warner, S | 1 |
| Al-Hilfi, A; Walker, KD | 1 |
| Bessudo, A; Dezube, BJ; Duncan, M; Evilevitch, L; Gabrail, N; Guo, W; Hamilton, E; Kumar, S; Lu, S; Patel, MR; Rodon, J; Sachdev, J; Yap, TA | 1 |
| Han, Y; Sun, W; Tong, L; Wu, S | 1 |
| Du, Y; Lin, L; Ou, X; Tang, Y; Wang, Y; Zhang, Z; Zou, J | 1 |
| Andrews, S; Barroilhet, LM; Bruce, JY; Chan, N; Eickhoff, J; Girda, E; Leal, TA; Liu, G; Malhotra, J; Mehnert, J; O'Regan, RM; Schmitz, N; Sharifi, MN; Turk, AA; Wesolowski, R; Wiley, E; Wisinski, KB | 1 |
| Bimali, M; Chiao, E; Cooley, T; Deeken, J; Haigentz, M; Henry, D; Moore, P; Ramos, J; Ratner, L; Rubinstein, P; Rudek, M; Sparano, J | 1 |
| Aref, AR; Gholami, MH; Hamblin, MR; Hashemi, F; Hashemi, M; Hushmandi, K; Khan, H; Kumar, AP; Mahabady, MK; Mirzaei, S; Nuri Ertas, Y; Saebfar, H; Samarghandian, S; Tajik, F; Zabolian, A; Zarrabi, A | 1 |
| Chan, WK; Chao, TY; Clarke, K; Cutler, D; Dai, MS; Deva, S; He, J; Hung, T; Jackson, CGCA; Kramer, D; Kwan, R; Ma, WW; Segelov, E; Yeh, HT; Zhi, J | 1 |
| F Huang, CY; Nguyen, CN; Ninh, TTK; Tran, TH | 1 |
| Kumar, D; Kumar, S; Sharma, P; Shri, R | 1 |
| Bi, J; Chen, P; Liu, H; Ning, X; Qu, Y; Shi, F; Tang, L; Xu, Y; Zhang, X | 1 |
| Cresswell, GM; He, Y; Lanman, NA; Lyle, LT; Meng, F; Ratliff, TL; Wang, J; Yeo, Y | 1 |
| Goto, M; Lee, KH; Ohkoshi, E; Wada, K; Yamashita, H | 1 |
| Hu, QH; Huang, SH; Lin, J; Wang, QY; Zhou, QH | 1 |
| An, JH; Chae, HK; Chu, SN; Kang, K; Oh, YI; Park, S; Seo, K; Youn, HY | 1 |
| Cai, Y; Gao, L; Gong, Y; Hong, Y; Li, L; Li, Q; Sun, X; Zheng, S | 1 |
| Abbona, A; Astigiano, S; Barbieri, O; Denaro, N; Garrone, O; Martini, S; Merlano, M; Paccagnella, M; Ruatta, F | 1 |
| Araki, T; Nagamine, A; Obayashi, K; Ohshima, S; Takahashi, E; Takahashi, Y; Uchiyama, C; Yamamoto, K; Yashima, H | 1 |
| Chen, YS; Han, M; Luo, YL; Xu, F; Zhou, ZH | 1 |
| Ding, J; Gao, H; Ge, M; Hu, Y; Liu, Y; Wang, D; Wang, X | 1 |
| Cao, YN; Gao, F; Jiang, T; Xu, JB; Zheng, LL | 1 |
| Adjei, AA; Azad, NS; Chan, WK; Cutler, D; Diamond, JR; Dy, GK; Jimeno, A; Kramer, D; Kwan, R; Lam, ET; Li, JJ; Ma, WW; Opyrchal, M; Zhi, J | 1 |
| Chen, Y; Hu, Q; Wang, S; Zhou, L | 1 |
| Bikinieva, F; Boichuk, S; Galembikova, A; Mustafin, I; Ryzkin, S; Zykova, S | 1 |
| Meissner, T; Rojas-Espaillat, L; Starks, DC; Williams, CB | 1 |
| Huang, P; Jiang, S; Lin, J; Zhang, Y | 1 |
| Najafi, M; Tang, Y; Wang, R; Zhao, S | 1 |
| Asghar, S; Chen, Z; Gao, D; Hu, R; Huang, L; Wang, Y; Xiao, Y; Ye, J; Yuan, C; Zhang, M | 1 |
| Bao, W; Li, X; Liu, M; Meng, J; Sun, M; Tian, Z; Wang, Z; Zhang, L | 1 |
| Bao, Y; Ishida, A; Maeki, M; Tani, H; Tokeshi, M | 1 |
| Chen, F; Hu, X; Lai, Y; Liu, X; Pan, J; Qu, X; Wang, T; Xu, L; Yu, H; Zhang, H | 1 |
| Charbe, NB; Lagos, CF; Ortiz, CAV; Palakurthi, SS; Tambuwala, M; Zacconi, FC | 1 |
| Chirkina, MV; Kuznetsov, SL; Mollaev, MD; Mollaeva, MR; Nikolskaya, ED; Sokol, MB; Yabbarov, NG; Zabolotsky, AI | 1 |
| Kalenik, S; Komorowska, D; Radzik, T; Rodacka, A | 1 |
| Kim, J; Wang, A; Wang, D; Wang, J; Wang, Q; Xia, J; Zhang, F; Zhang, S; Zhu, Y | 1 |
| Abadie, J; Boissenot, T; Bordat, A; Cailleau, C; Carvalho, O; Denis, S; Ferrere, M; Garcia-Argote, S; Ibrahim, N; Levêque, M; Nicolas, J; Pieters, G; Potiron, L; Tsapis, N | 1 |
| Akinade, T; Bhansali, D; Dalerba, P; Du, J; He, S; Leong, KW; Li, T; Rinebold, E; Ruan, J; Tong, Q; Valencia Salazar, LE; Wang, H; Zhong, Y; Zhou, J | 1 |
| Ma, X; Wang, D; Wang, P; Wu, Q; Yadav, D; Zhang, H; Zhang, Y; Zhou, J | 1 |
| Huang, SQ; Wang, LY; Zhang, HM; Zhang, L; Zhang, YC; Zhang, ZR | 1 |
| Chen, QW; Chen, WH; Han, ZY; Ji, P; Luo, GF; Song, WF; Wang, JW; Zhang, XZ | 1 |
| Babajani, A; Jamshidi, E; Manzari-Tavakoli, A; Niknejad, H; Tarasi, R | 1 |
| Fan, J; Fan, W; Lin, B; Wang, Y; Yin, W; Zang, F; Zhou, F | 1 |
| Ahmed Khalil, A; Alhumaydhi, FA; Aljohani, ASM; Bawazeer, S; Bouyahya, A; El-Esawi, MA; Javed, MS; Khan, IA; Khan, MA; Rauf, A; Rebezov, M; Shariati, MA; Thiruvengadam, M | 1 |
| Chen, H; Chen, Y; Le, Z; Liu, H; Liu, L; Liu, Z; Wen, Z; Yang, Z | 1 |
| Barry, W; Berlin, S; Birrer, MJ; Campos, S; Colella, T; Hang, L; Horowitz, N; Krasner, C; Liu, J; Lundquist, C; Matulonis, U; Penson, R; Shoni, M; Whalen, C; Zarwan, C | 1 |
| Smith, ER; Wang, JQ; Xu, XX; Yang, DH | 1 |
| Han, S; Li, Z; Sun, Y; Wang, C; Xu, L; Xu, P | 1 |
| Cheng, Y; Deng, X; Jia, L; Li, S; Lian, S; Lu, Y; Wang, J; Zhai, S | 1 |
| Endo, S; Hisamatsu, A; Horinouchi, M; Iguchi, K; Ikari, A; Matsunaga, T; Saito, H; Yoshino, Y | 1 |
| Aldhubiab, B; Anwer, MK; Asdaq, SMB; Fattepur, S; Gharsan, MA; Goudanavar, PS; Gowthami, B; Habeebuddin, M; Haroun, M; Islam, MM; Mahalakshmi, SVVNS; Meravanige, G; Naveen, NR; Prasanthi, S; Sreeharsha, N; Telsang, M | 1 |
| Fu, Y; Han, P; He, J; Huang, J; Jiao, Y; Khan, T; Ni, P; Yang, Z; Zhang, L; Zhou, R | 1 |
| Ma, XB; Shen, XM; Sun, ZJ; Wan, SC; Wang, S; Wu, ZZ; Xu, JM; Xu, Z; Yang, LL; Yang, QC; Ye, MJ; Zhang, MJ; Zhang, T | 1 |
| Albuni, MK; Alibrahim, H; Battikh, E; Diab, R; Elsayed Talat, N; Hafez, W; Motawea, KR; Nashwan, AJ; Rozan, SS; Sawaf, B; Shaheen, N; Shoib, S; Swed, S | 1 |
| Hong, Y; Khine, YY; Lu, H; Lu, M; Stenzel, MH; Wang, S; Zheng, J | 1 |
| Chen, Z; Dai, J; Dong, X; Guo, Y; Li, Y; Lou, X; Wang, S; Wei, S; Wu, M; Xia, F; Xue, L; Yi, X; Zhang, J; Zhou, S | 1 |
| Gu, M; Guo, J; Hou, J; Jiang, C; Jiang, Y; Jin, G; Li, H; Li, Q; Li, X; Li, Z; Liu, G; Liu, T; Qian, Y; Ren, B; Shen, J; Shi, Y; Xu, T; Zhang, Z; Zhao, J; Zhao, L; Zhou, T | 1 |
| Li, Z; Liang, N; Sun, S; Yan, P; Zhao, W | 1 |
| Chen, T; Chen, XJ; Liu, P; Liu, Q; Liu, W; Mo, Y; Wang, Q; Yuan, D; Yuan, Z | 1 |
| Hengerics Szabó, A; Kuruc, R; Masár, M; Nižnanská, Ž; Nižnanský, Ľ; Osinová, D; Szórádová, A | 1 |
| Dong, Y; Li, X; Wang, F; Xu, Z; Yang, K; Zhang, Y | 1 |
| Chen, W; Huang, D; Ji, Y; Pan, J; Wang, K; Wen, S; Zhao, B; Zhao, C | 1 |
| Chen, S; Jiang, M; Jiang, ZX; Ke, C; Li, Y; Long, H; Qiu, M; Ye, C; Zhang, L; Zhou, X; Zhu, L | 1 |
| Cheng, C; Du, C; Guo, X; Huang, T; Jiang, W; Li, P; Luo, Y; Ran, H; Ren, J; Tang, R; Wan, L; Wang, J; Wang, Z; Xie, Z; Zhou, Z | 1 |
| Ishida-Ishihara, S; Kawamoto, E; Kuroda, T; Matsuo, K; Matsura, A; Mishra, M; Sakai, R; Sato, F; Shimada, M; Shimada, Y; Tamaoki, N; Uehara, R; Yaguchi, K; Yamamoto, T; Yoshizawa, K | 1 |
| Dong, Z; Du, S; Guo, M; Hu, W; Lu, Y; Sun, M; Wang, C; Yu, X; Zhang, Q; Zhang, X | 1 |
| Huang, H; Liu, Q; Sun, Y | 1 |
| Choi, WI; Koo, H; Lee, JS; Oh, H; Park, E | 1 |
| Guo, Q; Meng, Y; Qiu, C; Shi, Q; Wang, C; Wang, J; Wu, Y; Xia, F; Xu, C; Zhang, J | 1 |
| Chu, J; Ju, R; Peng, X; Tian, Y; Wang, X; Wu, F | 1 |
| Higuchi, K; Inoue, K; Kishimoto, H; Kobayashi, H; Miyazaki, K; Shirasaka, Y; Suzuki, A | 1 |
| Li, X; Liu, C; Wang, J; Xing, H; Zhang, Y | 1 |
| Hou, G; Liu, Y; Meng, Q; Wang, Q; Zhao, F; Zhao, Q | 1 |
| Fan, N; Fang, A; He, X; Huang, Z; Li, G; Li, X; Qin, S; Song, X; Tian, M; Xiao, W; Xu, B | 1 |
| Boulos, JC; Dawood, M; Efferth, T; Fiebig, HH; Franke, K; Özenver, N; Papasotiriou, I; Rashan, LJ; Roos, WP; Wessjohann, LA | 1 |
| Bao, C; Bao, Y; Chen, G; Gao, X; Jing, Y; Li, B; Li, X; Song, D; Wang, Y; Waxman, S; Wu, C; Yang, J | 1 |
| Banala, VT; Gautam, S; Marwaha, D; Mishra, PR; Rai, N; Sharma, M; Shukla, RP; Singh, N; Tiwari, P; Urandur, S | 1 |
| Gabriël, AV; Hennink, WE; Le Gac, S; Pednekar, K; Prakash, J; Priwitaningrum, DL; Storm, G; Varela-Moreira, AA; Vellekoop, I | 1 |
| Ardisson-Araújo, DMP; Becker, G; Brusco, I; de Andrade, CM; Machado-De-Avila, RA; Oliveira, MS; Oliveira, SM; Palma, TV; Pillat, MM; Sampaio, TB; Scussel, R; Steiner, BT | 1 |
| Fu, J; Gao, D; Gao, X; Hou, H; Li, Y; Ling, P; Liu, Z; Lu, L; Sun, F; Tan, H; Tang, W; Wang, F; Wang, J; Zhao, F | 1 |
| Andriani, L; Deng, L; Hu, SY; Huang, MY; Li, DQ; Liao, L; Qian, JX; Shao, ZM; Yang, SY; Zhang, FL; Zhang, YL | 1 |
| Braiteh, FS; Hamilton, E; Huang, M; Liaw, DCH; Pant, S; Strauss, JF; Ulahannan, SV | 1 |
| Deng, X; Li, X; Qin, Z; Song, Y; Xu, Q; Yang, J; Yuan, Q | 1 |
| Burgos, V; González-Chavarría, I; Iturra-Beiza, H; Paz, C; Ulrich, H; Villegas, C | 1 |
| Dong, S; Guo, M; Hu, W; Jakkree, T; Jiao, Y; Lu, Y; Wang, C; Wang, J; Zhang, Q; Zhang, X | 1 |
| Heibloem, RE; Ilozumba, OUC; Komen, MMC; van den Hurk, CJG | 1 |
| Jiang, Y; Li, X; Liu, C; Wang, J; Xing, H; Zhang, H; Zhang, Y | 1 |
| Chen, J; Ding, H; Fang, Z; Gong, Q; Gu, L; Li, Y; Li, Z; Lin, L; Luo, K; Pan, D; Tian, X | 1 |
| Dvergsten, E; Gopalakrishnan, M; Karovic, S; Maitland, ML; Salem, AM | 1 |
| Huang, W; Wang, P; Wang, Y; Xia, X; Yan, D | 1 |
| Huang, J; Mo, F; Wu, X; Yan, J; Yang, Y; Yuan, Y; Zhang, S | 1 |
| Govindharaj, M; Kumari, N; Rath, SN; Thomas, T; Unni, HN | 1 |
| Javadi, A; Khandaghi, J; Mirzaei, H; Nami, Y; Salek, F | 1 |
| Che, Z; Chen, D; Cui, J; Ding, K; Jiang, H; Li, A; Shu, Y; Xie, Z; Zhou, J; Zou, L | 1 |
| Dai, Z; Deng, X; Ding, J; Dong, C; Jia, W; Leng, Q; Shen, Y; Xue, D; Yi, M; Zhang, C; Zhao, B; Zhao, R; Zhong, G | 1 |
| Beumer, JH; Egorin, MJ; Fears, CL; Fisher, GA; Fracasso, PM; Goodner, SA; Jones, GJ; Pearce, TE; Sikic, BI; Wildi, JD | 1 |
| Chen, W; Shuai, Q; Xie, W; Zhao, G | 1 |
| Dong, C; Guo, H; Li, S; Liang, X; Liu, R; Lu, Y; Tang, J; Wu, J; Yao, W; Zhang, H | 1 |
| Cetin, AE; Topkaya, SN; Yalcin-Ozuysal, O; Yazici, ZA | 1 |
| Amant, FCH; Beijnen, JH; Damoiseaux, D; Dorlo, TPC; Huitema, ADR; Janssen, JM; van Calsteren, K; van Hasselt, JGC | 1 |
| Cheng, J; Ji, J; Jiang, J; Liu, S; Luo, L; Pan, H; Shi, G; Su, H; Wu, S; Ying, N; Zeng, D; Zhang, M | 1 |
| Dong, Y; Li, X; Wang, F; Yang, K; Zhang, Y | 1 |
| Andersen, JR; Dominiak, HSH; Hasselsteen, SD; Herrstedt, J; Nielsen, SW | 1 |
| Cech, NB; Oberlies, NH | 1 |
| Cai, W; Fang, B; Hao, W; Jin, S; Wang, Y; Yuan, J; Zhang, J | 1 |
| Dong, X; Gao, J; Su, Y; Wang, Z; Wheeler, KA | 1 |
| Kang, X; Li, W; Qi, J; Song, J; Tang, BZ; Wang, L; Zhang, Y | 1 |
| Li, S; Li, X; Liang, N; Sun, S; Wang, S; Yan, P | 1 |
| Chen, L; Cui, W; Ding, T; Du, Y; Feng, W; Ruan, D; Ruan, Y; Wang, J | 1 |
| Jiang, Y; Li, X; Liu, C; Liu, J; Wang, Z; Zhang, Y | 1 |
| Chen, J; Chen, Y; Gao, X; Huang, Y; Jiang, T; Wang, J; Xiao, W; Xie, L; Zhou, S | 1 |
| de Wit, E; Flach, K; Franceschini-Santos, VH; Friskes, A; Hintzen, D; Ilic, M; Joosten, S; Liu, NQ; Manjón, AG; Manzo, SG; Medema, RH; Peric-Hupkes, D; Potgeter, L; Prekovic, S; Teunissen, H; van Schaik, T; van Steensel, B; Zwart, W | 1 |
| Zou, J | 1 |
| Chen, S; Guo, Q; Lan, X; Li, Q; Shen, Y; Wang, L; Xiao, H; Zhang, T | 1 |
| Chi, CH; Hung, CC; Hung, HY; Kuo, CY; Kuo, PC; Tsai, KC; Wu, IT; Yu, KH; Zeng, JW | 1 |
| De Sousa, F; Eskat, A; Harry, D; Meraldi, P; Olziersky, AM; Vassal, H; Wilhelm, T | 1 |
| Doan, VHM; Hoang, G; Jun, SW; Kim, CS; Kim, H; Kim, J; Manivasagan, P; Mondal, S; Nguyen, VT; Oh, J | 1 |
| Bu, J; Chang, E; Charron, DM; Chen, J; Coolens, C; Cui, D; Ding, L; Hou, W; Jeon, HH; Lou, JWH; Valic, M; Zheng, G | 1 |
| Hu, H; Lai, C; Wang, B; Xu, D; Xu, X; Zhen, Z; Zhou, H | 1 |
| Huang, Z; Jing, T; Li, M; Liu, F; Ran, H; Tang, L; Wang, W; Wang, Z; Xia, J; Xia, X | 1 |
| Gou, M; Huang, M; Huang, Y; Kang, T; Li, Y; Liu, J; Wang, S; Wang, Y; Wei, X; Xiong, M; Yang, L; Zhu, J | 1 |
| Bagheri Fam, S; Höcherl, A; Hrubý, M; Jäger, A; Jäger, E; Mælandsmo, GM; Nyström, B; Pandya, AD; Sandvig, K; Sincari, V; Skotland, T; Štěpánek, P | 1 |
| Feng, ZQ; Li, J; Wang, T; Xu, X; Yan, K; Yuan, T; Zheng, J | 1 |
| Ang, JE; Arkenau, HT; Beijnen, JH; Brunetto, AT; de Bono, JS; De Grève, J; de Jonge, MJA; Jager, A; Lolkema, MP; Marchetti, S; Mergui-Roelvink, MWJ; Schellens, JHM; Tchakov, I; van der Biessen, DA; van der Noll, R | 1 |
| Ang, JE; Arkenau, HT; Beijnen, JH; Brunetto, AT; de Bono, JS; de Jonge, MJA; Jager, A; Lolkema, MP; Marchetti, S; Mergui-Roelvink, MWJ; Schellens, JHM; Tchakov, I; van der Biessen, DA; van der Noll, R | 1 |
| Cao, Y; Gan, Q; Hua, D; Wang, C; Wang, Z; Yuan, H | 1 |
| Fu, Q; Hu, S; Lustburg, MB; Sparreboom, A; Sun, X | 1 |
| Chen, Q; Chen, Y; Fang, X; He, W; Li, J; Liang, H; Sha, X; Sun, Y | 1 |
| Du, Q; Qian, J; Shi, K; Xu, N; Yin, X; Zhao, Z; Zhou, X | 1 |
| Chu, K; Han, L; Li, T; Ouyang, H; Qiu, L; Wang, X; Xu, W; Zhang, X | 1 |
| Abd-Elrazek, AM; El-Dash, HA; Said, NI | 1 |
| Ahmed, M; Bissessur, R; Kabir, A; Nazeer, N | 1 |
| Bojko, A; Charzynska, A; Czarnecka-Herok, J; Dabrowski, M; Sikora, E | 1 |
| Ang, E; Ang, S; Bandla, A; Chan, A; Chan, G; Hairom, Z; Huang, Y; Kumarakulasinghe, NB; Lee, SC; Lee, YM; Lim, JSJ; Magarajah, G; Ngoi, N; Sundar, R; Tan, S; Thakor, N; Wilder-Smith, E; Wong, A | 1 |
| Carragher, B; Crowe, J; Ewert, KK; MacDonald, S; Potter, CS; Safinya, CR; Steffes, VM; Zhang, Z | 1 |
| Cheng, Y; Ji, Y | 1 |
| Abasi, S; Ahmadi, Z; Ashrafizadeh, M; Dehghannoudeh, G; Khanbabaei, H; Mohamadi, N; Mohammadinejad, R; Tamaddondoust, RN; Thakur, VK; Zarrabi, A | 1 |
| Lee, ES; Yu, HS | 1 |
| Russo, GL | 1 |
| Baker, D; Cole, T; Faccio, R; Faget, DV; Luo, X; Monahan, J; Murali, B; Ren, Q; Ricci, B; Schwarz, JK; Stewart, SA; Thotala, D; van Deursen, JM; Yao, Z | 1 |
| Huang, M; Li, L; Li, S; Liu, H; Liu, X; Wang, Y; Xue, J; Zheng, K | 1 |
| Clement Frey, F; Eberli, D; Kletzmayr, A; Millan, C; Zimmermann, M | 1 |
| Kawahara, B; Mascharak, PK; Sen, S | 1 |
| Cai, H; Huo, M; Li, L; Wang, H; Yin, T; Zhang, P; Zhang, Y; Zhou, J | 1 |
| Cui, F; Han, Y; Kawashima, Y; Li, S; Liang, N; Liu, J; Sun, S; Yan, P | 1 |
| Brors, B; Haibe-Kains, B; Kurilov, R | 1 |
| Aldonza, MBD; Han, J; Hong, JY; Im, SG; Kim, D; Kim, Y; Ku, J; Lee, MS; Lee, SK; Prayogo, MC; Ryu, HS; Tan, S; Yu, SJ | 1 |
| Gong, L; Li, R; Lin, Z; Xu, P; Yao, J; Yin, Y; Zhai, Z | 1 |
| Chen, Y; Dong, C; Jiang, Q; Qian, X; Wang, W; Wu, W; Yu, L | 1 |
| Dong, C; Liu, F; Shen, Y; Xiang, J; Zhou, Q; Zhou, Z | 1 |
| Banskota, S; Bhattacharya, J; Chilkoti, A; Dzuricky, M; Kirmani, N; Li, X; Saha, S; Spasojevic, I; Young, K; Yousefpour, P; Zakharov, N | 1 |
| Huo, M; Liu, Y; Wang, L; Yang, M; Yin, T; Zhou, J | 1 |
| Abliz, Z; Du, Q; Gao, S; He, J; Li, Y; Pang, X; Song, X; Zhang, J; Zhang, R | 1 |
| Farquhar-Smith, P; Gordon-Williams, R | 1 |
| Jain, S; Sahoo, SK; Singh, A | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Bhargava, R; Hu, Y; Lee, S; Lewis, MT; Loo, SK; Tan, Y; Wang, XS | 1 |
| Guo, Y; Hu, M; Hu, Q; Kong, L; Shang, L; Tu, K; Wang, M; Xu, M; Yu, Y; Zhang, Z | 1 |
| Brás, R; Caiado, J; Castells, M; Costa, L; Paulino, M | 1 |
| He, M; Hu, W; Li, C; Liu, Z; Wang, Y; Ye, M; Zhai, S; Zhang, H | 1 |
| Loi, S; Savas, P | 1 |
| Blum, C; Gibson-Corley, KN; Hamity, MV; Hammond, DL; White, SR | 1 |
| Chen, N; Kassir, N; Li, Y; Palmisano, M; Wang, X; Zhou, S | 1 |
| Fang, T; Jiang, Y; Zhang, CY; Zhou, Y | 1 |
| Ge, Z; Han, M; Ji, X; Li, J; Luo, B; Sun, X; Wang, Q; Zhang, W; Zhou, K | 1 |
| Deng, L; Dong, A; Feng, Z; Guo, J; Huang, P; Liu, X; Wang, C; Wang, W; Zhang, J | 1 |
| Qiu, D; Shao, F; Wilson, IW | 1 |
| Chenjun, M; Liefeng, Z; Tiantian, W; Yingying, H; Yusheng, S | 1 |
| Ashrafizadeh, M; Entezari, M; Hashemi, F; Hushmandi, K; Moghadam, ER; Mohammadinejad, R; Najafi, M; Zarrabi, A | 1 |
| Choi, JS; Park, JS | 1 |
| Gao, J; Li, A; Zhang, T | 1 |
| Cao, LP; Gao, Y; Shan, WG; Shen, M; Tang, L; Tu, CJ; Zhang, ZH; Zhu, ZF | 1 |
| Liu, H; Liu, JW; Liu, X; Wang, SL | 1 |
| B, S; Cha-Molstad, H; Han, HJ; Han, J; Hwang, J; Kim, BY; Kim, SO; Kwon, YT; Lee, KH; N R, T; Park, C; Ryoo, IJ; Soung, NK; Woo, M | 1 |
| Bae, SH; Hong, KM; Hong, Y; Jang, H; Kang, EK; Kim, HY; Kim, YH; Lee, EY; Lee, HO; Min, JW; Park, WY; Poojan, S; Sim, HW; Song, Y | 1 |
| Albano, G; Giorno, V; Román-Román, P; Román-Román, S; Serrano-Pérez, JJ; Torres-Ruiz, F | 1 |
| Hu, X; Pei, Q; Wang, J; Wang, Z; Xia, R; Xie, Z | 1 |
| Chen, X; Cheng, L; Dai, L; Deng, H; Jiang, M; Jiang, Q; Li, J; Li, Y; Lin, Y; Liu, Y; Qian, Z; Shi, G; Su, X; Tang, M; Wang, H; Wang, Q; Wang, Y; Yan, X; Yang, Q; Yu, D; Zhang, H; Zhang, L; Zhang, Y | 1 |
| Jahanbani, A; Shao, Z; Sheikholeslami, SM | 1 |
| Chen, Q; Chen, W; Chen, Y; Hu, M; Huang, Q; Peng, C; Peng, D; Wang, L; Zhang, W | 1 |
| Baird, L; Hishinuma, E; Saigusa, D; Suzuki, T; Takahashi, Y; Yamamoto, M | 1 |
| Clemons, WM; Gillman, CD; Glazer, ES; Hevener, KE; Hussain, SM; Kansal, RG; Kurosu, M; Miranda-Carboni, GA; Mitachi, K; Yun, HG | 1 |
| Li, J; Luo, K; Wang, G; Yin, S; Yu, H; Zhang, R | 1 |
| Chen, X; Du, T; Ji, M; Li, Y; Lin, S; Liu, Y; Lu, D; Sheng, L; Wang, Q; Xu, H; Xue, N; Zhang, J; Zhang, K; Zhang, Y; Zhang, Z | 1 |
| Barajas, A; Cadena, MA; Gregory, JV; Lahann, J; Mitragotri, S; Vogus, DR | 1 |
| Amgoth, C; Chen, S; Malavath, T; Tang, G | 1 |
| Bao, X; Xu, G; Yao, P | 1 |
| Chen, X; Li, L; Xu, W; Zhou, K; Zhu, Y | 1 |
| Ai, J; Chen, G; Chen, J; Cui, M; Feng, X; Li, K; Li, X; Liao, Q; Ma, D; Ma, N; Tang, M; Yin, Y; Zhang, S | 1 |
| Beijnen, JH; Burylo, AM; Damoiseaux, D; de Weger, VA; Hendrikx, JJMA; Huitema, ADR; Marchetti, S; Mergui-Roelvink, M; Moes, JJ; Nuijen, B; Rosing, H; Sawicki, E; Stuurman, FE; Vermunt, MAC | 1 |
| Fujiwara, K; Goto, K; Harada, T; Hayashi, T; Kaneda, H; Kenmotsu, H; Kimura, M; Kogure, Y; Koike, T; Matsui, R; Nishio, M; Nogami, N; Seto, T; Shimizu, S; Shimokawa, M; Suzuki, K; Takiguchi, T | 1 |
| Arnst, J | 1 |
| Boras, B; Chen, W; D'Argenio, DZ; Hu, W; Spilker, ME; Sung, T | 1 |
| Dong, J; Jiang, S; Wang, J; Wang, Z; Ying, Y; Zhang, L; Zhao, Q; Zhao, S; Zhao, Y; Zou, J | 1 |
| An, F; Aras, O; Han, S; Zhou, M | 1 |
| Jang, HR; Kim, CH; Shin, SB; Yim, H | 1 |
| Bhat, MK; Chaube, B; Deb, A; Malvi, P; Mayengbam, SS; Mohammad, N; Singh, A; Singh, SV | 1 |
| Groth, C; Umansky, V; Utikal, J; Weber, R | 1 |
| Arif, A; Ashraf, A; Changxing, L; Chishti, AA; Fang, D; Galani, S; Hassan, FU; Jianhua, L; Naveed, M; Qi, W; Rashid, Z; Saeed, M | 1 |
| Anbazhagan, R; Krishnamoorthi, R; Kumaresan, S; Lai, JY; Muthusamy, G; Rajendra Prasad, N; Tsai, HC; Yang, JM | 1 |
| Banstola, A; Choi, HG; Gautam, M; Jeong, JH; Kim, JO; Ku, SK; Pham, LM; Phung, CD; Poudel, K; Soe, Z; Tran, TH; Yong, CS | 1 |
| Ambriović-Ristov, A; Humphries, JD; Humphries, MJ; Samaržija, I; Tadijan, A | 1 |
| Fanarraga, ML; Hevia, LG | 1 |
| Borisov, I; Metelkin, E | 1 |
| Cánovas-Díaz, M; de Diego Puente, T; Gallego-Jara, J; Lozano-Terol, G; Sola-Martínez, RA | 1 |
| Mao, JW; Tan, XL; Yang, YH | 1 |
| Abak, A; Abbas Raza, SH; Ghafouri-Fard, S; Pichler, M; Shoorei, H; Taheri, M | 1 |
| Doi, J; Karakasis, K; Kasherman, L; Kitchlu, A; Lheureux, S; Oza, AM; Schiff, J | 1 |
| Hedrick, JL; Kng, J; Yang, C; Yang, YY; Zheng, Y | 1 |
| Li, C; Liu, J; Luo, Z; Shen, Q; Shi, L; Tseng, Y; Wang, X; Wang, Y; Zheng, W | 1 |
| Amant, FCH; Beijnen, JH; Bekkers, R; Boere, I; Dorlo, TPC; Drochytek, V; Fruscio, R; Halaska, MJ; Huitema, ADR; Janssen, JM; Ottevanger, P; Painter, RC; Schröder, CP; Van Calsteren, K; Witteveen, PO | 1 |
| Anjanappa, M; Ma, C; Nakshatri, H; Pandurangi, RS; Paulmurugan, R; Rajput, S; Tomasetti, M; Verapazham, ST | 1 |
| Ding, K; Parulekar, WR; Sridhar, SS | 1 |
| Clayton, JE; Fonseca, CL; Malaby, HLH; Marquis, C; Queen, KA; Stumpff, J; Vandal, SE; Wood, L | 1 |
| Chu, L; Gu, X; Ouyang, Y; Tong, X; Wang, J; Wang, K; Xu, M | 1 |
| Casazza, G; Cheli, S; Clementi, E; Cona, MS; Dalu, D; Demurtas, S; Fasola, C; Ferrario, S; Filipazzi, V; Gambaro, A; La Verde, N; Montrasio, C; Rota, S; Tosca, N | 1 |
| Deng, C; Liu, Y; Wang, Y; Wu, M; Yi, D; Yuan, W; Zhang, Q; Zhou, F | 1 |
| Cheng, J; Huang, L; Jin, J; Qi, H; Wan, J; Wang, H | 1 |
| Boere, IA; Bosch, TM; Cox, JM; Jager, A; Malmberg, R; Mathijssen, RHJ; Oomen-de Hoop, E; van den Bemt, PMLA; van Doorn, L; van Leeuwen, RWF | 1 |
| Feng, H; Jin, L; Li, J; Li, Z; Shi, J; Shi, L | 1 |
| Emami, J; Lavasanifar, A; Spada, A; Tuszynski, JA | 1 |
| Chen, J; Li, J; Li, M; Li, Q; Liang, Z; Qu, F; Tan, J; Wang, J; Wang, Y; Xu, N; Yan, Z; Yu, L; Zhou, JE | 1 |
| Barbolina, MV | 1 |
| Cathcart-Rake, EJ; Friday, BB; Lacouture, M; Loprinzi, CL; McCue, S; O'Connor, A; Piens, J; Register, T; Smith, D; Thomé, S; Young, S; Zahrieh, D | 1 |
| Chen, B; Chen, M; Chen, W; Du, H; Fu, C; Lu, Z; Pan, A; Tang, M; Wang, Y; Wang, Z; Xia, H; Yan, Y; Yin, Q; Yuan, X; Zhang, Q | 1 |
| Cheng, J; Chu, X; Huo, M; Liang, J; Yin, T; Zhou, J | 1 |
| Chen, Y; Feng, X; Gao, F; Hou, G; Ji, N; Li, H; Lu, B; Ma, Y; Wang, P; Yin, L; Zhang, L; Zhao, L | 1 |
| Cong, C; Gao, D; He, Y; Li, L; Liu, L; Wang, D; Zhang, X; Zhao, S | 1 |
| Breathnach, OS; Browne, K; Cowzer, D; Coyne, Z; Egan, K; Grogan, L; Hennessy, BT; Hennessy, MA; Keogh, RJ; Linehan, A; Milewski, M; Morris, PG | 1 |
| Koyakutty, M; Nair, SV; Pavithran, K; Thayath, J | 1 |
| Berges, A; Cho, H; Dean, E; Hong, JY; Irurzun-Arana, I; Kang, WK; Kim, KM; Kim, ST; Kozarewa, I; Lee, J; Lim, HY; Loembé, AB; Mortimer, P; Park, JO; Park, SH; Park, YS; Pierce, AJ; Smith, C; Smith, SA; Willis, S | 1 |
| Kianfar, E | 1 |
| Al-Mahayri, ZN; AlAhmad, MM; Ali, BR | 1 |
| Dyavaiah, M; S J, S; Subramanian, S; Veerabhadrappa, B | 1 |
| Aref, AR; Ashrafizadeh, M; Daneshi, S; Hashemi, F; Hushmandi, K; Khan, H; Kumar, AP; Mirzaei, S; Saleki, H; Samarghandian, S; Sharifzadeh, SO; Soleymani, L; Zabolian, A; Zarrabi, A | 1 |
| Gong, X; Han, Y; Liang, N; Pan, J; Sun, S | 1 |
| Bai, Y; Chen, X; Guo, X; Liu, T; Tian, R; Yuan, P; Zhang, Y; Zhu, M | 1 |
| Alberti, D; Bitonto, V; Geninatti Crich, S; Rakhshan, S; Stefania, R | 1 |
| Brandt, S; Colombo, I; Frattini, M; Gaggetta, S; Genta, S; Guidi, M; Martorana, F; Moser, L; Pascale, M; Samartzis, EP; Sessa, C; Stathis, A; Terrot, T | 1 |
| Chanu, P; Kotani, N; Sane, R; Wade, JR; Wang, N; Wilkins, J; Winkler, J; Yoshida, K | 1 |
| Lin, Z; Liu, JY; Wang, S; Weng, XL; Yang, DC; Zhang, HX | 1 |
| Gong, X; Li, S; Liang, N; Liu, J; Shi, H; Sun, S; Yan, P | 1 |
| Edaki, K; Kamioka, H; Kasahara, H; Ogihara, T; Tomono, T; Yano, K | 1 |
| Chen, J; Li, Q; Tang, C; Yin, C; Zhang, L | 1 |
| Li, J; Liu, R; Liu, Y; Sang, L; Wang, D; Wang, T; Wang, Z | 1 |
| Feng, N; He, Y; He, Z; Hou, X; Li, Y; Li, Z; Ruan, S; Sun, J; Wang, Z; Wu, T; Xia, Q; Zhang, Y | 1 |
| Lohrasbi-Nejad, A; Raeispour Shirazi, M; Rahpeyma, SA; Rashidi Monfared, S; Zolala, J | 1 |
| Chang, JY; Chang, LY; Chen, LH; Chen, YF; Shen, MR; Wu, PY; Yeh, YM | 1 |
| Bhardwaj, G; Fung, G; Ghosh, PM; Lam, KS; Liu, R; Shih, TC | 1 |
| Pu, X; Wei, Y; Zhao, L | 1 |
| Bharadwaj, G; Lam, KS; Li, X; Li, Y; Macarenco, AC; Narayanan, A; Nhan, V; Shi, Y; Vieira, LS; Xiao, W; Yang, D; Yang, S | 1 |
| Lian, Z; Liang, G; Tang, W; Yang, J; Yuan, Y; Zhao, Z | 1 |
| Eadens, M; Erlichman, C; Goetz, MP; Haddad, T; Lupu, R; Molina, J; Qin, R; Satele, D | 1 |
| Banković, J; Dinić, J; Fernandes, MX; Kovačević-Grujičić, N; Martín, VS; Ortega, N; Padrón, JM; Pešić, M; Podolski-Renić, A; Ríos-Luci, C | 1 |
| Acker, JP; Chen, J; Gu, Q; Gu, W; Kong, B; Patra, P; Wei, L; Yang, X | 1 |
| Bahadur, D; Banerjee, R; Gogoi, M; Jaiswal, MK; Sarma, HD | 1 |
| Bao, Y; Tan, S; Yin, M; Zhang, Z | 1 |
| Cai, P; Chen, X; Engl, W; Hu, B; Leow, WR; Lim, CT; Tan, NS; Wu, YL | 1 |
| Chen, H; Dai, Y; Li, F; Qiu, X; Tham, HP; Xiang, H; Xing, P; Yao, X; Yuan, W; Zhao, L; Zhao, Y; Zhu, L | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Apte, SM; Chon, HS; Kang, S; Lee, JK; Shahzad, MM; Wenham, RM; Williams-Elson, I | 1 |
| Burris, HA; Hart, L; Infante, JR; Jones, SF; Kurkjian, CD; Murphy, PB; Neuwirth, R; Pant, S; Patel, CG; Zohren, F | 1 |
| Bamodu, OA; Hsiao, M; Huang, CC; Lee, WH; Lin, CM; Shih, PH; Su, YK; Tzeng, YM; Wu, ATH; Yeh, CT | 1 |
| Aaronson, NK; Abyzov, A; Banck, MS; Beutler, AS; Dorsey, SG; Kanwar, R; Lavoie Smith, EM; Le-Rademacher, J; Loprinzi, CL; Pachman, DR; Qin, R; Ruddy, KJ; Seisler, D; Sloan, J | 1 |
| Andriguetti, NB; Antunes, MV; Linden, R; Perassolo, MS; Raymundo, S; Suyenaga, ES; Verza, SG | 1 |
| Cao, J; Chen, J; Chen, T; He, HJ; Huang, HL; Liu, G; Shi, YP; Wang, YH; Yang, LW; Yang, T; Yao, WM | 1 |
| Guan, J; He, Z; Lou, B; Mashayekhi, V; Mastrobattista, E; Sadeghi, N; Storm, G; Sun, F; Sun, J; Zhang, D | 1 |
| Chuang, VTG; Fang, J; Ishida, T; Ishima, Y; Kinoshita, R; Maeda, H; Maruyama, T; Nakamura, H; Okuhira, K; Otagiri, M; Shimizu, T; Watanabe, H | 1 |
| Fallon, JK; Liu, F; Ma, Y; Wang, Y; Xu, Z | 1 |
| Al-Najjar, BY; Alhnan, MA; El Nemr, S; Elhissi, AMA; Omer, HK | 1 |
| Li, C; Li, Z; Liow, SS; Loh, XJ; Owh, C; Wang, X; Wu, Q; Wu, YL | 1 |
| Eisenberg, MC; Jain, HV | 1 |
| Shi, X; Sun, X | 1 |
| Chao, JI; Chen, C; Chen, TH; Cheng, HC; Li, LY; Liao, WS; Lin, J; Lin, YW; Liu, KK; Raj, EN; Wang, CC | 1 |
| Guo, Y; He, Y; Kong, M; Shang, L; Song, Q; Tan, S; Wu, T; Yin, Y; Zhang, D; Zhang, Z; Zhao, Y | 1 |
| Chen, F; Di, Y; Gai, X; Jia, L; Li, T; Liu, W; Pan, W; Wang, Y; Yang, X; Zhu, Z | 1 |
| Boissenot, T; Bordat, A; Chacun, H; Fattal, E; Larrat, B; Paci, A; Poinsignon, V; Tsapis, N; Varna, M | 1 |
| Choi, JW; Chung, YH; Hong, JW; Kasala, D; Kim, SW; Lee, SH; Nam, K; Yun, CO | 1 |
| Ewert, KK; Fletcher, BJ; Murali, MM; Park, Y; Safinya, CR; Steffes, VM | 1 |
| Chen, Q; Jia, Y; Kuang, Y; Li, X; Li, Y; Liu, Y; Ma, X; Pu, X; Sun, M; Wang, Y; Wei, D; Yang, T; Yang, Y | 1 |
| Bryson, PD; Chen, X; Kim, YJ; Mac, J; Rohrs, JA; Siegler, EL; Siriwon, N; Wang, P | 1 |
| Ben-Josef, E; Chakravarti, A; Chatterjee, M; Harbrecht, M; Palanichamy, K; Robb, R; Seum, S; Thirumoorthy, K; Vedaie, M; Williams, TM | 1 |
| Han, H; Kim, H; Kim, K; Lee, H | 1 |
| Cui, H; Konstantopoulos, A; Porter, M; Wang, F; Zhang, P | 1 |
| Ambrose, S; Chen, D; Gu, Y; Huang, N; Lee, YH; Liang, Z; Luo, T; Qiu, H; Ren, J; Wang, L; Wang, Y; Wu, S; Yao, J; Ye, Z; Yin, R; Zeng, J; Zhang, J; Zhao, H; Zhen, J | 1 |
| Jin, Y; Liu, D; Ma, X; Wang, X; Yu, L; Zhao, K | 1 |
| Ma, L; Wei, Y; Xu, X; Zhang, L | 1 |
| Capeling, M; Chang, MYZ; Cheng, C; Cheng, WI; Commisso, A; Sun, H; Wang, Q; Wu, Y | 1 |
| Gao, WQ; Jin, J; Li, Q; Ma, J; Sun, LL; Zhu, RY | 1 |
| Cescon, D; El-Hachem, N; Haibe-Kains, B; Lupien, M; Mak, TW; Quevedo, R; Safikhani, Z; Silvester, J; Smirnov, P; Thu, KL | 1 |
| Chen, YS; Luo, YL; Su, YY; Wang, Y; Xu, F; Zhang, XY | 1 |
| Adenis, A; Bahamon, B; Behbakht, K; Coleman, RL; Danaee, H; Dees, EC; DeMichele, A; Ecsedy, J; Falchook, G; Gao, F; Huebner, D; Matulonis, U; Melichar, B; Niu, H; Perez, K; Sawrycki, P; Schilder, RJ; Shin, H; Zhang, J | 1 |
| Lee, RJ; Teng, L; Wang, L; Xu, C; Yao, J; Yu, B; Yu, G; Zhang, X; Zhang, Y | 1 |
| Florian, S; Mitchison, TJ; Pineda, J; Shi, J | 1 |
| Bijlsma, MF; Ebbing, EA; Krishnadath, KK; Mathôt, RAA; Medema, JP; Pistorius, MCM; Steins, A; van Laarhoven, HWM; Waasdorp, C; Wilmink, JW | 1 |
| Lechowski, R; Zabielska-Koczywąs, K | 1 |
| Hashimoto, M; Ishigaki, Y; Iwabuchi, K; Kamdar, RP; Matsui, T; Matsumoto, Y; Sakasai, R; Sharma, MK; Sunatani, Y | 1 |
| Chen, Y; Gao, X; Peng, F; Song, X; Wu, J; Yao, W | 1 |
| Leandersson, K; Mehmeti, M; Millrud, CR | 1 |
| Fukumura, M; Hatano, M; Kimura, K; Nomi, N; Nuno, Y; Ota, M; Wakuta, M; Yanai, R | 1 |
| Deng, C; Jiang, C; Lee, RJ; Xu, C; Yao, JU; Yu, BO; Zhang, X; Zhang, Y | 1 |
| Eshima, K; Fukushima, M; Iizuka, K; Jin, C; Zhang, C | 1 |
| Hu, X; Jing, X; Li, Y; Liu, S; Pei, Q; Xie, Z; Zheng, X | 1 |
| Gan, Z; He, F; Long, P; Su, H; Xiang, K; Xu, M; Yu, Q; Zhang, J; Zhang, X | 1 |
| Deng, W; Jia, Y; Lu, J; Qiu, J; Tan, H; Wang, S; Yuan, Z; Zheng, R | 1 |
| Banerjee, R; Chandan, R | 1 |
| Fu, S; Han, L; Lin, J; Liu, C; Lu, X; Yang, C; Zhao, C | 1 |
| Jeong, YY; Lee, BI; Moon, MJ; Park, HJ; Park, IK; Surendran, SP; Thomas, RG | 1 |
| Guo, P; Guo, S; Li, H; Rajabi, M; Shu, D; Shu, Y; Vieweger, M; Yin, H | 1 |
| Chen, S; Qi, C; Shen, Z; Wang, G; Wang, X; Williams, N; Yu, H | 1 |
| Chen, C; Chen, ZS; Fang, L; Huang, HQ; Li, CZ; Lin, LF; Qiu, GD; She, YQ; Xin, DS; Zhang, SQ; Zhang, SY; Zheng, JT; Zhou, L | 1 |
| Guan, Q; Jin, X; Shi, L; Xu, L; Yang, J; Zhu, X | 1 |
| Chenel, M; Fouliard, S; Friberg, LE; Hooker, AC; Karlsson, MO; Pierrillas, PB | 1 |
| Chernobrovkin, A; Pirmoradian, M; Sabatier, P; Saei, AA; Tokat, ÜG; Zubarev, RA | 1 |
| Ferris, C; Jerajani, K; Kulkarni, P; Nagesha, DK; Sridhar, S; Torchilin, VP; Upponi, JR | 1 |
| Adjei, AA; Bindeman, WE; Cao, S; Chanana, P; Dong, H; Dronca, RS; Harrington, SM; Jang, JS; Jen, J; Li, Y; Liu, X; Mansfield, AS; Markovic, SN; Park, SS; Yan, Y | 1 |
| Bosakova, Z; Eckschlager, T; Hampejsova, Z; Hobzova, R; Hrabeta, J; Janouskova, O; Kopeckova, K; Plch, J; Sirc, J; Venclikova, K | 1 |
| Al-Abbasi, FA; Al-Abd, AM; Aseeri, AH; Baghdadi, MA; El-Halawany, AM | 1 |
| Druzhkova, IN; Dudenkova, VV; Ignatova, NI; Lukina, MM; Shimolina, LE; Shirmanova, MV; Zagaynova, EV | 1 |
| He, Q; Li, M; Liu, Y; Mei, L; Rao, J; Zhang, Z | 1 |
| Chen, Q; He, Z; Kan, Q; Luo, C; Sun, B; Sun, J; Wang, M; Wang, Y; Yang, W; Yu, H; Zhang, H; Zhang, X | 1 |
| Boon, U; Huijbers, IJ; Jonkers, J; Linder, S; Maia, ARR; Medema, RH; Pritchard, CEJ; Song, JY; Vaarting, C; van Tellingen, O; Velds, A | 1 |
| Chowdhury, MR; Goto, M; Kamiya, N; Moniruzzaman, M; Moshikur, RM; Tahara, Y; Wakabayashi, R | 1 |
| Dolan, ME; Dudek, SM; Kim, D; Li, R; Ritchie, MD; Wheeler, HE | 1 |
| Cheng, H; Ding, Y; Djamila, A; Dong, Q; Han, Y; Tang, Z; Zhang, H; Zhou, J | 1 |
| Bloomfield, A; Dircksen, C; Dorton, R; Kleindl, P; Leamon, CP; Nelson, M; Reddy, JA; Santhapuram, H; Vetzel, M; Vlahov, IR | 1 |
| Allouch, A; Bertrand, P; Brenner, C; Dakhli, H; De Jong, D; Deutsch, E; Dugué, D; Gougeon, ML; Jaulin, F; Kroemer, G; Law, F; Martins, I; Mintet, E; Modjtahedi, N; Ojcius, DM; Perfettini, JL; Piacentini, M; Raza, SQ; Sabino, D; Thoreau, M; Voisin, L | 1 |
| Choudhury, H; Gorain, B; Kesharwani, P; Pandey, M | 1 |
| Ateeq, B; Behera, L; Kumar, N; Manzar, N; Tyeb, S; Verma, V | 1 |
| Cho, JW; Kim, JH; Kim, JS; Kim, WJ; Nam, YS; Park, K; Seah, GL; Yang, MY; Yu, JH | 1 |
| Cheng, H; Huang, G | 1 |
| An, L; Lin, J; Mu, X; Tao, C; Tian, Q; Yan, C; Yang, S | 1 |
| Gou, J; He, H; Liu, Y; Pu, C; Tan, X; Tang, X; Wang, Q; Wang, Y; Yin, T; Zhang, H; Zhang, Y | 1 |
| Cao, Y; Chen, Y; Gong, Y; Guo, Y; Li, P; Li, Y; Liu, F; Ran, H; Wang, Z | 1 |
| Bae, ON; Bian, Y; Chang, YK; Chung, JH; Kim, K; Lim, KM | 1 |
| Chen, F; Chen, H; Ding, N; Ji, L; Liu, B; Meng, F; Qian, H; Sha, H; Xu, Q; Yu, L; Zhang, L; Zhou, Y; Zhu, A | 1 |
| Ester, K; Guberović, I; Kralj, M; Marjanović, M; Martin-Kleiner, I; Mioč, M; Mlinarić-Majerski, K; Šumanovac Ramljak, T | 1 |
| Lee, JY; Nam, YS; Park, J; Park, JC; Son, HY | 1 |
| Choi, CA; In, I; Jeong, JH; Kim, YK; Lee, G; Lee, JE; Lee, S; Mazrad, ZAI; Park, SY; Ryplida, B | 1 |
| Newman, DJ | 1 |
| Bavbek, S; Bonadonna, P; Caralli, M; Castells, M; Cernadas, J; Cortellini, G; Costantino, MT; Dursun, AB; Gelincik, A; Lucchini, G; Pagani, M | 1 |
| Choi, MJ; Im, CS; Jeong, HY; Jeong, IH; Kang, SJ; Kim, MW; Lee, TS; Park, YS; Song, IH; You, YM | 1 |
| Ambudkar, SV; Cai, CY; Chen, ZS; Gupta, P; Ji, N; Kong, D; Lei, ZN; Shukla, S; Wang, JQ; Yang, Y | 1 |
| Colombo, MP; Garassino, MC; Sica, A; Torri, V | 1 |
| Batgerel, T; Jeong, YY; Kim, CS; Park, CH; Ramachandra Kurup Sasikala, A; Thomas, RG; Unnithan, AR | 1 |
| D'Incalci, M; Davoli, E; Falcetta, F; Franceschi, P; Giavazzi, R; Giordano, S; Jansen, J; Morosi, L; Postma, G; Prasad, M | 1 |
| Berveiller, P; Degrelle, SA; Evain-Brion, D; Fournier, T; Gil, S; Guibourdenche, J; Mir, O; Selleret, L; Tsatsaris, V | 1 |
| Kawara, H; Kawashima, Y; Maruyama, M; Noguchi, Y; Shimizu, Y; Tokuyama, Y; Uchiyama, K | 1 |
| Lin, T; Ren, L; Song, C; Thayumanavan, S; Zhang, Q | 1 |
| Cao, D; Huang, L; Kong, C; Li, H; Liang, L; Qin, H; Qu, X; Sun, Z; Wang, M; Wang, X; Xu, W; Yan, X; Zhang, Y | 1 |
| Chu, J; Peng, L; Sun, L; Wu, Q; Zhang, M; Zhang, Y; Zhong, B | 1 |
| Cass, AEG; Kobatake, E; Mashimo, Y; Matsumoto, R; Mie, M | 1 |
| D'Incalci, M; Davoli, E; Decio, A; Falcetta, F; Franceschi, P; Frapolli, R; Giavazzi, R; Giordano, S; Morosi, L; Prasad, M; Ubezio, P | 1 |
| Ge, XJ; Gong, YC; Li, YP; Li, ZL; Xiong, XY | 1 |
| Hu, Y; Liu, S; Luo, X; Wang, J; Xu, P | 1 |
| Burness, ML; Griggs, JJ; Hayes, DF; Henry, NL; Hertz, DL; Kidwell, KM; Marcath, LA; Poznak, CV; Robinson, AC; Schott, AF; Vangipuram, K | 1 |
| Aserin, A; Ezrahi, S; Garti, N | 1 |
| Su, Z; Wang, Q; Wu, Y; Xue, L; Xue, Y; Zhang, C; Zhang, L; Zhang, Y | 1 |
| Huang, M; Wang, Y; Xuan, G; Xue, J; Zheng, K | 1 |
| Chu, K; Guo, Y; Han, L; Li, T; Ouyang, H; Qiu, L; Wang, X; Xu, W | 1 |
| Arfan, M; Aziz, A; Imran, M; Irfan, M; Jabri, T; Kawish, M; Malik, MI; Rao, K; Shah, MR; Simjee, SU | 1 |
| Cerullo, V; Ciana, P; Garofalo, M; Kuryk, L; Mazzaferro, V; Rinner, B; Rizzi, N; Villa, A; Yliperttula, M | 1 |
| Bhatt, H; Biswas, S; Ghosh, B; Kumari, P; Rompicharla, SVK | 1 |
| Chaurasiya, B; He, W; Mohammad, IS; Teng, C; Wu, C; Yin, L | 1 |
| Chen, M; Li, R; Liu, C; Liu, Y; Song, F; Tian, J; Zhang, Q | 1 |
| Clyne, AM; Hamid, Q; Sun, W; Swaminathan, S | 1 |
| Beijnen, JH; Crombag, MBS; de Vries Schultink, AHM; Dorlo, TPC; Huitema, ADR; Joerger, M; Koolen, SLW; Mathijssen, RHJ; Schellens, JHM; van Erp, NP; Wijngaard, S | 1 |
| Castellano, G; Torrens, F | 1 |
| Choi, HG; Jeong, JH; Jin, SG; Kim, JO; Ku, SK; Nguyen, HT; Nguyen, LT; Phung, CD; Soe, ZC; Yang, KY; Yong, CS | 1 |
| Xie, Y; Yao, Y | 1 |
| Ashar, YV; Chen, ZS; Gao, HL; Gupta, P; Karadkhelkar, NM; Yoganathan, S | 1 |
| Gao, W; Gu, Y; Han, Z; Ma, Y; Wang, Z; Zhang, M; Zhou, Q | 1 |
| Hull, EE; Montgomery, MR | 1 |
| Baillet, A; Benoit, B; Cantaloube, I; Klipfel, L; Poüs, C; Salameh, J; Targa, B | 1 |
| Barry, BK; Goldstein, D; Grimison, P; Horvath, L; Li, T; Marthick, M; McCrary, JM; Park, SB; Sandler, CX; Timmins, HC | 1 |
| Jia, Y; Li, X; Lin, Y; Liu, Z; Long, L; Peng, C; Wang, C; Xiong, Y; Yuan, Y; Zhang, C; Zhou, X | 1 |
| Broadrup, R; Cardonick, E; Doan, MT; Jiang, H; Snyder, NW; Xu, P | 1 |
| Li, W; Xu, H; Xue, J | 1 |
| Chen, D; Hu, H; Huang, Z; Pan, S; Qiao, M; Shi, M; Sun, X; Yang, C; Zhang, J; Zhao, X | 1 |
| Li, D; Lu, Y; Tao, W; Wang, J; Yang, X | 1 |
| Bauer, TM; Faessel, H; Faller, DV; Harvey, RD; Lockhart, AC; Nemunaitis, J; Sedarati, F; Venkatakrishnan, K; Zhou, X | 1 |
| Dhagat, S; Eswari, JS; Yadav, M | 1 |
| Chen, G; He, Z; Li, X; Liu, J; Meng, Z; Miao, W; Ren, H; Wang, Y; Xu, Y | 1 |
| Han, G; Huang, K; Iris, A; Li, J; Ma, B; Mei, L; Qiu, Y; Sun, Y; Xie, J | 1 |
| Chai, Z; Chang, YT; Chen, J; Gao, J; Hu, Y; Huang, H; Lu, H; Wang, D; Zhou, M | 1 |
| Burke, W; Hsu, K; Learoyd, M; Shentu, J; Xu, B; Xu, J; Yuan, P; Zhu, M | 1 |
| Liang, F | 1 |
| Garg, S; Pramanik, A | 1 |
| Eom, SY; Hwang, SH; Lee, M; Yeom, H | 1 |
| Li, X; Shi, X; Zhang, C; Zheng, Q | 1 |
| Bilker, WB; DeMichele, A; Gross, R; Grover, S; Manshimba, P; Martei, YM; Monare, B; Ralefala, TB; Setlhako, DI; Shulman, LN | 1 |
| Jang, SI; Jeong, S; Lee, DH; Lee, DK; Na, K; Yang, S | 1 |
| Goldstein, D; McCrary, JM; Park, SB; Tan, AC; Trinh, T | 1 |
| Ding, X; Han, J; Luo, T; Pan, X; Tian, B; Zhang, J; Zhao, F | 1 |
| Mashayekhi-Sardoo, H; Mohammadpour, AH; Nomani, H; Sahebkar, A | 1 |
| Chen, W; Ge, Z; Japir, AAMM; Ke, W; Mukerabigwi, JF; Wang, Y; Yin, W; Zha, Z | 1 |
| Baek, G; Choi, C; Choi, H; Kim, Y; Lee, HC | 1 |
| Savitsky, K; Yu, X | 1 |
| Ebara, M; Lee, CM; Niiyama, E; Sakura, K; Uto, K | 1 |
| Cai, W; Dong, J; Feng, Y; Guo, X; Li, H; Sun, H; Wang, P; Zhou, Y; Zhuang, R | 1 |
| Blay, JY; Campone, M; Cannarile, MA; Cassier, PA; Christen, R; D'Angelo, SP; Delord, JP; Gomez-Roca, CA; Italiano, A; Jacob, W; Jegg, AM; Klaman, I; Le Tourneau, C; Loirat, D; Meneses-Lorente, G; Michielin, F; Ooi, CH; Reis, B; Ries, C; Rüttinger, D; Toulmonde, M; Watson, C; Weber, KL; Wonde, K | 1 |
| Cartagena-Albertus, JC; Engel Manchado, J; Moise, A; Montoya Alonso, JA; Moya García, S | 1 |
| Choi, JH; Choi, S; Kim, SJ; Lee, EJ; Shah, M; Woo, HG; Yoon, S | 1 |
| Bai, L; Gu, L; Ji, W; Li, X; Liu, G; Liu, Z; Wang, L; Wei, H; Wu, Q; Xie, D; Xu, T; Xue, Y; Yue, T; Zhang, H; Zhang, Y | 1 |
| Cikotiene, I; Dinić, J; Fernandes, MX; Karpaviciene, I; Padrón, JM; Pešić, M; Ríos-Luci, C | 1 |
| Beckman, JA; White, CJ | 1 |
| Hua, YM; Huang, KL; Huang, TW; Lin, KY; Loh, EW; Su, HC; Tam, KW | 1 |
| Chen, L; Zhu, L | 1 |
| Cheng, C; Huang, L; Jin, X; Mei, L; Sun, S; Sun, X; Zhang, J | 1 |
| Durazzo, A; Lucarini, M; Mobilia, MA; Nazhand, A; Omri, B; Santini, A | 1 |
| Carroll, T; Funabiki, H; Luo, JD; Paredes, M; Yamaguchi, N; Zierhut, C | 1 |
| Bai, P; Cao, D; Chen, L; Li, D; Li, W; Pei, H; Peng, A; Shu, X; Tang, M; Wang, F; Wen, J; Yang, J; Ye, H; Zheng, L; Zhu, Z | 1 |
| Chen, J; Cui, H; Guan, J; Li, S; Li, T; Li, Y; Li, Z; Song, X; Wan, J; Wu, Y; Xiao, C; Yang, X; Zhang, M | 1 |
| Lin, JM; Lin, L; Wu, Z; Zhang, W; Zheng, Y | 1 |
| Fu, Y; Gong, T; Hu, D; Huang, Y; Li, H; Luo, J; Zhang, P; Zhang, ZR | 1 |
| Chen, X; Guo, T; Li, H; Patterson, LH; Ren, X; Sun, X; Xu, J; Zhang, J | 1 |
| Kojima, C; Makiura, R; Nakahira, A; Nishio, Y; Watanabe, K | 1 |
| Christian, DA; Discher, DE; Harada, T; Pantano, DA; Rodriguez, PL; Tsai, RK | 1 |
| Benes, C; Borowsky, M; Burgess, S; Chen, L; Dastur, A; Lacy-Hulbert, A; Ohsumi, TK; Schmidt, EV; Stuart, L; Varshney, GK | 1 |
| Chen, XM; Fu, Q; Liu, SY; Lv, PP; Ma, GH; Wei, W; Yue, H; Yue, ZG | 1 |
| Adjei, AA; Belani, CP; Chow, LQ; Dy, GK; Fortin, C; Gupta, A; Jonker, DI; Laurie, SA; Nicholas, G; Park, JS; Patricia, D; Sbar, EI; Zhang, S | 1 |
| Fu, Q; Liu, F; Racette, K; Ramishetti, S; Tang, J; Wang, D; Wang, Y | 1 |
| Cutting, SM; Hoang, TV; Huynh, HA; Nguyen, HA; Nguyen, VA; Ninh, NT; Pham, AT; Phan, TN | 1 |
| Danhier, F; Danhier, P; Gallez, B; Jérôme, C; Laurent, S; Muller, RN; Préat, V; Schleich, N; Sibret, P; Ucakar, B | 1 |
| Du, Y; Hu, F; Li, C; Liu, F; Wang, Z; You, J; Yuan, H; Zhang, P; Zhou, J | 1 |
| El-Dakdouki, MH; Huang, X; Puré, E | 1 |
| Hertz, DL; Krens, SD; McLeod, HL | 1 |
| Cao, J; Chen, Y; Feng, T; Li, C; Liu, Y; Luo, X; Wang, B | 1 |
| Che, L; Chen, S; Chen, X; Dou, Y; He, H; Jia, Y; Li, S; Li, X; Song, L; Zhang, J; Zhou, J; Zhou, X | 1 |
| Chan Kwon, I; Choi, K; Choi, KY; Kim, K; Koo, H; Park, JH; Yoon, HY | 1 |
| Evers, BM; Gemeinhart, RA; Hollis, CP; Li, T; Weiss, HL | 1 |
| Fu, Q; Liu, F; Racette, K; Tang, J; Wang, D; Wang, Y | 1 |
| de Bruijn, P; de Graan, AJ; de Raaf, PJ; Elens, L; Engels, FK; Eskens, FA; Friberg, LE; Mathijssen, RH; Sparreboom, A; Sprowl, JA; van der Holt, B; van Schaik, RH; Verweij, J; Wiemer, EA | 1 |
| Iwamoto, T | 1 |
| Ambudkar, SV; Anreddy, N; Chen, ZS; Chufan, EE; Patel, A; Singh, S; Sodani, K; Stephani, R; Tiwari, AK | 1 |
| Nicolaou, KC; Valiulin, RA | 1 |
| Kang, H; Liu, D; Sun, C; Xiao, Y; Zhao, K | 1 |
| Du, YZ; Hu, FQ; Miao, J; Yuan, H; Zhang, XG | 1 |
| Yardley, DA | 1 |
| Avall-Lundqvist, E; González-Neira, A; Gréen, H; Hjerpe, E; Inglada-Pérez, L; Jara, C; Leandro-García, LJ; Leskelä, S; Mielgo, X; Pita, G; Robledo, M; Rodríguez-Antona, C | 1 |
| Gao, FY; Shen, JM; Tian, XZ; Xu, S; Yin, T | 1 |
| Kudlowitz, D; Muggia, F | 2 |
| Hertz, DL | 1 |
| Fung, AS; Tannock, IF; Ye, QJ; Yu, M | 1 |
| Inoue, K; Muranaka, T; Ohira, M; Sueoka, N; Tsubota, Y; Yamamoto, D; Yokoi, T | 1 |
| Ciccolini, J; Fanciullino, R; Milano, G | 1 |
| Gao, F; Huang, X; Wang, D | 1 |
| Fu, L; He, Q; Liu, Y; Ran, R; Tang, J; Yuan, M; Zhang, Q | 1 |
| Chang, YC; Chen, SY; Chiang, CS; Hu, SH; Liao, BJ | 1 |
| Bellapu, D; Giovinazzi, S; Ishov, AM; Morozov, VM | 1 |
| Barlev, NA | 1 |
| de Graan, AJ; Elbouazzaoui, S; Elens, L; Friberg, LE; Martens, JW; Mathijssen, RH; Nieuweboer, AJ; Smid, M; Sparreboom, A; van der Holt, B; van Schaik, RH; Verweij, J; Wiemer, EA | 1 |
| Abrieu, A; Boemer, U; Brands, M; Castedo, M; Galluzzi, L; Jemaà, M; Kepp, O; Koppitz, M; Kroemer, G; Lienau, P; Mumberg, D; Prechtl, S; Schulze, V; Senovilla, L; Siemeister, G; Vitale, I; Wengner, AM; Ziegelbauer, K | 1 |
| Cai, P; Fang, WS; Lu, P; Sharom, FJ | 1 |
| Chang, JY; Huang, HM; Lee, WH; Liou, JP; Liu, HE | 1 |
| Jie, J; Liu, Z; Tian, B; Yang, Y; Zhang, X; Zhou, M | 1 |
| Guo, A; Guo, S; Jin, F; Li, M; Li, Y; Liu, J; Lv, L; Shen, Y; Wang, F; Xu, X | 1 |
| Chen, J; Deng, L; Gao, B; Jing, X; Ke, X; Lian, J; Ma, L; Xiao, L; Yao, J; Zhang, Y; Zhao, Q | 1 |
| Lopes, Gde L | 1 |
| Apte, TG; Bhattacharyya, GS; Dasare, RR; Joshi, DA; Kasbekar, RB; Lopes, GL; Mengde, SD; Parikh, PM; Patil, PP; Phadke, GK; Ranade, AA | 1 |
| Baruchel, S; Elias, E; Kumar, S; Leadley, M; Marrano, P; Thorner, P; Zhang, L | 1 |
| Beckett, L; Chew, HK; Davies, AM; Gandara, DR; Ho, C; Lara, P; Lau, D; Mack, PC; Riess, JW; Sangha, RS | 1 |
| Itabashi, T; Kashiwaba, M; Kudo, K; Nihei, S; Sato, J; Takahashi, K | 1 |
| Chen, H; Chen, J; Feng, X; Gao, X; Hu, Q; Jiang, D; Jiang, X; Kang, T; Song, Q; Tu, Y; Yao, L | 1 |
| Perche, F; Taigind, A; Torchilin, VP; Wang, T; Zhu, L | 1 |
| Becker, S; Gellrich, D; Strieth, S | 1 |
| De Rosa, G; Navarro, G; Perche, F; Riehle, R; Salzano, G; Torchilin, VP | 1 |
| Andrzejewska, M; Januchowski, R; Wojtowicz, K; Zabel, M | 1 |
| Cao, W; Gao, X; Hu, K; Hu, L; Huang, Y; Jin, S; Li, S; Liang, XJ; Sun, Y; Wu, Y | 1 |
| Furuta, M; Koga, Y; Matsumura, Y; Ogata, K; Takigahira, M; Yamamoto, Y; Yasunaga, M | 1 |
| Li, J; Yin, H; Zhao, F | 1 |
| Chen, X; Eden, HS; Guo, J; Guo, N; Kiesewetter, DO; Lang, L; Li, Q; Niu, G; Xie, Q | 1 |
| Chae, SW; Kim, HJ; Kim, NH; Lee, HJ; Lee, K; Rhie, S; Xia, Y | 1 |
| Hall, RG; Jean, GW; Shah, S; Sigler, M | 1 |
| Gota, V; Mehta, M; Patel, K; Patil, A; Vavia, P | 1 |
| Beijnen, JH; Gelderblom, H; Guchelaar, HJ; Rosing, H; Scheulen, ME; Slingerland, M; van Warmerdam, LJ | 1 |
| Klier, U; Linnebacher, M; Maletzki, C; Stier, S | 1 |
| Biondo, A; Cassier, PA; Chen, E; de Bono, JS; Minton, S; Molife, LR; Papadopoulos, KP; Patnaik, A; Siu, LL; Sullivan, DM; Tetteh, E; Tolcher, AW; Vitfell-Rasmussen, J; Yan, L; Zernhelt, AM | 1 |
| Horwitz, SB; Wani, MC | 1 |
| Bloomfield, A; Dorton, R; Guan, J; Leamon, CP; Nelson, M; Reddy, JA; Vetzel, M | 1 |
| Dai, W; Gao, W; He, B; Hu, H; Lin, Z; Ma, K; Wang, J; Wang, X; Zhang, Q; Zhang, X | 1 |
| Chen, T; Huang, F; Liang, H; Tan, W; You, M; Zhu, G | 1 |
| Alfaro, V; Calles, A; Calvo, E; Coronado, C; Durán, I; Fernández-Teruel, C; García, M; Gil, M; Hidalgo, M; Prados, R; Salazar, R; Siguero, M | 1 |
| Aliberti, M; Baldo, P; Cecco, S; Giacomin, E; Leone, R | 1 |
| Amin, AR; Arbiser, JL; Beitler, JJ; Bonner, M; Chen, ZG; Huang, W; Koenig, L; Lee, MJ; Nannapaneni, S; Shin, DM; Shin, HJ; Wang, H; Wang, X | 1 |
| Du, F; Fang, X; Feng, C; Gu, J; Jiang, X; Xie, Y; Xin, H | 1 |
| Adams, PT; Atherton, PJ; Behrens, RJ; Dockter, TJ; Haluska, P; Leal, AD; Loprinzi, CL; Qin, R; Tiber, CH; Watanaboonyakhet, P; Weiss, M | 1 |
| Mazzocato, C | 1 |
| Alessandri, G; Bernardo, ME; Biagini, S; Conforti, A; Locatelli, F; Pessina, A; Proia, A; Starc, N | 1 |
| Beeram, M; Beyer, JC; Brachmann, RK; Darbonne, WC; Gore, L; Kim, AH; LoRusso, PM; Mason Shih, L; Messersmith, WA; Papadopoulos, KP; Patnaik, A; Ramakrishnan, V; Weekes, CD; Xiang, H; Xin, Y; Yu, R | 1 |
| Kratz, F | 1 |
| Beijnen, JH; de Weger, VA; Schellens, JH | 1 |
| Cao, J; Guo, W; Li, J; Li, W; Lv, F; Peng, W; Qian, J; Sun, S; Zhang, J; Zhang, W | 1 |
| Chan, J; Grainger, DW; Jin, Y; Liu, J; Wang, H; Wang, L; Wang, Y; Ying, W; Yu, L; Zhang, J | 1 |
| Kitagawa, Y; Kitajima, M; Matsuda, S; Oyama, T; Ozawa, S; Takeuchi, H | 1 |
| Shi, J; Zhou, Y; Zhu, Y | 1 |
| Muggia, FM | 1 |
| Amant, F; Beijnen, JH; Han, S; Heyns, L; Huitema, ADR; Mhallem Gziri, M; Schellens, JHM; van Calsteren, K; van Hasselt, JGC | 1 |
| Chen, N; Chopra, R; Li, Y; Palmisano, M; Ye, Y; Zhou, S | 1 |
| Lee, BJ; Tran, PH; Tran, TT | 1 |
| Matsumura, Y | 1 |
| Luo, Z; Nitin, N; Wang, MS | 1 |
| Hoffman, AS; Jang, Y; Kim, IS; Kim, J; Kim, WJ; Lee, BH; Mi Lee, Y; Namgung, R; Rhee, YM; Sokkar, P | 1 |
| da Silva Simão, DA; de Paula Lima, ED; Souza, RS; Teixeira, AL | 1 |
| Doerr, M; Kim, J; Kitchell, BE | 1 |
| Lammertsma, AA; van der Veldt, AA | 1 |
| Fujisaka, Y; Hayashi, H; Hayashi, N; Kawakami, H; Kurata, T; Nakagawa, K; Okamoto, W; Shin, E; Tsurutani, J | 1 |
| Alcoser, SY; Bonomi, CA; Borgel, SD; Collins, J; Divelbiss, R; Dougherty, KM; Hager, EJ; Holbeck, SL; Hollingshead, MG; Kaur, G; Kimmel, DJ; Kunkel, MW; Millione, A; Mullendore, ME; Newton, DL; Orsburn, BC; Stockwin, LH; Stotler, H | 1 |
| Busman, T; Cosgrove, D; Karantza, V; Mabry, M; Rudersdorf, N; Vlahovic, G; Wang, D; Xiong, H; Yang, J | 1 |
| Bahleda, R; Capri, G; Daglish, B; Del Conte, G; Gianni, L; Hospitel, M; Oprea, C; Sessa, C; Soria, JC; Varga, A | 1 |
| Alam, N; Dubey, RD; Gupta, PN; Jain, S; Khare, V; Nehate, C; Saneja, A | 1 |
| Affara, NI; Bergsland, E; Bornstein, S; Coussens, LM; Gong, Q; Gunderson, AJ; Irving, B; Johansson, M; Kulesz-Martin, M; Li, Y; Ma, Y; Medler, TR; Ruffell, B; Steinhoff, M; Wiesen, JF; Wong, MH | 1 |
| Discher, DE; Nair, P; Oltra, NS | 1 |
| Chen, X; Lang, L; Li, Y; Liu, X; Xie, P; Yan, C; Zhou, Q | 1 |
| Chen, Y; Dahmani, FZ; Wang, X; Yao, J; Yin, L; Zhou, J | 1 |
| Brana, I; Calles, A; Calvo, E; de Boer, CJ; LoRusso, PM; Puchalski, TA; Seetharam, S; Tabernero, J; Yee, LK; Zhong, B | 1 |
| Kao, LT; Lin, WJ | 1 |
| Higaki, K; Kimura, T; Ogawara, K; Yoshizawa, Y | 1 |
| Cabral, H; Kataoka, K | 1 |
| Fallon, JK; He, Z; Liu, D; Liu, F; Ma, Y; Wang, D; Wang, Y; Xu, XE; Yang, X; Zhao, Q | 1 |
| Alhamed, A; Chatterjee, A; Foster, DA; Hosny, C; Mukhopadhyay, S; Saqcena, M | 1 |
| Tamura, A; Yui, N | 1 |
| Carvalho, FL; Hernández-García, I; Hidalgo, M; Ramírez, N; Vera, R; Viúdez, A | 1 |
| Alessandri, G; Ami, D; Bernardo, ME; Bondiolotti, G; Bonomi, A; Ceccarelli, P; Ciusani, E; Coccè, V; Doglia, SM; Locatelli, A; Muraca, M; Parati, E; Pascucci, L; Pessina, A; Sisto, F; Viganò, L | 1 |
| Cao, J; Choi, HK; Choi, JS; Hasan, N; Naeem, M; Noh, J; Yoo, JW | 1 |
| Berveiller, P; Mir, O; Selleret, L | 1 |
| Boussery, K; Colin, P; De Bock, L; De Smet, L; Goeteyn, W; Van Bocxlaer, J; Vervaet, C | 1 |
| Gao, Y; Hedstrom, L; Kuang, Y; Long, MJ; Shi, J; Xu, B; Xu, C; Zhou, J | 1 |
| Banck, MS; Beutler, AS; Beyerlein, P; Boora, GK; Cunningham, JM; Kanwar, R; Klein, CJ; Kulkarni, AA; Le-Lindqwister, NA; Loprinzi, CL; Qin, R; Ruddy, KJ; Schroth, GP; Smalley, RL; Therneau, TM; Windebank, AJ; Wu, Y; Züchner, S | 1 |
| Danhier, F; Gallez, B; Jacobs, D; Po, C; Préat, V; Schleich, N; Ucakar, B | 1 |
| Chauhan, AS; Kumar, M; Tekade, M; Tekade, RK | 1 |
| Weaver, BA | 1 |
| Jeong, YY; Lee, S; Moon, M; Thomas, RG | 1 |
| Braun, J; Gonschorek, E; Huettelmaier, S; Jasinski-Bergner, S; Kalich, J; Schulz, K; Seliger, B; Stehle, F | 1 |
| Chen, P; Du, LC; Hu, HZ; Li, J; Li, YH; Luo, S; Tang, J; Wang, YS; Wei, YQ; Wen, YJ; Yang, DB; Zhang, P; Zhao, X | 1 |
| Gillespie, JW; Mei, LA; Parmar, CK; Petrenko, VA; Praveen, KP; Torchilin, VP; Wang, T; Yang, S | 1 |
| Gibbons, F; Krzyzanski, W; Mo, G; Schroeder, P | 1 |
| Cairns, MJ; Dass, C; Li, X; Saravolac, E; Sun, LQ; Yang, L; Yu, X | 1 |
| Raucher, D; Ryu, JS | 1 |
| Dai, W; Li, J; Wang, J; Wang, K; Wang, X; Zhang, H; Zhang, Q; Zhang, X; Zheng, N | 1 |
| Joerger, M | 2 |
| Guo, F; He, S; Hu, Q; Jiang, W; Li, L; Lin, Z; Liu, X; Liu, Y; Ma, X; Sang, Y; Shen, G; Su, C; Wan, Y; Wang, Y; Wei, Y; Ye, T; Yin, T; Yu, M | 1 |
| Forli, S | 1 |
| Dall'Acqua, S | 1 |
| Gao, H; He, Q; Liu, Y; Mei, L; Ran, R; Zhang, L; Zhang, Q; Zhang, Z | 1 |
| Du, LF; Duan, YR; Gao, F; Jin, LF; Li, F; Li, Z; Ma, J; Shen, M; Su, Y; Xing, LX; Zhu, MJ | 1 |
| Compton, N; Kendra, KL; O'Brien, ME; Ottesen, LH; Paul, EM; Plummer, R; Salgia, R; Suttle, AB; Villalona-Calero, MA; Xu, CF | 1 |
| Jiao, Y; Ren, Q; Sun, Y; Tang, X; Yang, W | 1 |
| Du, G; Fang, W; Fu, F; Lv, G; Ma, J; Ma, P; Tian, J; Wang, H; Wang, Z; Zhang, J | 1 |
| Brat, DJ; El-Rayes, BF; Kisiel, W; Liotta, DC; Lu, YJ; Moore, TW; Ndungu, JM; Parker, ET; Petersen, LC; Sarkaria, JN; Shoji, M; Snyder, JP; Sun, A; Zhu, S | 1 |
| Bartsch, R; Deutschmann, C; Felberbauer, FX; Hacker, S; Haslik, W; Kornauth, C; Mader, RM; Thallinger, C | 1 |
| Cao, H; He, W; Jin, Z; Lv, Y; Yao, J; Yin, L; Zhou, J | 1 |
| Friedlander, ML; Kiernan, MC; Krishnan, AV; Kwok, JB; Lewis, CR; Lin, CS; Loy, CT; Park, SB | 1 |
| Chen, HZ; Dong, X; Fang, C; Gao, YG; Guan, YY; Liu, HJ; Liu, YR; Lu, Q; Luan, X; Wang, C; Yang, SC | 1 |
| Bouvet, M; Fujiwara, T; Hiroshima, Y; Hoffman, RM; Kishimoto, H; Mii, S; Miwa, S; Tazawa, H; Uehara, F; Yano, S; Zhao, M | 1 |
| Danhier, F; Danhier, P; De Saedeleer, CJ; des Rieux, A; Fruytier, AC; Gallez, B; Préat, V; Schleich, N; Sonveaux, P | 1 |
| Ethiraj, KR; Sharma, N; Vindya, NG; Yadav, M | 1 |
| Chiang, WH; Fang, JH; Hu, SH; Lee, YT | 1 |
| Avgoustakis, K; Bikiaris, D; Karavelidis, V | 1 |
| Abu-Khalaf, MM; Azodi, M; Baumgart, MA; Chen, N; Deshpande, H; Digiovanna, MP; Doddamane, I; Gettinger, SN; Harris, LN; Hatzis, C; Hou, S; Lezon-Geyda, K; Schwartz, PE; Sullivan, C; Tuck, DP; Zelterman, D | 1 |
| Chen, Z; Fu, Q; Lv, P; Ma, G; Ni, D; Wei, W; Yue, H; Yue, Z; Zhang, L | 1 |
| Mabeta, P; Pepper, MS | 1 |
| Bialer, P; Carvajal, RD; Fury, MG; Gerecitano, JF; Ho, AL; Hyman, DM; Iasonos, A; Katabi, N; Konner, J; Lacouture, ME; Monson, KR; Snyder, AE; Spriggs, DR; Stasi, MA; Teitcher, JB; Voss, MH; Winkelmann, JL | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Cong, C; Dou, Y; Duan, L; Gao, A; Lai, Q; Sun, Y; Zheng, Y | 1 |
| Akcakanat, A; Chen, H; Culotta, KS; Do, KA; Doyle, LA; Gonzalez-Angulo, AM; Krop, I; Kurzrock, R; Li, Y; Liu, S; Meric-Bernstam, F; Mills, GB; Moulder-Thompson, S; Piha-Paul, S; Sahin, AA; Tarco, E; Velez-Bravo, V; Winer, EP | 1 |
| Belum, VR; Capriotti, JA; Capriotti, K; Goldfarb, S; Lacouture, ME; Lessin, S; Wu, S | 1 |
| Brower, V | 1 |
| Bampton, D; Block, MS; Chien, J; Dredge, K; Freyer, L; Giri, S; Hammond, E; Hoffmann, R; Millward, M; Mondal, S; Mullany, SA; Roy, D; Shridhar, V; Teoman, A; von Bismarck, A; Winterhoff, B | 1 |
| Gupta, R; Kim, YS; O'Neill, BE; Rapoport, N | 1 |
| Nguyen-Ngoc, T; Raymond, E | 1 |
| Kouchakzadeh, H; Safavi, MS; Shojaosadati, SA | 1 |
| Huo, M; Wang, L; Wu, Q; Yin, L; Yin, T; Zhou, J; Zhu, Q | 1 |
| Chen, AZ; Chen, WG; Kang, YQ; Liu, YG; Wang, SB; Wu, WG; Ye, SF; Zhang, R | 1 |
| Guo, P; Li, Z; Pan, W; Song, S; Tian, Y; Yang, X; Zheng, J | 1 |
| Agarwal, N; Bowles, DW; Diamond, JR; Friberg, G; Gamelin, E; Lam, ET; Rasmussen, E; Sharma, S; Soto, F; Sun, YN; Werner, TL; Wu, B | 1 |
| Cal, PM; Cordeiro, C; Frade, RF; Gois, PM | 1 |
| Moore, P; Viegas, J | 1 |
| Cai, K; Dai, L; Hou, Y; Hu, Y; Li, J; Liu, Y; Shen, X; Xu, G; Zhou, J | 1 |
| Dai, X; Jiang, Y; Tan, C | 1 |
| Ding, D; Niu, R; Tian, R; Wang, H | 1 |
| Medina, SH; Schneider, JP | 1 |
| Chen, S; Li, H; Liu, M; Ren, L; Ye, C; Zhang, Z; Zhou, X | 1 |
| Ghibradze, O; Kandelaki, M; Lesiovskaia, E; Samsonia, M | 1 |
| Amaral, L; Berger, W; Csábi, J; Dér, K; Hunyadi, A; Martins, A; Miklos, W; Molnár, J; Sipos, P; Szabó-Révész, P; Zalatnai, A | 1 |
| Guo, Z; He, T; Jiang, C; Li, E; Liu, F; Wang, Q; Xu, Z; Ying, L; Zhu, Z | 1 |
| An, L; Ding, Z; Du, W; Han, T; Liang, G; Wang, L; Yuan, Y; Zhang, H; Zhang, J | 1 |
| de Bruijn, P; de Graan, AJ; de Jonge, E; Mathijssen, RH; Sparreboom, A; van der Holt, B; van Schaik, RH; Verweij, J; Wiemer, EA | 1 |
| Logie, J; McLaughlin, CK; Shoichet, MS; Tam, RY | 1 |
| Atherton, PJ; Lafky, J; Loprinzi, CL; Pachman, DR; Ruddy, KJ; Seisler, D; Shinde, SS; Soori, G | 1 |
| Blanco, MD; Martínez, A; Olmo, R; Pérez, E; Teijón, C; Teijón, JM | 1 |
| Fallon, JK; Fu, Q; He, Z; Liu, D; Liu, F; Ma, Y; Wang, Y; Yang, X; Zhang, D | 1 |
| Bechi, B; Bennett, A; Cleveland, DW; Huels, D; Littler, S; Ly, P; Nelson, L; Procter, DJ; Ridgway, RA; Sansom, OJ; Schandl, C; Sloss, O; Sun, Y; Taylor, SS; Tighe, A; Topham, C | 1 |
| Cassata, G; Fiorica, C; Giammona, G; Loria, GR; Palumbo, FS; Pitarresi, G; Puleio, R | 1 |
| Chen, S; Li, X; Liu, M; Shi, Q; Xu, X; Zhang, J; Zhang, L; Zhang, X | 1 |
| Ang, JE; de Bono, J; Harris, D; Kristeleit, R; Kyle, F; Pelling, K; Pemberton, K; Rudman, S; Schnell, D; Solca, F; Spicer, J; Suder, A; Uttenreuther-Fischer, M | 1 |
| Aneja, R; Ogden, A; Xie, S; Zhou, J | 1 |
| Bida, O; Efroni, S; Gidoni, M; Ginsberg, D; Ideses, D | 1 |
| Cao, W; Gao, G; Gu, Y; Li, S; Liu, M; Shan, L; Wu, C; Xu, L; Zhao, L | 1 |
| Fang, JH; Hu, SH; Li, YT; Liao, CY; Lin, CT; Su, YL | 1 |
| Bekaii-Saab, T; Kleiber, B; Lustberg, MB; Mikhail, S; Monk, P; Mortazavi, A; Ruppert, AS; Villalona-Calero, M | 1 |
| Assanhou, AG; Kong, L; Li, W; Mo, R; Sun, H; Xue, L; Zhang, C; Zhang, L | 1 |
| Chang, JH; Kang, J; Kim, H; Kim, J; Lee, H; Moon, H; Sim, C | 1 |
| Abliz, Z; He, J; Jin, D; Liu, Y; Peng, J; Song, X; Xia, X; Xu, J; Zhang, X | 1 |
| Berndt, A; Cesca, M; D'Incalci, M; Davoli, E; Decio, A; Dirsch, O; Frapolli, R; Fuso Nerini, I; Giavazzi, R; Giordano, S; Micotti, E; Morosi, L; Richter, P; Zucchetti, M | 1 |
| Abasi, M; Abbasi, MM; Akbarzadeh, A; Jahanban-Esfahlan, R; Sani, HM | 1 |
| Bu, Z; Peng, L; Ye, X; Zhao, Q; Zhou, Y | 1 |
| Fu, L; Hu, J; Li, Q; To, KK; Wang, F; Wang, X; Xu, M; Yang, K; Zhang, X | 1 |
| Chen, G; Li, X; Mao, Y; Wang, S | 1 |
| Mo, R; Qu, D; Xu, X; Xue, L; Zhang, C; Zhang, N; Zhang, X | 1 |
| Abrieu, A; Castedo, M; Chibon, F; Jemaà, M; Kroemer, G; Lissa, D; Lledo, G; Manic, G; Morin, N; Reynes, C; Sistigu, A; Vitale, I | 1 |
| Lee, S; Lichtenthal, B; Ojima, I; Wang, C; Wang, X | 1 |
| Cabanillas, ME; Habra, MA | 1 |
| Hatem, E; He, T; Huang, ME; Lei, M; Vernis, L | 1 |
| Duan, Y; Gao, P; Huang, C; Shen, M; Sun, Y; Zhang, X | 1 |
| Cai, H; Cui, B; Huo, M; Liu, J; Wang, L; Yin, L; Yin, T; Zhou, J | 1 |
| Cho, H; Gao, J; Kwon, GS | 1 |
| Colby, AH; Colson, YL; Grinstaff, MW; Liu, R; Padera, RF; Schulz, MD | 1 |
| Abyzov, A; Banck, MS; Beutler, AS; Boora, GK; Kanwar, R; Kulkarni, AA; Loprinzi, CL; Ruddy, KJ; Sloan, J | 1 |
| Chen, W; Ji, X; Li, Z; Liu, J; Liu, Q; Luo, Y; Wang, J; Wang, W; Zhang, X | 1 |
| Cun, X; Gao, H; He, Q; Liu, Y; Lu, L; Shi, K; Yang, Y; Zhang, L; Zhang, Q | 1 |
| Gupta, P; Manna, SK; Mokhamatam, RB; Raviprakash, N; Zaidi, AH | 1 |
| Wen, L; Xing, D; Yang, S; Zhong, J | 1 |
| Li, J; Sun, D; Wang, F; Wang, R | 1 |
| Cao, Z; Hu, Y; Jiang, T; Jiang, X; Ling, L; Pang, Z; She, X; Shen, S; Tuo, Y; Zhang, B; Zhao, J | 1 |
| Chen, XX; Gao, F; Qu, XX; Tian, XC; Wang, D; Wen, G; Zhou, XL | 1 |
| Luo, YL; Xu, F; Xu, JW | 1 |
| Cárpen, O; Chen, P; Davidson, B; Elgaaen, BV; Hautaniemi, S; Huhtinen, K; Kallio, MJ; Lønning, PE; Mäki-Jouppila, J; Pruikkonen, S; Straume, AH; Tambe, M | 1 |
| Eggers, PK; Lim, LY; Mo, J; Raston, CL; Yuan, ZX | 1 |
| Chandrasekar, V; Goldman, A; Khater, Y; Korimerla, N; Kulkarni, A; Mashelkar, RA; Natarajan, S; Rao, P; Sabbisetti, VS; Sengupta, S | 1 |
| Feng, SL; Liu, L; Liu, ZQ; Ma, WZ; Xie, Y; Yao, XJ; Yuan, ZW | 1 |
| Alzghari, SK; Chee, W; La-Beck, NM; Petersen, GH; Sankari, SS | 1 |
| Chen, L; Jing, X; Li, Z; Xie, Z; Zheng, X | 1 |
| Deng, J; Hu, Y; Jiang, T; Jiang, X; Mei, H; Pang, Z; She, X; Shen, S; Shi, W; Wang, S; Zhang, B | 1 |
| Fu, Q; Hargrove, D; Lu, X | 1 |
| Bouvet, M; Fujiwara, T; Han, Q; Hoffman, RM; Li, S; Takehara, K; Tan, Y; Yano, S; Zhao, M | 1 |
| Discher, DE; Karthick, SA; Lavasanifar, A; Nair, PR; Spinler, KR; Vakili, MR | 1 |
| Sharma, A; Srivastava, G; Tripathi, S | 1 |
| Ding, Y; Gu, X; Hua, P; Shen, L; Wang, R; Yin, L; Zhou, J | 1 |
| Egashira, N; Kaname, T; Kawashiri, T; Shiraishi, H; Tsutsumi, K | 1 |
| Deming, TJ; Negri, GE | 1 |
| Byrne, KT; Vonderheide, RH | 1 |
| Duan, XC; Guo, Y; Huang, D; Ren, W; Song, P; Yao, X; Yin, YF; Zhang, S; Zhang, SS; Zhang, X; Zhong, T | 1 |
| Chaudhary, A; Chow, LQ; Denlinger, CS; Gao, L; Lin, Y; Shepard, DR; Smith, DC; Tan, AR; Wang, D | 1 |
| Bernabeu, E; Chiappetta, DA; Gonzalez, L; Legaspi, MJ; Moretton, MA | 1 |
| Li, X; Liang, DS; Qi, XR; Su, HT | 1 |
| Chen, Y; Gao, W; Li, T; Park, K; Thompson, DH | 1 |
| Chekerov, R; Darvin, ME; Eucker, J; Fuss, H; Jung, S; Kühnhardt, D; Lademann, J; Lee, BN; Patzelt, A; Sehouli, J; Yu, RX | 1 |
| Bousbaa, H; Brandão, P; Cidade, H; Fonseca, J; Marques, S; Pinto, MM; Silva, PM | 1 |
| Campagnol, D; Dreussi, E; Giodini, L; Marangon, E; Posocco, B; Re, FL; Toffoli, G | 1 |
| Hood, AP; Merl, MY; Nguyen, LH; Yenilmez, A | 1 |
| De Coen, R; De Geest, BG; Karalic, I; Louage, B; Nuhn, L; Risseeuw, MD; Van Calenbergh, S; Vanparijs, N | 1 |
| Rhee, I | 1 |
| Fujiwara, Y; Horiike, A; Inatani, M; Iwasa, S; Kitazono, S; Kondo, S; Nishio, M; Tamura, K; Tanabe, Y; Tanaka, J; Yamamoto, N; Yanagitani, N | 1 |
| Li, Z; Liow, SS; Loh, XJ; Qiu, YK; Wang, H; Wu, YL | 1 |
| Chen, Y; Gong, D; He, G; He, L; Jin, Q; Li, S; Song, X; Tan, X; Wu, J; Xu, B; Yang, L; Yu, T; Zeng, J | 1 |
| Afzal, M; Alamgir, K; Bano, S; Nazir, S; Waraich, MM | 1 |
| Lin, W; Sun, T; Xie, Z; Zhang, W | 1 |
| Brito, AM; Cavaco, MC; Gouveia, LF; Kreutzer, B; Pereira, C; Silva-Lima, B; Videira, M | 1 |
| Chang, CS; Chen, CY; Huang, CF; Hung, CC; Lee, CY; Lin, CM; Lin, HC; Si Tou, TC | 1 |
| Chen, X; Loh, XJ; Owh, C; Qiu, YK; Wu, YL | 1 |
| Chen, J; Chen, Q; Dong, Z; Feng, L; Liang, C; Liu, Z; Song, G; Song, X | 1 |
| Cappelletti, G; D'Incalci, M; Davoli, E; Falciola, L; Frapolli, R; Giordano, S; Licandro, SA; Morosi, L; Pifferi, V; Veglianese, P; Visentin, S; Zucchetti, M | 1 |
| Baptista, PV; Carvalheiro, MC; Corvo, ML; Costa, PM; Fernandes, AR; Figueiredo, S; Jesus, J; Martins, LM; Martins, P; Rosa, D | 1 |
| Ang, JE; de Bono, J; Enting, D; Irshad, S; Kristeleit, R; Pelling, K; Pemberton, K; Schnell, D; Spicer, J; Uttenreuther-Fischer, M | 1 |
| Liu, Y; Mu, S; Olerile, LD; Selotlegeng, L; Wang, T; Zhang, B; Zhang, J; Zhang, N | 1 |
| Chen, FC; Li, LJ; Wang, LH; Zhang, J; Zhang, XM; Zheng, XY | 1 |
| Chen, J; Han, X; Jiang, M; Lin, G; Liu, D; Luo, C; Ma, Y; Na, K; Sun, M; Wang, Y; Zhang, N; Zhang, R | 1 |
| Garcia, J; Green, L; Morrow, PK | 1 |
| Amini, A; Azadeh, P; Dashti-Khavidaki, S; Farasatinasab, M; Jafari, A; Joybari, AY; Sarbaz, S; Yaseri, M | 1 |
| Cesca, M; Davoli, E; Decio, A; Ferrari, M; Frapolli, R; Fuso Nerini, I; Giavazzi, R; Giordano, S; Licandro, SA; Maiezza, M; Maurizio, D; Morosi, L; Zucchetti, M | 1 |
| Park, J; Sun, B; Yeo, Y | 1 |
| Aldonza, MB; Hong, JY; Lee, SK | 1 |
| Manna, SK; Verma, N | 1 |
| Nandagopal, K; Routh, S | 1 |
| Bomba, HN; Gu, Z; Hu, Q; Qian, C; Sun, W; Xin, H | 1 |
| Darko, KO; He, C; Huang, Y; Liu, Z; Peng, M; Su, Q; Tao, T; Yang, X; Yin, T | 1 |
| Alqahtani, S; Ambudkar, SV; Anreddy, N; Chen, ZS; Kaddoumi, A; Patel, BA; Shukla, S; Singh, S; Talele, TT; Wang, YJ; Zhang, GN; Zhang, YK | 1 |
| Dieras, V; Evans, TJ; Giordano, H; Goble, S; Jaw-Tsai, S; Middleton, MR; Molife, LR; Plummer, R; Roxburgh, P; Spicer, J; Wilson, RH | 1 |
| Danyuo, Y; Dozie-Nwachukwu, S; E Oberaifo, O; J Ani, C; Malatesta, K; Obayemi, JD; Odusanya, OS; Soboyejo, WO; Zebaze Kana, MG | 1 |
| Cheng, H; Gao, H; Liu, M; Loh, XJ; Wu, YL; Yang, DP; Zheng, C | 1 |
| Cohen, L; Driver, L; Eng, C; Lopez, G; Lyle, R; McQuade, J; Novy, D; Prinsloo, S; Ramondetta, L | 1 |
| Allen, C; Dunne, M; Sofias, AM; Storm, G | 1 |
| Ambudkar, SV; Chen, ZS; Fu, LW; Huang, LH; Kathawala, RJ; Patel, A; Patel, BA; Qiu, LH; Shukla, S; Wang, YJ; Yang, DH; Zhang, H; Zhang, YK | 1 |
| Castell, C; Jiang, J; Lager, J; Liu, L; Mutch, D; Traynor, AM; Wheler, J | 1 |
| Abida, W; Bialer, P; Drilon, A; Erinjeri, JP; Fury, MG; Gerecitano, JF; Gounder, M; Harding, JJ; Ho, AL; Hyman, DM; Iasonos, A; Iyer, G; Jhaveri, K; Katabi, N; Lacouture, ME; Li, BT; Makker, V; Monson, KR; Razavi, P; Smyth, LM; Teitcher, JB; Voss, MH | 1 |
| Dall'Angelo, S; De Cesare, M; Folini, M; Frigerio, M; Lazzari, P; Manca, I; Sani, M; Spiga, M; Testa, A; Usai, I; Zaffaroni, N; Zanda, M; Zuco, V | 1 |
| An, R; Matei, D; Merrill, D; Nolte, DD; Sun, H; Turek, J | 1 |
| Chen, JS; Chen, PM; Chu, Z; Figg, WD; Gardner, ER; Liau, CT; Lin, YC; Sparreboom, A; Wang, HM; Yang, MH | 1 |
| Green, H | 1 |
| Balcerzak, SP; Bekaii-Saab, TS; Chan, KK; Grever, MR; Ivy, PS; Kraut, EH; Liu, J | 1 |
| Belani, CP; Chatta, GS; Egorin, MJ; Friedland, DM; Ivy, SP; Lagattuta, TF; Potter, DM; Ramalingam, SS; Ramanathan, RK; Remick, SC; Sikorski, RP; Stoller, RG | 1 |
| Choi, KH; Jang, SM; Jeong, MH; Kang, KH; Kim, JW; Kim, WH; Park, SI; Song, KH; Song, PI | 1 |
| Haapa-aho, V; Järvinen, K; Korhonen, H; Pikkarainen, J; Pulkkinen, M; Seppälä, J; Tarvainen, T; Wirth, T | 1 |
| Ber, E; Chandna, P; Garbuzenko, OB; Khandare, JJ; Minko, T; Pozharov, VP; Saad, M | 1 |
| Choi, M; Gadgeel, SM; Heilbrun, LK; Jiang, PQ; Smith, DW | 1 |
| Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
| Adamo, L; Conticello, C; De Maria, R; Giannone, I; Gulisano, M; Musumeci, T; Pignatello, R; Puglisi, G; Vicari, L | 1 |
| Giannakakou, P; Hamel, E; Liotta, D; Malik, S; Snyder, JP; Thomas, SL; Zhong, D; Zhou, W | 1 |
| Allievi, C; Daud, A; Eisenfeld, A; Kudelka, AP; Oldham, FB; Rabinowitz, I; Singer, JW; Skubitz, K; Verschraegen, CF | 1 |
| Akase, T; Doi, M; Harada, T; Yamada, Y | 1 |
| Franke, RM; Sparreboom, A | 1 |
| Kwok, TT; Tsang, WP | 1 |
| Biganzoli, L; Di Leo, A; Licitra, S; Moretti, E; Pestrin, M; Zafarana, E | 1 |
| Gokmen-Polar, Y; Miller, KD | 1 |
| Benezra, R; Bertolini, F; Colleoni, M; Daenen, LG; Emmenegger, U; Henke, E; Kerbel, RS; Langenberg, MH; Man, S; Mancuso, P; Roodhart, JM; Shaked, Y; Strieter, RM; Tang, T; Voest, EE; Witte, L; Xu, P; Zhu, Z | 1 |
| Arnold, RD; Awada, A; Bulitta, JB; Daifuku, R; Gelderblom, H; Hanauske, AR; Jusko, WJ; Kessler, DR; Luciano, G; Pratt, J; Zhao, P | 2 |
| Damjanov, N; Dul, JL; Fetterly, GJ; Fiedler-Kelly, J; Fishman, M; Grahn, A; Grasela, TH; Kane, MP; Lecomte, D; Rubin, EH; Sherman, JW; Tan, AR | 1 |
| Hanson, DC; Krieg, AM; Luu, R; Makinen, SR; Patel, S; Vicari, AP; Weeratna, RD; Zhang, N | 1 |
| Ambudkar, SV; Ashby, CR; Chen, LM; Chen, ZS; Dai, CL; Fu, LW; Huang, Y; Liang, YJ; Liu, DG; Robey, RW; Shi, CJ; Su, XD; Tiwari, AK; Wang, SR; Wu, CP | 1 |
| Danhier, F; Feron, O; Jérôme, C; Lecouturier, N; Marchand-Brynaert, J; Préat, V; Vroman, B | 1 |
| Awada, A; Dumez, H; Gil, T; Graefe, T; Hanauske, AR; Musib, L; Piccart, M; Simms, L; Yilmaz, E | 1 |
| Ghaidi, F; Joshi, B; Kojic, LD; Nabi, IR; Nedev, H; Saragovi, HU; Wiseman, SM | 1 |
| Bernstein, M; Blaney, SM; Geller, JI; Perentesis, J; Wall, D | 1 |
| Fujimitsu, Y; Kojima, H; Kojima, T; Kure, N; Matsui, T; Mochizuki, Y; Uemura, T | 1 |
| Gao, LL; Huang, XE; Zhang, Q | 1 |
| Allievi, C; Angiuli, P; Eisenfeld, A; Mita, A; Mita, M; Romero, O; Rowinsky, EK; Sarantopoulos, J; Takimoto, CH; Verschraegen, CF | 1 |
| Altschuler, SJ; Martinez, ED; Slack, MD; Wu, LF | 1 |
| Barnett, J; Cuthbertson, A; Morrison, MS; Ricketts, SA; Tessier, J; Wedge, SR | 1 |
| Berton Rigaud, D; Bootle, D; Bourbouloux, E; Calvo, F; Campone, M; Dutreix, C; Levy, V; Raymond, E; Shand, N; Zoellner, U | 1 |
| Georgoulias, V; Kotsakis, A; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Saridaki, Z; Souglakos, J; Vardakis, N | 1 |
| Elstad, NL; Fowers, KD | 1 |
| Angove, H; Curry, J; Fazal, L; Lyons, J; Reule, M; Thompson, N; Wallis, N | 1 |
| Davey, R; Stordal, B | 1 |
| Auer, G; Brenton, JD; Chen, JG; Downward, J; East, P; Eklund, AC; Endesfelder, D; Habermann, JK; Hardcastle, T; Howell, M; Kim, SN; Kschischo, M; Lee, A; Li, Q; Ng, C; Nicke, B; Ried, T; Roy, R; Schuett, M; Swanton, C; Szallasi, Z; Wylie, P | 1 |
| Kennedy, AM; Nam, KH; Rapoport, NY; Scaife, CL; Shea, JE | 1 |
| Fu, Q; He, Z; Sui, X; Sun, J; Yan, Z; Zhang, W | 1 |
| Goshima, F; Ino, K; Ishida, D; Iwaki, M; Kajiyama, H; Kikkawa, F; Luo, CH; Nawa, A; Nishiyama, Y; Shibata, K; Tanino, T; Tsurumi, T; Yamamoto, E | 1 |
| Ang, PCS; Chowbay, B; Hee, SW; Leong, SS; Lim, WT; Tan, EH; Toh, CK; Wong, NS | 1 |
| Camidge, DR; Chow, LQ; Cohen, RB; Diab, S; Eckhardt, SG; Fox, NL; Gore, L; Gustafson, DL; Hariharan, S; Langer, CJ; Leong, S; Miceli, R; O'Bryant, C; Padavic, K; Smith, M; von Mehren, M | 1 |
| Bartollino, S; Bertucci, C; Campiani, G; Cicchillitti, L; Cimitan, S; Fattorusso, C; Ferlini, C; Gallo, D; Mozzetti, S; Persico, M; Raspaglio, G; Scambia, G | 1 |
| Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE | 1 |
| Chen, LM; Chien, AJ; Dubey, S; Fong, L; Huang, Y; Hylton, NM; Illi, JA; Jahan, TM; Kashani-Sabet, M; Ko, AH; Koch, KM; Korn, WM; Moasser, MM; Rosenberg, JE; Ryan, CJ; Small, EJ; Yeh, BM | 1 |
| Fridley, BL; Jenkins, GD; Kalari, KR; Li, L; Lingle, W; Lou, Z; Pei, H; Petersen, G; Wang, L | 1 |
| Azad, N; Figg, WD; Gardner, E; Graves, C; Imamura, CK; Kohn, EC; Kotz, H; Minasian, L; Perroy, A; Raggio, M; Sarosy, GA | 1 |
| Alamara, C; Chatzidarellis, E; Georgiadis, E; Giza, L; Makrilia, N; Syrigos, KN | 1 |
| Bekaii-Saab, T; Byrd, JC; Culler, K; Grever, MR; Lesinski, GB; Lucas, DM; Ramaswamy, B; Ruppert, AS; Schaaf, LJ; Shapiro, CL; Wilkins, D; Wright, JJ; Young, DC | 1 |
| Huang, HC; Mitchison, TJ; Orth, JD; Shi, J | 1 |
| Carpenter, AE; Kim, S; Mitchison, TJ; Orth, JD; Rudnicki, S; Shamu, CE; Tsui, M; Xie, T | 1 |
| Ashby, CR; Chen, A; Chen, X; Chen, ZS; Hopper-Borge, E; Kuang, YH; Lei, Y; Ouyang, J; Shen, T; Tiwari, AK; Zhou, Y | 1 |
| Bekaii-Saab, TS; Carson, WE; Ferketich, AK; Grever, MR; Guenterberg, KD; Lamb, TA; Ramaswamy, B; Roda, JM; Shapiro, CL; Young, DC | 1 |
| Albanell, J; Angst, R; Berk, L; Coceani, N; Cresta, S; Gianni, L; Haluska, F; Hess, D; Locatelli, A; Maur, M; Rivera, VM; Rojo, F; Sessa, C; Tosi, D; Viganò, L | 1 |
| Chen, T; Sun, Q; Wang, X; Wei, X | 1 |
| Chakravarty, G; Honer Zu Bentrup, K; Mondal, D; Roy, U | 1 |
| Chen, J; Chen, S; Duan, L; Kong, L; Luo, J; Qiu, X; Wang, R | 1 |
| Dash, AK; Singh, S | 1 |
| Bao, C; Cui, D; He, R; Ji, J; Li, N; Ruan, J; Song, H; Wang, K | 1 |
| Irimia, D; Toner, M | 1 |
| De Larco, JE; Dronava, H; Furcht, LT; Park, CA | 1 |
| Chen, HZ; Fang, C; Lu, Q; Xie, J; Yu, DH | 1 |
| Lay, CL; Liu, HQ; Liu, Y; Tan, HR | 1 |
| Chiorean, EG; Hall, SD; Jones, DR; Malireddy, S; Schneider, B; Sloop, MI; Sweeney, CJ; Waddell, MJ; Younger, AE; Yu, M | 1 |
| Hansen, JK; Hassan, R; Ho, M; Kawa, S; Onda, M; Pastan, I; Xiang, L; Zhang, Y | 1 |
| He, Q; Huang, Y; Sheikh, MS; Shi, J | 1 |
| Minami, H; Mukohara, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N | 1 |
| Chatterjee, SK; Chung, I; Mu, CJ; Olsen, RR; Patel, N; Vrbanac, V; Waghorne, C; Zetter, BR | 1 |
| Kavallaris, M | 1 |
| Cascón, A; García-Donas, J; Hernando, S; Hurtado, A; Jara, C; Landa, I; Leandro-García, LJ; Leskelä, S; López-Jiménez, E; Martínez, A; Milne, RL; Montero-Conde, C; Robledo, M; Rodríguez-Antona, C; Vicario, JC | 1 |
| Chandna, P; Khandare, JJ; Minko, T; Patil, ML; Saad, M; Taratula, O; Zhang, M | 1 |
| Gaitanis, A; Staal, S | 1 |
| Armstrong, TD; Emens, LA; Jaffee, EM; Lam, SS; Pfannenstiel, LW | 1 |
| Batrakova, EV; Bronich, TK; Jordan, R; Kabanov, AV; Li, S; Luxenhofer, R; Roques, C; Schulz, A | 1 |
| Jiang, BH; Liu, LZ; Liu, N; Meng, Q; You, YP; Zhao, P | 1 |
| Chang, MC; Chen, CA; Chen, YL; Cheng, WF; Chiang, YC; Ho, CM; Hsieh, CY; Sun, WZ; Syu, MH | 1 |
| Agemy, L; Greenwald, DR; Karmali, PP; Kotamraju, VR; Ruoslahti, E; Sugahara, KN; Teesalu, T | 1 |
| Charron, D; Gelin, C; Marin-Esteban, V; Mooney, N | 1 |
| Balkissoon, J; Boxall, J; Chaplin, DJ; Ganesan, TS; Gaya, A; Nathan, PD; Poupard, L; Rustin, GJ; Shreeves, G; Stratford, MR; Wang, D; Zweifel, M | 1 |
| Twelves, C; Woodward, EJ | 1 |
| Alfaro, V; Chu, Q; Forouzesh, B; Lebedinsky, C; Mita, A; Nieto, A; Rowinsky, EK; Schwartz, G; Soto-Matos, A; Tolcher, AW | 1 |
| Rodríguez-Antona, C | 1 |
| Cheng, FY; Su, CH; Wu, PC; Yeh, CS | 1 |
| Altschuler, SJ; Ku, CJ; Singh, DK; Steininger, RJ; Wichaidit, C; Wu, LF | 1 |
| Pineda de la Losa, F; Prieto García, A | 1 |
| Chang, DC; Feng, C; Le, XF; Luo, HW; Luo, KQ; Tian, HL; Xu, NN; Yu, T; Zhou, LY | 1 |
| Bhar, P; Biakhov, MY; Desai, N; Iglesias, J; Kononova, GV; Loibl, S; Schmid, AN | 1 |
| Bathula, SR; Conwell, C; Huang, L; Liu, F; Liu, Y; Park, JY; Zhang, Y | 1 |
| Buhl-Jensen, P; Crowley, E; de Bono, JS; Engelholm, SA; Knoblauch, P; Lassen, U; Molife, LR; Penson, RT; Sinha, R; Sorensen, M; Tjornelund, J; Vidal, L | 1 |
| Jin, P; Li, K; Li, Q; Su, B; Wang, L; Zeng, L; Zhang, Y | 1 |
| Ahmad, A; Azmi, AS; Banerjee, S; Kong, D; Li, Y; Sarkar, FH; Wang, Z | 1 |
| Dobrowolski, JC; Rode, JE; Sadlej, J | 1 |
| Kiesewetter, DO; Kurdziel, KA | 1 |
| Hashimoto, Y; Henmi, N; Hirata, R; Kamada, F; Katsuragawa, M; Kobayashi, R; Matsunami, J; Sato, Y; Shibanami, A; Tada, T; Taniguchi, R; Tsumaki, R | 1 |
| Briasoulis, E; Fountzilas, G; Golfinopoulos, V; Karina, M; Papakostas, P; Pavlidis, N | 1 |
| Stathopoulos, GP | 1 |
| Bergmeier, S; Cao, Y; Chen, X; Liu, Y; Zhang, W | 1 |
| Beck, JF; Palani, CD; Sonnemann, J | 1 |
| Abbasi, M; Berthiaume, LG; Lavasanifar, A; Uludağ, H; Weinfeld, M | 1 |
| Bondarenko, IN; Jagiello-Gruszfeld, A; Kellum, A; Messam, C; Mostafa Kamel, Y; Patwardhan, R | 1 |
| Huang, B; Kirn, DH; Sikorski, R; Thorne, SH | 1 |
| Cho, SH; Jeon, H; Kim, K; Kim, SY; Kwon, IC; Lee, BS; Oh, KS; Song, JY; Yuk, SH | 1 |
| Farrell, D; Grodzinski, P; Panaro, NJ; Ptak, K | 1 |
| Figg, WD; Gardner, ER; Kelly, M; Lee, KJ; Li, H; Moore, W; Springman, E | 1 |
| Hosoda, M; Takahashi, H; Takahashi, M; Todo, S | 1 |
| Bone, EA; de Jonge, M; Desar, I; Eskens, FA; Hooftman, L; Timmer-Bonte, JN; van Herpen, CM; Verweij, J | 1 |
| Bak, A; Bush, TL; Cee, VJ; Chung, G; Deak, HL; Dussault, I; Eden, P; Geuns-Meyer, S; Hodous, BL; Kendall, RL; McElroy, P; Nguyen, HN; Olivieri, PR; Patel, VF; Payton, M; Radinsky, R; Romero, K; Ross, S; Schenkel, LB; Stanton, M; Ziegler, B | 1 |
| Abdullah, SM; Ahmad, M; Aman, A; Halimi, SM; Iqbal, Z; Kaleem, WA; Khan, I; Nisar, M; Qayum, M; Saeed, M; Shah, H | 1 |
| Caruso, F; Heath, JK; Nice, EC; Ochs, CJ; Such, GK; Yan, Y | 1 |
| Chang, HL; Donahoe, PK; Li, X; MacLaughlin, DT; Nicolaou, F; Pieretti-Vanmarcke, R; Wei, X | 1 |
| Fadlalla, K; Samuel, T; Turner, T; Yehualaeshet, TE | 1 |
| Fu, Y; Jiang, S; Wang, Z; Zhang, Y; Zu, Y | 1 |
| Gajbhiye, V; Jain, K; Jain, NK; Kesharwani, P; Tekade, RK | 1 |
| Bersani, S; Caliceti, P; Pirazzini, M; Salmaso, S | 1 |
| Chu, Y; Liu, N; Xiong, S; Zheng, Y; Zhu, Y | 1 |
| Chang, JY; Chang, WT; Huang, WL; Lai, WW; Lin, CC; Su, WC; Yeh, HH | 1 |
| Azrak, RG; Rempinski, DR; Rustum, YM; Saifo, MS | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Blumenschein, GR; Chao, RC; Cohen, RB; Heath, EI; Kim, ST; Loconte, NK; Lorusso, PM; Ruiz-Garcia, A; Wilding, G | 1 |
| Arumugham, T; Burris, HA; Dar, MM; Dowlati, A; Fang, L; Gainer, SD; Hodge, JP; Infante, JR; Jones, SF; Lager, JJ; Nishioka, J; Suttle, AB; Tan, AR | 1 |
| Lemasters, JJ; Maldonado, EN; Mullins, MR; Patnaik, J | 1 |
| Nagykálnai, T | 1 |
| Han, JW; Kim, H; Kim, NH; Kim, SN; Kim, YK; Lee, HY; Park, YS | 1 |
| Dou, S; Du, JZ; Huang, SY; Leong, KW; Mao, CQ; Song, EW; Sun, TM; Wang, J; Yao, YD; Zhang, PZ | 1 |
| Anisimov, AP; Cragg, MS; Erenpreisa, J; Huna, A; Ianzini, F; Kosmacek, EA; Salmina, K | 1 |
| Gardner, NM; Guzmán, E; Naylor, GJ; Paterson, I; Wright, AE | 1 |
| Gao, Z; Gupta, R; Jeong, EK; Kennedy, AM; Kim, T; Liu, X; Mohan, P; Nam, KH; Parker, DL; Payne, A; Rapoport, N; Scaife, C; Shea, J; Todd, N | 1 |
| Dou, G; Qiu, R; Sun, M; Tang, L; Xu, B; Zhang, P | 1 |
| Eng, L; Ibrahim-zada, I; Jarjanazi, H; Meschian, M; Ozcelik, H; Pritchard, KI; Savas, S | 1 |
| Beck, SL; Cohen, JA; Lavoie Smith, EM; Pett, MA | 1 |
| Eldar-Boock, A; Lupu, R; Miller, K; Sanchis, J; Satchi-Fainaro, R; Vicent, MJ | 1 |
| Kip, K; Overcash, J; Tofthagen, C | 1 |
| Hirsch, HA; Iliopoulos, D; Struhl, K | 1 |
| Au, JL; Lu, Z; Shen, Z; Wientjes, MG; Wong, HL | 1 |
| Chi, K; Doyle, A; Eisenhauer, EA; Elit, L; Hirte, H; Kollmannsberger, C; Mazurka, J; Oza, AM; Sederias, J; Siu, LL; Walsh, W | 1 |
| Ishii, T; Kawashima, T; Kouyama, Y; Masaka, T; Matsuzawa, Y; Muto, S; Okuno, H; Shirai, K; Yokoyama, Y | 1 |
| Ahmed, S; Kaur, K; Lavasanifar, A; Shahin, M | 1 |
| Frey, K; Neri, D; Pasche, N; Villa, A; Woytschak, J; Wulhfard, S | 1 |
| Ran, S; Ray, MA; Toth, LA; Trammell, RA; Verhulst, S | 1 |
| Dash, AK; Jain, N; Joshi, SS; Munt, DJ; Trickler, WJ | 1 |
| Carvalheira, JB; Dias, MM; Osório-Costa, F; Rocha, GZ; Ropelle, ER; Rossato, FA; Saad, MJ; Vercesi, AE | 1 |
| Li, G; Liu, J; Mao, L; Pang, Y; Sun, J; Wang, R; Yan, D; Zhu, X | 1 |
| Ducros, C; Montana, M; Rathelot, P; Terme, T; Vanelle, P; Verhaeghe, P | 1 |
| Adams, S; Alagkiozidis, I; Benencia, F; Carpenito, C; Coukos, G; Facciabene, A; Jonak, Z; June, CH; Powell, DJ; Tsiatas, M | 1 |
| Marsh, RE; Sawyer, M; Tuszyński, JA; Vos, KJ | 1 |
| Fukushima-Uesaka, H; Katori, N; Kawanishi, T; Kunitoh, H; Kurose, K; Matsumura, Y; Naito, M; Nishimaki-Mogami, T; Nokihara, H; Ohe, Y; Okuda, H; Sai, K; Saijo, N; Saito, Y; Sawada, J; Sekine, I; Tamura, T; Yamamoto, N; Yomota, C; Yoshida, T | 1 |
| Bast, RC; Le, XF | 1 |
| Hu, X; Li, X; Liu, S; Liu, T; Qian, Y; You, Y; Zhang, G | 1 |
| Gounder, M; Kane, M; Karantza, V; Levinson, K; Lin, H; Lin, Y; Mehnert, JM; Moss, R; Poplin, E; Rubin, EH; Shih, WJ; Sovak, M; Stein, MN; Tan, AR; White, E | 1 |
| Printz, C | 1 |
| Cui, Z; He, B; Qu, W; Wang, JC; Wang, YB; Zhang, H; Zhang, JY; Zhang, Q | 1 |
| Bodnar, L; Duchnowska, R; Grala, B; Smoter, M; Stec, R; Szczylik, C | 1 |
| Liu, R; Liu, W; Song, N; Tu, Q; Wang, J; Zhang, Y | 1 |
| Chen, ZG; Giannakakou, P; Gjyrezi, A; Koenig, L; Li, J; Nie, S; Shin, DM; Shin, EH; Tighiouart, M; Wang, X; Wang, Y | 1 |
| Liu, Z; Pan, L; Ren, Y; Xu, HM | 1 |
| Ahmed, AA; Bartholomeusz, G; Bast, RC; Broom, B; Goldsmith, J; Grandjean, G; Le, XF; Lu, Z; Wang, X | 1 |
| Hao, Y; Visser-Grieve, S; Yang, X | 1 |
| Fang, W; Liu, S; Nie, Y | 1 |
| Chester, J; Coffey, M; Diaz, R; Harrington, K; Ilett, E; Kottke, T; Melcher, A; Mukhopadhyay, D; Nuovo, G; Pandha, H; Pulido, J; Selby, P; Thompson, J; Vile, R | 1 |
| Doris, E; Ducongé, F; Dupont, DM; Garofalakis, A; Gombert, K; Gravel, E; John, J; Mackiewicz, N; Ogier, J; Tavitian, B | 1 |
| Liu, Y; Yan, B; Zhang, B | 1 |
| Honda, K; Imaishi, H; Kamura, T; Takemoto, S; Terada, A; Ushijima, K; Wada, H | 1 |
| Ando, M; Fujiwara, Y; Hashimoto, K; Hirata, T; Katsumata, N; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K; Yunokawa, M | 1 |
| Campos-Arroyo, D; Martínez-Lazcano, JC; Melendez-Zajgla, J | 1 |
| Kim, YC; Ko, H; Yoon, HE; Yoon, JH; You, H | 1 |
| Chen, L; Chen, Y; Fang, X; Gao, X; Gu, J; Jiang, X; Jiang, Y; Law, K; Ren, Q; Ren, X; Sha, X; Wang, X; Xin, H | 1 |
| Krishnan, J; Li, C; Stebbing, J; Xu, XY | 1 |
| Beijnen, JH; Hendrikx, JJ; Hillebrand, MJ; Rosing, H; Schellens, JH; Schinkel, AH; Thijssen, B | 1 |
| Amiji, M; Duan, Z; Milane, L | 1 |
| Bae, SM; Choi, KY; Hoffman, AS; Kim, IS; Kim, JH; Kim, K; Kwon, IC; Lee, BH; Min, KH; Na, MH; Park, RW; Shin, H; Yang, YJ | 1 |
| Achilefu, S; Cui, S; Du, C; Gu, Y; Qian, Z; Shan, L; Wan, S | 1 |
| Perez, JM; Santra, S | 1 |
| Agadjanian, H; Chu, D; Farkas, DL; Gray, HB; Gross, Z; Hwang, JY; Lubow, J; Ma, J; Medina-Kauwe, LK; Sims, J | 1 |
| Aljančić, IS; Banković, J; Jadranin, M; Marković, ID; Momčilović, M; Pešić, M; Ruždijić, S; Tanić, N; Tešević, VV; Todorović, NM; Vajs, VE; Vučković, I | 1 |
| Fukushima, H; Gao, D; Inuzuka, H; Lau, AW; Liu, P; Wan, L; Wang, Z; Wei, W | 1 |
| Fleming, MQ; Jia, F; Mallapragada, SK; Zhang, B | 1 |
| Axiak, SM; Bilof, KJ; Decedue, CJ; Henry, CJ; Howell, J; Kim, DY; Selting, KA; Tate, D | 1 |
| Au, JL; Gao, Y; Lu, Z; Wang, J; Wientjes, MG | 1 |
| Chen, C; Li, W; Liu, Y; Su, S; Wu, Y; Xu, Q | 1 |
| Cheng, D; Gong, F; Miao, X; Shuai, X; Wang, W | 1 |
| Cho, SH; Kim, K; Kim, SY; Kwon, IC; Lee, JH; Oh, KS; Oh, S; Yuk, SH | 1 |
| Colson, YL; Grinstaff, MW; Wolinsky, JB | 1 |
| Campbell, TC; Huang, TC | 1 |
| Bushman, J; Garbuzenko, OB; Gounder, MK; Kohn, J; Minko, T; Sheihet, L | 1 |
| Heuer, V; Kummer, G; Neumann, H; Roy, R; Schultheis, B; Strumberg, D | 1 |
| Chen, S; Huang, Y; Luo, LM; Song, P; Wang, X; Yu, KF; Zhang, Q; Zhang, X; Zhao, BX; Zhao, Y | 1 |
| Bouchard, D; Brenner, A; Chandhasin, C; Elian, K; Gabrail, N; Kurzrock, R; Mita, A; Moulder, S; Sankhala, K; Sarantopoulos, J; Smith, C | 1 |
| Alessandri, G; Arnaldo, C; Bonomi, A; Cappelletti, G; Cartelli, D; Cavicchini, L; Ciusani, E; Coccè, V; Falchetti, ML; Ferrari, M; Invernici, G; Locatelli, A; Marfia, G; Navone, S; Pallini, R; Parati, E; Pessina, A; Sisto, F; Viganò, L | 1 |
| Diao, Y; Fu, J; Lu, C; Luo, L; Xin, Y; Xu, Y; Yin, Z | 1 |
| Byun, Y; Chung, SW; Kim, D; Seo, K | 1 |
| Cheng, C; Fu, LW; Huang, HB; Liang, YJ; To, KK; Wang, F; Wang, XK; Zhang, X; Zhou, W; Zhou, WJ | 1 |
| Bessonov, AA; Dashian, GA; Kolar'kova, VV; Paltuev, RM; Pen'kov, KD; Remizov, AS; Semiglazov, VF; Semiglazov, VV; Semiglazova, TIu; Vasil'ev, AG | 1 |
| Akino, T; Akiyama, K; Hida, K; Hida, Y; Inoue, N; Ishikawa, S; Kawamoto, T; Kondoh, M; Maishi, N; Matsuda, A; Ohga, N; Sadamoto, Y; Shindoh, M | 1 |
| Berti, L; Fung, G; Lam, KS; Li, Y; Luo, J; Tseng, HP; Xiao, K; Xiao, W | 1 |
| Ball, M; Chester, J; Coffey, M; Gore, ME; Hall, GD; Harrington, KJ; Karapanagiotou, EM; Larkin, J; Melcher, AA; Mettinger, K; Newbold, K; Nutting, C; Pandha, HS; Roulstone, V; Syrigos, KN; Tanay, M; Thompson, B; Twigger, K; Vile, RG | 1 |
| Isaka, K; Kuroda, M; Nishi, H; Ohyashiki, J; Oikawa, K; Takanashi, M; Xu, M; Yoshimoto, T | 1 |
| Breen, S; Chang, Y; Coats, S; Coffman, K; Czapiga, M; Fazenbaker, C; Gingles, N; Inigo, I; Jallal, B; Lavallee, T; Leow, CC; Peterson, N; Ricketts, SA; Soukharev, S; Woods, R | 1 |
| Vaidya, B; Vyas, SP | 1 |
| Awada, A; Azim, HA | 1 |
| Chan, DC; DeLaney, T; Edwards, A; Frederick, B; Gladstone, M; Raben, D; Stickel, S; Su, TT; Yoon, P; Zheng, D | 1 |
| Chen, X; Ding, Q; Gu, N; Liu, D; Teng, G; Wen, S; Wu, W; Zhang, X | 1 |
| Castañeda, G; Contento, AM; Muñoz, L; Rodríguez, J | 1 |
| Borgå, O; Häggström, J; Nyman, H; Rivera, P; von Euler, H | 1 |
| Dai, W; Li, RT; Liang, L; Lin, SW; Lu, JK; Xiang, Y; Yang, TY; Zhang, Q; Zhang, Y | 1 |
| Koroleva, IA; Mochalova, AS | 1 |
| Etheridge, AS; Kroll, DJ; Mathews, JM | 1 |
| Weissig, V | 1 |
| Hou, L; Yao, J; Zhang, Q; Zhou, J | 1 |
| Bai, H; Chivukula, P; Clamme, JP; Co, E; Jiang, X; Jin, Y; Liu, X; Liu, Y; Taylor, WD; Tsang, KY; Wang, H; Wang, Y; Yang, D; Ying, W; Yu, L | 1 |
| Aamdal, S; Barrett, S; Barriuso, J; Boven, E; Burke, W; de Vries, EG; Emeribe, U; Freyer, G; Hartog, V; Jones, R; Kaye, S; Kristensen, GB; Kuenen, B; Nyakas, M; Pietersma, D; Pujade-Lauraine, E; Ruijter, R; Sandhu, S; Stuart, M; Tan, DS | 1 |
| Choi, K; Choi, SH; Han, MH; Heo, R; Kim, K; Kwon, IC; Park, JH; Park, K; Saravanakumar, G; Song, IC; Yoon, HY | 1 |
| Chen, J; Gu, Q; Huang, M; Xing, JZ; Zhang, X | 1 |
| Chang, YT; Choi, SY; Jung, DW; Kim, CH; Oh, ES; Park, SH; Williams, DR | 1 |
| Chen, X; Liu, X; Scott, H; Sun, J; Wang, S; Zhang, Q; Zhang, X | 1 |
| Fang, X; Han, L; Huang, Y; Qin, J; Shen, M; Wang, J; Yang, VC | 1 |
| Li, D; Wang, H; Wei, J; Yang, C; Yang, Z; Yin, Z; Zhao, H | 1 |
| Chia, FS; Loh, XJ; Yee, BJ | 1 |
| Baker, SD; de Graan, AJ; Friberg, LE; Loos, WJ; Mathijssen, RH; van der Bol, JM; van der Holt, B; van Doorn, L; Verweij, J; Wiemer, EA | 1 |
| Ball, HA; Burris, HA; Dar, MM; Dowlati, A; Gainer, SD; Infante, JR; Jones, SF; Levinson, KT; Lindquist, D; Moss, RA; Spigel, DR; Suttle, AB; Tan, AR | 1 |
| Chen, IW; Chen, PJ; Chen, SY; Chiang, CS; Hu, SH; Liao, BJ | 1 |
| Carugati, E; Neri, D; Pasche, N; Pretto, F; Wulhfard, S | 1 |
| Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, H; Kim, KP; Kim, TW; Lee, JL; Lim, HS; Ryu, MH | 1 |
| Cai, H; Huang, Y; Jing, X; Liu, S; Liu, T; Qi, R; Song, H; Xiao, H; Yan, L; Yang, Q; Zheng, Y | 1 |
| Chi, S; Ge, M; Jin, Y; Shi, G; Shi, Q; Wang, S; Wang, Y; Xu, S; Zhang, X | 1 |
| Cao, F; Huang, A; Li, H; Li, S; Ping, Q; Su, Z; Sun, M; Xiao, Y; Zhang, C | 1 |
| Jain, S; Kumar, D; Swarnakar, NK; Thanki, K | 1 |
| Green, H; Hasmats, J; Jara, C; Khan, MS; Kupershmidt, I; Lundeberg, J; Mielgo, X; Rodríguez-Antona, C; Su, QJ | 1 |
| Ahn, S; Chen, J; Costello, TA; Dalton, JT; Dalton, MN; Li, CM; Li, W; Lu, Y; Miller, DD; Narayanan, R; Snyder, LM | 1 |
| Beijnen, JH; Feiss, G; Huitema, AD; Jaehde, U; Joerger, M; Kraff, S; Moritz, B; Schellens, JH | 1 |
| Danhier, F; Danhier, P; De Preter, G; Gallez, B; Jordan, B; Karroum, O; Magotteaux, N; Préat, V; Ucakar, B | 1 |
| Wang, H; Yang, Z | 1 |
| Ashwanikumar, N; Deepa, G; Kumar, GS; Pillai, JJ | 1 |
| Bendell, JC; Burris, HA; Infante, JR; Jones, SF; Mohyuddin, A; Thompson, DS; Yardley, DA | 1 |
| Awasthi, A; Jaggi, M; Kulkarni, H; Kulkarni, S; Madaan, A; Mishra, SK; Singh, AT; Singh, P; Verma, R | 1 |
| Baek, JS; Cho, CW; Shin, SC; So, JW | 1 |
| Dou, GF; Fu, ST; Gan, H; Gu, RL; Meng, ZY; Wang, B; Wu, ZN; Yang, LQ; Zhan, DW; Zhu, XX | 1 |
| Gilbert, KS; Secrist, JA; Waud, WR | 1 |
| Baguley, BC; Basse, B; Daukste, L; Wall, DJ | 1 |
| Diaz, Y; Leon, K; Lopez, A; Tundidor, Y | 1 |
| Jeong, SY; Kim, DE; Kim, JY; Kim, K; Kwon, IC; Lee, S; Na, JH; Oh, KS; Yuk, SH | 1 |
| Aomori, T; Araki, T; Hashita, T; Iizuka, K; Makino, H; Nakamura, T; Sekizuka, M; Yamamoto, K | 1 |
| Aman, A; Ernsting, MJ; Li, SD; Murakami, M; Press, B; Undzys, E | 1 |
| Azevedo Próspero dos Santos, II; de Graaf, AJ; Hennink, WE; Kok, RJ; Mastrobattista, E; Pieters, EH; Rijkers, DT; van Nostrum, CF; Vermonden, T | 1 |
| Barbolosi, D; Faivre, C; Iliadis, A | 1 |
| Koudelka, S; Turánek, J | 1 |
| Arriola, E; Cohen, RB; De Castro Carpeño, J; Herbst, RS; Kim, S; Kozloff, MF; Krzakowski, M; Martin, LP; Olszanski, AJ; Rado, TA; Rosbrook, B; Samuel, TA; Tarazi, J; Tortorici, M | 1 |
| Chen, Y; Cohen, RB; Herbst, RS; Kim, S; Kozloff, MF; Martin, LP; Olszanski, AJ; Rado, T; Rosbrook, B; Samuel, TA; Starr, A; Tarazi, J; Tortorici, M | 1 |
| Beumer, JH; Cotarla, I; Deeken, J; Egorin, MJ; Elston, B; Firozvi, K; Hartley, ML; He, AR; Hwang, J; Koh, EY; Liu, M; Malik, S; Marshall, JL; Pishvaian, MJ; Slack, R; Strychor, S | 1 |
| Covell, DG | 1 |
| Alperstein, D; Kloog, Y; Kraitzer, A; Zilberman, M | 1 |
| Beijnen, J; Huitema, A; Koolen, S; Moes, J; Nuijen, B; Schellens, J | 1 |
| Chen, X; Jin, MM; Kang, S; Kim, EJ; Kim, J; Kim, N; Park, S | 1 |
| Ait-Oudhia, S; Mager, DE; Straubinger, RM | 1 |
| Black, AJ; Morris, DG | 1 |
| Kuei, S; Pessino, V; Valentine, MT; Yu, D | 1 |
| Arnould, T; Fransolet, M; Genin, M; Leclere, L; Maincent, A; Michiels, C; Notte, A; Riquier, H; Sermeus, A | 1 |
| Bhowmick, NA; Billet, S; Das, S; Fernandez, A; Fisher, PB; Kitada, S; Mitra, S; Noberini, R; Pasquale, EB; Pellecchia, M; Stebbins, JL; Wang, S; Wu, B; Zhang, Z | 1 |
| Berveiller, P; Broutin, S; Camps, S; Deroussent, A; Gil, S; Mir, O; Paci, A; Seck, A; Tréluyer, JM; Vinot, C | 1 |
| Bersani, S; Caliceti, P; Gallon, E; Mastrotto, F; Ravazzolo, E; Salmaso, S | 1 |
| Chen, X; Fang, W; Jin, J; Lang, L; Li, Y; Zhou, Q; Zhu, Z | 1 |
| Chen, L; Chen, S; Chen, Y; Fang, X; Gu, J; Jiang, X; Sha, X; Xia, W; Xie, Y; Xin, H; Xu, X | 1 |
| Erickson, D; Mak, M; Reinhart-King, CA | 1 |
| An, F; Li, Y; Liu, Z; Yang, Y; Zhang, X | 1 |
| Tkaczuk, KH; Yared, JA | 1 |
| Hu, LY; Li, X; Lu, MK; Wu, ZH | 1 |
| Desai, S; Fodstad, O; Khong, HT; Klos, KS; Liu, H; Liu, Z; McClellan, S; Schmitt, DC; Tan, M; Zhou, M | 1 |
| Chen, W; Cheng, G; Du, Y; Fu, F; Tian, J; Wang, H; Wang, T; Ye, L; Zhang, L | 1 |
| Ehrnrooth, E; Lahogue, A; Machiels, JP; Pelling, K; Rottey, S; Vermorken, JB; Wind, S | 1 |
| Hu, D; Hu, X; Pan, Q; Wang, B; Wu, H; Xie, J | 1 |
| Lanning, NJ; MacKeigan, JP; Niemi, NM; Westrate, LM | 1 |
| Chen, XG; Chen, ZS; Fang, Y; Fu, LW; He, D; Liang, YJ; Qiu, HJ; Singh, S; Talele, TT; Wang, XK; Zhang, GQ; Zhao, XQ | 1 |
| Baker, DL; Bhana, S; Huang, X; Johnson, J; Norman, DD; Parrill, AL; Ren, F; Xu, L | 1 |
| Bhaskar, S; Roy, A; Singh, MS; Upadhyay, P | 1 |
| Hess, KR; Hong, D; Naing, A; Nwosu, U; Tsimberidou, AM; Wheler, J; Wolff, RA; Ye, Y | 1 |
| Lipp, HP | 1 |
| Bocci, G; Danesi, R; Di Paolo, A | 1 |
| Hong, WK | 1 |
| Beijnen, JH; Mathôt, RA; Schellens, JH; van den Bongard, HJ; van Tellingen, O | 1 |
| Fife, K; Ganjoo, KN; Gordon, MS; Loehrer, PJ; Poirier, S; Sandler, AB; Seshadri, R; Warner, RE | 1 |
| Tsukuda, M | 1 |
| de Boeck, G; de Bruijn, E; de Jonge, MJ; Dumez, H; Guetens, G; Highley, M; Louwerens, M; Mantel, M; Pawinsky, A; Planting, AS; Van Oosterom, AT; Verweij, J | 1 |
| Bauer, J; Besenval, M; Caldiera, S; Cuvier, C; Lebecq, A; Marty, M; Monnerat, C; Pérard, D; Semiond, D; Sessa, C; Van Den Bosch, S | 1 |
| Li, C | 1 |
| Ludueña, RF; Xu, K | 1 |
| Blagosklonny, MV | 1 |
| Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vlachonikolis, J | 1 |
| Calvert, H; Calvert, P; Gallant, G; Ghielmini, M; Gupta, E; Plummer, R; Renard, J; Sessa, C; Voi, M | 1 |
| Ashley, DM; Baum, CM; Caruso, DA; Koina, C; Radcliff, FJ; Riordan, MJ; Roberts, AW; Tang, ML; Woulfe, SL | 1 |
| Cox, K; Faul, MM; Keyes, K; Mann, L; Shih, C; Teicher, BA; Treadway, P | 1 |
| Ackland, S; Hall, K; Levi, J; Lewis, C; Marx, G | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malas, K; Mavroudis, D; Pallis, A; Samonis, G; Souglakos, J | 1 |
| Dziadyk, JM; Fan, W; Fang, Y; Huang, Y; Norris, JS | 1 |
| Brierre, JE; Buller, EJ; Cole, JL; Fontenot, MF; Lormand, NA; Rainey, JM; Rinaldi, DA; Stagg, MP | 1 |
| Akerley, W; Kennedy, T; Leone, L; Rathore, R; Ready, N; Safran, H; Sikov, W | 1 |
| Ackland, SP; Clarke, S; Garg, MB; Millward, MJ; Rischin, D; Smith, J; Toner, GC; Zalcberg, J | 1 |
| Aström, G; Bergh, J; Berglund, A; Brodin, O; de la Torre, M; Fjällskog, ML; Glimelius, B; Hagberg, H; Larsson, R; Nygren, P; Oberg, K; Parö, G; Tholander, B; von Heideman, A | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G | 1 |
| Friess, T; Osl, F; Scheuer, WV; Schneider, T; Stockinger, H | 1 |
| Martin, M | 1 |
| Cappellini, GA; Ficorella, C; Marchetti, P; Ronzino, G; Urien, S | 1 |
| Behrens, P; Brinkmann, U; Wellmann, A | 1 |
| Browman, G; Cowan, DH; Evans, WK; Nefsky, M; Pater, J | 1 |
| Egorin, MJ | 1 |
| Bontenbal, M; Nooter, K; Smorenburg, CH; Sparreboom, A; Stoter, G; Verweij, J | 1 |
| Baker, SD; Donehower, RC; McIntire, GL; Sparreboom, A; Swindell, CS; van Zomeren, DM; Verweij, J; Wolff, AC; Zabelina, Y | 1 |
| Chachoua, A; Hamilton, A; Lee, J; Muggia, FM; Sewak, S; Sorich, J; Taneja, S; Utate, M | 1 |
| Behringer, D; Häring, B; Holländer, N; Massing, U; Mielke, S; Mross, K; Unger, C | 1 |
| Duan, Z; Lamendola, DE; Penson, RT; Seiden, MV; Yusuf, RZ | 1 |
| Tishler, RB | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Butzbach, D; Cairdella, M; Capanna, T; DiPaola, RS; Dvorzhinski, D; Eid, J; Goodin, S; Rubin, E; Shih, JW; Todd, MB; Toppmeyer, D | 1 |
| Baick, CH; Chiou, JY; Fruehauf, JP; Mehta, RS; Nalcioglu, O; Su, MY; Wang, J; Yu, H | 1 |
| al-Jazayrly, G; Edelman, MJ; Gandara, DR; Houston, J; Lara, PN; Lau, DH; Lauder, I; Lim, N; Tanaka, M | 1 |
| Alessandrino, PE; Bertolini, A; Collovà, E; Danova, M; Ferrari, S; Porta, C; Riccardi, A; Rovati, B | 1 |
| Brockstein, BE; Mani, S; Masters, GA; Ratain, MJ | 1 |
| Hausheer, F; Murphy, M; Pendyala, L; Schwartz, G; Smith, P; Zdanowicz, J | 1 |
| Bianco, AR; Caputo, R; Carlomagno, F; Ciardiello, F; Damiano, V; Fontanini, G; Tortora, G; Troiani, T; Veneziani, BM; Vitagliano, D | 1 |
| Appia, F; Basser, R; Cebon, J; Chipman, M; Davis, ID; Green, M; Grigg, A; Mitchell, PL; Ng, S; Zalcberg, J | 1 |
| Dropcho, S; Fife, K; Hanna, N; Seitz, DE; Sweeney, C | 1 |
| Bergh, J; Freijs, A; Henningsson, A; Karlsson, MO; Larsson, R; Nygren, P; Sandström, M; Sparreboom, A | 1 |
| Duncan, MW; Eckhardt, SG; Gustafson, DL; Holden, SN; Long, ME; Pierson, AS; Zirrolli, JA | 1 |
| Barboule, N; Baricault, L; Héliez, C; Valette, A | 1 |
| Beers, S; Capanna, T; DiPaola, RS; Doyle-Lindrud, S; Dvorzhinski, D; Goodin, S; Poplin, E; Rubin, E; Shih, J; Thalasila, A | 1 |
| Choy, H; Saha, D | 1 |
| Flaherty, KT; Hahn, SM; O'Dwyer, PJ; Redlinger, M; Stevenson, JP | 1 |
| Anthoney, A; Gatzemeier, U; Kaye, S; Reck, M; Twelves, C | 1 |
| Bernstein, ML; Blaney, S; Hayashi, RJ; Sullivan, J; Vietti, T; Weitman, S | 1 |
| Aarons, L; Beijnen, JH; Burgess, M; Callies, S; de Alwis, DP; Harris, A; Schellens, JH; Vasey, P | 1 |
| Sakashita, A; Sato, A; Taguchi, S | 1 |
| Sparreboom, A; Verweij, J | 1 |
| Extermann, M | 1 |
| Ledbetter, S; Pratt, BM; Teicher, BA; Walter-Yohrling, J | 1 |
| Arquette, MA; Fears, CL; Fracasso, PM; Goodner, SA; Govindan, R; Herzog, TJ; Picus, J; Rader, JS; Rodriguez, LC; Tan, BR | 1 |
| Geney, R; Ojima, I | 1 |
| Behrns, K; Bernard, SA; Calvo, B; Cance, W; Churchel, MA; Detterbeck, FC; Koruda, M; Ollila, D; Poole, ME; Weissler, MC | 1 |
| Markman, M | 4 |
| Brenton, JD; Caldas, C | 1 |
| Bekele, BN; Bucana, CD; Doan, DD; Fidler, IJ; Greenberg, JS; Holsinger, FC; Jasser, SA; Myers, JN; Schiff, BA; Swan, EA; Younes, MN | 1 |
| Goodin, S; Gounder, M; Lin, Y; Medina, M; Much, J; Musanti, R; Orlando, T; Pennick, M; Rubin, E; Shih, W; Toppmeyer, DL; Vyas, V | 1 |
| Fu, LN; Gao, Y; Guo, XL; Lin, GJ; Qian, LP; Wang, JJ; Xu, Q; Xu, SR; Zhao, H | 1 |
| Herbst, RS; Khuri, FR | 1 |
| Anthony, FH; Baker, SD; Bradley, MO; Brahmer, JR; Carducci, MA; Carducci, MK; Donehower, RC; Swindell, CS; Webb, NL; Witman, PA; Wolff, AC; Zabelina, Y | 1 |
| Bottone, MG; Brison, O; Ciomei, M; Gorrini, C; Lazzè, MC; Pellicciari, C; Scovassi, AI; Soldani, C; Tognon, G | 1 |
| Baker, SD; Boonstra, JG; Loos, WJ; Sparreboom, A; Verweij, J | 1 |
| Doroshow, JH; Frankel, P; Galvin, I; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Longmate, J; Mack, PC; Martel, CL | 1 |
| Frangioni, JV; Maison, W | 1 |
| Cho, YS; Chou, TC; Danishefsky, SJ; Dong, H; Gabarda, AE; Rivkin, A; Tong, WP; Yoshimura, F | 1 |
| Horwitz, SB; McDaid, H; Orr, GA; Verdier-Pinard, P | 1 |
| Corey, B; Savarese, DM; Savy, G; Vahdat, L; Wischmeyer, PE | 1 |
| Francia, G; Green, SK; Isidoro, C; Kerbel, RS | 1 |
| Albeck, M; Cohen, YI; Freidkin, I; Kalechman, Y; Kershenovich, A; Khomenok, G; Lebenthal, I; Longo, DL; Mardor, Y; Michowiz, S; Orenstein, A; Ram, Z; Rappaport, ZH; Sredni, B; Teitz, S; Weil, M | 1 |
| Bowden, C; de Heus, G; de Jonge, MJ; Hartman, CM; Loos, WJ; Planting, AS; Soepenberg, O; Sparreboom, A; Verweij, J | 1 |
| Barutcu, I; Esen, AM; Gullu, H; Ozdemir, R; Sezgin, AT | 1 |
| Jordan, MA; Wilson, L | 2 |
| Burton, A; Cata, JP; Cordella, JV; Dougherty, PM; Weng, HR | 1 |
| Albers, A; Odoux, C | 1 |
| Bangert, S; Bishop, WR; Fossella, FV; Glisson, BS; Herbst, RS; Hong, WK; Khuri, FR; Kies, MS; Kim, ES; Kirschmeier, P; Lu, C; Meyers, ML; Munden, RF; Papadimitrakopoulou, V; Shin, DM; Statkevich, P; Tendler, C; Thall, PF; Thompson, E; Wang, XM; Zhu, Y | 1 |
| Gligorov, J; Lotz, JP | 1 |
| Bang, YJ; Chung, JY; Heo, DS; Kim, DW; Kim, NK; Kim, SC; Kim, TY; Shin, SG | 1 |
| Blumenschein, GR; Fossella, FV; Herbst, RS; Lu, C; Madden, T; Meyers, CA; Munden, R; Papadimitrakopoulou, V; Puduvalli, VK; Smythe, LG; Tran, HT; Truong, M; Zinner, R | 1 |
| Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA | 1 |
| Baguley, BC; Coutts, R; Furneaux, CE; Isaacs, RJ; Jose, CC; Kirker, JA; Marshall, ES; Matthews, JH; Morton, RP; Rice, ML; Shaw, JH; White, JB; Whittaker, JR | 1 |
| Dellon, AL; Livengood, MS; Maloney, CT; Swier, P; Werter, S | 1 |
| Devries, A; Haidenberger, A; Lukas, P; Nevinny-Stickel, M; Saurer, M; Seppi, T; Skvortsov, S; Skvortsova, I | 1 |
| Goodin, S; Hait, WN; Rubin, E | 1 |
| Briasoulis, E; Karavasilis, V; Pavlidis, N; Pentheroudakis, G; Rammou, D; Tzamakou, E | 1 |
| Lee, SB; Lee, YM; Park, EK | 1 |
| Awada, M; Busch, R; Fanara, P; Hellerstein, MK; Killion, S; Laprade, KL; Mahsut, A; Stark, JM; Turner, H; Turner, S | 1 |
| Braguer, D; Briand, C; Camoin, L; Carré, M; Pasquier, E; Pourroy, B; Rebaï, O | 1 |
| Gotfryd, K; Jurek, A; Klein, A; Kubit, P; Siaśkiewicz, A; Turyna, B | 1 |
| Cole, C; Greystoke, A; Harries, M; Judson, I; Kaye, S; O'Donnell, A; Reade, S; Scurr, M; Twelves, C | 1 |
| Langer, CJ | 1 |
| Brakora, KA; Duan, Z; Seiden, MV | 1 |
| Horwitz, KB; Jacobsen, BM; Richer, JK; Schittone, SA | 1 |
| Harada, M; Haro, T; Ikesue, H; Ishida, M; Itoh, Y; Kotsubo, K; Mishima, K; Oishi, R; Uchida, M; Yoshikawa, M | 1 |
| Raisch, KP; Safavy, A | 1 |
| Egorin, MJ; Hollis, D; Lichtman, SM; Miller, AA; Ratain, MJ; Rosner, GL | 1 |
| Cunningham, C; Grove, W; Kraker, A; Nemunaitis, J; Olivares, J; Olson, S; Pauer, LR; Williams, A | 1 |
| Dizon, DS | 1 |
| Chung, H; Jeong, SY; Kwon, IC; Lee, IH; Park, YT; Roh, K | 1 |
| Hennequin, C | 1 |
| Flaherty, K; Konkle, BA; Kramer, A; Morgan, M; O'Dwyer, PJ; Stevenson, JP; Veronese, ML | 1 |
| Dowling, M; Harris, E; Kao, GD; Keutmann, MK; Kim, M; Voong, KR | 1 |
| Adjei, AA; Bruzek, LM; Cheng, S; Croghan, GA; Dy, GK; Erlichman, C; Furth, A; Hanson, LJ; Kaufmann, SH; Mandrekar, S; Martell, RE; Peethambaram, P; Pitot, HC; Reid, JM | 1 |
| Arezzo, J; Bartley, P; Chia, M; Daly, M; Davis, ID; Green, M; Harrison, L; Kiers, L; MacGregor, L; Michael, M; Quinn, M; Rosenthal, M | 1 |
| Braguer, D; Briand, C; Honore, S; Jordan, MA; Lehmann, M; Pasquier, E; Pourroy, B | 1 |
| Debatin, KM; Fulda, S | 1 |
| Bouvier, E; Monneret, C; Schmidt, F | 1 |
| Rochat, B | 1 |
| Epstein, AL; Hu, P; Khawli, LA | 1 |
| Ayral-Kaloustian, S; Cai, P; Chaudhary, I; Fawzi, M; Frost, P; Gaydos, C; Gibbons, J; Gu, J; Li, F; Lotvin, J; Lucas, J; Mansour, T; Petersen, R; Ruppen, M; Skotnicki, J; Toral-Barza, L; Yu, K; Zask, A; Zhu, T | 1 |
| Duivenvoorden, W; Matthews, D; Richard, C; Th'ng, JP; Wright, PS; Yau, J | 1 |
| Leberthon, B; McGowen, P; Presant, CA; Thompson, E; Vergara, L | 1 |
| Armstrong, RC; Augeri, DJ; Belli, BA; Bruncko, M; Deckwerth, TL; Dinges, J; Elmore, SW; Fesik, SW; Hajduk, PJ; Joseph, MK; Kitada, S; Korsmeyer, SJ; Kunzer, AR; Letai, A; Li, C; Mitten, MJ; Nettesheim, DG; Ng, S; Nimmer, PM; O'Connor, JM; Oleksijew, A; Oltersdorf, T; Petros, AM; Reed, JC; Rosenberg, SH; Shen, W; Shoemaker, AR; Tahir, SK; Thompson, CB; Tomaselli, KJ; Wang, B; Wendt, MD; Zhang, H | 1 |
| Aitchison, RD; Basche, ML; Cooper, W; Eckhardt, SG; Holden, SN; Kobayashi, H; Lockridge, JA; O'Bryant, CL; Rothenberg, ML; Sandler, AB; Usman, N; Wolin, M | 1 |
| Beals, B; De, T; Desai, N; Figg, WD; Hawkins, M; Scripture, CD; Sparreboom, A; Trieu, V; Williams, PJ; Yang, A | 1 |
| Garber, K | 2 |
| Lin, C; Liu, ZR; Yang, L | 1 |
| Behringer, D; Gelderblom, H; Mielke, S; Mross, K; Sparreboom, A; Steinberg, SM; Unger, C | 1 |
| Chi, KN; Chia, SK; Dixon, R; Gelmon, KA; Newman, MJ; Sikic, B; Wacher, VJ | 1 |
| Feng, SS; Zhang, Z | 1 |
| Cree, IA; Di Nicolantonio, F; Di Palma, S; Fernando, A; Gabriel, FG; Glaysher, S; Gulliford, T; Higgins, B; Hurren, J; Johnson, P; Knight, LA; Lamont, A; Mercer, SJ; Sharma, S; Somers, SS; Toh, S; Whitehouse, PA; Yiangou, C | 1 |
| Lesniak, MS | 1 |
| Chan, KK; Fischer, B; Grever, M; Lavelle, J; Otterson, GA; Shah, M; Villalona-Calero, MA; Wei, X | 1 |
| Castells, MC; Lee, CW; Matulonis, UA | 1 |
| Man, M; Rugo, H | 1 |
| Advani, R; Chin, DL; Fisher, GA; Halsey, J; Jacobs, CD; Lum, BL; Sikic, BI | 1 |
| Kekre, N; McNulty, J; Naderi, J; Pandey, S | 1 |
| Conroy, M; Cree, IA; Fernando, A; Knight, LA; Kurbacher, CM; Polak, M | 1 |
| Gradishar, WJ | 1 |
| Budman, DR | 1 |
| Hohmann, AG | 1 |
| Chou, TC; Danishefsky, SJ; Dong, H; Tong, WP; Zhang, X | 1 |
| Ballard, EE; Dowell, JE; Hunt, WC; Jumper, CA; Krieger, JA; Rabinowitz, I; Shah, SR; Stanford, BL | 1 |
| Argyriou, AA; Chroni, E; Iconomou, G; Kalofonos, HP; Katsoulas, G; Koutras, A; Makatsoris, T; Papapetropoulos, S; Polychronopoulos, P | 1 |
| Baker, SD; Sparreboom, A; Verweij, J | 1 |
| Campbell, KJ; Desai, N; Hawkins, MJ; Hersh, E; Long, K; Nyman, DW; Richardson, K; Trieu, V; Von Hoff, DD | 1 |
| Kim, SY; Lee, SB; Lee, YM; Park, EK | 1 |
| Dodd, M; Dowling, G; Jansen, C; Kramer, J; Miaskowski, C | 1 |
| Amino, N; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M | 1 |
| Bernareggi, A; Bissett, D; Boddy, AV; Calvert, AH; Cassidy, J; Griffin, M; Plummer, ER; Robson, L; Sludden, J; Todd, R; Verrill, MW | 1 |
| Argyriou, AA; Chroni, E; Iconomou, G; Kalofonos, HP; Koutras, A; Polychronopoulos, P | 1 |
| Garsa, A; Henningsson, A; Karlsson, MO; Locatelli, A; Loos, WJ; Marsh, S; McLeod, HL; Mielke, S; Mross, K; Sparreboom, A; Verweij, J; Viganò, L | 1 |
| Danis, PO; Rubio, FM; Young, DH | 1 |
| Cunningham, C; Eisenfeld, A; Gray, M; Mennel, R; Nemunaitis, J; Oldham, F; Pippen, J; Senzer, N | 1 |
| Corti, A; Curnis, F; Gallo-Stampino, C; Gasparri, A; Sacchi, A; Toma, S | 1 |
| Fujimura, M; Inoue, K; Isobe, K; Komagata, H; Sakai, H; Shirai, T; Tabei, T; Yoneda, S | 1 |
| Double, JA; Nicolaou, A; Pavillard, V; Phillips, RM | 1 |
| André, N; Meille, C | 1 |
| Cheung, MN; Chow, LW; Fong, JH; Loo, WT | 1 |
| Amino, N; Hisamichi, H; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M | 1 |
| Jiang, W; Li, L; Wang, Y; Yang, Z; Zhang, Z | 1 |
| Raghavan, D; Suh, T | 1 |
| Byrd, J; Cullinan, SA; Egorin, MJ; Hollis, D; Lester, EP; Lichtman, SM; Millard, F; Miller, AA; Parise, RA; Ratain, MJ; Rhoades, CA; Rosen, DM; Rosner, GL | 1 |
| Bouma-ter Steege, JC; Castermans, K; Dings, RP; Dirkx, AE; Griffioen, AW; Kwee, L; Mayo, KH; oude Egbrink, MG; Thijssen, VL; van der Schaft, DW; Wagstaff, J | 1 |
| Dong, Y; Feng, SS | 2 |
| Beijnen, JH; Huitema, AD; Joerger, M; Schellens, JH; van den Bongard, DH | 1 |
| Colville, JA; Ginsberg, MS; Hricak, H; Ilson, D; Kalaigian, J; Mazumdar, M; Schwartz, GK; Schwartz, LH; Wang, L | 1 |
| Alderden-Los, C; Beijnen, JH; Rosing, H; Schellens, JH; Sharma, A; Veltkamp, SA | 1 |
| Fife, K; Foster, A; Fukunaga, A; Kelich, S; Li, L; Murry, D; Rosenberg, L; Schneider, B; Sweeney, C; Yoder, C | 1 |
| Cardenal, F; García, M; Germà-Lluch, JR; Gil, M; Izquierdo, MA; Martínez, M; Mesía, R; Navarro, M; Pérez, X; Pontón, JL; Salazar, R; Valentí, V | 1 |
| Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ | 1 |
| Aletti, G; Baldi, A; Bible, KC; Catalano, V; Chien, J; Cliby, WA; Ehrmann, M; Hartmann, LC; Kalli, KR; Kaufmann, SH; Keeney, GL; Lee, YK; Muretto, P; Shridhar, V; Staub, J | 1 |
| Agarwala, S; Argiris, A; Bergsland, E; Rugo, H; Wanebo, HJ | 1 |
| Davis, TH | 1 |
| Barry, JJ; Blagosklonny, MV; Demidenko, ZN; Donskoy, E; Giovino, M; Herrmann, RA; Szynal, C; Whalen, AM | 1 |
| Aoyagi, N; Fukushima-Uesaka, H; Kamatani, N; Kaniwa, N; Katori, N; Kunitoh, H; Kurose, K; Minami, H; Nakajima, Y; Ohe, Y; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Tamura, T; Yamamoto, N; Yoshida, T; Yoshitani, T | 1 |
| Calvo, E; Rowinsky, EK | 1 |
| Fidler, IJ | 1 |
| Beijnen, JH; Binlich, F; Garrigue, JS; Huitema, AD; Lallemand, F; Lambert, G; Nol, A; Nuijen, B; Schellens, JH; Thijssen, B; Veltkamp, SA | 1 |
| Argyriou, AA; Chroni, E; Iconomou, G; Kalofonos, HP; Koutras, A; Papapetropoulos, S; Polychronopoulos, P | 1 |
| Bloch, SH; Dayton, PA; Doinikov, A; Ferrara, KW; Matsunaga, TO; Penrose, K; Schumann, P; Zhao, S; Zutshi, R | 1 |
| Huang, HB; Lin, PL; Lin, ZC; Liu, T; Zhong, JT | 1 |
| Bisonni, R; Calvani, M; D'Iddio, S; Graziano, F; Lippe, P; Mancinelli, A | 1 |
| Frost, A; Holländer, N; Massing, U; Mross, K; Unger, C; Ziroli, V | 1 |
| Kosmas, C; Tsavaris, N | 1 |
| Duivenvoorden, WC; Richard, C; Th'ng, JP; Yau, J | 1 |
| Appleman, L; Bukowski, R; Cooper, W; Grover, J; Lockhart, AC; Mayer, PR; Rothenberg, ML; Shapiro, M; Wang, KK; Zhu, AX | 1 |
| Hayashi, Y; Kiso, Y; Skwarczynski, M | 1 |
| Armirotti, A; Balbi, A; Bestoso, F; Cavalli, F; Damonte, G; Degan, P; Ledda, B; Mazzei, M; Miele, M; Ottaggio, L | 1 |
| Eckelman, WC; Hirsch, JI; Kalen, JD; Kiesewetter, DO; Kurdziel, KA | 1 |
| Kingston, DG | 1 |
| Beeram, M; Hamilton, M; Hammond, LA; Hidalgo, M; Kreisberg, JI; Mita, MM; Nadler, P; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Wolf, J; Wood, D | 1 |
| Beijnen, JH; Fetell, MR; Huitema, AD; Nol, A; Rosing, H; Schellens, JH; Veltkamp, SA | 1 |
| de Bree, E; Georgatos, SD; Georgoulias, V; Michalakis, J; Polioudaki, H; Romanos, J; Theodoropoulos, PA; Tsiftsis, DD | 1 |
| Bukowski, RM; Curtis, D; Frank, E; Lipton, A; Ready, NE; Statkevich, P; Zhu, Y | 1 |
| Berkenblit, A; Dahl, TA; Dezube, BJ; Eder, JP; Ryan, DP; Seiden, MV; Sherman, ML; Supko, JG; Tatsuta, N | 1 |
| Anthony, SP; Arseneau, JC; Berman, BS; Cunningham, CC; Fowers, KD; Nemunaitis, JJ; Samlowski, WE; Vukelja, SJ | 1 |
| Black, EJ; Earnshaw, WC; Gillespie, DA; Scott, MT; Vagnarelli, P; Walker, M; Zachos, G | 1 |
| Collichio, FA; Dees, EC; Goldberg, RM; Hawkins, MJ; Ivanova, A; Lindley, C; Mu, H; O'Neil, BH; Socinski, MA; Stinchcombe, TE; Walko, CM | 1 |
| Bensussan, A; Bizzini, B; Gallo, RC; Genne, P; Larcier, P; Le Buanec, H; Paturance, S; Rad, FH; Ryffel, B; Uzan, G; Zagury, D | 1 |
| Basse, B; Ubezio, P | 1 |
| Au, JL; Lu, D; Lu, Z; Wientjes, MG | 1 |
| Azzoli, CG; Dunne, M; Farmer, A; Ginsberg, MS; Gomez, J; Henry, R; Jones, J; Kris, MG; Krug, LM; Miller, VA; Pizzo, B; Sirotnak, FM; Steffen, R; Tyson, L; Venkatraman, E | 1 |
| Huxham, LA; Kyle, AH; Minchinton, AI; Yeoman, DM | 1 |
| Chen, YC; Guh, JH; Ho, YF; Huang, YC; Kuo, SC; Lin, TP; Lu, PH; Pan, SL; Teng, CM | 1 |
| Bai, L; Guo, G; Jin, C; Tian, F; Wu, H | 1 |
| Argiris, AE; Belani, CP; Egorin, MJ; Lagattuta, TF; Musguire, LA; Parise, RA; Potter, DM; Ramalingam, SS; Ramananthan, RK; Ramanathan, RK; Stoller, RG; Zwiebel, JA | 1 |
| Alberti, DB; Bailey, HH; Binger, KA; Gottardis, MM; Martell, RE; Mulkerin, DL; Thomas, JP; Wilding, G | 1 |
| Pishko, MV; Zahr, AS | 1 |
| Beeram, M; Hammond, S; Lewis, LD; MacKay, K; Mita, AC; Mita, MM; Olszanski, AJ; Perez, RP; Rowinsky, EK; Simmons, C; Stone, AJ; Tuck, DP; Walovitch, RC | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Giassas, S; Kalykaki, A; Kentepozidis, N; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Vamvakas, L | 1 |
| Fukushima-Uesaka, H; Goto, Y; Kamakura, S; Kamatani, N; Kaniwa, N; Katori, N; Kim, SR; Kimura, H; Kitakaze, M; Komamura, K; Kunitoh, H; Kurose, K; Minami, H; Minami, N; Nakajima, Y; Ohe, Y; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Soyama, A; Sugai, K; Tamura, T; Tomoike, H; Yamamoto, N; Yoshida, T; Yoshitani, T | 1 |
| Fan, W; Kraft, AS; Sui, M; Xiong, X | 1 |
| Sachdev, D | 1 |
| Cheng, KD; Kong, JQ; Wang, W; Zhu, P | 1 |
| Sawyer, MB; Steed, H | 1 |
| Fojo, T; Menefee, M | 1 |
| Bartlett, DL; Brown, CK; Demarco, RA; Dong, Xda E; Ito, N; Lotze, MT; Popovic, P; Shand, SH; Watkins, S; Winikoff, S; Zeh, HJ | 1 |
| Bergquist, H; Gee, MS; Josephson, L; Mahmood, U; Upadhyay, R; Weissleder, R | 1 |
| Stinchcombe, TE | 1 |
| Chipman, SD; Oldham, FB; Pezzoni, G; Singer, JW | 1 |
| Comijn, E; De Marco, C; Peters, GJ; Tesei, A; Zaffaroni, N; Zoli, W | 1 |
| Awada, A; Ismael, GF; Mano, MS; Rosa, DD | 1 |
| Banerjee, S; Chellappan, S; Rastogi, S; Simon, GR | 1 |
| Agarwal, R; Barrett, D; Bear, HD; Hirsch, JI; Kalen, JD; Kurdziel, KA; McCumiskey, JF; Wilson, JD | 1 |
| Hassan, R; Pastan, I; Xiang, L; Zhang, Y | 1 |
| Georgoulias, V; Kalbakis, K; Kalykaki, A; Kouroussis, C; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Vamvakas, L; Vardakis, N | 1 |
| Barnes, J; Boudreau, N; Cayer, ML; Conway, D; Heckman, CA; Li, Y; Uppal, SO; Wendt, E | 1 |
| Bozionelou, V; Georgoulias, V; Gioulbasanis, I; Kalykaki, A; Karabeazis, A; Karampeazis, A; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kim, IW; Peng, XX; Robey, RW; Shen, T; Shi, Z; Shukla, S; Si, QS | 1 |
| Cheng, G; Li, X; Liu, G; Wang, N; Xu, S; Yan, Z; Yang, H; Yu, J | 1 |
| Ambudkar, SV; Barnett, D; Bates, SE; Finley, EM; Fojo, T; Oldham, RK; Robey, RW; Shukla, S | 1 |
| Al-Abd, AM; Kim, SY; Kuh, HJ; Kun, N; Lee, JH | 1 |
| Dufresne, A; Pivot, X; Viel, E; Villanueva, C | 1 |
| Benita, S; Debotton, N; Kadouche, J; Parnes, M | 1 |
| Abzah, A; Farraj, Z; Friedman, E; Hussein, O; Tamam, S; Zidan, J | 1 |
| Chiang, CS; Chuang, WL; Hong, JH; Liu, WC; McBride, WH; Tsai, ML | 1 |
| Li, C; Wallace, S | 1 |
| Gonzalez-Angulo, AM; Hortobagyi, GN | 1 |
| Chien, JT; Du, SY; Jiang, MC; Liao, CF; Lin, CH; Luo, SF; Shen, TY | 1 |
| Böhme, C; Cerny, T; Demmer, R; Gillessen, S; Schmitz, SF; Strasser, F; Thuerlimann, B | 1 |
| Mohan, R; Panda, D; Rathinasamy, K; Singh, P | 1 |
| Forbes, NS; Henson, MA; Venkatasubramanian, R | 1 |
| Bellet, RE; Creekmore, AN; Egorin, MJ; Ellis, MJ; Fracasso, PM; Fu, CJ; Gao, F; Goodner, SA; Govindan, R; Linette, GP; Pentikis, HS; Picus, J; Tan, BR; Wildi, JD; Zumbrun, SC | 1 |
| Desai, N; Hawkins, MJ; Soon-Shiong, P | 1 |
| Mitchison, T; Orth, JD; Shi, J | 1 |
| Alberti, D; Eickhoff, J; Kolesar, J; Lee, F; Leith, C; Liu, G; Marnocha, R; McNeel, DG; Schell, K; Traynor, A; Wilding, G; Zwiebel, J | 1 |
| Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Krishnamurthi, S; Ness, A; Nock, C; Remick, SC; Sanborn, SL | 1 |
| Boucher, Y; Jain, RK; Nagano, S; Perentes, JY | 1 |
| Bacon, P; Baker, N; Dean, S; Pettengell, R; Theti, D; Willis, F | 1 |
| Beriel, H; Jacrot, M; Leroux, D; Mouriquand, C; Picot, F; Potier, P; Riondel, J | 1 |
| Bentley, S; Bernard, S; Brecher, M; Graham, M; Johnston, C; Serody, J; Shea, T; Steagall, A; Vaisman, A; Wiley, J | 1 |
| Fumoleau, P; Lemevel, B; Maugard-Louboutin, C; Perrocheau, G | 1 |
| Alberti, D; Arzoomanian, R; Feierabend, C; Schiller, JH; Spriggs, D; Storer, B; Tutsch, K | 2 |
| Faulds, D; Spencer, CM | 1 |
| Green, MR; Lilenbaum, RC; MacManus, DA | 1 |
| Brewster, L; Green, MR; Hargis, JB; Hollis, DR; Lilenbaum, RC; Miller, AA; O'Brien, SM; Ratain, MJ; Rosner, GL; Schilsky, RL | 1 |
| Reynolds, T | 1 |
| Eckhardt, S | 1 |
| Aamdal, S; Catimel, G; Sternberg, C; Sulkes, A; van Hoesel, Q; Verweij, J; Wolff, I | 1 |
| Aapro, M; Bruno, R | 1 |
| Hochster, H; Speyer, J; Wasserheit, C | 1 |
| Cortes, JE; Pazdur, R | 1 |
| Greco, FA; Hainsworth, JD | 4 |
| Egorin, MJ; Gianni, L; Kearns, CM | 1 |
| Chapman, A; Gallo, J; Greenberg, R; Hudes, GR; McAleer, C; Obasaju, C | 1 |
| Bhalla, KN; Kumar, GN; Walle, T; Walle, UK | 2 |
| Garin, AM; Gorbunova, VA; Orel, NF; Roshchin, EM; Tiuliandin, SA; Voĭnarevich, OA | 1 |
| Beijnen, JH; Huizing, MT; Misser, VH; Pieters, RC; Pinedo, HM; ten Bokkel Huinink, WW; Veenhof, CH; Vermorken, JB | 1 |
| Shparik, IV | 1 |
| Bissery, MC; Lavelle, F; Nohynek, G; Sanderink, GJ | 1 |
| Schriivers D [corrected to Schrijvers, D]; Schrijvers, D; van Oosterom, AT | 1 |
| McNeil, C | 1 |
| Chaudhry, V; Cornblath, DR; Donehower, RC; Ettinger, DS; Forastiere, AA; Grochow, LB; Lubejko, BG; Rowinsky, EK; Sartorius, SE | 1 |
| Adler, KM; Brophy, NA; Fisher, GA; Halsey, J; Lum, BL; Sikic, BI; Yahanda, AM | 1 |
| Kaye, SB | 1 |
| Armand, JP; de Forni, M | 1 |
| Bates, SE; Dickstein, B; Fojo, AT; Lee, JS; Paull, K; Scala, S; Wilson, W; Zhan, Z | 1 |
| Wall, ME; Wani, MC | 2 |
| Klaassen, U; Seeber, S | 1 |
| Bergh, J; Brodin, O; Csoka, K; Fridborg, H; Glimelius, B; Hagberg, H; Jonsson, B; Kreuger, A; Nygren, P; Tholander, B | 1 |
| Párkányi, C; Politzer, P | 1 |
| Hurwitz, CA; Pratt, CB; Ragab, AH; Ravindranath, Y; Relling, MV; Strother, DR; Vietti, TJ; Weitman, SD | 1 |
| Culotta, E; Koshland, DE | 1 |
| Nagy, K | 1 |
| Diehl, V; Steinmetz, T | 2 |
| Schalhorn, B | 2 |
| Beijnen, JH; Bekos, EJ; Duncan, GF; Farmen, RH; Gaver, RC; Tay, LK; Willey, TA | 1 |
| Hurwitz, CA; Pratt, CB; Relling, MV; Shuster, JJ; Sonnichsen, DS | 1 |
| Donehower, RC; Lesser, GJ; Monsarrat, B; Rowinsky, EK; Wright, M | 1 |
| Bruno, R; Sanderink, GJ | 1 |
| de Vries, EG; Guchelaar, HJ; Mulder, NH; ten Napel, CH | 1 |
| Cuvier, C; Espie, M; Extra, JM; Giacchetti, S; Marty, M | 1 |
| Foa, R; Norton, L; Seidman, AD | 1 |
| Adams, J; Arbuck, SG; Canetta, R; Cazenave, LA; Christian, MC; Cole, KE; Fisherman, JS; Friedman, MA; Sarosy, G; Suffness, M | 1 |
| Denicoff, AM; Lepore, JM; McCabe, MS; Noone, MH | 1 |
| Auzannet, V; Awada, A; de Valeriola, D; Kerger, J; Lips, S; Lossignol, D; Piccart, MJ; Ravoet, C; Sculier, JP; Tomiak, E | 1 |
| Hitt, C | 1 |
| Verweij, J | 1 |
| Rowinsky, EK | 4 |
| Burris, HA | 2 |
| Gabel, M; Khil, MS; Kim, JH; Kim, SH; Lee, YJ; Ryu, S | 1 |
| Ariyoshi, Y; Fukuoka, M; Furue, H; Furuse, K; Hasegawa, K; Ishitani, K; Kanamaru, R; Niitani, H; Noda, K; Taguchi, T | 1 |
| Bruno, R; Clavel, M; Extra, JM; Le Bail, N; Marty, M; Rousseau, F | 1 |
| Wasielewski, S | 1 |
| Stone, R | 1 |
| Burris, H; Eckardt, J; Fields, S; Irvin, R; Kalter, S; Kuhn, J; Rodriguez, G; Shaffer, D; Smith, L; Weiss, G | 1 |
| Arbuck, SG; Chaudhry, V; Donehower, RC; Eisenhauer, EA; Rowinsky, EK | 1 |
| Donehower, RC; Rowinsky, EK | 3 |
| Lubejko, BG; Sartorius, SE | 1 |
| Arbuck, SG; Canetta, R; Christian, MC; Onetto, N | 1 |
| Arbuck, SG; Cheson, BD; Phillips, PH | 1 |
| Cohen, PR; Kavanagh, JJ; Kudelka, AP; Pazdur, R; Raber, MN | 1 |
| Eisenhauer, E | 1 |
| Long, K; Long, R | 1 |
| Pronk, LC; Stoter, G; Verweij, J | 1 |
| Crinis, NA; Millward, MJ; Morton, CG; Webster, LK | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Gonzalves, L; Lokich, J; Moore, C; Zipoli, T | 1 |
| Fleming, GF; Janisch, L; Ratain, MJ; Vogelzang, NJ; Vokes, EE | 1 |
| Nishiwaki, Y; Saijo, N; Sasaki, Y; Tamura, T | 1 |
| Guy, RK; Nicolaou, KC; Potier, P | 1 |
| Akutsu, M; Kano, Y; Miura, Y; Suzuki, K; Tsunoda, S; Yazawa, Y | 1 |
| Armand, JP; Couteau, C; Goncalves, E; Terret, C; Yakendji, K | 1 |
| Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L | 1 |
| Palackdharry, CS | 1 |
| Ogawa, M | 1 |
| Pronk, LC; Schellens, JH; Verweij, J | 1 |
| Arioka, H; Eguchi, K; Fukuoka, K; Funayama, Y; Ishida, T; Kunito, H; Kurokawa, H; Nishio, K; Nomoto, T; Ohe, Y; Ohta, S; Ohtsu, T; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T; Yamamoto, N | 1 |
| Barnicle, M; Blendowski, C; Goodman, M; Lydon, J; Petersen, J; Stewart, I; Wickham, R | 1 |
| Hájek, R; Slavik, M; Vorlicek, J | 1 |
| Halle, M | 1 |
| Aapro, M | 1 |
| Dieras, V; Pouillart, P | 1 |
| Mani, S; Ratain, MJ | 1 |
| Conte, PF; Gennari, A; Salvadori, B; Tognoni, A | 1 |
| Berghorn, EJ; Creaven, PJ; Loewen, G; Meropol, NJ; Pendyala, L; Perez, RP; Raghavan, D | 1 |
| Freund, W; Hausamen, TU; Lipke, J; Löffler, TM | 1 |
| Hilkens, PH; Pronk, LC; van den Bent, MJ; van Putten, WL; Vecht, CJ; Verweij, J | 1 |
| Blanc, C; Bruno, R; de Boer-Dennert, M; Harteveld, M; Hilkens, PH; Ma, J; Planting, AS; Pronk, LC; Schellens, JH; Stoter, G; van den Bent, MJ; van der Burg, ME; Verweij, J | 1 |
| Crimmins, DL; Fracasso, PM; Hock, KG; Scott, MG | 1 |
| Fossella, FV; Hong, WK; Huber, MH; Lee, JS; Lippman, SM; Newman, RA; Wester, M | 1 |
| Linsenmeyer, ME; Millward, MJ; Rischin, D; Urch, ME; Webster, LK; Woodcock, DM | 1 |
| Casaretti, R; Comella, G; Comella, P; Daponte, A; De Rosa, L; Frasci, G; Gallipoli, A; Gravina, A; Parziale, A | 1 |
| Clark, G; Faivre, S; Hanauske, A; Izbicka, E; Raymond, E; Rowinsky, EK; Von Hoff, DD | 1 |
| MacConnachie, AM | 1 |
| Adamson, PC; Balis, FM; Berg, SL; Blaney, SM; Krailo, MD; Mosher, R; O'Brien, M; Poplack, DG; Reaman, GH; Seibel, NL | 1 |
| Ciavattini, A; Di Stefano, G; Garzetti, GG; Provinciali, M | 1 |
| Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; Verweij, J | 2 |
| Valero, V | 2 |
| Bookman, MA; Kloth, DD; Kover, PE; Ozols, RF; Smolinski, S | 1 |
| Egan, CL; Guzzo, CA; Laughinghouse, KA; Li, LJ; Tangoren, IA; Weinberg, JM | 1 |
| Chaitchik, S; Inbar, M; Merimsky, O | 1 |
| Asbury, R; Boros, L; Chang, AY; Hui, L; Rubins, J | 1 |
| Bishop, JF; Macarounas-Kirchman, K | 1 |
| Eckardt, JR | 1 |
| Kraynak, MA | 1 |
| Yee, GC | 1 |
| Bruno, R; Hille, D; Lebecq, A; Riva, A; Thomas, L | 1 |
| Bruno, R; Burris, HA; Chevallier, B; Fossella, FV; Fumoleau, P; Hille, D; Kaye, SB; Ravdin, PM; Rigas, JR; Riva, A; Seidman, AD; Sheiner, LB; ten Bokkel Huinnink, WW; Valero, V; van Oosterom, AT; Verweij, J; Vivier, N | 1 |
| Dörken, B; Köhne, CH; Kretzschmar, A | 1 |
| Berkowitz, R; Bunnell, CA; Buswell, L; Muto, M; Sheets, E; Shulman, LN; Thompson, L | 1 |
| de Bruijn, EA; Groult, V; Locci-Tonelli, D; Planting, AS; Pronk, LC; Schellens, JH; Schrijvers, D; van Oosterom, AT; Verweij, J | 2 |
| Eisenhauer, EA; Vermorken, JB | 1 |
| Bontenbal, M; Hilkens, PH; Sillevis Smitt, PA; van den Bent, MJ; van Raaij-van den Aarssen, VJ; Verweij, J | 1 |
| Saijo, N; Sekine, I; Yamazaki, S | 1 |
| Dell, J; Gurnani, M; Hajian, G; Lipari, P; Nielsen, LL | 1 |
| Batist, G; Brown, TD; Budman, D; Egorin, MJ; Hohl, R; Jahan, TM; Kearns, CM; Ratain, MJ; Rosner, GL; Schilsky, RL; Venook, AP | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Thomas, M | 1 |
| Anderson, N; Lokich, J | 1 |
| Bauknecht, T; Häring, B; Hauns, B; Maier-Lenz, H; Meerpohl, HG; Mross, K; Unger, C | 1 |
| Bruno, R; Kearns, CM; Kuhn, JG; McLeod, HL | 1 |
| Beijnen, JH; Meerum Terwogt, JM; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW | 1 |
| Blagosklonny, MV; Fojo, T; Poruchynsky, MS; Rudin, CM; Wang, EE | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Lokich, J; Moore, C; Sonneborn, H; Strong, D | 1 |
| Brouwer, E; de Vos, AI; Gianni, L; Locatelli, A; Loos, WJ; Nooter, K; Sparreboom, A; Stoter, G; van der Burg, ME; Verweij, J; Viganò, L | 1 |
| Garcia, AA; Jeffers, S; Keren-Rosenberg, S; Koda, R; Muggia, FM; Parimoo, D; Rogers, M | 1 |
| Aylesworth, C; Campbell, E; Chaturvedi, P; Drengler, R; Eckhardt, SG; Hammond, L; Harding, MW; Kraynak, M; Rowinsky, EK; Smith, L; Stephenson, J; Villalona, M; Von Hoff, DD; Wang, YM | 1 |
| Aylesworth, C; Burris, HA; Eckardt, JR; Eckhardt, SG; Forral, K; Kraynak, MA; Nicol, SJ; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Sharma, A; Stephens, CD; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR | 1 |
| Bernard, S; Brouwer, KL; Gonzalez, P; Lawrence, P; Letrent, SP; Mudd, PN; Radomski, KM; Socinski, MA; Steagall, A | 1 |
| Au, JL; Gan, Y; Weaver, JR | 1 |
| Baille, P; Bruno, R; Millward, M; Montay, G; Schellens, JH; Verweij, J; Webster, LK | 1 |
| Miyata, Y; Nakanomyo, H; Nishiwaki, Y; Ohtsu, T; Saijo, N; Sasaki, Y; Tamura, T | 1 |
| Karlsson, G; Ragnarson Tennvall, G | 1 |
| Hilkens, PH; Pronk, LC; Stoter, G; van den Bent, MJ; van Putten, WL; Verweij, J | 1 |
| Boucher, J; Corey, B; Savarese, D | 1 |
| Sparano, JA | 1 |
| Burris, H | 1 |
| Au, JL; Gan, Y; Wientjes, MG | 1 |
| Armand, JP; Couteau, C | 1 |
| Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Schiza, S | 1 |
| Chamberlin, HA; Cohen, D; Emanuel, SL | 1 |
| Baker, SD; Burris, HA; Cobb, PW; Diab, SG; Drengler, R; Eckhardt, SG; Finizio, M; Hammond, L; Joshi, A; Kraynak, M; Rodriguez, GI; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Morrissey, LH | 1 |
| MacDonald, N | 1 |
| Aylesworth, C; Bellet, R; Burris, H; Peacock, N; Petit, T; Ravdin, P; Rodriguez, G; Rowinsky, EK; Smetzer, L; Smith, L; Von Hoff, DD | 1 |
| Barón, A; Bearman, SI; Cagnoni, PJ; DeBoom, T; Jones, RB; Matthes, S; Nieto, Y; Shpall, EJ | 1 |
| Choy, H | 4 |
| Balis, FM; Blaney, SM; Hutchinson, R; Krailo, M; Mosher, RB; O'Brien, M; Reaman, GH; Seibel, NL | 1 |
| Potemski, P; Płuzańska, A | 1 |
| Dhanikula, AB; Panchagnula, R | 1 |
| Bishop, WR; Izbicka, E; Lawrence, RA; Petit, T; Von Hoff, DD; Weitman, S | 1 |
| Candalh, E; Kramar, A; Lebecq, A | 1 |
| Au, JL; Jang, SH; Kuh, HJ; Weaver, JR; Wientjes, MG | 1 |
| Chou, TC; Fennelly, DW; Grant, SC; Heelan, RT; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR; Sirotnak, FM | 1 |
| Arbuck, SG; Bhalla, KN; Ibrado, AM; Javed, T; Kumar, GN; Reed, C; Stuart, RK; Walle, T; Walle, UK | 1 |
| Yarchoan, R | 1 |
| Bertucci, D; Goh, BC; Mani, S; Ratain, MJ; Vogelzang, NJ; Vokes, EE | 1 |
| Anastasopoulos, D; Briasoulis, E; Fountzilas, G; Karavasilis, V; Kostadima, V; Pavlidis, N; Rammou, D; Tzamakou, E | 1 |
| Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Mayer, F | 1 |
| Beijnen, JH; de Wit, R; Lieverst, J; Nannan Panday, VR; Rosing, H; Schellens, JH; Schornagel, JH; Schot, M; ten Bokkel Huinink, WW | 1 |
| Greco, FA | 1 |
| Koechli, OR; Little, JB; Mariotta, M; Mirimanoff, RO; Perewusnyk, G; Rutz, HP; von Knebel Doeberitz, M | 1 |
| Cheong, N; Corn, BW; Curran, WJ; Guan, J; Iliakis, G; Kurdoglu, B | 1 |
| Cook, JA; Herscher, LL; Mitchell, JB; Pacelli, R; Pass, HI; Russo, A | 1 |
| Bishop, JF; Francis, P; Ganju, V; Millward, MJ; Nawaratne, S; Rischin, D; Toner, GC; Webster, LK | 1 |
| Burger, HU; Burris, HA; Drengler, RL; Eckhardt, SG; Griffin, T; Kraynak, M; Moczygemba, J; Reigner, B; Rodrigues, G; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR | 1 |
| Boente, M; Bookman, MA; Gallo, J; Johnson, S; Kindsfather, S; Litwin, S; Millenson, MM; Ozols, RF; Rogers, B; Rosenblum, N; Schilder, RJ | 1 |
| Evtushenko, OI | 1 |
| Beijnen, JH; Koopman, FJ; Malingré, MM; Meerum Terwogt, JM; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; van Tellingen, O | 1 |
| Bianchi, AB; Girit, E; Hellström, I; Hellström, KE; Henderson, AJ; Lasch, S; Trail, PA; TrailSmith, MD; Willner, D | 1 |
| Arakawa, H; Kodera, T; Morishima, H; Morita, M; Nishimura, S; Ohkubo, M; Okura, A | 1 |
| Miller, M | 1 |
| Baccala, P; Berg, D; Clark, JW; Finkelstein, D; Fuchs, CS; Grenon, N; Grossbard, ML; Lynch, TJ; Mayer, RJ; Ryan, DP; Seiden, MV | 1 |
| Antonopoulos, MJ; Katsikas, M; Kosmas, C; Malamos, NA; Polyzos, A; Tsavaris, NB | 1 |
| Ando, Y | 1 |
| Bartholomeus, S; Bleiberg, H; Brassinne, C; Cazenave, I; de Valeriola, D; Hennebert, P; Kerger, J; Kusenda, Z; Lefresne-Soulas, F; Piccart, M; Selleslags, J; Van Den Neste, E; Wythouck, H | 1 |
| Beijnen, JH; Bult, A; Huizing, MT; Lustig, V; Rodenhuis, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; van Warmerdam, LJ | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Hanson, LJ; Kastrissios, H; Klein, CE; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA | 1 |
| Cazenave, LA; Egorin, MJ; Fears, CA; Fears, CL; Fracasso, PM; Litchman, M; Rosen, DM; Westerveldt, P; Westervelt, P; Zuhowski, EG | 1 |
| Hudis, CA; Münster, PN | 1 |
| Egodage, KL; Slavik, M; Svojanovsky, SR; Wilson, GS; Wu, J | 1 |
| Bamias, A; Katsimbri, P; Pavlidis, N | 1 |
| Collins, JM | 1 |
| Bol, CJ; Palmer, PA; Sparreboom, A; van Beurden, V; van der Burg, ME; van der Gaast, A; van Zuylen, L; Verweij, J; Woestenborghs, R | 1 |
| Barnett, D; Oldham, RK; Reid, WK | 1 |
| Aebi, S; Benbatoul, K; Christen, RD; D'Agostino, HR; Darrah, D; de las Alas, MM; Gately, DP; Howell, SB; Kirmani, S; Los, G; McClay, EF; Plaxe, SC; Weiner, DE | 1 |
| Almand, B; Carbone, DP; Clark, JI; Gabrilovich, DI; Kwon, ED; Lindman, B; Nadaf, S; Resser, JR | 1 |
| Cohen, RB; de Souza, P; Haden, K; Mueller, SC | 1 |
| Bishop, J; Boyer, M; Davison, J; Emmett, E; McClure, B; Michael, M; Millward, M; Rischin, D; Smith, J; Zalcberg, J | 1 |
| Beijnen, JH; Duchin, K; Huinink, WW; Koopman, FJ; Lieverst, J; Malingré, MM; Rosing, H; Schellens, JH; Swart, M; Terwogt, JM; van Tellingen, O | 1 |
| Abad, A; Guillot, M; Martin, C; Plasencia, C; Taron, M | 1 |
| Bahlitzanakis, N; Froudarakis, M; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Retalis, G | 1 |
| Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J | 1 |
| Armand, JP; Lavelle, F | 1 |
| Liang, Y; Liu, Q; Wu, D | 1 |
| Burtness, BA; Cheng, Y; DiStasio, SA; Leffert, JJ; Li, X; McKeon, A; Murren, JR; Peccerillo, K; Pizzorno, G | 1 |
| Brouwer, E; Gianni, L; Loos, WJ; Mross, K; Sparreboom, A; van Zuylen, L; Verweij, J | 1 |
| Brouwer, E; Nooter, K; Sparreboom, A; Stoter, G; van Zuylen, L; Verweij, J | 1 |
| Fujiwara, K; Hyodo, I; Kashimura, M; Kurata, T; Saeki, T; Shimada, Y; Takashima, S; Tamura, T; Wakasugi, H; Yamamoto, N | 1 |
| Brooks, SE; Day, RS; Dobson, JM; Doyle, LA; Egorin, MJ; Meisenberg, BR; Nemieboka, NN; Tait, NS; Tkaczuk, KH; Van Echo, DA; Zamboni, WC | 1 |
| Briasoulis, E; Karavasilis, V; Pavlidis, N | 1 |
| Baker, SD; Britten, CD; Denis, LJ; Drengler, R; Duchin, K; Johnson, T; Kuhn, J; Rowinsky, EK; Siu, LL | 1 |
| Apostolaki, S; Georgoulias, V; Kotsakis, A; Koukourakis, M; Mavromanomakis, E; Peraki, M; Sarra, E; Souglakos, J; Vlachonikolis, J | 1 |
| Armand, JP; Bruno, R; Couteau, C; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Lokiec, F; Risse, ML; Riva, A; Rougier, P; Ruffié, P | 1 |
| Hyman, W; Lawson, JM; Maples, PB; Nemunaitis, J; Ordonez, G; Richards, D; Seamour, B; Stein, L; Tong, AW; Vukelja, S | 1 |
| Egorin, MJ; Fracasso, PM; Kerr, I; Litchman, M; Michael, M; Moore, MJ; Oza, AM; Patnaik, A; Rivkin, S; Siu, LL; Warner, E | 1 |
| Böhlke, I; Bokemeyer, C; Derigs, G; Hartmann, JT; Kanz, L; Mayer, F; Schröder, M; Von Pawel, J | 1 |
| Gojo, I; Tkaczuk, KH | 1 |
| Besenval, M; D'Aloisio, S; Daigneault, L; Eisenhauer, E; Fisher, B; Forand, D; Gelmon, KA; Génier, L; Latreille, J; Lebecq, A; Tolcher, A; Vernillet, L | 1 |
| Doyle, LA; Edelman, MJ; Egorin, MJ; Hausner, PF; Meisenberg, BR; Tait, NS; Tkaczuk, KH; Van Echo, DA; Zamboni, WC | 1 |
| Agelaki, S; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Reppa, D; Samonis, G; Souglakos, J; Vardakis, N | 1 |
| Beijnen, JH; Duchin, K; Huinink, WW; Koopman, FJ; Malingré, MM; Rosing, H; Schellens, JH; Swart, M; van Tellingen, O | 1 |
| Iñiguez, C; Larrodé, P; Mauri, JA; Mayordomo, JI; Morales, F; Trés, A | 1 |
| Lokich, J | 1 |
| Abraham, J; Bakke, S; Bates, S; Bergan, R; Chico, I; Choyke, P; Figg, WD; Fojo, T; Goldspiel, B; Kang, MH; Meadows, B; Merino, M; Robey, R; Rutt, A; Smith, T; Steinberg, S | 1 |
| Adelman, D; Breed, J; Fyfe, G; Gaudreault, J; Gordon, MS; Holmgren, E; Margolin, K; Novotny, W; Stalter, S | 1 |
| Gewirtz, AM; Majka, M; Pertusini, E; Ratajczak, J; Ratajczak, MZ; Vaughn, D | 1 |
| Huang, PS; Oliff, A | 1 |
| Beijnen, JH; Koopman, FJ; Malingré, MM; Richel, DJ; Rosing, H; Schellens, JH; Schot, ME; Ten Bokkel Huinink, WW | 1 |
| Adams, AL; Boente, M; Bookman, MA; Ciccotto, S; Gallo, JM; Millenson, MM; Ozols, RF; Padavic-Shallers, K; Rogatko, A; Rogers, B; Rosenblum, N; Schilder, RJ; Weiner, LM | 1 |
| Lorusso, PM | 1 |
| Brescia, FJ; Green, MR; Rocha Lima, CM; Sherman, CA; Urbanic, JJ | 1 |
| Boccardo, F; Foglia, G; Marenghi, C; Miglietta, L; Nizzo, R; Ragni, N | 1 |
| Emens, LA; Jaffee, EM; Machiels, JP; Reilly, RT | 1 |
| Ahmad, I; Ali, S; Janoff, A; Masters, G; Mayhew, E; Minchey, S; Peters, A | 1 |
| Dive, C; Makin, G | 1 |
| Aylesworth, C; Britten, CD; Felton, S; Ferrante, KJ; Gupta, E; Hammond, LA; Hidalgo, M; Molpus, K; Patnaik, A; Rowinsky, EK; Schwartz, G; Skillings, J; Smith, L; Sonnichsen, DS; Stephenson, J; Tortora, A; Weiss, G | 1 |
| Cleary, I; Clynes, M; Connolly, L; Liang, Y; McDonnell, S; Meleady, P | 1 |
| Beijnen, JH; Duchin, K; Koopman, FJ; Lieverst, J; Malingré, MM; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; van Tellingen, O | 2 |
| Aapro, M; Rowinsky, E | 1 |
| Advani, R; Fisher, GA; Halsey, J; Hausdorff, J; Litchman, M; Lum, BL; Sikic, BI | 1 |
| Prescott, LM | 1 |
| Au, JL; Jang, SH; Wientjes, MG | 1 |
| Sparreboom, A; van Zuylen, L; Verweij, J | 1 |
| Beijnen, JH; Bouma, M; Nuijen, B; Schellens, JH | 1 |
| Beijnen, JH; Malingré, MM; Schellens, JH | 1 |
| Bruno, R; Montay, G; Rhodes, GR; Veyrat-Follet, C; Vivier, N | 1 |
| Ratain, MJ; Sawyer, M | 1 |
| Gianni, L; Grasselli, G; Locatelli, A; Vigano, L | 1 |
| Cantrell, CL; Dunleavy, TL; Dunphy, FR; Harrison, BR; Petruska, PJ; Pincus, SM; Richart, JM; Visconti, JL | 1 |
| Kuroi, K; Tanaka, C; Toi, M | 1 |
| Bauer, KS; Bostick-Bruton, F; Figg, WD; Fuse, E; Goldspiel, B; Kohn, EC; Kulpa, V; Liotta, LA; Minasian, L; Noone, M; Pluda, J; Reed, E; Sarosy, GA; Tompkins, A | 1 |
| Hori, H; Kinashi, Y; Masunaga, SI; Murayama, C; Nagasawa, H; Nishimura, Y; Ono, K; Sadahiro, S; Suzuki, M; Takagaki, M; Tsuchiya, I; Uto, Y | 1 |
| Botwood, N | 1 |
| Heymanns, J; Köppler, H; Weide, R | 1 |
| Theisen, C | 1 |
| Beijnen, JH; Hoekman, K; Huijskes, RV; Nannan Panday, VR; Rosing, H; Van den Brande, J; Verheijen, RH; Vermorken, JB | 1 |
| Agelaki, S; Androulakis, N; Christodoulakis, M; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Samonis, G; Sarra, E; Souglakos, J | 1 |
| Dhanikula, AB; Kaul, CL; Kaur, KJ; Panchagnula, R; Sekhon, JS; Singh, I | 1 |
| Beijnen, JH; Duchin, K; Malingré, MM; Schellens, JH; Ten Bokkel Huinink, WW | 1 |
| Anthony, FH; Baker, SD; Bradley, MO; Devanesan, P; Donehower, RC; Swindell, CS; Webb, NL; Witman, PA; Wolff, AC | 1 |
| Beijnen, JH; Mackay, M; Malingré, MM; Schellens, JH; Ten Bokkel Huinink, WW | 1 |
| Bhargava, P; Dahut, W; Figuera, M; Fried, K; Gehan, E; Hanfelt, J; Hawkins, MJ; Lefebvre, P; Marshall, JL; Rizvi, NA; Williams, M | 1 |
| Goldwasser, F; Misset, JL | 1 |
| Altieri, DC; Kim, RW; Li, J; Mesri, M; Wall, NR | 1 |
| Berger, NA; Berger, SJ; Dowlati, A; Gerson, SL; Haaga, J; Liu, L; Remick, SC; Spiro, TP; Willson, JK | 1 |
| Anthony, FH; Baker, SD; Bradley, MO; Chander, MC; Devanesan, P; He, L; Hemamalini, S; Horwitz, SB; Swindell, CS; Webb, NL; Witman, PA | 1 |
| Markman, M; Zanotti, KM | 1 |
| Boyer, J; Ferguson, PR; Harkin, DP; Johnston, PG; Latif, T; Longley, DB; Lynch, M; Maxwell, P | 1 |
| Alexander, W; Chang, EH; Huang, CC; Pirollo, KF; Rait, A; Tang, WH; Xiang, LM; Xu, L | 1 |
| Horowitz, J | 1 |
| Banerjee, D | 1 |
| Bardelmeijer, HA; Beijnen, JH; Koopman, FJ; Malingré, MM; Ouwehand, M; Rosing, H; Schellens, JH; Schot, ME; Ten Bokkel Huinink, WW; Van Tellingen, O | 1 |
| Inoue, S; Omoteyama, K; Salah-Eldin, AE | 1 |
| Behringer, D; Gelderblom, H; Mielke, S; Mross, K; Sparreboom, A; ten Tije, AJ; van Zomeren, DM; Verweij, J | 1 |
| Whelan, J | 1 |
| Wilke, H | 1 |
| Bertucci, D; Eng, C; Fleming, GF; Jacobs, RH; Mauer, AM; Ratain, MJ; Rotmensch, J | 1 |
| Blanchard, JM | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| de Wit, R; Loos, WJ; Louwerens, M; Smorenburg, C; Sparreboom, A; Verweij, J | 1 |
| Garfield, D | 1 |
| Prendergast, GC | 1 |
| Iimura, S; Ishiyama, T; Ohsuki, S; Soga, T; Terasawa, H; Uoto, K | 1 |
| Christodoulou, C; Efstathiou, E; Klouvas, G; Papazachariou, E; Plyta, M; Skarlos, DV; Zervakis, D | 1 |
| Brant, J; Nielsen, E | 1 |
| Barazzoul, J; Eden, L; Endres, S; Ilson, D; Kelsen, D; Maslak, P; O'Reilly, E; Perkins, P; Saltz, L; Schwartz, GK; Sharma, S; Spriggs, D; Stoltz, M; Tong, W | 1 |
| Balcerzak, S; Bender, J; Brooks, R; Chan, KK; D'Ambrosio, S; Gibson-D'Ambrosio, R; Grever, M; Kraut, E; Liu, J; Stanley, H | 1 |
| Hasegawa, K; Hiramatsu, Y; Hongo, A; Kodama, J; Kudo, T; Kuramoto, H; Masuyama, H; Mizutani, Y; Nagao, S; Okuda, H; Yoshinouchi, M | 1 |
| Oza, AM | 1 |
| Ahmed, FY; Cassidy, J; Ferguson, MJ | 1 |
| Bedikian, A; Desai, N; Ellerhorst, JA; Esmaeli, B; Hortobagyi, GN; Ibrahim, NK; Legha, S; Ring, SE; Rivera, E; Soon-Shiong, P; Theriault, RL | 1 |
| Boehme, C; Cerny, T; D'Addario, G; Morant, R | 1 |
| Bol, CJ; Brouwer, E; de Vries, R; Eskens, FA; Nooter, K; Palmer, PA; Sparreboom, A; van der Gaast, A; van Zuylen, L; Verweij, J | 1 |
| Baker, SD; Brahmer, JR; Sparreboom, A; Verweij, J; Zhao, M | 1 |
| Clinton, S; Erdal, S; Hauger, M; Kraut, E; Monk, P; Nadella, P; Otterson, GA; Shah, M; Shapiro, C; Stanek, M; Villalona-Calero, MA | 1 |
| Briasoulis, E; Haidou, C; Karavasilis, V; Pavlidis, N; Piperidou, C; Tzamakou, E | 1 |
| Amiji, M; Nsereko, S | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, Ch; Mavroudis, D; Samonis, G; Souglakos, J | 1 |
| Beck, J; Boehlke, I; Bokemeyer, C; Hartmann, JT; Kanz, L; Mayer, F; Schroeder, M; von Pawel, J | 1 |
| Marchettini, P; Mohamed, F; Stuart, OA; Sugarbaker, PH; Yoo, D | 1 |
| Amato, I | 1 |
| Cheson, BD | 1 |
| Bayssas, MM; Benvenuto, J; Bready, B; Fuentes, A; Jaiyesimi, I; Moore, D; Newman, BM; Newman, RA; Pazdur, R; Vreeland, F | 1 |
| Kaye, SB; Schwartsmann, G; Workman, P | 1 |
| Arbuck, SG; Canetta, RM; Onetto, N; Rowinsky, EK | 1 |
| Pokalo, CL | 1 |
| Spriggs, DR; Tondini, C | 1 |
| Edgington, SM | 1 |
| Lavelle, F; Naudin, A; Riou, JF | 1 |
| Weiss, RB | 1 |
| Brown, T; Cagnola, J; Craig, J; Havlin, K; Koeller, J; Kuhn, J; Phillips, J; Rizzo, J; Von Hoff, D; Weiss, G | 1 |
| Langreth, R | 1 |
| Aldhous, P | 1 |
| Clark, B; Ettinger, DS; Forastiere, AA; Gilbert, MR; Grochow, LB; Lubejko, BG; McGuire, WP; Noe, DA; Rowinsky, EK; Sartorius, SE | 1 |
| Christian, MC; Donehower, RC; Fisherman, JS; Guarnieri, T; McGuire, WP; Rowinsky, EK | 1 |
| Hiller, S | 1 |
| Chabner, BA; Clendennin, NJ; Horwitz, SB; Purvis, JD | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Diasio, RB; Stagg, MP | 1 |
| Krakoff, IR; Legha, SS; Tenney, DM | 1 |
| Gralla, RJ; Kris, MG; O'Connell, JP; Parente, RM; Schiff, PB; Wertheim, MS; Young, CW | 1 |
| Brundrett, RB; Cates, AE; Chen, TL; Colvin, M; Donehower, RC; Ettinger, DS; Grochow, LB; Longnecker, SM | 1 |
| Dutcher, JP; Lipton, RB; Paietta, E; Schwartz, EL; Strauman, JJ; Wiernik, PH | 1 |
| Dutcher, JP; Einzig, A; Lipton, RB; Schwartz, EL; Strauman, JJ; Wiernik, PH | 1 |
| Chen, X; Gu, J; Huang, M; Yin, D; Zhang, M; Zhao, X | 1 |
| Du, J; Gu, C; Han, M; Lu, W; Qiao, J; Shang, W; Wang, W; Yin, W; Zhu, M | 1 |
276 review(s) available for paclitaxel and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
Quest for Efficacious Next-Generation Taxoid Anticancer Agents and Their Tumor-Targeted Delivery.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Taxoids | 2018 |
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Chemistry, Pharmaceutical; Humans; Inflammation; Neoplasms; Pyrimidines; Structure-Activity Relationship | 2019 |
Coumarin-containing hybrids and their anticancer activities.
Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure-Activity Relationship | 2019 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Artemisia: a promising plant for the treatment of cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Artemisia; Cell Proliferation; Humans; Molecular Structure; Neoplasms; Neoplasms, Experimental; Plant Extracts; Plants, Medicinal | 2020 |
Emerging nanotechnology based combination therapies of taxanes for multiple drug-resistant cancers.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Gold; Metal Nanoparticles; Micelles; Nanotechnology; Neoplasms; Paclitaxel; Taxoids | 2022 |
Emerging nanomedicines of paclitaxel for cancer treatment.
Topics: Cell Line, Tumor; Drug Delivery Systems; Humans; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel; Prodrugs | 2022 |
The interactions of paclitaxel with tumour microenvironment.
Topics: Antineoplastic Agents; Humans; Immunotherapy; Neoplasms; Paclitaxel; Tumor Microenvironment | 2022 |
The development of peptide-drug conjugates (PDCs) strategies for paclitaxel.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell-Penetrating Peptides; Humans; Neoplasms; Paclitaxel; Water | 2022 |
Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity.
Topics: Drug Resistance; Drug Resistance, Neoplasm; Humans; MicroRNAs; Neoplasms; Paclitaxel; RNA, Circular; RNA, Long Noncoding; RNA, Untranslated | 2022 |
Mechanistic Insights and Docking Studies of Phytomolecules as Potential Candidates in the Management of Cancer.
Topics: Antineoplastic Agents; Bibenzyls; Colchicine; Curcumin; Humans; Molecular Docking Simulation; Neoplasms; Paclitaxel | 2022 |
Mechanisms of cancer cell death induction by paclitaxel: an updated review.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Mitosis; Neoplasms; Paclitaxel | 2022 |
Natural Radiosensitizers in Radiotherapy: Cancer Treatment by Combining Ionizing Radiation with Resveratrol.
Topics: Biological Products; Curcumin; Genistein; Humans; Neoplasms; Paclitaxel; Papaverine; Radiation Tolerance; Radiation-Sensitizing Agents; Radiation, Ionizing; Resveratrol | 2022 |
Recent Developments and Anticancer Therapeutics of Paclitaxel: An Update.
Topics: Antineoplastic Agents; Humans; Nanoparticles; Neoplasms; Paclitaxel; Taxus | 2022 |
Paclitaxel resistance related to nuclear envelope structural sturdiness.
Topics: Apoptosis; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Neoplasms; Nuclear Envelope; Paclitaxel; Taxoids | 2022 |
Pembrolizumab versus paclitaxel for previously treated, advanced gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized clinical trials.
Topics: Humans; Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2022 |
Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasms; Odds Ratio; Paclitaxel; Prospective Studies; Sarcopenia | 2023 |
Natural Taxanes: From Plant Composition to Human Pharmacology and Toxicity.
Topics: Female; Humans; Male; Neoplasms; Paclitaxel; Plant Extracts; Taxoids; Taxus | 2022 |
Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy.
Topics: Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Humans; Neoplasms; Nucleic Acids; Paclitaxel | 2023 |
Current Perspectives on Paclitaxel: Focus on Its Production, Delivery and Combination Therapy.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Humans; Neoplasms; Paclitaxel; Polymers | 2023 |
Epothilones as Natural Compounds for Novel Anticancer Drugs Development.
Topics: Antineoplastic Agents; Capecitabine; Epothilones; Humans; Neoplasms; Paclitaxel; Tubulin Modulators | 2023 |
Nano delivery system for paclitaxel: Recent advances in cancer theranostics.
Topics: Cell Line, Tumor; Drug Delivery Systems; Humans; Nanoparticle Drug Delivery System; Nanoparticles; Neoplasms; Paclitaxel; Precision Medicine | 2023 |
From plant to cancer drug: lessons learned from the discovery of taxol.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Products; Humans; Neoplasms; Paclitaxel; Plants; Population Health | 2023 |
Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
Topics: Antineoplastic Agents, Immunological; B7-H1 Antigen; Humans; Hypothyroidism; Immune Checkpoint Inhibitors; Neoplasms; Network Meta-Analysis; Paclitaxel; Pneumonia; Programmed Cell Death 1 Receptor | 2023 |
Site-specific delivery of cisplatin and paclitaxel mediated by liposomes: A promising approach in cancer chemotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Delivery Systems; Humans; Liposomes; Neoplasms; Paclitaxel | 2023 |
Chitosan-based advanced materials for docetaxel and paclitaxel delivery: Recent advances and future directions in cancer theranostics.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Chitosan; Docetaxel; Drug Carriers; Humans; Hydrogen-Ion Concentration; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel; Solubility; Static Electricity; Theranostic Nanomedicine | 2020 |
Reaction of carbon monoxide with cystathionine β-synthase: implications on drug efficacies in cancer chemotherapy.
Topics: Antineoplastic Agents; Carbon Monoxide; Cystathionine beta-Synthase; Doxorubicin; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Reactive Oxygen Species | 2020 |
Recent advances in understanding chemotherapy-induced peripheral neuropathy.
Topics: Antineoplastic Agents; Humans; Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Quality of Life | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
The Research Progress of Taxol in Taxus.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomedical Research; Humans; Neoplasms; Paclitaxel; Taxus | 2021 |
Curcumin in cancer therapy: A novel adjunct for combination chemotherapy with paclitaxel and alleviation of its adverse effects.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Curcumin; Humans; Neoplasms; Paclitaxel | 2020 |
[Progress on utilizing mesenchymal stem cells as cellular delivery system for targeting delivery of as drug/gene for anti-tumor therapy].
Topics: Antineoplastic Agents; Doxorubicin; Drug Delivery Systems; Gene Transfer Techniques; Humans; Mesenchymal Stem Cells; Neoplasms; Paclitaxel; Research | 2020 |
When Taxol met tubulin.
Topics: Animals; History, 20th Century; History, 21st Century; Humans; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Tubulin | 2020 |
Gold nanoparticle‑mediated delivery of paclitaxel and nucleic acids for cancer therapy (Review).
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Gold; Humans; Metal Nanoparticles; Neoplasms; Nucleic Acids; Paclitaxel | 2020 |
Recent Advances in Paclitaxel-based Self-Delivery Nanomedicine for Cancer Therapy.
Topics: Cell Line, Tumor; Drug Delivery Systems; Drug Therapy, Combination; Humans; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel | 2021 |
Biotechnological approaches to the production of plant-derived promising anticancer agents: An update and overview.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Biotechnology; Humans; Lignans; Neoplasms; Paclitaxel; Plants, Medicinal | 2020 |
KANK family proteins in cancer.
Topics: Actin Cytoskeleton; Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Focal Adhesions; Gene Expression Regulation, Neoplastic; Humans; Microtubules; Neoplasms; Paclitaxel; Protein Domains; Signal Transduction; Treatment Outcome; Vincristine | 2021 |
Microtubule cytoskeleton-disrupting activity of MWCNTs: applications in cancer treatment.
Topics: Apoptosis; Cell Cycle; Centrosome; Cytoskeleton; Humans; Microtubules; Nanotubes, Carbon; Neoplasms; Paclitaxel; Phenotype; Tubulin | 2020 |
A Compressive Review about Taxol
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Drug Resistance, Neoplasm; Humans; M Phase Cell Cycle Checkpoints; Microtubules; Neoplasms; Paclitaxel; Taxus | 2020 |
Research progress on the source, production, and anti-cancer mechanisms of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Paclitaxel | 2020 |
Role of non-coding RNAs in modulating the response of cancer cells to paclitaxel treatment.
Topics: Animals; Antineoplastic Agents; CRISPR-Cas Systems; Drug Carriers; Drug Compounding; Drug Resistance, Neoplasm; Gene Editing; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasms; Oligonucleotides; Paclitaxel; RNA, Long Noncoding; Signal Transduction | 2021 |
Angiogenesis Inhibitors as Anti-Cancer Therapy Following Renal Transplantation: A Case Report and Review of the Literature.
Topics: Angiogenesis Inhibitors; Bevacizumab; Humans; Kidney Transplantation; Neoplasms; Paclitaxel | 2021 |
The Uniqueness of Albumin as a Carrier in Nanodrug Delivery.
Topics: Albumins; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Carriers; Half-Life; Humans; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Neoplasms; Paclitaxel; Serum Albumin, Human | 2021 |
Dichotomous role of microtubule associated protein tau as a biomarker of response to and a target for increasing efficacy of taxane treatment in cancers of epithelial origin.
Topics: Biomarkers; Humans; Microtubules; Neoplasms; Paclitaxel; tau Proteins; Taxoids; Tubulin | 2021 |
Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Drug Carriers; Drug Compounding; Drug Delivery Systems; Gelatin; Humans; Milk Proteins; Nanoparticles; Neoplasms; Paclitaxel; Plant Proteins; Serum Albumin | 2021 |
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers; Genome-Wide Association Study; Humans; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Pharmacogenetics | 2021 |
New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Neoplasms; Paclitaxel | 2021 |
Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review).
Topics: Antineoplastic Combined Chemotherapy Protocols; Curcumin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel | 2017 |
Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel.
Topics: Animals; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Humans; Neoplasms; Paclitaxel; Pharmacogenetics; Taxoids | 2017 |
Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Humans; Microtubule-Associated Proteins; Microtubules; Neoplasms; Paclitaxel | 2017 |
[Advances and prospects of taxol biosynthesis by endophytic fungi].
Topics: Endophytes; Fungi; Industrial Microbiology; Microorganisms, Genetically-Modified; Neoplasms; Paclitaxel; Taxus | 2016 |
Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?
Topics: Animals; Anti-Inflammatory Agents; Antimitotic Agents; Antineoplastic Agents; Humans; Micronuclei, Chromosome-Defective; Neoplasms; Paclitaxel | 2017 |
The Use of Liposomes and Nanoparticles as Drug Delivery Systems to Improve Cancer Treatment in Dogs and Cats.
Topics: Animals; Antibiotics, Antineoplastic; Cat Diseases; Cats; Cisplatin; Clinical Trials as Topic; Databases, Factual; Dog Diseases; Dogs; Doxorubicin; Drug Compounding; Liposomes; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols | 2017 |
Paclitaxel loaded vitamin E-TPGS nanoparticles for cancer therapy.
Topics: Animals; Drug Delivery Systems; Humans; Nanoparticles; Nanotechnology; Neoplasms; Paclitaxel; Vitamin E | 2018 |
Synthesis and Activity of Epothilone D.
Topics: Cell Survival; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Epothilones; Humans; Mitosis; Neoplasms; Paclitaxel; Tubulin Modulators | 2018 |
Are Microbial Endophytes the 'Actual' Producers of Bioactive Antitumor Agents?
Topics: Animals; Antineoplastic Agents; Bacteria; Biological Products; Endophytes; Fungi; Humans; Maytansine; Neoplasms; Paclitaxel; Plants; Porifera; Rhizosphere; Urochordata | 2018 |
Basic principles of drug delivery systems - the case of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Biological Availability; Biological Transport; Drug Delivery Systems; Drug Stability; Emulsions; Glycerol; Humans; Microtubules; Mitosis; Nanostructures; Neoplasms; Paclitaxel; Solubility; Solvents; Tumor Cells, Cultured | 2019 |
The effect of diabetes mellitus on pharmacokinetics, pharmacodynamics and adverse drug reactions of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperglycemia; Insulin; Neoplasms; Paclitaxel | 2019 |
Mesenchymal Stem Cell-Derived Extracellular Vesicles as Therapeutics and as a Drug Delivery Platform.
Topics: Drug Carriers; Extracellular Vesicles; Humans; Lysosomal-Associated Membrane Protein 2; Mesenchymal Stem Cells; Metabolic Engineering; Neoplasms; Paclitaxel; Regeneration; Tetraspanins | 2019 |
Combined strategies for tumor immunotherapy with nanoparticles.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Dendritic Cells; Docetaxel; Doxorubicin; Galectin 1; Gold; Humans; Immunity, Cellular; Immunity, Humoral; Immunotherapy; Killer Cells, Natural; Lymphocyte Activation; Macrophage Activation; Nanoparticles; Neoplasms; Organ Specificity; Paclitaxel; Receptors, Chimeric Antigen | 2019 |
Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Humans; Incidence; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Solvents | 2019 |
Prophylactic management for taxane-induced nail toxicity: A systematic review and meta-analysis.
Topics: Cryotherapy; Docetaxel; Humans; Nail Diseases; Neoplasms; Oils, Volatile; Onycholysis; Paclitaxel; Paronychia; Pigmentation Disorders; Plant Oils; Taxoids; Waxes | 2019 |
Progress in research on paclitaxel and tumor immunotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotechnology; Fermentation; Fungi; Humans; Immunotherapy; Neoplasms; Paclitaxel | 2019 |
Rewiring cellular metabolism for heterologous biosynthesis of Taxol.
Topics: Antineoplastic Agents, Phytogenic; Humans; Metabolic Engineering; Neoplasms; Paclitaxel; Taxus; Trees | 2020 |
Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Doxorubicin; Drug Delivery Systems; Humans; Liposomes; Neoplasms; Paclitaxel; Treatment Outcome | 2013 |
[Paclitaxel induced apoptotic genes and pathways alterations: a review].
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Humans; MAP Kinase Signaling System; Neoplasms; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphatidylinositol 3-Kinases; Signal Transduction | 2013 |
nab-Paclitaxel mechanisms of action and delivery.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Paclitaxel | 2013 |
Defining risks of taxane neuropathy: insights from randomized clinical trials.
Topics: Axons; Bridged-Ring Compounds; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Nanoparticles; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Randomized Controlled Trials as Topic; Taxoids | 2013 |
Germline pharmacogenetics of paclitaxel for cancer treatment.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Genome-Wide Association Study; Germ Cells; Humans; Neoplasms; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide | 2013 |
Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs.
Topics: Albumins; Animals; Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Humans; Nanoparticles; Neoplasms; Paclitaxel; Treatment Outcome | 2013 |
Dosing considerations for obese patients receiving cancer chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Docetaxel; Humans; Neoplasms; Obesity; Paclitaxel; Taxoids; Vincristine | 2013 |
Nature as a remarkable chemist: a personal story of the discovery and development of Taxol.
Topics: Antineoplastic Agents, Phytogenic; Drug Discovery; Humans; Neoplasms; Paclitaxel | 2014 |
Safety and efficacy evaluation of albumin-bound paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Humans; Neoplasms; Paclitaxel | 2014 |
A clinical update of using albumin as a drug vehicle - a commentary.
Topics: Albumin-Bound Paclitaxel; Albumins; Diabetes Mellitus; Doxorubicin; Drug Carriers; Humans; Insulin Detemir; Insulin, Long-Acting; Molecular Structure; Neoplasms; Paclitaxel; Serum Albumin | 2014 |
Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel--a review.
Topics: Administration, Metronomic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Interactions; Humans; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Taxoids | 2014 |
Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Female; Humans; Liver Diseases; Logistic Models; Male; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Nonlinear Dynamics; Paclitaxel; Young Adult | 2014 |
The drug discovery by nanomedicine and its clinical experience.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Cisplatin; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Drug Discovery; Epirubicin; Gas Chromatography-Mass Spectrometry; Humans; Mass Spectrometry; Micelles; Nanomedicine; Nanoparticles; Neoplasms; Neoplasms, Experimental; Organoplatinum Compounds; Paclitaxel; Polyethylene Glycols; Polyglutamic Acid; Proteins | 2014 |
In vivo imaging as a pharmacodynamic marker.
Topics: Antineoplastic Agents; Carbon Radioisotopes; Docetaxel; Fluorine Radioisotopes; Humans; Neoplasms; Paclitaxel; Positron-Emission Tomography; Taxoids; Tissue Distribution; Treatment Outcome | 2014 |
Paclitaxel formulations: challenges and novel delivery options.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Proliferation; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Nanostructures; Neoplasms; Paclitaxel; Structure-Activity Relationship | 2014 |
From stealthy polymersomes and filomicelles to "self" Peptide-nanoparticles for cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Humans; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Peptides; Polymers; Tumor Burden | 2014 |
Progress of drug-loaded polymeric micelles into clinical studies.
Topics: Antineoplastic Agents; Camptothecin; Delayed-Action Preparations; Drug Carriers; Epirubicin; Humans; Irinotecan; Micelles; Neoplasms; Paclitaxel; Platinum Compounds; Polymers | 2014 |
Nab-paclitaxel: a flattering facelift.
Topics: Albumins; Animals; Antineoplastic Agents; Biological Transport; Biomarkers; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Nanomedicine; Neoplasms; Paclitaxel; Treatment Outcome | 2014 |
Elastin-like polypeptide for improved drug delivery for anticancer therapy: preclinical studies and future applications.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Drug Delivery Systems; Elastin; Hot Temperature; Humans; Neoplasms; Paclitaxel; Peptides; Permeability | 2015 |
Metabolism of the taxanes including nab-paclitaxel.
Topics: Albumins; Animals; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Humans; Liver; Neoplasms; Paclitaxel; Taxoids | 2015 |
Epothilones: From discovery to clinical trials.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Clinical Trials as Topic; Drug Design; Epothilones; Humans; Microtubules; Mitosis; Molecular Docking Simulation; Neoplasms; Paclitaxel; Protein Binding; Structure-Activity Relationship; Tubulin Modulators | 2014 |
Natural products as antimitotic agents.
Topics: Antimitotic Agents; Antineoplastic Agents; Bibenzyls; Biological Products; Humans; Ligands; Microtubules; Neoplasms; Paclitaxel; Protein Binding; Structure-Activity Relationship; Tubulin; Vinca Alkaloids | 2014 |
Tubulins - the target for anticancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Chalcones; Clinical Trials as Topic; Colchicine; Humans; Macrolides; Neoplasms; Paclitaxel; Protein Binding; Structure-Activity Relationship; Tubulin; Tubulin Modulators; Vinca Alkaloids | 2015 |
Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Killer Cells, Natural; Neoplasms; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Escape; Tumor Microenvironment | 2015 |
The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Nail Diseases; Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators | 2015 |
Reinvention of chemotherapy: drug conjugates and nanoparticles.
Topics: Ado-Trastuzumab Emtansine; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Drug Carriers; Humans; Maytansine; Nanoparticles; Nanotechnology; Neoplasms; Paclitaxel; Trastuzumab | 2015 |
Efficient delivery of therapeutic agents by using targeted albumin nanoparticles.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Extracellular Matrix; Folic Acid; Humans; Hydrophobic and Hydrophilic Interactions; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Paclitaxel; Transferrin | 2015 |
Microtubule-Binding Proteins as Promising Biomarkers of Paclitaxel Sensitivity in Cancer Chemotherapy.
Topics: Biomarkers, Tumor; Drug Resistance, Neoplasm; Humans; Microtubule Proteins; Neoplasms; Paclitaxel; Precision Medicine | 2016 |
Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis.
Topics: Albumins; Antineoplastic Agents; Humans; Incidence; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Risk; Severity of Illness Index; Taxoids | 2017 |
Treatment regimens of classical and newer taxanes.
Topics: Albumins; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Liver; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome; Tubulin Modulators | 2016 |
Taxane anticancer agents: a patent perspective.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Drug Design; Female; Humans; Male; Nanostructures; Neoplasms; Paclitaxel; Patents as Topic; Taxoids | 2016 |
Lenvatinib: Role in thyroid cancer and other solid tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Everolimus; Humans; Infant; Iodine Radioisotopes; Mice; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Receptors, Growth Factor; Signal Transduction; Thyroid Neoplasms; Thyroidectomy; Xenograft Model Antitumor Assays | 2016 |
PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Gels; Humans; Lactates; Micelles; Neoplasms; Paclitaxel; Phase Transition; Polyesters; Polyethylene Glycols; Solubility | 2016 |
Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance).
Topics: Alleles; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Male; Multidrug Resistance-Associated Protein 2; Neoplasms; Odds Ratio; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide | 2016 |
A review of the ligands and related targeting strategies for active targeting of paclitaxel to tumours.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Humans; Ligands; Micelles; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Paclitaxel; Protein Binding; Receptors, Cell Surface | 2016 |
Recent advances in design, synthesis and bioactivity of paclitaxel-mimics.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Multiple; Humans; Mice; Molecular Structure; Neoplasms; Paclitaxel; Taxoids | 2016 |
Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Camptothecin; Cisplatin; Doxorubicin; Humans; Irinotecan; Neoplasms; Paclitaxel; Polyethylene Glycols; Treatment Outcome | 2016 |
Nanocarriers in cancer clinical practice: a pharmacokinetic issue.
Topics: Antineoplastic Agents; Doxorubicin; Drug Carriers; Drug Delivery Systems; Humans; Neoplasms; Paclitaxel; Quality of Life | 2017 |
Diverse macrophages polarization in tumor microenvironment.
Topics: Adaptive Immunity; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Movement; Cell Polarity; Cytokines; Humans; Immunity, Innate; Macrophage Activation; Macrophages; Neoplasms; Paclitaxel; Tumor Microenvironment | 2016 |
Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; China; Dexamethasone; Drug Hypersensitivity; Humans; Injections, Intravenous; Neoplasms; Paclitaxel; Premedication | 2017 |
Patent Survey of Resveratrol, Taxol, Podophyllotoxin, Withanolides and Their Derivatives Used in Anticancer Therapy.
Topics: Humans; Neoplasms; Paclitaxel; Patents as Topic; Podophyllotoxin; Resveratrol; Stilbenes; Withanolides | 2017 |
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.
Topics: Androgen Antagonists; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Estrogen Receptor Modulators; Fluorouracil; Gemcitabine; Humans; Metformin; Methotrexate; Neoplasms; Paclitaxel; Tubulin Modulators | 2017 |
The battle of "nano" paclitaxel.
Topics: Animals; Humans; Nanoparticles; Neoplasms; Paclitaxel | 2017 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
Taxanes in the elderly: can we gain as much and be less toxic?
Topics: Aged; Aged, 80 and over; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2009 |
OncoGel (ReGel/paclitaxel)--clinical applications for a novel paclitaxel delivery system.
Topics: Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Carriers; Humans; Neoplasms; Paclitaxel; Polyethylene Glycols; Polyglactin 910 | 2009 |
A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; BRCA1 Protein; Cell Line, Tumor; Cisplatin; Female; Genes, BRCA1; Humans; Neoplasms; Oxidoreductases; Paclitaxel; Phenotype; Treatment Outcome | 2009 |
Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery.
Topics: Albumin-Bound Paclitaxel; Albumins; Clinical Trials as Topic; Drug Delivery Systems; Humans; Neoplasms; Paclitaxel | 2009 |
Microtubules and resistance to tubulin-binding agents.
Topics: Animals; Drug Resistance, Neoplasm; Humans; Microtubules; Neoplasms; Paclitaxel; Protein Binding; Tubulin; Tubulin Modulators | 2010 |
Liposomal doxorubicin and nab-paclitaxel: nanoparticle cancer chemotherapy in current clinical use.
Topics: Albumins; Doxorubicin; Humans; Liposomes; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel | 2010 |
Scheduling of taxanes: a review.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Drug Administration Schedule; Humans; Neoplasms; Paclitaxel; Taxoids; Trastuzumab | 2010 |
Pharmacogenomics of paclitaxel.
Topics: Clinical Trials as Topic; Humans; Microtubules; Neoplasms; Paclitaxel; Pharmacogenetics | 2010 |
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Neoplasms; Paclitaxel; Receptors, Notch; Signal Transduction; Tamoxifen; Taxoids; Trastuzumab | 2010 |
PET imaging of multidrug resistance in tumors using 18F-fluoropaclitaxel.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorine Radioisotopes; Humans; Neoplasms; Paclitaxel; Positron-Emission Tomography | 2010 |
Liposomal cisplatin: a new cisplatin formulation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Evaluation, Preclinical; Female; Humans; Male; Nanoparticles; Neoplasms; Paclitaxel | 2010 |
[Non-pegylated doxorubicin (Myocet®) as the less cardiotoxic alternative of free doxorubicin].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Doxorubicin; Heart Diseases; Humans; Neoplasms; Paclitaxel; Taxoids; Trastuzumab | 2010 |
Albumin-bound paclitaxel: the benefit of this new formulation in the treatment of various cancers.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Neoplasms; Paclitaxel; Standard of Care; Taxoids | 2011 |
Src family kinases and paclitaxel sensitivity.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Neoplasms; Paclitaxel; RNA Interference; src-Family Kinases | 2011 |
The role of Tau protein in resistance to paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; tau Proteins; Taxoids | 2011 |
Enabling anticancer therapeutics by nanoparticle carriers: the delivery of Paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Drug Carriers; Humans; Lactic Acid; Magnetite Nanoparticles; Metal Nanoparticles; Nanoparticles; Nanotubes, Carbon; Neoplasms; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2011 |
The two faces of FBW7 in cancer drug resistance.
Topics: Amyloid Precursor Protein Secretases; Apoptosis; Benzenesulfonates; Biphenyl Compounds; Cell Cycle Proteins; Drug Resistance, Neoplasm; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; MAP Kinase Signaling System; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Niacinamide; Nitrophenols; Paclitaxel; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Sulfonamides; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Ubiquitination; Vincristine | 2011 |
Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.
Topics: Animals; Antineoplastic Agents; Apoptosis; Humans; Nanomedicine; Neoplasms; Paclitaxel | 2011 |
Local drug delivery strategies for cancer treatment: gels, nanoparticles, polymeric films, rods, and wafers.
Topics: Antineoplastic Agents, Phytogenic; Biocompatible Materials; Chitosan; Decanoic Acids; Drug Delivery Systems; Gels; Humans; Microspheres; Nanoparticles; Neoplasms; Paclitaxel; Polyesters; Polymers | 2012 |
Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis.
Topics: Antineoplastic Agents, Phytogenic; Humans; Neoplasm Staging; Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Clinical development of new formulations of cytotoxics in solid tumors.
Topics: Aminopterin; Anthracyclines; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Folic Acid Antagonists; Humans; Irinotecan; Neoplasms; Paclitaxel; Topoisomerase I Inhibitors | 2012 |
Drug profiles.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Drug Approval; Drug Costs; Humans; Ipilimumab; Lenalidomide; Medical Oncology; Neoplasms; Paclitaxel; Thalidomide | 2012 |
Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Bone Marrow; Carboplatin; Cell Cycle Proteins; Databases, Genetic; DNA-Binding Proteins; Female; Gene Expression; Genetic Markers; Lung Neoplasms; Male; Neoplasms; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins | 2012 |
Polymer nanoparticles--a novel strategy for administration of Paclitaxel in cancer chemotherapy.
Topics: Antibodies; Antineoplastic Agents, Phytogenic; Aptamers, Nucleotide; Drug Carriers; Folic Acid; Humans; Hydrogen-Ion Concentration; Nanoparticles; Neoplasms; Paclitaxel; Peptides; Polymers; Receptors, Vascular Endothelial Growth Factor | 2012 |
Liposomal paclitaxel formulations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Humans; Liposomes; Neoplasms; Paclitaxel | 2012 |
Update on taxane development: new analogs and new formulations.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Approval; Drug Design; Humans; Neoplasms; Paclitaxel; Taxoids; United States; United States Food and Drug Administration | 2012 |
[nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Chemistry, Pharmaceutical; Female; Humans; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel | 2013 |
The pharmacological bases of the antiangiogenic activity of paclitaxel.
Topics: Angiogenesis Inhibitors; Angiotensin I; Antineoplastic Agents, Phytogenic; Gene Expression Regulation, Neoplastic; Humans; Liposomes; Models, Molecular; Nanoparticles; Neoplasms; Paclitaxel; Thrombospondin 1; Vascular Endothelial Growth Factor A | 2013 |
[Prevention and treatment for adverse events induced by chemotherapy].
Topics: Anaphylaxis; Antineoplastic Agents; Brain Diseases; Cisplatin; Docetaxel; Fluorouracil; Humans; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Vomiting, Anticipatory | 2002 |
Poly(L-glutamic acid)--anticancer drug conjugates.
Topics: Anthracyclines; Antimetabolites; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; DNA; Drug Carriers; Drug Delivery Systems; Humans; Neoplasms; Paclitaxel; Polyglutamic Acid | 2002 |
Weekly administration of paclitaxel: theoretical and clinical basis.
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Neoplasms; Paclitaxel | 2002 |
CSE1L/CAS: its role in proliferation and apoptosis.
Topics: Active Transport, Cell Nucleus; alpha Karyopherins; Animals; Apoptosis; Cell Division; Cellular Apoptosis Susceptibility Protein; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Knockout; Mitosis; Models, Biological; Neoplasms; Paclitaxel; Phosphorylation; Tumor Cells, Cultured | 2003 |
Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Interleukin-6; Neoplasms; Paclitaxel; Tubulin | 2003 |
Potential for combined modality therapy of cyclooxygenase inhibitors and radiation.
Topics: Angiogenesis Inhibitors; Animals; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Docetaxel; Humans; Isoenzymes; Lung Neoplasms; Membrane Proteins; Neoplasms; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Radiation-Sensitizing Agents; Taxoids | 2003 |
[Hypersensitivity reactions to cancer chemotherapeutic agents].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cisplatin; Drug Eruptions; Drug Hypersensitivity; Fever; Histamine H1 Antagonists; Humans; Lymphoma, Non-Hodgkin; Neoplasms; Paclitaxel; Respiration Disorders; Rituximab; Trastuzumab | 2003 |
BMS-184476 Bristol-Myers Squibb.
Topics: Animals; Clinical Trials, Phase II as Topic; Drugs, Investigational; Humans; Neoplasms; Paclitaxel; Taxoids; Technology, Pharmaceutical | 2003 |
Management of toxicities associated with the administration of taxanes.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2003 |
Mode of action of docetaxel - a basis for combination with novel anticancer agents.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Follow-Up Studies; Humans; Male; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pharmacogenetics; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Mechanisms of Taxol resistance related to microtubules.
Topics: Amino Acid Sequence; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Microtubules; Molecular Sequence Data; Neoplasms; Paclitaxel; Tubulin | 2003 |
Prevention of chemotherapy and radiation toxicity with glutamine.
Topics: Anthracyclines; Antineoplastic Agents; Dietary Supplements; Digestive System; Glutamine; Glutathione; Heart Diseases; Humans; Neoplasms; Paclitaxel; Radiation Injuries | 2003 |
Microtubules as a target for anticancer drugs.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Cycle; Colchicine; Drug Resistance, Neoplasm; Drug Synergism; Humans; Microtubules; Neoplasms; Paclitaxel; Spindle Apparatus; Vinca Alkaloids | 2004 |
Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Drug Interactions; Humans; Membrane Glycoproteins; Molecular Structure; Neoplasms; Paclitaxel; Receptors, Tumor Necrosis Factor; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2004 |
Preclinical pharmacology of the taxanes: implications of the differences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2004 |
Tubulin-targeting agents.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Paclitaxel; Taxoids; Tubulin | 2003 |
CT-2103: emerging utility and therapy for solid tumours.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Polyglutamic Acid; Taxoids | 2004 |
[Association of taxanes and radiotherapy: preclinical and clinical studies].
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Tumor Cells, Cultured | 2004 |
New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Synergism; Humans; Microtubule-Associated Proteins; Microtubules; Neoplasms; Paclitaxel; Sensitivity and Specificity; Tubulin; Tumor Cells, Cultured | 2004 |
[Glucuronyl paclitaxel (Taxol) derivatives as tumor activated prodrugs].
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Humans; Neoplasms; Paclitaxel; Prodrugs | 2005 |
Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism.
Topics: Antineoplastic Agents; Benzamides; Biotransformation; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Isoenzymes; Neoplasms; Paclitaxel; Piperazines; Polymorphism, Genetic; Pyrimidines; Tamoxifen | 2005 |
Novel advances in drug delivery to brain cancer.
Topics: Animals; Antineoplastic Agents; Biodegradation, Environmental; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Delivery Systems; Humans; Models, Anatomic; Models, Chemical; Neoplasms; Paclitaxel; Polymers; Time Factors | 2005 |
Paclitaxel poliglumex. Cell Therapeutics/Chugai Pharmaceutical.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Paclitaxel; Polyglutamic Acid; Structure-Activity Relationship; Taxoids | 2005 |
Potential mechanisms for chemotherapy-induced impairments in cognitive function.
Topics: Anemia; Animals; Antineoplastic Agents; Attention; Blood-Brain Barrier; Cognition Disorders; Cyclophosphamide; Doxorubicin; Encephalitis; Fluorouracil; Humans; Inflammation; Language; Learning; Memory; Menopause; Methotrexate; Neoplasms; Oncology Nursing; Paclitaxel; Psychomotor Performance; Spatial Behavior | 2005 |
Taxanes in paediatric oncology: and now?
Topics: Antineoplastic Agents, Phytogenic; Child; Clinical Trials as Topic; Docetaxel; Humans; Medical Oncology; Neoplasms; Paclitaxel; Pediatrics; Taxoids | 2006 |
Targeting growth factors and angiogenesis; using small molecules in malignancy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Genes, ras; Humans; Melanoma; Nanostructures; Neoplasms; Paclitaxel; Proto-Oncogene Proteins B-raf; Receptors, Growth Factor; Signal Transduction | 2006 |
Novel agents that target tublin and related elements.
Topics: Administration, Oral; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents; Aurora Kinases; Drugs, Investigational; Emulsions; Humans; Microtubules; Neoplasms; Paclitaxel; Polyglutamic Acid; Protein Serine-Threonine Kinases; Taxoids; Tubulin | 2006 |
Paclitaxel prodrugs: toward smarter delivery of anticancer agents.
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Neoplasms; Paclitaxel; Prodrugs | 2006 |
The shape of things to come: structural and synthetic studies of taxol and related compounds.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Paclitaxel; Structure-Activity Relationship; Tubulin | 2007 |
[Recent advances in the biosynthesis of Taxol].
Topics: Antineoplastic Agents, Phytogenic; Arteriosclerosis; Docetaxel; Genes, Plant; Genetic Engineering; Neoplasms; Paclitaxel; Taxoids; Taxus | 2007 |
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Topics: Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epothilones; Humans; Microtubules; Neoplasms; Paclitaxel; Taxoids; Tubulin Modulators | 2007 |
Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel.
Topics: Albumins; Antineoplastic Agents; Clinical Trials as Topic; Drug Carriers; Drug Compounding; Humans; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Solvents | 2007 |
Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Drug Carriers; Estradiol; Humans; Macromolecular Substances; Neoplasms; Paclitaxel; Polyglutamic Acid; Tubulin | 2006 |
Novel cytotoxic drugs: old challenges, new solutions.
Topics: Albumins; Antineoplastic Agents; Drug Design; Drug Resistance, Neoplasm; Epothilones; Humans; Models, Biological; Neoplasms; Paclitaxel; Taxoids | 2008 |
Imaging multidrug resistance with 4-[18F]fluoropaclitaxel.
Topics: Antineoplastic Agents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Positron-Emission Tomography; Radiopharmaceuticals | 2007 |
[Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue].
Topics: Animals; Bone Marrow; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Hypersensitivity; Drug Resistance, Neoplasm; Epothilones; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Taxoids; Tubulin Modulators | 2008 |
Polymer-drug conjugates: recent development in clinical oncology.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Carriers; Drug Evaluation, Preclinical; Humans; Neoplasms; Paclitaxel; Polyglutamic Acid; Polymers | 2008 |
Optimal schedule of paclitaxel: weekly is better.
Topics: Antineoplastic Agents; Humans; Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2008 |
Microtubule assembly dynamics: an attractive target for anticancer drugs.
Topics: Animals; Antineoplastic Agents; Benomyl; Griseofulvin; Humans; Microtubules; Mitosis; Models, Biological; Models, Molecular; Neoplasms; Paclitaxel; Protein Conformation; Sulfonamides; Tubulin; Vinblastine | 2008 |
Protein nanoparticles as drug carriers in clinical medicine.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Carriers; Humans; Nanoparticles; Nanotechnology; Neoplasms; Paclitaxel | 2008 |
[Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Hypersensitivity; Drug Tolerance; Female; Humans; Male; Neoplasms; Neutropenia; Organoplatinum Compounds; Paclitaxel; Taxoids | 1995 |
Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Paclitaxel | 1994 |
[Use of taxol in the management of malignant tumors].
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Testicular Neoplasms | 1995 |
Early clinical studies with docetaxel. Docetaxel Investigators Group.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Neoplasms; Paclitaxel; Taxoids | 1995 |
Cardiotoxicity and cardioprotection during chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Heart; Heart Diseases; Humans; Interleukin-2; Male; Neoplasms; Paclitaxel; Razoxane; Retrospective Studies; Survivors | 1995 |
Docetaxel.
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1995 |
Paclitaxel pharmacokinetics and pharmacodynamics.
Topics: Clinical Trials as Topic; Humans; Linear Models; Models, Biological; Neoplasms; Paclitaxel | 1995 |
[Current issues in the chemotherapy of malignant tumors. Taxol (paclitaxel), Taxoter].
Topics: Animals; Breast Neoplasms; Clinical Trials as Topic; Humans; Neoplasms; Neoplasms, Experimental; Paclitaxel | 1994 |
Taxanes: a new class of antitumor agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Screening Assays, Antitumor; Humans; Mice; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids | 1995 |
[Taxenes: a new hope of clinical oncology in the 90-ies].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
Clinical reversal of multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Verapamil | 1994 |
Docetaxel (Taxotere) in the treatment of solid tumors other than breast and lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
Cardiotoxicity of chemotherapy.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Fluorouracil; Heart Diseases; Humans; Mice; Mitoxantrone; Neoplasms; Paclitaxel; Prospective Studies; Rabbits; Rats; Razoxane | 1994 |
Reversal of multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Clinical Trials as Topic; Drug Resistance, Multiple; Humans; Neoplasms; Paclitaxel; Tumor Cells, Cultured; Verapamil; Vincristine | 1994 |
Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture.
Topics: Animals; Awards and Prizes; Camptothecin; Chemistry, Physical; Clinical Trials as Topic; Drug Screening Assays, Antitumor; History, 20th Century; Humans; Medical Oncology; Neoplasms; Neoplasms, Experimental; Paclitaxel; Societies, Medical; United States | 1995 |
[Experiences with taxanes exemplified by paclitaxel (taxol) for internal medicine oncologic indications].
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Humans; Male; Neoplasms; Paclitaxel; Treatment Outcome | 1994 |
[Paclitaxel (taxol)--a cytostatic drug with a new kind of mechanism of action].
Topics: Cell Division; Female; Humans; Microtubules; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Paclitaxel; Spindle Apparatus | 1993 |
[Paclitaxel (taxol)--a cytostatic drug with a new type of mechanism of action].
Topics: Antineoplastic Agents, Phytogenic; Cell Survival; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Male; Microtubules; Multicenter Studies as Topic; Neoplasms; Paclitaxel; Survival Rate | 1993 |
Taxol: pharmacology, metabolism and clinical implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Humans; Neoplasms; Paclitaxel | 1993 |
Pharmacokinetics and metabolism of Taxotere (docetaxel).
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1993 |
Clinical, toxicological and pharmaceutical aspects of the antineoplastic drug taxol: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasms; Paclitaxel | 1994 |
Taxoids: a new class of cytotoxic agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Neoplasms; Paclitaxel; Taxoids | 1994 |
Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arrhythmias, Cardiac; Cell Cycle; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Hypersensitivity; Drug Screening Assays, Antitumor; Gastrointestinal Diseases; Humans; Mice; Microtubules; Neoplasms; Neoplasms, Experimental; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Polyethylene Glycols; Taxoids; Tubulin | 1994 |
Clinical development of Taxol.
Topics: Animals; Clinical Trials as Topic; Humans; Neoplasms; Paclitaxel | 1993 |
Nursing management of the patient receiving Taxol therapy.
Topics: Humans; Neoplasms; Nursing Assessment; Paclitaxel; Patient Education as Topic | 1993 |
Update on the antitumor activity of paclitaxel in clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel | 1994 |
Pharmaceutical issues of paclitaxel. Preclinical pharmacology and phase I clinical trials.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Drug Hypersensitivity; Drug Screening Assays, Antitumor; Humans; Neoplasms; Neutropenia; Paclitaxel | 1994 |
Clinical toxicities encountered with paclitaxel (Taxol).
Topics: Alopecia; Arrhythmias, Cardiac; Brain Diseases; Clinical Trials as Topic; Drug Administration Schedule; Drug Hypersensitivity; Gastrointestinal Diseases; Humans; Immunoglobulin E; Models, Biological; Muscular Diseases; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Risk Factors | 1993 |
The clinical pharmacology of paclitaxel (Taxol).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Compartmentation; Clinical Trials as Topic; DNA Repair; Humans; Injections, Intraperitoneal; Kidney; Leukocyte Count; Liver; Microtubules; Neoplasms; Paclitaxel | 1993 |
Current dosage and schedule issues in the development of paclitaxel (Taxol).
Topics: Animals; Bone Marrow Diseases; Clinical Trials as Topic; Dogs; Dose-Response Relationship, Drug; Drug Evaluation; Drug Evaluation, Preclinical; Drug Hypersensitivity; Humans; Mice; Microtubules; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Rats; Time Factors | 1993 |
The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1993 |
An overview of experience with TAXOL (paclitaxel) in the U.S.A.
Topics: Breast Neoplasms; Head and Neck Neoplasms; Heart; Humans; Lung Neoplasms; Neoplasms; Nervous System; Paclitaxel; United States | 1993 |
Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lethal Dose 50; Lung Neoplasms; Microtubules; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1995 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
[Chemotherapy of solid tumor].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasms; Paclitaxel; Survival Rate | 1996 |
Emerging drug treatments for solid tumours.
Topics: Amifostine; Antineoplastic Agents; Aziridines; Deoxycytidine; Gemcitabine; Humans; Indolequinones; Indoles; Neoplasms; Organoplatinum Compounds; Paclitaxel; Protein Kinase C; Topoisomerase I Inhibitors | 1996 |
Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Evaluation, Preclinical; Humans; Japan; Microtubule-Associated Proteins; Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vinblastine; Vindesine; Vinorelbine | 1996 |
Intraperitoneal taxol.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Humans; Injections, Intraperitoneal; Neoplasms; Paclitaxel | 1996 |
Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Melanoma; Microtubules; Neoplasms; Nervous System Neoplasms; Ovarian Neoplasms; Paclitaxel | 1996 |
The scientific rationale for developing taxoids.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Therapy, Combination; Humans; Microtubules; Neoplasms; Paclitaxel; Taxoids | 1996 |
Infusional chemotherapy with new drugs: taxanes, vinorelbine and topoisomerase I inhibitors.
Topics: Antineoplastic Agents; Camptothecin; Drug Delivery Systems; Enzyme Inhibitors; Humans; Infusions, Parenteral; Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1995 |
Promising new agents in oncologic treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1996 |
Paclitaxel via 1-hour infusion: clinical experience.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Humans; Infusions, Parenteral; Lung Neoplasms; Neoplasms; Paclitaxel | 1996 |
The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Microtubules; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1997 |
Docetaxel (taxotere, Rhone-Poulenc Rorer).
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Monitoring; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Generalized pustular dermatosis following paclitaxel therapy.
Topics: Adult; Antineoplastic Agents, Phytogenic; Biopsy, Needle; Breast Neoplasms; Diagnosis, Differential; Drug Eruptions; Female; Humans; Neoplasms; Paclitaxel; Skin Diseases, Vesiculobullous | 1997 |
[Taxanes: a breakthrough in cancer chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Docetaxel in combination with fluorouracil for advanced solid tumors.
Topics: Adult; Aged; Animals; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Mice; Middle Aged; Mucous Membrane; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1997 |
Paclitaxel pharmacology and other tumor types.
Topics: Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Endometrial Neoplasms; Esophageal Neoplasms; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphoma; Male; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Platinum Compounds; Sarcoma, Kaposi; Stomach Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 1997 |
The pharmacoeconomics of cancer therapies.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Quality of Life | 1997 |
Antitumor activity of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Pharmaceutical aspects of docetaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Cost-utility analysis of taxane therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cost-Benefit Analysis; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1997 |
[Docetaxel in treatment of other solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 1997 |
The taxoids. Comparative clinical pharmacology and therapeutic potential.
Topics: Alopecia; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids | 1998 |
[Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Hypersensitivity; Female; Humans; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Pharmacological action of paclitaxel].
Topics: Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Paclitaxel; Plants, Medicinal | 1999 |
Localized paclitaxel delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line; Drug Delivery Systems; Forecasting; Humans; Neoplasms; Paclitaxel; Regional Blood Flow | 1999 |
Therapy for Kaposi's sarcoma: recent advances and experimental approaches.
Topics: Administration, Oral; Alitretinoin; Anthracyclines; Antineoplastic Agents; Cyclohexanes; Humans; Immunosuppressive Agents; Liposomes; Neoplasms; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sarcoma, Kaposi; Sesquiterpenes; Thalidomide; Tretinoin | 1999 |
Principles of chemoradiation: theoretical and practical considerations.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Chemotaxis, Leukocyte; Clinical Trials as Topic; Combined Modality Therapy; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Radiation-Protective Agents; Radiation-Sensitizing Agents | 1999 |
Taxanes in combined-modality therapy for solid tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids | 1999 |
[The administration of Docetaxel (taxoter): a new stage in chemotherapy of cancer].
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1999 |
Role of taxanes in adjuvant therapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2000 |
Combining taxanes with radiation for solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2000 |
[Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] .
Topics: Anti-HIV Agents; Antineoplastic Agents; Cyclosporine; Depsipeptides; Docetaxel; Doxorubicin; Humans; Neoplasms; Neuromuscular Diseases; Oligopeptides; Organoplatinum Compounds; Paclitaxel; Peripheral Nervous System Diseases; Procarbazine; Reverse Transcriptase Inhibitors; Suramin; Taxoids; Vinca Alkaloids | 2000 |
Drug-targeting strategies in cancer therapy.
Topics: Antineoplastic Agents; Bombesin; Doxorubicin; Drug Delivery Systems; Endopeptidases; Glucuronidase; Gonadotropin-Releasing Hormone; Humans; Neoplasms; Oligopeptides; Paclitaxel; Prodrugs; Receptors, Peptide; Somatostatin | 2001 |
Oxaliplatin in tumors other than colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Female; Humans; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2000 |
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2001 |
Taxanes in combined modality therapy for solid tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2001 |
Chemotherapy: friend or foe to cancer vaccines?
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immune Tolerance; Models, Biological; Neoplasms; Paclitaxel | 2001 |
Modulating sensitivity to drug-induced apoptosis: the future for chemotherapy?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Drug Resistance; Enzyme Inhibitors; Flavonoids; Genes, Dominant; Humans; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Neoplasms; Paclitaxel | 2001 |
Docetaxel: assessing a range of activity.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2001 |
Role of formulation vehicles in taxane pharmacology.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chemistry, Pharmaceutical; Cyclosporine; Drug Hypersensitivity; Drug Resistance, Multiple; Glycerol; Humans; Micelles; Neoplasms; Nervous System Diseases; Paclitaxel; Polysorbates; Surface-Active Agents | 2001 |
Progress in the development of alternative pharmaceutical formulations of taxanes.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Cyclodextrins; Docetaxel; Drug Compounding; Emulsions; Humans; Neoplasms; Paclitaxel; Prodrugs; Solvents; Surface-Active Agents; Taxoids | 2001 |
Oral delivery of taxanes.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cyclosporine; Cyclosporins; Docetaxel; Humans; Mice; Mice, Knockout; Neoplasms; Paclitaxel; Taxoids | 2001 |
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Computer Simulation; Docetaxel; Humans; Lung Neoplasms; Models, Statistical; Neoplasms; Nonlinear Dynamics; Paclitaxel; Prospective Studies; Research Design; Taxoids | 2001 |
Body surface area as a determinant of pharmacokinetics and drug dosing.
Topics: Adult; Animals; Anthropometry; Antineoplastic Agents; Area Under Curve; Body Surface Area; Carboplatin; Cardiac Output; Child; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Kidney; Liver; Medical Oncology; Neoplasms; Paclitaxel; Taxoids | 2001 |
Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Pharmaceutical; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Interactions; Glycerol; Humans; Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Radiotherapy, Adjuvant; Taxoids; Vinca Alkaloids | 2001 |
[Clinical use of oxaliplatin in solid tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Prostatic Neoplasms; Vinblastine; Vinorelbine | 2001 |
Prevention and management of antineoplastic-induced hypersensitivity reactions.
Topics: Antineoplastic Agents; Asparaginase; Docetaxel; Drug Hypersensitivity; Humans; Neoplasms; Organoplatinum Compounds; Paclitaxel; Podophyllotoxin; Taxoids | 2001 |
Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Genes, p53; Genetic Therapy; Genetic Vectors; Glioblastoma; Head and Neck Neoplasms; Humans; Injections; Interleukin-2; Liver Neoplasms; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasms; Ovarian Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Recombinant Fusion Proteins; Salvage Therapy; Signal Transduction; Treatment Outcome; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 1999 |
Apoptosis and anticancer drug resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Drug Resistance, Neoplasm; fas Receptor; Humans; Mitochondria; Neoplasms; Neuropeptides; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; ras Proteins; Receptors, Tumor Necrosis Factor | 2001 |
[Molecular mechanisms of oncogenic transformation: what's new?].
Topics: Animals; Antineoplastic Agents, Phytogenic; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Disease Progression; Drug Resistance; Fusion Proteins, bcr-abl; Humans; Mice; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Neural Cell Adhesion Molecules; Paclitaxel; Protein Serine-Threonine Kinases; Radiation Tolerance; Rats; Thrombospondins; Transforming Growth Factor beta; Tuberous Sclerosis | 2002 |
Actin' up: RhoB in cancer and apoptosis.
Topics: Actins; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Division; DNA Damage; Enzyme Induction; Enzyme Inhibitors; Farnesyltranstransferase; Guanosine Triphosphate; Humans; Mice; Multigene Family; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Prenylation; Protein Processing, Post-Translational; ras Proteins; rhoB GTP-Binding Protein; Signal Transduction; Stress, Physiological | 2001 |
Chemotherapy-induced neurotoxicity: assessment and interventions for patients at risk.
Topics: Antineoplastic Agents; Cisplatin; Cytarabine; Humans; Ifosfamide; Methotrexate; Neoplasms; Neurotoxicity Syndromes; Nursing Assessment; Oncology Nursing; Paclitaxel; Vinca Alkaloids | 2002 |
Clinical development of P glycoprotein modulators in oncology.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials as Topic; Cyclosporins; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Male; Neoplasm Proteins; Neoplasms; Organ Specificity; Ovarian Neoplasms; Paclitaxel | 2002 |
The role of pro-drug therapy in the treatment of cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Delivery Systems; Fluorouracil; Humans; Neoplasms; Paclitaxel; Prodrugs | 2001 |
Laboratory and phase I studies of new cancer drugs.
Topics: Antineoplastic Agents; Bryostatins; Camptothecin; Docetaxel; Humans; Lactones; Macrolides; Neoplasms; Paclitaxel; Taxoids | 1992 |
Taxol: the first of the taxanes, an important new class of antitumor agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Evaluation; Drug Evaluation, Preclinical; Drugs, Investigational; Female; Forecasting; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1992 |
Taxol. Out of the woods.
Topics: Alkaloids; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Transplantation, Heterologous | 1991 |
Hypersensitivity reactions.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomycin; Chlorambucil; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Drug Hypersensitivity; Etoposide; Fluorouracil; Humans; Ifosfamide; Melphalan; Methotrexate; Mitomycins; Neoplasms; Paclitaxel; Pentostatin; Procarbazine; Teniposide | 1992 |
Vinca alkaloids.
Topics: Alkaloids; Animals; Combined Modality Therapy; Drug Interactions; Humans; Neoplasms; Paclitaxel; Vinblastine; Vinca Alkaloids; Vincristine; Vinorelbine | 1991 |
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Chick Embryo; Dosage Forms; Drug Administration Schedule; Humans; Microtubules; Neoplasms; Neoplasms, Experimental; Paclitaxel; Vinca Alkaloids | 1991 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
339 trial(s) available for paclitaxel and Benign Neoplasms
| Article | Year |
|---|---|
Safety and Tolerability of Weekly Genexol-PM, a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel, with Carboplatin in Gynecologic Cancer: A Phase I Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Micelles; Neoplasms; Paclitaxel; Polymers | 2023 |
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Neoplasms; Paclitaxel | 2021 |
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Cetuximab; Female; Follow-Up Studies; Genome-Wide Association Study; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2022 |
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Hydrazines; Lung Neoplasms; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia; Triazoles; Vomiting | 2022 |
A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors.
Topics: Bayes Theorem; Humans; Inhibitor of Apoptosis Proteins; Japan; Neoplasms; Paclitaxel; Thiazoles; Treatment Outcome | 2022 |
Efficacy of Siriraj, in-house-developed, frozen gloves for cold therapy reduction of chemotherapy-induced peripheral neuropathy in gynecological cancer patients: randomized controlled trial.
Topics: Adult; Antineoplastic Agents; Cryotherapy; Humans; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 2022 |
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Humans; Indazoles; Neoplasms; Paclitaxel; Piperidines; Vascular Endothelial Growth Factor A | 2022 |
A phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerases | 2022 |
A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Fatigue; Humans; Maximum Tolerated Dose; Neoplasms; Paclitaxel; Treatment Outcome | 2022 |
Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Benzoxazoles; Cohort Studies; Humans; Imidazoles; Morpholines; Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Pyridines; TOR Serine-Threonine Kinases | 2022 |
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Erlotinib Hydrochloride; Humans; Neoplasms; Paclitaxel | 2022 |
Sarcopenia as a Determinant of the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Non-Small-Cell Lung; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Neoplasms; Odds Ratio; Paclitaxel; Prospective Studies; Sarcopenia | 2023 |
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases; Enzyme Inhibitors; Fulvestrant; Humans; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase | 2023 |
Minimal added value of wetting hair before scalp cooling to prevent chemotherapy-induced alopecia in cancer patients - results from the Dutch Scalp Cooling Registry.
Topics: Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Hair; Humans; Hypothermia, Induced; Neoplasms; Paclitaxel; Registries; Scalp | 2023 |
A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cyclosporins; Humans; Neoplasms; Paclitaxel | 2023 |
Prevention of Taste Alterations in Patients with Cancer Receiving Paclitaxel- or Oxaliplatin-Based Chemotherapy-A Pilot Trial of Cannabidiol.
Topics: Cannabidiol; Dysgeusia; Humans; Neoplasms; Oxaliplatin; Paclitaxel; Pilot Projects; Taste | 2023 |
Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2).
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capsules; Carboplatin; Fatigue; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Phthalazines; Piperazines; Tablets; Thrombocytopenia | 2020 |
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Phthalazines; Piperazines; Treatment Outcome; Young Adult | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Population Pharmacokinetics and Exposure-Response Analysis of nab-Paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
Topics: Adolescent; Albumins; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Male; Models, Biological; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Tissue Distribution | 2021 |
A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Ritonavir | 2021 |
Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cells, Cultured; Deoxycytidine; Doxorubicin; Filgrastim; Gemcitabine; Humans; Incidence; Models, Biological; Myelopoiesis; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Primary Cell Culture; Risk Assessment; Treatment Outcome | 2020 |
The added value of H
Topics: Adult; Aged; Aged, 80 and over; Chemoprevention; Clemastine; Dexamethasone; Drug Hypersensitivity; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Male; Medical Futility; Middle Aged; Neoplasms; Netherlands; Paclitaxel; Premedication; Ranitidine; Severity of Illness Index; Treatment Outcome | 2021 |
Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Combinations; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Morpholines; Neoplasms; Paclitaxel; Pyrimidines; Skin Neoplasms; Sulfonamides | 2021 |
Phase I Dose-Escalation Study of the Dual PI3K-mTORC1/2 Inhibitor Gedatolisib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Middle Aged; Morpholines; Neoplasm Staging; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Retrospective Studies; Triazines | 2021 |
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Prednisolone; Pyrimidines | 2021 |
A phase I study of cilengitide and paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Integrin alphaVbeta3; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Receptors, Vitronectin; Snake Venoms; Treatment Outcome | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Research Design; Sirolimus; Thrombocytopenia | 2017 |
TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoxazoles; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Middle Aged; Multiprotein Complexes; Neoplasms; Paclitaxel; Pyrimidines; TOR Serine-Threonine Kinases; Trastuzumab; Treatment Outcome; Young Adult | 2017 |
Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
Topics: Adult; Aged; Alleles; Aurora Kinase A; Azepines; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2017 |
Role of Skin Tests in the Diagnosis of Immediate Hypersensitivity Reactions to Taxanes: Results of a Multicenter Study.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Skin Tests | 2019 |
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cyclopentanes; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Drug Interactions; Enzyme Inhibitors; Female; Fluconazole; Humans; Itraconazole; Male; Middle Aged; Neoplasms; Paclitaxel; Pyrimidines | 2019 |
Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; China; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Tablets | 2019 |
Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Macrophage Colony-Stimulating Factor; Macrophages; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Skin; Treatment Outcome; Young Adult | 2019 |
Assessment of the administration of maropitant and loperamide to dogs with cancer for the prevention and reduction of adverse effects associated with the administration of paclitaxel.
Topics: Animals; Antidiarrheals; Antiemetics; Antineoplastic Agents, Phytogenic; Diarrhea; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Loperamide; Male; Neoplasms; Paclitaxel; Quinuclidines; Random Allocation; Vomiting | 2019 |
A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperidines; Pyrroles; Treatment Outcome; Triazines | 2013 |
Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Pemetrexed | 2013 |
Bioequivalence of Liposome-Entrapped Paclitaxel Easy-To-Use (LEP-ETU) formulation and paclitaxel in polyethoxylated castor oil: a randomized, two-period crossover study in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Castor Oil; Chemistry, Pharmaceutical; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Solvents; Therapeutic Equivalency; Young Adult | 2013 |
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Exanthema; Fatigue; Febrile Neutropenia; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Stomatitis; Taxoids; Tinnitus; Treatment Outcome; Young Adult | 2014 |
Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bevacizumab; Carboplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Tetrahydroisoquinolines | 2014 |
North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Female; Glutathione; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Placebos | 2014 |
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Male; Middle Aged; Neoplasms; Neuropilin-1; Paclitaxel; Treatment Outcome; Young Adult | 2014 |
Phase I and pharmacokinetic study of polymeric micelle‑formulated paclitaxel in adult Chinese patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; China; Female; Humans; Male; Maximum Tolerated Dose; Micelles; Middle Aged; Neoplasms; Paclitaxel | 2014 |
Exploration of paclitaxel (Taxol) as a treatment for malignant tumors in cats: a descriptive case series.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Diarrhea; Drug Administration Schedule; Infusions, Intravenous; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Vomiting | 2015 |
Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; ErbB Receptors; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2014 |
A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.
Topics: Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Sulfonamides; Treatment Outcome | 2014 |
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Docetaxel; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Serine; Taxoids; Young Adult | 2014 |
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Broadly Neutralizing Antibodies; Carboplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids | 2015 |
A multicenter phase I study of pazopanib in combination with paclitaxel in first-line treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides | 2015 |
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel; Positron-Emission Tomography; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome; Young Adult | 2015 |
SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug Administration Schedule; Drug Eruptions; Fatigue; Female; Heterocyclic Compounds, 3-Ring; Humans; Hyperglycemia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Treatment Outcome | 2015 |
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Synergism; Female; Humans; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasms; Ovarian Neoplasms; Paclitaxel; Saponins; Tumor Cells, Cultured; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Demography; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Recombinant Fusion Proteins; Treatment Outcome | 2015 |
4β-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Cytochrome P-450 CYP3A; Docetaxel; Female; Humans; Hydroxycholesterols; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Young Adult | 2015 |
Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.
Topics: Acute Pain; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hypesthesia; Male; Middle Aged; Neoplasms; Paclitaxel; Paresthesia; Peripheral Nervous System Diseases; Pilot Projects; Placebos; Pregabalin; Quality of Life; Surveys and Questionnaires | 2016 |
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Topics: Administration, Intravenous; Administration, Oral; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; ErbB Receptors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Time Factors; Treatment Outcome; United Kingdom | 2015 |
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.
Topics: Activation, Metabolic; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Esophageal Neoplasms; Fatigue; Female; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Prodrugs; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation; Young Adult | 2015 |
Lack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Drug Interactions; Female; Humans; Incidence; Least-Squares Analysis; Male; Middle Aged; Neoplasms; Paclitaxel; Ramucirumab; Young Adult | 2016 |
Phase Ia/Ib study of the pan-class I PI3K inhibitor pictilisib (GDC-0941) administered as a single agent in Japanese patients with solid tumors and in combination in Japanese patients with non-squamous non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizumab; Carboplatin; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Sulfonamides; Treatment Outcome | 2017 |
A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Quinazolines | 2017 |
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Prognosis; Survival Rate; Tissue Distribution | 2017 |
Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Female; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Humans; Male; Middle Aged; Neoplasms; Neurofeedback; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Platinum Compounds; Survivors; Taxoids; Time Factors; Treatment Outcome; Waiting Lists | 2017 |
Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinoxalines; Sulfonamides | 2017 |
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Morpholines; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Prognosis; PTEN Phosphohydrolase; Tissue Distribution | 2017 |
Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycerol; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel | 2008 |
A phase I and pharmacokinetic study of weekly oxaliplatin followed by paclitaxel in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Drug Administration Schedule; Female; History, 17th Century; Humans; Male; Maximum Tolerated Dose; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2008 |
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzoquinones; Drug Administration Schedule; Drug Interactions; Female; Humans; Lactams, Macrocyclic; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel | 2008 |
A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Polyglutamic Acid; Prognosis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
[Evaluation of short-time premedication with d-chlorpheniramine maleate injection for paclitaxel-induced hypersensitivity reaction].
Topics: Adult; Aged; Aged, 80 and over; Chlorpheniramine; Drug Hypersensitivity; Female; Humans; Injections; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Time Factors | 2008 |
Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Cell Survival; Chemistry, Pharmaceutical; Chromatography, Liquid; Cross-Over Studies; Female; Humans; Leukocyte Count; Linear Models; Male; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Neutrophils; Paclitaxel; Stem Cells; Structure-Activity Relationship; Tandem Mass Spectrometry | 2009 |
Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients.
Topics: Adult; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Chromatography, Liquid; Cross-Over Studies; Drug Delivery Systems; Female; Humans; Leukocyte Count; Linear Models; Male; Middle Aged; Models, Biological; Monte Carlo Method; Nanoparticles; Neoplasms; Paclitaxel; Structure-Activity Relationship; Tandem Mass Spectrometry; Tissue Distribution | 2009 |
Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Female; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Paclitaxel | 2008 |
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Neoplasms; Paclitaxel; Pemetrexed; Thyroid Neoplasms; Young Adult | 2009 |
Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response Relationship, Drug; Humans; Ifosfamide; Neoplasms; Paclitaxel; Young Adult | 2009 |
A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Female; Fluorouracil; Glucocorticoids; Granisetron; Humans; Infusions, Intravenous; Liposomes; Male; Methylprednisolone; Middle Aged; Neoplasms; Paclitaxel; Premedication; Treatment Outcome; Young Adult | 2009 |
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Polyglutamic Acid; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fever; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2009 |
Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol-PM) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Chemistry, Pharmaceutical; Drug Administration Schedule; Female; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Salvage Therapy; Treatment Outcome | 2010 |
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Young Adult | 2009 |
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
Topics: Administration, Oral; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Injections, Intravenous; Lapatinib; Male; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2009 |
A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome; Triazoles; Young Adult | 2009 |
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Boronic Acids; Bortezomib; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Paclitaxel; Proliferating Cell Nuclear Antigen; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2010 |
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL10; Chemokine CXCL9; Cohort Studies; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Interferon-gamma; Interleukin-12; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Phosphorylation; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2009 |
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Drug Interactions; Female; Humans; Injections, Intravenous; Intracellular Signaling Peptides and Proteins; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Phthalazines; Pyridines; Transaminases; Treatment Outcome | 2010 |
Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Linear Models; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nanoparticles; Neoplasms; Neurotoxicity Syndromes; Paclitaxel | 2010 |
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Life Expectancy; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Patient Selection; Stilbenes | 2010 |
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2010 |
nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Female; Humans; Liver Diseases; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Pilot Projects | 2010 |
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasms; Paclitaxel; Sulfonamides | 2010 |
Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Treatment Outcome; Young Adult | 2010 |
A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carboplatin; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydrazines; Male; Middle Aged; Neoplasms; Paclitaxel; Placebos; Platelet Count; Polypharmacy; Pyrazoles; Treatment Outcome; Young Adult | 2010 |
A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Aminopeptidases; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fatigue; Female; Glycine; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel | 2010 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Endpoint Determination; Female; Half-Life; Hematologic Diseases; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome | 2011 |
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Indazoles; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides; Survival Rate; Tissue Distribution; Treatment Outcome | 2010 |
Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors.
Topics: Adult; Antineoplastic Agents; Ataxia; Dose-Response Relationship, Drug; Epothilones; Female; Genetic Engineering; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome | 2011 |
The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Comorbidity; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Nursing Assessment; Oncology Nursing; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pain Measurement; Reproducibility of Results; Risk Factors; Taxoids | 2011 |
Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Sirolimus | 2012 |
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Humans; Male; MAP Kinase Signaling System; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinases; Neoplasms; Paclitaxel; Pyrazines; Treatment Outcome | 2011 |
Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Breast Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Humans; Japan; Male; Metabolic Clearance Rate; Middle Aged; Nanoparticles; Nausea; Neoplasm Metastasis; Neoplasms; Paclitaxel; Treatment Outcome | 2012 |
Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Dog Diseases; Dogs; Drug Delivery Systems; Kidney; Liver; Nanoparticles; Neoplasms; Paclitaxel; Spleen; Tissue Distribution | 2011 |
Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Area Under Curve; Brain; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Peptides; Treatment Outcome; Young Adult | 2012 |
Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Combined Modality Therapy; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Mammalian orthoreovirus 3; Middle Aged; Nausea; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Stomatitis; Treatment Outcome | 2012 |
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines | 2012 |
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Pyrimidines; Sulfonamides; Treatment Outcome | 2012 |
A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: crossover comparisons with intravenous paclitaxel.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Cross-Over Studies; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Young Adult | 2013 |
A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Panobinostat; Treatment Outcome | 2012 |
Effect of ethanol in Paclitaxel injections on the ethanol concentration in exhaled breath.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breath Tests; Ethanol; Exhalation; Female; Humans; Japan; Male; Middle Aged; Neoplasms; Paclitaxel | 2012 |
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Imidazoles; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Treatment Outcome | 2012 |
Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Imidazoles; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Taxoids; Treatment Outcome | 2012 |
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperazines; Pyrimidines; Radiotherapy, Adjuvant; Severity of Illness Index; Treatment Outcome | 2012 |
Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.
Topics: Administration, Metronomic; Administration, Oral; Antineoplastic Agents, Phytogenic; Biological Availability; Calorimetry, Differential Scanning; Drug Stability; Drug Storage; Excipients; Female; Half-Life; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Permeability; Povidone; Sodium Dodecyl Sulfate; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2013 |
Clinical trials involving the oncolytic virus, reovirus: ready for prime time?
Topics: Antineoplastic Agents; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Head and Neck Neoplasms; Humans; Mammalian orthoreovirus 3; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Severity of Illness Index; Treatment Outcome | 2012 |
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Quinazolines | 2013 |
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel | 2013 |
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Drug Interactions; Female; Gemcitabine; Half-Life; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors.
Topics: Adolescent; Adult; Aged; Biological Availability; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Molecular Structure; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 2002 |
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Female; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome | 2002 |
Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Urologic Neoplasms | 2002 |
A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel | 2002 |
Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics.
Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Confidence Intervals; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Probability; Risk Assessment; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: results of a clinical trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cells, Cultured; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Predictive Value of Tests | 2002 |
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.
Topics: Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Surface Area; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Prospective Studies | 2003 |
A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Delivery Systems; Estramustine; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Tubulin; Vinblastine; Vinorelbine | 2003 |
Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Leukocyte Count; Liver Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutrophils; Paclitaxel | 2002 |
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cell Survival; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2003 |
Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Thrombocytopenia; Treatment Outcome | 2003 |
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.
Topics: Adult; Aged; Docetaxel; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2003 |
Phase I trial of carboplatin and paclitaxel with escalating doses of oral topotecan in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Topotecan | 2003 |
A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Interferon-alpha; Isotretinoin; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasms; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Treatment Outcome | 2003 |
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2003 |
A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Paclitaxel | 2003 |
Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study.
Topics: Anemia; Antineoplastic Agents, Phytogenic; Child; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Neoplasms; Neutropenia; Paclitaxel; Patient Selection; Platelet Count | 2003 |
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cohort Studies; Dibenzocycloheptenes; Drug Combinations; Drug Interactions; Drug Resistance, Multiple; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Quinolines | 2003 |
Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids; Treatment Outcome | 2003 |
A phase I study of gemcitabine and docetaxel for advanced stage solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Patient Selection; Taxoids | 2003 |
A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Molecular Structure; Neoplasms; Paclitaxel | 2003 |
Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docosahexaenoic Acids; Fatty Acids; Female; Humans; Male; Middle Aged; Models, Chemical; Neoplasms; Paclitaxel; Taxoids; Time Factors | 2003 |
Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Plasminogen Activator Inhibitor 1; Tirapazamine; Triazines; Vascular Endothelial Growth Factor A | 2003 |
Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Cohort Studies; Decision Making; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome | 2004 |
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Farnesyltranstransferase; Fatigue; Female; Heart Arrest; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperidines; Pyridines; Treatment Outcome | 2004 |
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Male; Micelles; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Polymers; Time Factors | 2004 |
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclohexanes; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Sesquiterpenes | 2004 |
Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel | 2004 |
Phase I/II study of DHA-paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cohort Studies; Disease Progression; Docosahexaenoic Acids; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Time Factors | 2004 |
Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.
Topics: Acetylation; Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Chromatography, High Pressure Liquid; Cohort Studies; Drug Therapy, Combination; Female; Histones; Humans; Male; Mass Spectrometry; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Phenylenediamines; Treatment Outcome | 2004 |
Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors.
Topics: Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Polyglutamic Acid; Taxoids; Thrombocytopenia; Treatment Failure | 2005 |
A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Carboplatin; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel | 2005 |
A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytokines; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Interleukin-6; Leukemia Inhibitory Factor; Lipase; Male; Middle Aged; Neoplasms; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Placebos; Prospective Studies; Proteins | 2005 |
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Interactions; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Receptors, Vascular Endothelial Growth Factor; RNA, Catalytic | 2005 |
Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Female; Humans; Injections, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2005 |
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Female; Humans; Infusion Pumps; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proportional Hazards Models; Time Factors; Treatment Outcome | 2005 |
A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Arthralgia; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols | 2005 |
A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fenretinide; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 2005 |
Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.
Topics: Adult; Aged; Carboplatin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Inpatients; Male; Middle Aged; Neoplasms; Outpatients; Paclitaxel; Skin Tests | 2005 |
A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclosporins; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel | 2005 |
A randomized trial assessing the utility of a test-dose program with taxanes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cost Control; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2005 |
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Area Under Curve; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Nanostructures; Neoplasm Staging; Neoplasms; Paclitaxel; Treatment Outcome | 2005 |
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Paclitaxel; Polyglutamic Acid; Polymers; Time Factors | 2005 |
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gene Frequency; Genotype; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Retrospective Studies; White People | 2005 |
Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Carboplatin; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polyglutamic Acid; Survival Rate; Taxoids | 2005 |
Breath alcohol concentrations in Japanese outpatients following paclitaxel and docetaxel infusion.
Topics: Adult; Aged; Alcoholic Intoxication; Antineoplastic Agents, Phytogenic; Asian People; Breast Neoplasms; Breath Tests; Carcinoma, Non-Small-Cell Lung; Docetaxel; Ethanol; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Outpatients; Ovarian Neoplasms; Paclitaxel; Taxoids | 2005 |
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Paclitaxel; Prospective Studies | 2006 |
Measuring tumor response and shape change on CT: esophageal cancer as a paradigm.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Macrolides; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibroblast Growth Factors; Humans; Injections, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Recombinant Proteins; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2007 |
A phase I clinical and pharmacokinetic study of paclitaxel and docetaxel given in combination in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2006 |
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome | 2007 |
A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclosporine; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Emulsifying Agents; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Safety; Solubility; Tissue Distribution; Treatment Outcome | 2006 |
Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation.
Topics: Administration, Oral; Antineoplastic Agents; Dietary Supplements; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome; Vitamin E | 2006 |
Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carnitine; Chromatography, High Pressure Liquid; Creatinine; Docetaxel; Female; Glucose; Humans; Infusions, Intravenous; Kidney; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Phosphates; Taxoids; Urea; Vinblastine; Vinorelbine | 2007 |
PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
Topics: Adult; Antineoplastic Agents; Body Surface Area; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel | 2006 |
A simplified premedication protocol for one-hour paclitaxel infusion in various combinations.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dimethindene; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Ranitidine; Time Factors | 2006 |
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Female; Fever; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Treatment Outcome | 2007 |
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Skin | 2006 |
Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capsules; Chemistry, Pharmaceutical; Cyclosporine; Drinking; Drug Administration Schedule; Female; Humans; Infant; Infant, Newborn; Male; Neoplasms; Paclitaxel | 2007 |
Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Piperidines; Pyridines; Time Factors | 2007 |
Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Hydrazines; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Paclitaxel; Time Factors; Treatment Outcome | 2007 |
Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Injections; Male; Middle Aged; Neoplasms; Paclitaxel | 2007 |
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carboplatin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasms; Paclitaxel | 2007 |
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Dietary Supplements; Docetaxel; Female; Folic Acid Antagonists; Homocysteine; Humans; Male; Methylmalonic Acid; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Vitamins | 2007 |
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Female; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Vorinostat | 2007 |
Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Female; Humans; Imidazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel | 2007 |
Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Capsules; Chromatography, Liquid; Drug Delivery Systems; Female; Humans; Hydrophobic and Hydrophilic Interactions; Male; Mass Spectrometry; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome | 2007 |
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Survival Rate | 2007 |
A dose escalation study of the biweekly administration of paclitaxel, oxaliplatin and capecitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2007 |
Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).
Topics: Adenosine Triphosphatases; Alkaloids; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Biological Factors; Biological Transport; Cell Line; Cell Line, Tumor; Cyclosporins; Depsipeptides; Fluorescent Dyes; Fluorouracil; Humans; Insecta; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Prazosin; Quinolines; Rhodamine 123; Verapamil; Vinblastine | 2008 |
Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Double-Blind Method; Dysgeusia; Female; Glutamine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Risk Factors; Taste; Taxoids; Treatment Outcome | 2008 |
Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Docosahexaenoic Acids; Drug Resistance, Neoplasm; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carboplatin; Combined Modality Therapy; Down-Regulation; Female; Gene Expression; Genes, bcl-2; Humans; Male; Neoplasms; Oligonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Thionucleotides | 2008 |
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Thalidomide | 2008 |
Pegfilgrastim successfully mobilizes megakaryocyte progenitors into the peripheral blood in subjects with solid tumours.
Topics: Adolescent; Adult; Antineoplastic Agents; Carboplatin; Colony-Forming Units Assay; Combined Modality Therapy; Filgrastim; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Megakaryocytes; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Stem Cells | 2008 |
A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1995 |
Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Topics: Aged; Bone Marrow Diseases; Drug Administration Schedule; Drug Hypersensitivity; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Musculoskeletal Diseases; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 1994 |
A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
Topics: Drug Hypersensitivity; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Time Factors | 1994 |
A phase I trial of paclitaxel and etoposide for metastatic or recurrent malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 1995 |
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Remission Induction; Thrombocytopenia; Topotecan; United States | 1995 |
Phase II studies of docetaxel in the treatment of various solid tumours. EORTC Early Clinical Trials Group and the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Head and Neck Neoplasms; Humans; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Sarcoma; Stomach Neoplasms; Taxoids | 1995 |
One-hour paclitaxel infusion schedules: a phase I/II comparative trial.
Topics: Blood Cell Count; Breast Neoplasms; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Premedication; Remission Induction | 1995 |
Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Estramustine; Female; Humans; Male; Neoplasms; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms | 1995 |
Taxol metabolism and disposition in cancer patients.
Topics: Adult; Biotransformation; Chromatography, High Pressure Liquid; Feces; Female; Half-Life; Humans; Male; Mass Spectrometry; Middle Aged; Neoplasms; Paclitaxel | 1995 |
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Least-Squares Analysis; Male; Middle Aged; Neoplasms; Neuromuscular Diseases; Paclitaxel | 1993 |
Clinical reversal of multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Verapamil | 1994 |
Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.
Topics: Adolescent; Adult; Child; Child, Preschool; Female; Humans; Infusions, Intravenous; Male; Neoplasms; Paclitaxel; Treatment Outcome | 1993 |
Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Neoplasms; Paclitaxel | 1994 |
Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.
Topics: Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1994 |
Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Premedication; Prospective Studies; Remission Induction | 1994 |
[Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug].
Topics: Adolescent; Adult; Aged; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1994 |
Paclitaxel (Taxol): phase I/II trial comparing 1-hour infusion schedules.
Topics: Adult; Aged; Alopecia; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Thrombocytopenia; Time Factors; Treatment Outcome | 1994 |
Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1993 |
Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1993 |
Plasma alcohol concentrations in patients following paclitaxel infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Ethanol; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Solvents | 1996 |
Multi-day fractionated administration schedule for paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Neoplasms; Paclitaxel; Treatment Outcome | 1995 |
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Treatment Failure | 1996 |
Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Female; Histamine Antagonists; Humans; Hypotension; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Premedication | 1995 |
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Topics: Antidiarrheals; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Irinotecan; Loperamide; Male; Neoplasms; Neutropenia; Paclitaxel; Remission Induction; Taxoids; Topoisomerase I Inhibitors | 1996 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Tolerance; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukocyte Count; Male; Mesna; Middle Aged; Neoplasms; Neutropenia; Neutrophils; Paclitaxel; Recombinant Proteins; Remission Induction | 1996 |
Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Dexamethasone; Drug Administration Schedule; Drug Hypersensitivity; Female; Glucocorticoids; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel | 1996 |
Early phase studies with paclitaxel/low-dose carboplatin in patients with solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Tolerance; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Neoplasms; Paclitaxel; Treatment Outcome | 1996 |
Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
Topics: Adult; Aged; Anti-Allergic Agents; Antiemetics; Antineoplastic Agents, Phytogenic; Cimetidine; Clemastine; Dexamethasone; Drug Administration Schedule; Female; Histamine H2 Antagonists; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Ondansetron; Paclitaxel | 1996 |
Paclitaxel via 1-hour infusion: clinical experience.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Humans; Infusions, Parenteral; Lung Neoplasms; Neoplasms; Paclitaxel | 1996 |
Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Nervous System Diseases; Paclitaxel; Paresthesia; Taxoids | 1997 |
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Paclitaxel; Taxoids; Vomiting | 1997 |
HPLC method for monitoring SDZ PSC 833 in whole blood.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Cross Reactions; Cyclosporine; Cyclosporins; Drug Monitoring; Fluorescence Polarization Immunoassay; Humans; Immunosuppressive Agents; Neoplasms; Paclitaxel; Reproducibility of Results | 1997 |
A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Synergism; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Methotrexate; Middle Aged; Neoplasms; Paclitaxel | 1996 |
Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Neoplasms; Paclitaxel; Recombinant Proteins; Retreatment | 1997 |
Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Docetaxel; Drug Administration Schedule; Female; Humans; Incidence; Infant; Infusions, Intravenous; Male; Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome | 1997 |
Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.
Topics: Aged; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Docetaxel; Female; Humans; Neoplasms; Paclitaxel; Reproducibility of Results; Sensitivity and Specificity; Taxoids | 1997 |
Docetaxel and cyclophosphamide in patients with advanced solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Humans; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 1997 |
Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Hypersensitivity; Female; Glucocorticoids; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Ranitidine; Retrospective Studies | 1997 |
Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Cyclophosphamide; Dexamethasone; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Premedication; Remission Induction; Sarcoma; Taxoids | 1997 |
Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel | 1997 |
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bayes Theorem; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Taxoids | 1998 |
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel | 1998 |
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Vomiting | 1998 |
Lhermitte's sign following chemotherapy with docetaxel.
Topics: Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Middle Aged; Neoplasms; Paclitaxel; Spinal Cord; Spinal Cord Diseases; Taxoids | 1998 |
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1998 |
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bilirubin; Chromatography, High Pressure Liquid; Cohort Studies; Female; Humans; Infusions, Intravenous; Liver; Male; Middle Aged; Neoplasms; Paclitaxel | 1998 |
Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Clinical phase I study with one-hour paclitaxel infusion.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel | 1998 |
Co-administration of cyclosporin enables oral therapy with paclitaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cyclosporine; Drug Therapy, Combination; Humans; Infusions, Intravenous; Mice; Mice, Knockout; Neoplasms; Paclitaxel | 1998 |
Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Estramustine; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Paclitaxel | 1998 |
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Resistance, Multiple; Female; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Piperidines; Pyridines | 1998 |
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 1998 |
Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Paclitaxel; Recombinant Proteins; Skin Neoplasms; Time Factors | 1998 |
Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Infusions, Intravenous; Likelihood Functions; Lung Neoplasms; Metabolic Clearance Rate; Neoplasms; Paclitaxel; Prospective Studies; Sampling Studies; Specimen Handling; Taxoids | 1997 |
Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion.
Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Dexamethasone; Diphenhydramine; Dose-Response Relationship, Drug; Drug Hypersensitivity; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Leukocyte Count; Neoplasms; Paclitaxel; Ranitidine; Time Factors | 1995 |
Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Dexamethasone; Docetaxel; Female; Glucocorticoids; Humans; Male; Middle Aged; Neoplasms; Nervous System Diseases; Paclitaxel; Prospective Studies; Taxoids | 1998 |
Weekly schedules of docetaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1998 |
Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Glioblastoma; Humans; Lung Neoplasms; Lymphocytes; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pelvic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis; Taxoids; Treatment Outcome | 1999 |
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Feasibility Studies; Follow-Up Studies; Heart Failure; Humans; Immunosuppression Therapy; Middle Aged; Nausea; Neoplasms; Paclitaxel; Pyrazoles; Pyrazolones; Treatment Outcome | 1999 |
Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Recombinant Proteins; Thrombocytopenia; Topotecan; Treatment Outcome | 1999 |
A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1999 |
Acute encephalopathy: a new toxicity associated with high-dose paclitaxel.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Hepatic Encephalopathy; Humans; Neoplasms; Paclitaxel; Psychotropic Drugs | 1999 |
Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial.
Topics: Adolescent; Adult; Child; Child, Preschool; Docetaxel; Dose-Response Relationship, Drug; Drug Eruptions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infant; Male; Neoplasms; Neutropenia; Paclitaxel; Recombinant Proteins; Taxoids | 1999 |
Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 1999 |
Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Microsomes, Liver; Middle Aged; Neoplasms; Paclitaxel; Patient Selection; Treatment Outcome | 1999 |
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Administration Schedule; Drug Evaluation; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Quinazolines; Thiophenes | 1999 |
Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1999 |
UFT/calcium folinate plus weekly paclitaxel for solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Routes; Female; Follow-Up Studies; Humans; Leucovorin; Middle Aged; Neoplasms; Paclitaxel; Tegafur; Treatment Outcome; Uracil | 1999 |
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms; Paclitaxel | 1999 |
Docetaxel (Taxotere) administered in weekly schedules.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1999 |
A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Interactions; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Heart; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Random Allocation | 1999 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bilirubin; Capecitabine; Cohort Studies; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 1999 |
Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasms; Paclitaxel | 1999 |
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Biotransformation; Cyclosporine; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 1999 |
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms; Nervous System Diseases; Neutropenia; Outpatients; Paclitaxel; Taxoids; Thrombocytopenia | 2000 |
A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2000 |
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Alopecia; Antineoplastic Agents, Phytogenic; Area Under Curve; Aspartate Aminotransferases; Breast Neoplasms; Diarrhea; Docetaxel; Fatigue; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Taxoids; Time Factors | 2000 |
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Humans; Infusions, Intravenous; Irinotecan; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclosporins; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome | 2000 |
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cryotherapy; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Taxoids | 2000 |
The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Male; Middle Aged; Mouth Mucosa; Neoplasms; Neutropenia; Paclitaxel; Quinolines; Stomatitis; Taxoids; Vomiting | 2000 |
Phase I study of CBT-1 and Taxol in patients with Taxol resistant cancers.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Biological Factors; Bone Marrow Diseases; Combined Modality Therapy; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Humans; Hyperpigmentation; Male; Middle Aged; Neoplasms; Paclitaxel; Salvage Therapy; Treatment Outcome | 2000 |
Clinical significance of defective dendritic cell differentiation in cancer.
Topics: Adult; Aged; Antibodies; Antineoplastic Agents; Carboplatin; Cell Count; Cell Differentiation; Cytokines; Dendritic Cells; Endothelial Growth Factors; Flow Cytometry; Growth Substances; Humans; Lymph Nodes; Lymphokines; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Phase I and pharmacokinetic study of oral paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 2000 |
Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Docetaxel; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm, Residual; Neoplasms; Paclitaxel; Taxoids | 2000 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; Capecitabine; Carboxylic Ester Hydrolases; Deamination; Deoxycytidine; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Fever; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Paronychia; Prodrugs; Remission Induction; Taxoids; Treatment Outcome | 2000 |
Therapeutic drug monitoring of paclitaxel (Zisu) in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Monitoring; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2000 |
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Paclitaxel | 2000 |
Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
Topics: Antineoplastic Agents, Phytogenic; Glycerol; Humans; Infusions, Intravenous; Neoplasms; Paclitaxel; Surface-Active Agents | 2000 |
Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Paclitaxel; Platelet Count; Recombinant Proteins; Taxoids; Topotecan | 2000 |
Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions.
Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Humans; Ketotifen; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids | 2000 |
Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclosporins; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
UFT/leucovorin plus weekly paclitaxel in the treatment of solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasms; Paclitaxel; Tegafur; Uracil | 2000 |
A phase I study of paclitaxel, UFT, and leucovorin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasms; Paclitaxel; Tegafur; Uracil | 2000 |
Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Phase I study of docetaxel and topotecan in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Topotecan | 2000 |
A dose escalation study of weekly docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fever; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2000 |
Phase I clinical trial of weekly combined paclitaxel plus docetaxel in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythema; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD56 Antigen; Cyclosporins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorescent Dyes; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Rhodamines; T-Lymphocytes | 2001 |
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Drug Interactions; Endothelial Growth Factors; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Lymphokines; Male; Middle Aged; Neoplasms; Paclitaxel; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cyclosporine; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Hospitalization; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Stomatitis; Topotecan | 2001 |
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Solubility; Taxoids | 2001 |
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carcinoma, Small Cell; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Stomach Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms | 2001 |
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Cyclosporine; Drug Combinations; Female; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel | 2001 |
A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Cyclosporins; Doxorubicin; Drug Interactions; Drug Resistance, Multiple; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Treatment Outcome | 2001 |
Phase I dose escalation study of topotecan combined with alternating schedules of paclitaxel and carboplatin in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Topotecan; Treatment Outcome | 2001 |
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Middle Aged; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Recurrence; Time Factors; Treatment Outcome; Triazoles; Tumor Cells, Cultured | 2001 |
Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions.
Topics: Adult; Aged; Aged, 80 and over; Anaphylaxis; Clemastine; Dexamethasone; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Ranitidine; Treatment Outcome | 2001 |
A dose-finding study of the weekly administration of paclitaxel in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel | 2001 |
Pharmacokinetic study of paclitaxel as a 3-hour infusion in an Indian population: 135 mg/m2 vs. 175 mg/m2.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; India; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Tissue Distribution | 2001 |
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Area Under Curve; Cyclosporine; Drug Combinations; Feces; Glycerol; Humans; Intestinal Absorption; Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Polysorbates; Solvents | 2001 |
Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Drug Administration Schedule; Female; Glycerol; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Surface-Active Agents; Thrombocytopenia; Time Factors | 2002 |
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Feasibility Studies; Female; Humans; Liposomes; Male; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Safety; Treatment Outcome | 2001 |
Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Synergism; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia.
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Hypothermia, Induced; Ifosfamide; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Severity of Illness Index; Treatment Outcome | 2002 |
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinases; Female; Flavonoids; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Piperidines | 2002 |
Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; DNA Adducts; Dose-Response Relationship, Drug; Drug Interactions; Head and Neck Neoplasms; Humans; Leukocytes; Mass Spectrometry; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Platinum; Reproducibility of Results | 2002 |
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Area Under Curve; Castor Oil; Chemistry, Pharmaceutical; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Nervous System Diseases; Paclitaxel; Particle Size; Stomatitis; Taxoids; Treatment Outcome | 2002 |
Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Thymidine Phosphorylase | 2002 |
Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Infusions, Intravenous; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Survival Rate | 2002 |
A phase I study of oral uracil-ftorafur plus folinic acid in combination with weekly paclitaxel in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Survival Analysis; Tegafur; Treatment Outcome | 2002 |
Phase I trial of Taxotere: five-day schedule.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Mouth Mucosa; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1992 |
Laboratory and phase I studies of new cancer drugs.
Topics: Antineoplastic Agents; Bryostatins; Camptothecin; Docetaxel; Humans; Lactones; Macrolides; Neoplasms; Paclitaxel; Taxoids | 1992 |
Taxol administered as a 120 hour infusion.
Topics: Adult; Aged; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel | 1992 |
Taxol. Out of the woods.
Topics: Alkaloids; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Transplantation, Heterologous | 1991 |
A phase I trial of taxol given by a 6-hour intravenous infusion.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Microtubules; Middle Aged; Neoplasms; Paclitaxel; Time Factors | 1991 |
Sequences of taxol and cisplatin: a phase I and pharmacologic study.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Cisplatin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Microtubules; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases | 1991 |
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Chick Embryo; Dosage Forms; Drug Administration Schedule; Humans; Microtubules; Neoplasms; Neoplasms, Experimental; Paclitaxel; Vinca Alkaloids | 1991 |
Novel chemotherapeutic agents in early clinical development.
Topics: Adenine; Alkaloids; Anthraquinones; Antineoplastic Agents; Biphenyl Compounds; Camptothecin; Humans; Imides; Irinotecan; Isoquinolines; Naphthalimides; Neoplasms; Organophosphonates; Paclitaxel; Pyrazoles; Quinazolines; Sulfonylurea Compounds; Terpenes; Trimetrexate | 1990 |
Phase I trial of taxol given as a 3-hour infusion every 21 days.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Immediate; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Paclitaxel | 1986 |
1072 other study(ies) available for paclitaxel and Benign Neoplasms
| Article | Year |
|---|---|
BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Division; Cell Line, Tumor; Colchicine; Drug Screening Assays, Antitumor; G2 Phase; Humans; Indoles; KB Cells; Male; Mice; Mice, Nude; Microtubules; Mitochondria; Mitosis; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Tubulin; Tubulin Modulators; Xenograft Model Antitumor Assays | 2004 |
Synthesis and biological activity of analogues of the antimicrotubule agent N,beta,beta-trimethyl-L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]- N(1),3-dimethyl-L-valinamide (HTI-286).
Topics: Amines; Animals; Cell Death; Cell Division; Cell Line; Cyclization; Esters; Humans; Inhibitory Concentration 50; Methylamines; Mice; Microtubules; Molecular Structure; Neoplasms; Oligopeptides; Oxidation-Reduction; Peptides; Pyruvic Acid; Structure-Activity Relationship; Tubulin | 2004 |
CHMIS-C: a comprehensive herbal medicine information system for cancer.
Topics: Antineoplastic Agents, Phytogenic; Databases, Factual; Internet; National Institutes of Health (U.S.); Neoplasms; Phytotherapy; Plant Preparations; United States; United States Food and Drug Administration | 2005 |
Synthesis and biological activity of (+)-hedychilactone A and its analogs from (+)-sclareolide.
Topics: Angiogenesis Inhibitors; Cells, Cultured; Diterpenes; Endothelium, Vascular; Humans; Neoplasms; Neovascularization, Physiologic; Nitric Oxide; Umbilical Veins | 2006 |
Kinase-mediated trapping of bi-functional conjugates of paclitaxel or vinblastine with thymidine in cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Drug Design; Humans; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Kinases; Structure-Activity Relationship; Substrate Specificity; Thymidine; Vinblastine | 2006 |
Conjugated indole-imidazole derivatives displaying cytotoxicity against multidrug resistant cancer cell lines.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Resistance, Multiple; Humans; Imidazoles; Indoles; Inhibitory Concentration 50; Neoplasms; Structure-Activity Relationship | 2006 |
Synthesis of 2'-paclitaxel methyl 2-glucopyranosyl succinate for specific targeted delivery to cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Membrane; Chemical Phenomena; Chemistry, Physical; Chromatography, High Pressure Liquid; Glucose Transport Proteins, Facilitative; Humans; Indicators and Reagents; Neoplasms; Paclitaxel; Solubility; Succinates | 2007 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Discovery of 5-(4-hydroxy-6-methyl-2-oxo-2H-pyran-3-yl)-7-phenyl-(E)-2,3,6,7-tetrahydro-1,4-thiazepines as a new series of apoptosis inducers using a cell- and caspase-based HTS assay.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Humans; Models, Chemical; Neoplasms; Structure-Activity Relationship; Thiazepines; Tubulin | 2007 |
Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines.
Topics: Amides; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Death; Drug Resistance, Multiple; Fluorescent Antibody Technique; Humans; Indoles; Indolizines; Neoplasms; RNA, Messenger; Structure-Activity Relationship; Tumor Cells, Cultured | 2008 |
Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Coumarins; Drug Resistance, Multiple; Humans; Molecular Structure; Neoplasms; Oxygen; Pyranocoumarins; Pyrans; Sensitivity and Specificity; Structure-Activity Relationship; Substrate Specificity | 2008 |
Synthesis and antitumor activity evaluations of albumin-binding prodrugs of CC-1065 analog.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Duocarmycins; Female; Humans; Indoles; Mice; Molecular Structure; Neoplasm Transplantation; Neoplasms; Prodrugs; Serum Albumin; Structure-Activity Relationship | 2008 |
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory can
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Enzyme Inhibitors; Humans; Kinesins; Neoplasms; Piperidines; Pyrroles; Taxoids | 2008 |
Design, synthesis, and anti-tumor evaluation of novel symmetrical bis-benzimidazoles.
Topics: Animals; Antineoplastic Agents; Base Sequence; Bisbenzimidazole; Cell Line, Tumor; DNA; Drug Design; Humans; Inhibitory Concentration 50; Models, Molecular; Neoplasms; Nucleic Acid Conformation | 2009 |
Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Mice; Mice, Nude; Neoplasms; Pyrimidines; Structure-Activity Relationship; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.
Topics: Anisoles; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Inhibitory Concentration 50; Models, Chemical; Naphthalenes; Neoplasms; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2008 |
Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker.
Topics: Acridines; Animals; Antineoplastic Agents, Alkylating; Carbamates; Carbonates; Cell Line, Tumor; DNA; Dose-Response Relationship, Drug; Drug Design; Half-Life; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Neoplasms; Rats; Xenograft Model Antitumor Assays | 2009 |
Cytotoxic activity and inhibitory effect on nitric oxide production of triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae).
Topics: Animals; Antineoplastic Agents, Phytogenic; Apiaceae; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Humans; Macrophages; Mice; Neoplasms; Nitric Oxide; Oleanolic Acid; Plant Roots; Saponins; Triterpenes | 2009 |
Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes.
Topics: Animals; Antineoplastic Agents, Alkylating; Aza Compounds; Breast Neoplasms; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Survival; Cross-Linking Reagents; DNA; Female; Humans; Indenes; Mice; Mice, Nude; Neoplasms; Remission Induction; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2009 |
Solvent free synthesis, anti-inflammatory and anticancer activity evaluation of tricyclic and tetracyclic benzimidazole derivatives.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Microwaves; Neoplasms; Ovarian Neoplasms | 2010 |
Synthesis of cholestane glycosides bearing OSW-1 disaccharide or its 1-->4-linked analogue and their antitumor activities.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Cholestanes; Cholestenones; Cytotoxins; Drug Screening Assays, Antitumor; Glycosides; Humans; Models, Molecular; Neoplasms; Ornithogalum; Saponins; Structure-Activity Relationship | 2010 |
Antitumor agents 283. Further elaboration of desmosdumotin C analogs as potent antitumor agents: activation of spindle assembly checkpoint as possible mode of action.
Topics: Alkenes; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Ketones; Models, Biological; Molecular Structure; Neoplasms; Spindle Apparatus | 2011 |
Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; Humans; Mice; Mice, Nude; Mustard Plant; Neoplasms; Quinazolines; Structure-Activity Relationship; Urea; Xenograft Model Antitumor Assays | 2011 |
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.
Topics: Antineoplastic Agents; Benzopyrans; Cell Line, Tumor; Cell Survival; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; HCT116 Cells; HL-60 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; K562 Cells; Mitoxantrone; Molecular Structure; Neoplasms; Paclitaxel; Stereoisomerism; Structure-Activity Relationship; Vincristine | 2011 |
Synthesis and biological activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents.
Topics: Aniline Compounds; Antimitotic Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Humans; Microtubules; Mitosis; Neoplasms; Pyrimidines; Stereoisomerism; Structure-Activity Relationship; Tubulin Modulators; Tumor Cells, Cultured | 2011 |
Synthesis and biological evaluation of 1,9-disubstituted β-carbolines as potent DNA intercalating and cytotoxic agents.
Topics: Antineoplastic Agents; Carbolines; Cell Line, Tumor; Cytotoxins; DNA; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Intercalating Agents; Neoplasms | 2011 |
Novel 4-azasteroidal N-glycoside analogues bearing sugar-like D ring: synthesis and anticancer activities.
Topics: Antineoplastic Agents; Azasteroids; Cell Line, Tumor; Cell Survival; Female; Glycosides; Humans; Male; Neoplasms | 2011 |
A modular approach to trim cellular targets in anticancer drug discovery.
Topics: Anaphase; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Drug Discovery; Humans; Metaphase; Neoplasms; Oxidation-Reduction; Pyrimidines; Structure-Activity Relationship | 2011 |
One-pot synthesis and biological evaluation of 2-pyrrolidinyl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazole: a unique, highly active antimicrotubule agent.
Topics: Animals; Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; G2 Phase; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Thiazoles; Tubulin; Tubulin Modulators | 2011 |
Design and synthesis of simplified taxol analogs based on the T-Taxol bioactive conformation.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Design; Humans; Models, Molecular; Molecular Conformation; Neoplasms; Paclitaxel; Tubulin | 2011 |
Cytotoxic esterified diterpenoid alkaloid derivatives with increased selectivity against a drug-resistant cancer cell line.
Topics: Alkaloids; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Diterpenes; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Neoplasms; Paclitaxel; Structure-Activity Relationship | 2012 |
In vivo evaluation of oral anti-tumoral effect of 3,4-dihydroquinazoline derivative on solid tumor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms; Quinazolines; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2012 |
Antitumor agents 292. Design, synthesis and pharmacological study of S- and O-substituted 7-mercapto- or hydroxy-coumarins and chromones as potent cytotoxic agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Chromones; Coumarins; Cytotoxins; Drug Design; Drug Screening Assays, Antitumor; Humans; Neoplasms | 2012 |
Synthesis of terphenyl benzimidazoles as tubulin polymerization inhibitors.
Topics: Benzimidazoles; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tubulin; Tubulin Modulators; Tumor Cells, Cultured | 2012 |
Antitumor activity of annonaceous acetogenins in HepS and S180 xenografts bearing mice.
Topics: Acetogenins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Mice; Molecular Structure; Neoplasms; Transplantation, Heterologous | 2012 |
Protuboxepin A, a marine fungal metabolite, inducing metaphase arrest and chromosomal misalignment in tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Aquatic Organisms; Aspergillus; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromosome Pairing; Drug Screening Assays, Antitumor; Humans; Metaphase; Microtubules; Neoplasms; Oxepins; Structure-Activity Relationship; Tubulin | 2012 |
Zizimauritic acids A-C, three novel nortriterpenes from Ziziphus mauritiana.
Topics: Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Humans; Neoplasms; Plant Roots; Staphylococcal Infections; Staphylococcus aureus; Triterpenes; Ziziphus | 2012 |
Synthesis and biological evaluation of novel pyranochalcone derivatives as a new class of microtubule stabilizing agents.
Topics: Animals; Antineoplastic Agents; Benzopyrans; Cell Line; Cell Proliferation; Chalones; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Hep G2 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubules; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tubulin Modulators | 2013 |
Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Blood-Brain Barrier; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Drug Design; Drug Resistance, Neoplasm; HCT116 Cells; Humans; K562 Cells; MCF-7 Cells; Mice; Mice, Nude; Microtubules; Neoplasms; Polymerization; Sulfonamides; Tubulin; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Design, synthesis and biological evaluation of millepachine derivatives as a new class of tubulin polymerization inhibitors.
Topics: Animals; Antineoplastic Agents; Benzopyrans; Binding Sites; Cell Line, Tumor; Cell Proliferation; Chalcones; Colchicine; Drug Design; Drug Screening Assays, Antitumor; Female; G2 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; K562 Cells; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Neoplasms; Protein Binding; Protein Structure, Tertiary; Structure-Activity Relationship; Transplantation, Heterologous; Tubulin; Tubulin Modulators | 2013 |
Furanylazaindoles: potent anticancer agents in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Female; Heterocyclic Compounds, 2-Ring; HT29 Cells; Humans; Indoles; Inhibitory Concentration 50; Mice, Nude; Molecular Structure; Neoplasms; Polymerization; Sulfonamides; Tubulin; Xenograft Model Antitumor Assays | 2013 |
New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Cell Survival; Colchicine; Drug Screening Assays, Antitumor; Guanidines; Hedgehog Proteins; Humans; M Phase Cell Cycle Checkpoints; Mice; Molecular Docking Simulation; Neoplasms; Polymerization; Protein Binding; Pyrroles; Signal Transduction; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2014 |
Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fibroblasts; Humans; Hydroxamic Acids; Indoles; Neoplasms; Neoplastic Stem Cells; Structure-Activity Relationship | 2015 |
Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.
Topics: Antineoplastic Agents; Aurora Kinase A; Cell Line, Tumor; Cell Proliferation; Humans; Indazoles; Neoplasms; Protein Kinase Inhibitors; Structure-Activity Relationship | 2015 |
Progress Toward the Development of Noscapine and Derivatives as Anticancer Agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Neoplasms; Noscapine | 2015 |
Synthesis and activities towards resistant cancer cells of sulfone and sulfoxide griseofulvin derivatives.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Griseofulvin; Humans; Neoplasms; Sulfones; Sulfoxides | 2015 |
Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Catechin; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flavonols; Humans; Methylation; Models, Molecular; Molecular Structure; Neoplasm Proteins; Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2015 |
New Indole Tubulin Assembly Inhibitors Cause Stable Arrest of Mitotic Progression, Enhanced Stimulation of Natural Killer Cell Cytotoxic Activity, and Repression of Hedgehog-Dependent Cancer.
Topics: Animals; Cell Division; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Hedgehog Proteins; Humans; Indoles; Killer Cells, Natural; Mice; Mitosis; Neoplasms; NIH 3T3 Cells; Tubulin | 2015 |
Synthesis and bio-evaluation of novel quinolino-stilbene derivatives as potential anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Neoplasms; Quinolines; Stilbenes; Tubulin; Tubulin Modulators | 2015 |
Indomethacin derivatives as tubulin stabilizers to inhibit cancer cell proliferation.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Indomethacin; Molecular Structure; Neoplasms; Protein Stability; Structure-Activity Relationship; Tubulin; Tumor Cells, Cultured | 2016 |
Discovery of novel heteroarylmethylcarbamodithioates as potent anticancer agents: Synthesis, structure-activity relationship analysis and biological evaluation.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Neoplasms; Oxadiazoles; Structure-Activity Relationship; Thiocarbamates | 2016 |
Anticancer activity studies of cubebin isolated from Piper cubeba and its synthetic derivatives.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Humans; Lignans; Models, Molecular; Neoplasms; Piper; Seeds | 2016 |
Study on the synthesis and biological activities of α-substituted arylacetates derivatives.
Topics: Acetates; alpha-Glucosidases; Animals; Antineoplastic Agents; Cell Line, Tumor; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Neoplasms; Rats; Solanaceous Alkaloids; Structure-Activity Relationship | 2016 |
Synthesis and antitumor activity of novel substituted uracil-1'(N)-acetic acid ester derivatives of 20(S)-camptothecins.
Topics: Acetates; Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; Humans; Mice, Nude; Neoplasms; Topoisomerase I Inhibitors; Uracil | 2017 |
Ortho group activation of a bromopyrrole ester in Suzuki-Miyaura cross-coupling reactions: Application to the synthesis of new microtubule depolymerizing agents with potent cytotoxic activities.
Topics: Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Halogenation; Humans; Microtubules; Molecular Docking Simulation; Neoplasms; Pyrroles; Rats | 2017 |
In Vivo and Mechanistic Studies on Antitumor Lead 7-Methoxy-4-(2-methylquinazolin-4-yl)-3,4-dihydroquinoxalin-2(1H)-one and Its Modification as a Novel Class of Tubulin-Binding Tumor-Vascular Disrupting Agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Mice, Nude; Molecular Docking Simulation; Neoplasms; Quinazolines; Tubulin; Tubulin Modulators | 2017 |
Vinblastine 20' Amides: Synthetic Analogues That Maintain or Improve Potency and Simultaneously Overcome Pgp-Derived Efflux and Resistance.
Topics: Amides; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasms; Structure-Activity Relationship; Tubulin; Tubulin Modulators; Vinblastine | 2017 |
Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Drug Design; Glycolysis; HeLa Cells; Humans; Mitosis; Naphthoquinones; Neoplasms; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Tubulin; Tubulin Modulators | 2018 |
Synthesis and biological evaluation of (1-aryl-1H-pyrazol-4-yl) (3,4,5-trimethoxyphenyl)methanone derivatives as tubulin inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Molecular Docking Simulation; Neoplasms; Pyrazoles; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2018 |
Discovery of the cancer cell selective dual acting anti-cancer agent (Z)-2-(1H-indol-3-yl)-3-(isoquinolin-5-yl)acrylonitrile (A131).
Topics: Acrylonitrile; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Neoplasms; Rats | 2018 |
Synthesis and biological evaluation of novel larotaxel analogues.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Mice, SCID; Molecular Docking Simulation; Neoplasms; Structure-Activity Relationship; Taxoids | 2018 |
Novel nicotinoyl pyrazoline derivates bearing N-methyl indole moiety as antitumor agents: Design, synthesis and evaluation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Design; Female; HEK293 Cells; HeLa Cells; Humans; Indoles; Mice, Nude; Mitosis; Models, Molecular; Neoplasms; Pyrazoles; Tubulin Modulators; Uterine Cervical Neoplasms | 2018 |
Synthesis of 5H-pyrido[3,2-b]pyrrolizin-5-one tripentone analogs with antitumor activity.
Topics: Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; MCF-7 Cells; Neoplasms; Pyridines; Pyrroles; Structure-Activity Relationship | 2018 |
Sterically induced conformational restriction: Discovery and preclinical evaluation of novel pyrrolo[3,2-d]pyrimidines as microtubule targeting agents.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Mice, Nude; Microtubules; Molecular Docking Simulation; Neoplasms; Pyrimidines; Pyrroles; Stereoisomerism; Tubulin; Tubulin Modulators | 2018 |
Design, synthesis and biological evaluation of quinoline-indole derivatives as anti-tubulin agents targeting the colchicine binding site.
Topics: Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Colchicine; Drug Design; Drug Screening Assays, Antitumor; Heterografts; Humans; Indoles; K562 Cells; Neoplasms; Quinolines; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2019 |
Synthesis, antiproliferative and apoptosis induction potential activities of novel bis(indolyl)hydrazide-hydrazone derivatives.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; HEK293 Cells; Humans; Hydrazones; Indoles; MAP Kinase Signaling System; Neoplasms; Reactive Oxygen Species | 2019 |
4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
Topics: Antineoplastic Agents; Apoptosis; Binding Sites; Cell Proliferation; Colchicine; Drug Resistance, Neoplasm; Humans; Molecular Docking Simulation; Neoplasms; Quinolones; Tubulin; Tubulin Modulators | 2019 |
Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
Topics: A549 Cells; Acrylates; Animals; Antineoplastic Agents; Apoptosis; Benzoates; Drug Design; ErbB Receptors; Humans; Mice, Nude; Molecular Docking Simulation; Naphthoquinones; Neoplasms; Tubulin; Tubulin Modulators | 2019 |
Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Design; G2 Phase Cell Cycle Checkpoints; Humans; Membrane Potential, Mitochondrial; Mice; Molecular Docking Simulation; Molecular Structure; Neoplasms; Protein Binding; Pyridines; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2020 |
Discovery of a chiral fluorinated azetidin-2-one as a tubulin polymerisation inhibitor with potent antitumour efficacy.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Azetidines; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Stability; G2 Phase Cell Cycle Checkpoints; Humans; Mice; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tubulin; Tubulin Modulators; Xenograft Model Antitumor Assays | 2020 |
Design, synthesis and biological evaluation of vinyl selenone derivatives as novel microtubule polymerization inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Humans; K562 Cells; Male; Mice, Inbred ICR; Neoplasms; Organoselenium Compounds; Tubulin; Tubulin Modulators; Vinyl Compounds | 2020 |
Discovery of lysosome-targeted covalent anticancer agents based on isosteviol skeleton.
Topics: A549 Cells; Antineoplastic Agents; Cell Death; Diterpenes, Kaurane; Drug Design; Humans; Lysosomes; Neoplasms | 2021 |
Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colchicine; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Neoplasms; Neovascularization, Physiologic; Structure-Activity Relationship; Tubulin; Tubulin Modulators | 2021 |
Structure-Based Design and Synthesis of N-Substituted 3-Amino-β-Carboline Derivatives as Potent αβ-Tubulin Degradation Agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Carbolines; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; G2 Phase Cell Cycle Checkpoints; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms; Protein Binding; Rats; Structure-Activity Relationship; Tubulin; Tubulin Modulators; Xenograft Model Antitumor Assays | 2022 |
Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel | 2022 |
Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Ferroptosis; Humans; Microtubules; Neoplasms; Stilbenes | 2022 |
PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Female; Humans; Hyaluronoglucosaminidase; Mice; Neoplasms; Paclitaxel; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Microfluidic assembly of small-molecule prodrug cocktail nanoparticles with high reproducibility for synergistic combination of cancer therapy.
Topics: Cell Line, Tumor; Drug Delivery Systems; Humans; Microfluidics; Nanoparticles; Neoplasms; Paclitaxel; Prodrugs; Reproducibility of Results | 2021 |
Reversing Multidrug Resistance by Inducing Mitochondrial Dysfunction for Enhanced Chemo-Photodynamic Therapy in Tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Indoles; Liposomes; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasms; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Xenograft Model Antitumor Assays | 2021 |
Engineering Paclitaxel Prodrug Nanoparticles via Redox-Activatable Linkage and Effective Carriers for Enhanced Chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Disulfides; Drug Liberation; Drug Therapy; Female; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; NIH 3T3 Cells; Oxidation-Reduction; Paclitaxel; Prodrugs | 2021 |
Topics: Amides; Amino Acids; Cell Line, Tumor; Drug Carriers; Esters; Inositol; Nanoparticles; Neoplasms; Paclitaxel | 2021 |
Transferrin receptors/magnetic resonance dual-targeted nanoplatform for precise chemo-photodynamic synergistic cancer therapy.
Topics: Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Humans; Magnetic Resonance Spectroscopy; Nanoparticles; Neoplasms; Paclitaxel; Photochemotherapy; Receptors, Transferrin; Transferrin | 2022 |
Cancer microcell initiation and determination.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Count; Cell Line, Tumor; Cell Nucleus; Cell Self Renewal; Cell Survival; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Endosomal Sorting Complexes Required for Transport; Female; Fibroblasts; Green Fluorescent Proteins; HeLa Cells; Humans; Indicators and Reagents; Melanoma; Microscopy, Electron; NADP; Neoplasm Recurrence, Local; Neoplasms; Neutral Red; Paclitaxel; Stress, Physiological; Time-Lapse Imaging; Transcription Factors; Transfection; Uterine Cervical Neoplasms | 2021 |
LRGCPND: Predicting Associations between ncRNA and Drug Resistance via Linear Residual Graph Convolution.
Topics: Algorithms; Antineoplastic Agents; Cisplatin; Computational Biology; Drug Resistance; Drug Resistance, Neoplasm; Humans; MicroRNAs; Models, Theoretical; Neoplasms; Paclitaxel; RNA, Untranslated | 2021 |
Effect of targeting ligand designation of self-assembly chitosan-poloxamer nanogels loaded Paclitacel on inhibiting MCF-7 cancer cell growth.
Topics: Cell Line, Tumor; Chitosan; Drug Carriers; Folic Acid; Humans; Ligands; MCF-7 Cells; Nanogels; Nanoparticles; Neoplasms; Paclitaxel; Poloxamer | 2022 |
Elevated (Pro)renin Receptor Expression by Anti-Cancer Drugs, Carboplatin and Paclitaxel, in Cultured Cancer Cells: Possible Involvement of Apoptosis and Autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carboplatin; Humans; Neoplasms; Paclitaxel; Renin; RNA, Messenger; Vacuolar Proton-Translocating ATPases | 2021 |
A Low Dose of Hydrous Icaritin Nano-Formulation with Remarkable Efficacy and Tumor Targeting in Cancer Therapy.
Topics: Cell Line, Tumor; Flavonoids; Humans; Nanoparticles; Neoplasms; Paclitaxel; Particle Size | 2021 |
Laser Therapy as a Preventive Approach for Oral Mucositis in Cancer Patients Undergoing Chemotherapy: The Potential Role of Superoxide Dismutase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Low-Level Light Therapy; Male; Middle Aged; Neoplasms; Oxidative Stress; Paclitaxel; Stomatitis; Superoxide Dismutase | 2021 |
FOXM1-mediated activation of phospholipase D1 promotes lipid droplet accumulation and reduces ROS to support paclitaxel resistance in metastatic cancer cells.
Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Lipid Droplets; Mice; Neoplasms; Paclitaxel; Phospholipase D; Reactive Oxygen Species | 2022 |
Rosmarinic acid suppresses inflammation, angiogenesis, and improves paclitaxel induced apoptosis in a breast cancer model via NF3 κB-p53-caspase-3 pathways modulation.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Cinnamates; Depsides; Inflammation; Mice; Neoplasms; Neovascularization, Pathologic; NF-kappa B; Paclitaxel; Rosmarinic Acid; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2021 |
Co-Delivery of Paclitaxel and shMCL-1 by Folic Acid-Modified Nonviral Vector to Overcome Cancer Chemotherapy Resistance.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Drug Carriers; Drug Resistance, Neoplasm; Folic Acid; G2 Phase Cell Cycle Checkpoints; Humans; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Nanocomposites; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Transfection | 2021 |
Paclitaxel-Loaded Biotinylated Fe
Topics: Animals; Carbon; Cell Line, Tumor; Hydrogen Peroxide; Mice; Nanoparticles; Neoplasms; NIH 3T3 Cells; Paclitaxel; Prodrugs; Reactive Oxygen Species | 2021 |
Reprogramming Cancer Stem-like Cells with Nanoforskolin Enhances the Efficacy of Paclitaxel in Targeting Breast Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Survival; Colforsin; Drug Carriers; Drug Liberation; Female; Humans; Liquid Crystals; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Tissue Distribution; Transplantation, Heterologous | 2021 |
Transport Behavior of Commercial Anticancer Drug Protein-Bound Paclitaxel (Paclicad) in a Micron-Sized Channel.
Topics: Albumin-Bound Paclitaxel; Antineoplastic Agents; Capillaries; Humans; Neoplasms; Paclitaxel | 2022 |
Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression.
Topics: CD47 Antigen; Humans; Immunosuppression Therapy; Immunotherapy; Lymphoma; Macrophages; Neoplasms; Paclitaxel; Phagocytosis; Tumor Microenvironment | 2022 |
Combination of ruthenium (II) polypyridyl complex Δ-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD-mediated pyroptosis.
Topics: Animals; Caspase 1; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; Mice; Neoplasms; Paclitaxel; Phosphate-Binding Proteins; Pore Forming Cytotoxic Proteins; Pyroptosis; Ruthenium | 2022 |
Mucus Penetrating and Cell-Binding Polyzwitterionic Micelles as Potent Oral Nanomedicine for Cancer Drug Delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Humans; Micelles; Mucus; Nanomedicine; Neoplasms; Paclitaxel; Polyethylene Glycols; Polymers | 2022 |
3D printed drug-loaded implantable devices for intraoperative treatment of cancer.
Topics: Animals; Drug Delivery Systems; Mice; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Printing, Three-Dimensional | 2022 |
Biocatalysis of precursors to new-generation SB-T-taxanes effective against paclitaxel-resistant cancer cells.
Topics: Acetyl Coenzyme A; Acetyltransferases; Biocatalysis; Neoplasms; Paclitaxel; Substrate Specificity; Tandem Mass Spectrometry; Taxoids | 2022 |
Characterization of Caerulomycin A as a dual-targeting anticancer agent.
Topics: 2,2'-Dipyridyl; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Mice; Neoplasms; Paclitaxel; Pyridines; Tubulin | 2022 |
Drug-loaded nanoparticles conjugated with genetically engineered bacteria for cancer therapy.
Topics: Cell Line, Tumor; Escherichia coli; Humans; Liposomes; Nanoparticles; Neoplasms; Paclitaxel | 2022 |
Safety and Tolerability of Carboplatin and Paclitaxel in Cancer Patients with HIV (AMC-078), an AIDS Malignancy Consortium (AMC) Study.
Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytochrome P-450 CYP3A Inhibitors; HIV Infections; Humans; Neoplasms; Paclitaxel | 2022 |
Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors.
Topics: Administration, Intravenous; Administration, Oral; Antineoplastic Agents; Humans; Neoplasms; Paclitaxel | 2022 |
Application of Computational Screening Tools and Nanotechnology for Enhanced Drug Synergism in Cancer Therapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Synergism; Early Detection of Cancer; Humans; Nanoparticles; Nanotechnology; Neoplasms; Paclitaxel | 2023 |
Hypoxia responsive and tumor-targeted mixed micelles for enhanced cancer therapy and real-time imaging.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Folic Acid; Humans; Hypoxia; Micelles; Neoplasms; Paclitaxel | 2022 |
A single local delivery of paclitaxel and nucleic acids via an immunoactive polymer eliminates tumors and induces antitumor immunity.
Topics: Cell Line, Tumor; Humans; Immunotherapy; Neoplasms; Nucleic Acids; Paclitaxel; Polymers | 2022 |
Bioactivity inspired C
Topics: Alkaloids; Diterpenes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Verapamil; Vincristine | 2022 |
Surface charge switchable nano-micelle for pH/redox-triggered and endosomal escape mediated co-delivery of doxorubicin and paclitaxel in treatment of lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Animals; Doxorubicin; Drug Carriers; Drug Delivery Systems; Endosomes; Hydrogen-Ion Concentration; Mice; Micelles; Neoplasms; Oxidation-Reduction; Paclitaxel; Tumor Microenvironment | 2022 |
Retrospective analysis of efficacy and safety of oral paclitaxel for treatment of various cancers in dogs (2017-2021).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Humans; Neoplasms; Paclitaxel; Retrospective Studies | 2022 |
Legumain/pH dual-responsive lytic peptide-paclitaxel conjugate for synergistic cancer therapy.
Topics: Antineoplastic Agents; Cysteine Endopeptidases; Humans; Hydrogen-Ion Concentration; Neoplasms; Paclitaxel; Peptides; Tumor Microenvironment | 2022 |
Effect of Eribulin on Angiogenesis and the Expression of Endothelial Adhesion Molecules.
Topics: Furans; Humans; Intercellular Adhesion Molecule-1; Ketones; Neoplasms; Paclitaxel; Transforming Growth Factor beta; Tumor Microenvironment; Vinorelbine | 2022 |
Comparison of the Antiemetic Effect of Aprepitant/granisetron and Palonosetron Combined with Dexamethasone in Gynecological Cancer Patients Treated with Paclitaxel and Carboplatin Combination Regimen.
Topics: Anorexia; Antiemetics; Aprepitant; Carboplatin; Dexamethasone; Female; Granisetron; Humans; Nausea; Neoplasms; Paclitaxel; Palonosetron; Retrospective Studies; Vomiting | 2022 |
pH-sensitive carbon nanotubes graft polymethylacrylic acid self-assembly nanoplatforms for cellular drug release.
Topics: Antineoplastic Agents; Drug Carriers; Drug Liberation; Humans; Hydrogen-Ion Concentration; Micelles; Nanotubes, Carbon; Neoplasms; Paclitaxel; Particle Size; Polymethacrylic Acids | 2022 |
Hybrid micelles loaded with chemotherapeutic drug-photothermal agent realizing chemo-photothermal synergistic cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Mice; Mice, Inbred BALB C; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Photosensitizing Agents | 2022 |
Molecular-docking-guided design, palladium-catalyzed synthesis and anticancer activity of paclitaxel-benzoxazoles hybrids.
Topics: Antineoplastic Agents; Benzoxazoles; Catalysis; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Paclitaxel; Palladium; Structure-Activity Relationship | 2022 |
Self-emulsifying System Co-loaded with Paclitaxel and Coix Seed Oil Deeply Penetrated to Enhance Efficacy in Cervical Cancer.
Topics: Cell Line, Tumor; Coix; Fluorescein-5-isothiocyanate; HeLa Cells; Humans; Neoplasms; Paclitaxel; Plant Oils | 2023 |
2-Amino-Pyrrole-Carboxylate Attenuates Homology-Mediated DNA Repair and Sensitizes Cancer Cells to Doxorubicin.
Topics: Antineoplastic Agents; DNA Damage; DNA Repair; Doxorubicin; Humans; Neoplasms; Paclitaxel; Pyrroles | 2022 |
Antineoplastic Enzyme as Drug Carrier with Activatable Catalytic Activity for Efficient Combined Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Female; Glucose Oxidase; Humans; Hydrogen Peroxide; Nanoparticles; Neoplasms; Paclitaxel; Sorafenib; Tumor Microenvironment | 2022 |
Dual-targeted enzyme-sensitive hyaluronic acid nanogels loading paclitaxel for the therapy of breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Hyaluronic Acid; Mice; Mice, Inbred BALB C; Micelles; Nanogels; Neoplasms; Paclitaxel; Rats | 2022 |
Polymeric micelle-based nanoagents enable phototriggering combined chemotherapy and photothermal therapy with high sensitivity.
Topics: Animals; Cell Line, Tumor; Hyperthermia, Induced; Infrared Rays; Mice; Mice, Inbred BALB C; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Phototherapy; Photothermal Therapy; Polymers | 2022 |
Preparation of size-tunable sub-200 nm PLGA-based nanoparticles with a wide size range using a microfluidic platform.
Topics: Drug Carriers; Humans; Lactic Acid; Microfluidics; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2022 |
Sequentially Activatable Polypeptide Nanoparticles for Combinatory Photodynamic Chemotherapy of Breast Cancer.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Mice; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Peptides; Photochemotherapy; Photosensitizing Agents; Polymers | 2022 |
PCSK9 conjugated liposomes for targeted delivery of paclitaxel to the cancer cell: A proof-of-concept study.
Topics: HEK293 Cells; Humans; Ligands; Liposomes; Neoplasms; Paclitaxel; Proprotein Convertase 9; Proprotein Convertases; Receptors, LDL | 2022 |
Alpha-fetoprotein mediated targeting of polymeric nanoparticles to treat solid tumors.
Topics: alpha-Fetoproteins; Cell Line, Tumor; Drug Carriers; Humans; Nanoparticles; Neoplasms; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers | 2022 |
Paclitaxel-loaded ginsenoside Rg3 liposomes for drug-resistant cancer therapy by dual targeting of the tumor microenvironment and cancer cells.
Topics: Ginsenosides; Humans; Lipopolysaccharides; Liposomes; Neoplasms; Paclitaxel; Tumor Microenvironment | 2023 |
A Polymer Prodrug Strategy to Switch from Intravenous to Subcutaneous Cancer Therapy for Irritant/Vesicant Drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Esters; Humans; Irritants; Mice; Neoplasms; Paclitaxel; Polymers; Prodrugs; Tissue Distribution | 2022 |
Therapeutic Nanocarriers Inhibit Chemotherapy-Induced Breast Cancer Metastasis.
Topics: Animals; Antineoplastic Agents; Cytokines; Mice; Nanoparticles; Neoplasms; Paclitaxel | 2022 |
Porphyrin Centered Paclitaxel Tetrameric Prodrug Nanoassemblies as Tumor-Selective Theranostics for Synergized Breast Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Mice; Nanoparticles; Neoplasms; Paclitaxel; Photosensitizing Agents; Porphyrins; Precision Medicine; Prodrugs | 2023 |
Comparison of two methods for tumour-targeting peptide modification of liposomes.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Liposomes; Mice; Neoplasms; Paclitaxel; Peptides; Tumor Microenvironment | 2023 |
Interference of Glucose Bioavailability of Tumor by Engineered Biohybrids for Potentiating Targeting and Uptake of Antitumor Nanodrugs.
Topics: Biological Availability; Escherichia coli; Escherichia coli Infections; Glucose; Humans; Nanoparticles; Neoplasms; Paclitaxel | 2022 |
Anti-cancer effects of human placenta-derived amniotic epithelial stem cells loaded with paclitaxel on cancer cells.
Topics: Apoptosis; Culture Media, Conditioned; Drug Delivery Systems; Epithelial Cells; Humans; Neoplasms; Paclitaxel; Stem Cells | 2022 |
The correlation between paclitaxel chemotoxicity and the plasma albumin level in cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hypoalbuminemia; Neoplasms; Paclitaxel; Serum Albumin | 2022 |
Nanoadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels.
Topics: Antigens, Neoplasm; Endothelial Cells; Humans; Lymph Nodes; Lymphatic Vessels; Neoplasms; Paclitaxel | 2022 |
Combination of polythyleneimine regulating autophagy prodrug and Mdr1 siRNA for tumor multidrug resistance.
Topics: Autophagy; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Nanoparticles; Neoplasms; Paclitaxel; Polyethyleneimine; Prodrugs; RNA, Small Interfering | 2022 |
Combination of Se-methylselenocysteine, D-α-tocopheryl succinate, β-carotene, and L-lysine can prevent cancer metastases using as an adjuvant therapy.
Topics: alpha-Tocopherol; Animals; Antioxidants; Apoptosis; beta Carotene; Cell Line, Tumor; Cell Proliferation; Lysine; Mice; Neoplasms; Paclitaxel; Quality of Life; Succinates | 2022 |
Availability of aldo-keto reductase 1C3 and ATP-binding cassette B1 as therapeutic targets for alleviating paclitaxel resistance in breast cancer MCF7 cells.
Topics: Adenosine Triphosphate; Aldehydes; Humans; MCF-7 Cells; Neoplasms; Paclitaxel | 2023 |
Enhancement of Anti-Tumoral Properties of Paclitaxel Nano-Crystals by Conjugation of Folic Acid to Pluronic F127: Formulation Optimization, In Vitro and In Vivo Study.
Topics: Drug Liberation; Folic Acid; Humans; Neoplasms; Paclitaxel; Poloxamer | 2022 |
A dual-response drug delivery system with X-ray and ROS to boost the anti-tumor efficiency of TPZ
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Hypoxia; Mice; Neoplasms; Paclitaxel; Reactive Oxygen Species; Tirapazamine; Tumor Hypoxia; X-Rays | 2022 |
Diselenide-Based Dual-Responsive Prodrug as Pyroptosis Inducer Potentiates Cancer Immunotherapy.
Topics: Humans; Immunotherapy; Neoplasms; Paclitaxel; Prodrugs; Pyroptosis; Tumor Microenvironment | 2023 |
Dual drug delivery system of RAPTA-C and paclitaxel based on fructose coated nanoparticles for metastatic cancer treatment.
Topics: Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Fructose; Humans; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Polymers; Ruthenium; Tissue Distribution | 2023 |
Microenvironmentally Responsive Chemotherapeutic Prodrugs and CHEK2 Inhibitors Self-Assembled Micelles: Protecting Fertility and Enhancing Chemotherapy.
Topics: Cell Line, Tumor; Checkpoint Kinase 2; Drug Delivery Systems; Female; Fertility; Humans; Micelles; Neoplasms; Paclitaxel; Prodrugs | 2023 |
Tumor Targeting and pH-Sensitive Inclusion Complex Based on HP-β-CD as a Potential Carrier for Paclitaxel: Fabrication, Molecular Docking, and Characterization.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chitosan; Drug Carriers; Excipients; Folic Acid; Humans; Hydrogen-Ion Concentration; Molecular Docking Simulation; Neoplasms; Paclitaxel | 2023 |
Multifunctional Graphene Oxide Nanodelivery Platform for Breast Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Neoplasm; Mice; Mice, Nude; Micelles; Neoplasms; Oligopeptides; Paclitaxel; Polyethylene Glycols; Vitamin E; Zebrafish | 2022 |
Effective Delivery of Paclitaxel-Loaded Ferritin via Inverso CendR Peptide for Enhanced Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Ferritins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Peptides | 2023 |
Robust Construction of Supersmall Zwitterionic Micelles Based on Hyperbranched Polycarbonates Mediates High Tumor Accumulation.
Topics: Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Humans; Micelles; Neoplasms; Paclitaxel; Polycarboxylate Cement; Polyethylene Glycols | 2023 |
Self-Assembly of Precisely Fluorinated Albumin for Dual Imaging-Guided Synergistic Chemo-Photothermal-Photodynamic Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Emulsions; Humans; Mice; Nanoparticles; Neoplasms; Paclitaxel; Photochemotherapy; Phototherapy; Serum Albumin, Bovine; Theranostic Nanomedicine | 2023 |
NIR Activated Multimodal Therapeutics Based on Metal-Phenolic Networks-Functionalized Nanoplatform for Combating against Multidrug Resistance and Metastasis.
Topics: Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Humans; Metals; Nanoparticles; Neoplasms; Paclitaxel; Phototherapy; Tumor Microenvironment | 2023 |
Tetraploidy-linked sensitization to CENP-E inhibition in human cells.
Topics: Cell Line; Chromosomal Proteins, Non-Histone; Humans; Microtubules; Mitosis; Neoplasms; Paclitaxel; Tetraploidy | 2023 |
Combined Thermosensitive Gel Co-Loaded with Dermaseptin-PP and PTX Liposomes for Effective Local Chemotherapy.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Hydrogels; Liposomes; Mice; Mice, Nude; Neoplasms; Paclitaxel | 2023 |
The Quantification of Paclitaxel and Its Two Major Metabolites in Biological Samples by HPLC-MS/MS and Its Application in a Pharmacokinetic and Tumor Distribution Study in Xenograft Nude Mouse.
Topics: Animals; Chromatography, High Pressure Liquid; Heterografts; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Reproducibility of Results; Tandem Mass Spectrometry | 2023 |
Levan nanoparticles with intrinsic CD44-targeting ability for tumor-targeted drug delivery.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Fructans; Mice; Nanoparticles; Neoplasms; Paclitaxel; Reproducibility of Results | 2023 |
Dual Sensitization Anti-Resistant Nanoparticles for Treating Refractory Breast Cancers via Apoptosis-Inducing.
Topics: Animals; Apoptosis; Cell Line, Tumor; Mice; Nanoparticles; Neoplasms; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Porphyrins | 2023 |
The Glycosylated
Topics: Antineoplastic Agents; Cell Membrane; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Humans; Mucin-1; Neoplasms; Paclitaxel | 2023 |
Redox-responsive paclitaxel-pentadecanoic acid conjugate encapsulated human serum albumin nanoparticles for cancer therapy.
Topics: Cell Line, Tumor; Disulfides; Humans; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel; Serum Albumin, Human | 2023 |
A cascade-responsive nanoplatform with tumor cell-specific drug burst release for chemotherapy.
Topics: Antineoplastic Agents; Humans; Matrix Metalloproteinase 2; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Polymers; Tumor Microenvironment | 2023 |
Molecular Modes of Action of an Aqueous
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Molecular Docking Simulation; Neoplasms; Nerium; Paclitaxel; Plant Extracts; Tubulin | 2023 |
Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colchicine; Humans; Neoplasms; Paclitaxel; Tubulin; Vincristine | 2023 |
Self-Assembled Redox-Sensitive Polymeric Nanostructures Facilitate the Intracellular Delivery of Paclitaxel for Improved Breast Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Hyaluronic Acid; Mice; Micelles; Nanostructures; Neoplasms; Oxidation-Reduction; Paclitaxel | 2023 |
Evaluation of paclitaxel-loaded polymeric nanoparticles in 3D tumor model: impact of tumor stroma on penetration and efficacy.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Mice; Micelles; Nanoparticles; Neoplasms; NIH 3T3 Cells; Paclitaxel; Polyethylene Glycols; Polymers | 2023 |
Kinin B
Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Bradykinin; Cancer Pain; Hyperalgesia; Mice; Neoplasms; Paclitaxel; Pain; Receptor, Bradykinin B1; Receptor, Bradykinin B2 | 2023 |
Glycol-Split Heparin-Linked Prodrug Nanoparticles Target the Mitochondrion Apparatus for Cancer Metastasis Treatment.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Drug Delivery Systems; Glycols; Heparin; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Paclitaxel; Prodrugs | 2023 |
Destabilization of microrchidia family CW-type zinc finger 2 via the cyclin-dependent kinase 1-chaperone-mediated autophagy pathway promotes mitotic arrest and enhances cancer cellular sensitivity to microtubule-targeting agents.
Topics: CDC2 Protein Kinase; Cell Cycle Proteins; Chaperone-Mediated Autophagy; Humans; Microtubules; Mitosis; Neoplasms; Paclitaxel; Transcription Factors | 2023 |
Controllable release of self-assembled reduction-sensitive paclitaxel dimer prodrug and tetrandrine nanoparticles promotes synergistic therapy against multidrug-resistant cancer.
Topics: Disulfides; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HeLa Cells; Humans; Nanoparticles; Neoplasms; Paclitaxel; Polymers; Prodrugs; Reactive Oxygen Species | 2023 |
A paclitaxel prodrug nanoparticles with glutathion/reactive oxygen species dual-responsive and CD206 targeting to improve the anti-tumour effect.
Topics: Cell Line, Tumor; Humans; Male; Nanoparticles; Neoplasms; Paclitaxel; Prodrugs; Reactive Oxygen Species; Tumor Microenvironment | 2023 |
Reduction-Responsive Docetaxel Prodrug Encapsulated within Human Serum Albumin Nanoparticles for Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Mice; Nanoparticles; Neoplasms; Paclitaxel; Prodrugs; Serum Albumin, Human | 2023 |
Stimuli-responsive heparin-drug conjugates co-assembled into stable nanomedicines for cancer therapy.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Heparin; Mice; Mice, Inbred BALB C; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Photosensitizing Agents | 2023 |
Model-based approach to identify predictors of paclitaxel-induced myelosuppression in "real-world" administration.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Neoplasms; Neutrophils; Paclitaxel; Taxoids | 2023 |
Redox-responsive drug-inhibitor conjugate encapsulated in DSPE-PEG
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Mice; Micelles; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel | 2023 |
Exploring the mechanism by which quercetin re-sensitizes breast cancer to paclitaxel: network pharmacology, molecular docking, and experimental verification.
Topics: ErbB Receptors; Molecular Docking Simulation; Neoplasms; Network Pharmacology; Paclitaxel; Quercetin | 2023 |
On-chip mixing of cancer cells and drug using LED enabled 2D opto-wetting droplet platforms.
Topics: Antineoplastic Agents; Azo Compounds; Neoplasms; Paclitaxel; Surface Tension | 2023 |
Apoptosis induction in cancer cell lines and anti-inflammatory and anti-pathogenic properties of proteinaceous metabolites secreted from potential probiotic Enterococcus faecalis KUMS-T48.
Topics: Anti-Inflammatory Agents; Apoptosis; Enterococcus faecalis; HT29 Cells; Humans; Iran; Neoplasms; Paclitaxel; Probiotics | 2023 |
JP1 normalizes tumor vasculature to suppress metastasis and facilitate drug delivery by inhibiting IL-8.
Topics: Humans; Interleukin-8; Neoplasms; Neovascularization, Pathologic; Oxygen; Paclitaxel; Tumor Microenvironment | 2023 |
Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Herpesvirus 1, Human; Humans; Mice; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Tumor Microenvironment | 2023 |
Efficient pH-Responsive Nano-Drug Delivery System Based on Dynamic Boronic Acid/Ester Transformation.
Topics: Antineoplastic Agents; Boronic Acids; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Nanoparticle Drug Delivery System; Nanoparticles; Neoplasms; Paclitaxel; Tumor Microenvironment | 2023 |
STNM1 in human cancers: role, function and potential therapy sensitizer.
Topics: Cell Division; Cell Line, Tumor; Cell Proliferation; Humans; MicroRNAs; Neoplasms; Paclitaxel; Stathmin | 2023 |
Plasmonic Functional Assay Platform Determines the Therapeutic Profile of Cancer Cells.
Topics: Antineoplastic Agents; Doxorubicin; Fluorouracil; Humans; MCF-7 Cells; Neoplasms; Paclitaxel | 2023 |
Semi-physiological Enriched Population Pharmacokinetic Modelling to Predict the Effects of Pregnancy on the Pharmacokinetics of Cytotoxic Drugs.
Topics: Antineoplastic Agents; Child; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Models, Biological; Neoplasms; Paclitaxel; Pregnancy | 2023 |
Dual-targeted delivery of paclitaxel and indocyanine green with aptamer-modified ferritin for synergetic chemo-phototherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Ferritins; Humans; Hyperthermia, Induced; Indocyanine Green; Nanoparticles; Neoplasms; Paclitaxel; Phototherapy | 2023 |
Neutrophil-Mediated Delivery of Nanocrystal Drugs via Photoinduced Inflammation Enhances Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Inflammation; Mice; Nanoparticles; Neoplasms; Neutrophils; Paclitaxel; Tumor Microenvironment | 2023 |
A photo-triggered self-accelerated nanoplatform for multifunctional image-guided combination cancer immunotherapy.
Topics: Animals; Cell Membrane; Female; Fluorescence; Hypoxia; Immunotherapy; Mice; Neoplasms; Paclitaxel; Prodrugs | 2023 |
Sulfur dioxide-releasing polymeric micelles based on modified hyaluronic acid for combined cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Humans; Hyaluronic Acid; Micelles; Neoplasms; Paclitaxel; Polymers; Sulfur Dioxide | 2023 |
Targeting Adhesive Tumor Adventitia via Injectable Electrospun Short Fibers in Perfusion of Intraperitoneal Sporadic Tumors.
Topics: Adventitia; Humans; Neoplasms; Paclitaxel; Perfusion; Proteins | 2023 |
Paclitaxel prodrug-encapsulated polypeptide micelles with redox/pH dual responsiveness for cancer chemotherapy.
Topics: Animals; Cell Line, Tumor; Disulfides; Drug Carriers; Hydrogen-Ion Concentration; Mice; Micelles; Neoplasms; Oxidation-Reduction; Paclitaxel; Peptides; Polyethylene Glycols; Prodrugs; Spectroscopy, Fourier Transform Infrared | 2023 |
Biguanide-anchored albumin-based nanoplatform inhibits epithelial-mesenchymal transition and reduces the stemness phenotype for metastatic cancer therapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Biguanides; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Humans; Nanoparticles; Neoplasms; Paclitaxel | 2023 |
Perturbations in 3D genome organization can promote acquired drug resistance.
Topics: Cell Line, Tumor; DNA Methylation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel | 2023 |
Zwitterionic dendrimer self-assembled nanodrugs with high drug loading for enhanced anti-tumor ability.
Topics: Dendrimers; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Liberation; Humans; Micelles; Nanoparticles; Neoplasms; Paclitaxel | 2023 |
Novel (-)-arctigenin derivatives inhibit signal transducer and activator of transcription 3 phosphorylation and P-glycoprotein function resensitizing multidrug resistant cancer cells in vitro and in vivo.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Phosphorylation; STAT3 Transcription Factor; Xenograft Model Antitumor Assays; Zebrafish | 2023 |
Mild replication stress causes chromosome mis-segregation via premature centriole disengagement.
Topics: Antineoplastic Agents, Phytogenic; Carcinogenesis; Cell Line, Tumor; Centrioles; Chromosomal Instability; Chromosome Segregation; DNA Damage; G2 Phase Cell Cycle Checkpoints; Humans; Microtubules; Neoplasms; Paclitaxel; Spindle Apparatus; Stress, Physiological | 2019 |
Anti-EGFR antibody conjugated thiol chitosan-layered gold nanoshells for dual-modal imaging-guided cancer combination therapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chitosan; Combined Modality Therapy; Diagnostic Imaging; Drug Liberation; ErbB Receptors; Erythrocytes; Female; Gold; Humans; Mice, Inbred BALB C; Mice, Nude; Nanoshells; Neoplasms; Paclitaxel; Photoacoustic Techniques; Sulfhydryl Compounds; Theranostic Nanomedicine | 2019 |
A Nanoemulsion with A Porphyrin Shell for Cancer Theranostics.
Topics: Animals; Chlorophyll; Drug Carriers; Emulsions; Ethiodized Oil; Humans; KB Cells; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Photoacoustic Techniques; Porphyrins; Theranostic Nanomedicine; Xenograft Model Antitumor Assays | 2019 |
iRGD-paclitaxel conjugate nanoparticles for targeted paclitaxel delivery.
Topics: Animals; Cell Proliferation; Cell Survival; Delayed-Action Preparations; Drug Stability; Endocytosis; Humans; Integrin alpha Chains; MCF-7 Cells; Mice; Nanoparticles; Neoplasms; Oligopeptides; Paclitaxel; Particle Size | 2019 |
Melanin-loaded biocompatible photosensitive nanoparticles for controlled drug release in combined photothermal-chemotherapy guided by photoacoustic/ultrasound dual-modality imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Delayed-Action Preparations; Female; Fluorocarbons; Human Umbilical Vein Endothelial Cells; Humans; Melanins; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Paclitaxel; Photoacoustic Techniques; Phototherapy; Polylactic Acid-Polyglycolic Acid Copolymer; Tissue Distribution; Ultrasonography | 2019 |
Modular Engineering of Targeted Dual-Drug Nanoassemblies for Cancer Chemoimmunotherapy.
Topics: Animals; Antigen Presentation; Apoptosis; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Drug Therapy; Female; Imiquimod; Immunotherapy; Mice, Inbred BALB C; Nanoparticles; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Rats, Sprague-Dawley; Tissue Distribution | 2019 |
Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Cell Line, Tumor; Female; HeLa Cells; Humans; Hydrodynamics; Macrophages; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Polymers; Reactive Oxygen Species; Tissue Distribution; Treatment Outcome | 2019 |
Magnetic Janus particles as a multifunctional drug delivery system for paclitaxel in efficient cancer treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Humans; Magnetic Phenomena; Magnetics; Mice; Multifunctional Nanoparticles; Neoplasms; NIH 3T3 Cells; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer | 2019 |
Donor-Acceptor-Type Conjugated Polymer-Based Multicolored Drug Carriers with Tunable Aggregation-Induced Emission Behavior for Self-Illuminating Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Female; Fluorescence; Humans; Mice; Mice, Inbred BALB C; Neoplasms; Paclitaxel; Polymers | 2019 |
Predicting Paclitaxel Disposition in Humans With Whole-Body Physiologically-Based Pharmacokinetic Modeling.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Mice; Models, Biological; Neoplasms; Paclitaxel; Tissue Distribution | 2019 |
A carbohydrate mimetic peptide modified size-shrinkable micelle nanocluster for anti-tumor targeting and penetrating drug delivery.
Topics: Animals; Antineoplastic Agents; Carbohydrates; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Endocytosis; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Male; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Peptides; Polyethylene Glycols; Spheroids, Cellular; Static Electricity; Tissue Distribution | 2019 |
Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apolipoprotein B-100; Biomimetic Materials; Colloids; Drug Delivery Systems; Drug Liberation; Endocytosis; Folic Acid; HeLa Cells; Humans; Lipids; Lipoproteins, LDL; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Peptides; Polyethylene Glycols; Static Electricity | 2019 |
Evaluation of intestinal permeation enhancement with carboxymethyl chitosan-rhein polymeric micelles for oral delivery of paclitaxel.
Topics: Administration, Oral; Animals; Anthraquinones; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Caco-2 Cells; Chitosan; Disease Models, Animal; Drug Carriers; Drug Compounding; Humans; Intestinal Mucosa; Male; Mice; Micelles; Neoplasms; Paclitaxel; Permeability; Rats; Tissue Distribution; Verapamil | 2020 |
The role of propolis against paclitaxel-induced oligospermia, sperm abnormality, oxidative stress and DNA damage in testes of male rats.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Apitherapy; Disease Models, Animal; DNA Damage; Humans; Male; Neoplasms; Oligospermia; Oxidative Stress; Paclitaxel; Propolis; Rats; Semen; Sperm Motility; Testis | 2020 |
Diatoms embedded, self-assembled carriers for dual delivery of chemotherapeutics in cancer cell lines.
Topics: Adamantane; Antineoplastic Combined Chemotherapy Protocols; Cyclodextrins; Diatomaceous Earth; Doxorubicin; Drug Antagonism; Drug Carriers; Drug Compounding; Drug Synergism; HeLa Cells; Humans; Nanoparticles; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel | 2020 |
Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents.
Topics: Antineoplastic Agents; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Fluorouracil; Humans; Irinotecan; Methotrexate; Neoplasms; Oxaliplatin; Paclitaxel; Phenotype; Tumor Cells, Cultured | 2019 |
Safety and tolerability of cryocompression as a method of enhanced limb hypothermia to reduce taxane-induced peripheral neuropathy.
Topics: Adult; Aged; Cryotherapy; Docetaxel; Extremities; Female; Humans; Hypothermia, Induced; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Peripheral Nervous System Diseases; Pilot Projects; Retrospective Studies; Treatment Outcome | 2020 |
PEGylation of Paclitaxel-Loaded Cationic Liposomes Drives Steric Stabilization of Bicelles and Vesicles thereby Enhancing Delivery and Cytotoxicity to Human Cancer Cells.
Topics: Delayed-Action Preparations; Humans; Liposomes; Neoplasms; Paclitaxel; PC-3 Cells; Polyethylene Glycols | 2020 |
Mitochondria-targeting nanomedicine self-assembled from GSH-responsive paclitaxel-ss-berberine conjugate for synergetic cancer treatment with enhanced cytotoxicity.
Topics: Berberine; Cell Line, Tumor; Drug Delivery Systems; Escherichia coli; Mitochondria; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel; Staphylococcus aureus | 2020 |
Honeycomb-like pH-responsive γ-cyclodextrin electrospun particles for highly efficient tumor therapy.
Topics: Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Liberation; gamma-Cyclodextrins; Humans; Hydrogen-Ion Concentration; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols | 2020 |
Toward a Personalized Use of Paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Approval; Humans; Microtubules; Neoplasms; Paclitaxel; Patents as Topic; Precision Medicine; United States; United States Food and Drug Administration | 2019 |
Therapy-Induced Senescence Drives Bone Loss.
Topics: Animals; Antineoplastic Agents; Cellular Senescence; Disease Models, Animal; Doxorubicin; Femur; Humans; Injections, Intraperitoneal; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mice; Mice, Transgenic; Neoplasms; Osteoporosis; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Protein Serine-Threonine Kinases; X-Ray Microtomography | 2020 |
Tumor Targeting Chemo- and Photodynamic Therapy Packaged in Albumin for Enhanced Anti-Tumor Efficacy.
Topics: Animals; Apoptosis; Cytoplasm; Doxorubicin; Drug Carriers; Female; Humans; Liver Neoplasms, Experimental; Mice; Nanoparticles; Neoplasms; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Reactive Oxygen Species; Recombinant Fusion Proteins; Serum Albumin, Human | 2020 |
An Automatable Hydrogel Culture Platform for Evaluating Efficacy of Antibody-Based Therapeutics in Overcoming Chemoresistance.
Topics: A549 Cells; Aldehyde Dehydrogenase, Mitochondrial; Alginates; Antineoplastic Agents, Immunological; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Chitosan; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Heme Oxygenase-1; High-Throughput Screening Assays; Humans; Hydrogels; Male; Neoplasms; Paclitaxel; Proteomics | 2020 |
Co-delivery of silybin and paclitaxel by dextran-based nanoparticles for effective anti-tumor treatment through chemotherapy sensitization and microenvironment modulation.
Topics: Cell Line, Tumor; Dextrans; Humans; Nanoparticles; Neoplasms; Paclitaxel; Prospective Studies; Silybin; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Tumor-targeting and redox-sensitive micelles based on hyaluronic acid conjugate for delivery of paclitaxel.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disulfides; Drug Delivery Systems; Hemolysis; Humans; Hyaluronic Acid; In Vitro Techniques; MCF-7 Cells; Mice; Micelles; Microscopy, Electron, Transmission; Neoplasms; Oxidation-Reduction; Paclitaxel; Polyethylene Glycols; Polymers; Rabbits; Tetrazolium Salts; Thiazoles; X-Ray Diffraction | 2020 |
Assessment of modelling strategies for drug response prediction in cell lines and xenografts.
Topics: Animals; Biomarkers, Pharmacological; Cell Line, Tumor; Erlotinib Hydrochloride; Humans; Imidazoles; Indoles; Lapatinib; Machine Learning; Mice; Neoplasms; Organ Specificity; Paclitaxel; Piperazines; Prognosis; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2020 |
Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Genomics; Glycolysis; Humans; Induction Chemotherapy; Models, Biological; Molecular Targeted Therapy; Mutation; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Protein Kinase Inhibitors; Treatment Failure; Treatment Outcome | 2020 |
Erythrocyte-mimicking paclitaxel nanoparticles for improving biodistributions of hydrophobic drugs to enhance antitumor efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Liberation; Erythrocyte Membrane; Female; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Tissue Distribution; Xenograft Model Antitumor Assays | 2020 |
A self-assembled carrier-free nanosonosensitizer for photoacoustic imaging-guided synergistic chemo-sonodynamic cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Chlorophyllides; Drug Carriers; Endocytosis; Female; Fluorescent Dyes; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Paclitaxel; Porphyrins; Radiation-Sensitizing Agents; Singlet Oxygen; Theranostic Nanomedicine; Tissue Distribution; Transplantation, Heterologous | 2020 |
Self-assembly of oxidation-responsive polyethylene glycol-paclitaxel prodrug for cancer chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Humans; Micelles; Neoplasms; Paclitaxel; Polyethylene Glycols; Prodrugs | 2020 |
Genetically Encoded Stealth Nanoparticles of a Zwitterionic Polypeptide-Paclitaxel Conjugate Have a Wider Therapeutic Window than Abraxane in Multiple Tumor Models.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Mice; Mice, Nude; Nanoconjugates; Neoplasms; Paclitaxel; Peptides; Treatment Outcome | 2020 |
Novel Chitosan Derivatives with Reversible Cationization and Hydrophobicization for Tumor Cytoplasm-Specific Burst Co-delivery of siRNA and Chemotherapeutics.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Cations; Chitosan; Cytoplasm; Drug Carriers; Female; Glutathione; Humans; Hyaluronic Acid; Mice; Mice, Nude; Micelles; Neoplasms; Paclitaxel; Particle Size; Polyethyleneimine; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2020 |
Evaluation of the tumor-targeting efficiency and intratumor heterogeneity of anticancer drugs using quantitative mass spectrometry imaging.
Topics: A549 Cells; Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Humans; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Prodrugs | 2020 |
Magnetic nanoparticles for amalgamation of magnetic hyperthermia and chemotherapy: An approach towards enhanced attenuation of tumor.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Humans; Hyperthermia, Induced; Magnetic Fields; Magnetics; Magnetite Nanoparticles; MCF-7 Cells; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Neoplasms; Paclitaxel | 2020 |
Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ETS Translocation Variant 6 Protein; Female; Gene Expression Regulation, Neoplastic; Gene Fusion; Gene Rearrangement; Genomics; Humans; Mutation; Neoplasms; Oncogene Proteins, Fusion; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-ets; Repressor Proteins; Triple Negative Breast Neoplasms; Whole Genome Sequencing | 2020 |
Co-Delivery of Paclitaxel and Interleukin-12 Regulating Tumor Microenvironment for Cancer Immunochemotherapy.
Topics: Animals; Cell Line, Tumor; Immunotherapy; Interleukin-12; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Paclitaxel; Tumor Microenvironment | 2020 |
Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic: Outcomes and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Cetuximab; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Immunoglobulin E; Male; Middle Aged; Neoplasms; Outpatients; Paclitaxel; Portugal; Retrospective Studies; Risk Factors; Skin Tests; Taxoids; Trastuzumab; Young Adult | 2020 |
Deep imaging for visualizing nitric oxide in lipid droplets: discovering the relationship between nitric oxide and resistance to cancer chemotherapy drugs.
Topics: Animals; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Fluorescent Dyes; HeLa Cells; Humans; Lipid Droplets; Mice; Neoplasms; Nitric Oxide; Paclitaxel | 2020 |
Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer.
Topics: Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Double-Blind Method; Humans; Immunotherapy; Neoplasms; Paclitaxel | 2020 |
Nicotinamide riboside relieves paclitaxel-induced peripheral neuropathy and enhances suppression of tumor growth in tumor-bearing rats.
Topics: Animals; Female; Neoplasms; Niacinamide; Paclitaxel; Peripheral Nervous System Diseases; Pyridinium Compounds; Rats | 2020 |
Co-Delivery of Paclitaxel and Doxorubicin by pH-Responsive Prodrug Micelles for Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Delivery Systems; Drug Liberation; Humans; Hydrogen-Ion Concentration; Mice; Micelles; Neoplasms; NIH 3T3 Cells; Paclitaxel; Particle Size; Polymers; Prodrugs; Static Electricity | 2020 |
Lipoprotein-Inspired Nanocarrier Composed of Folic Acid-Modified Protein and Lipids: Preparation and Evaluation of Tumor-Targeting Effect.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Carriers; Drug Liberation; Endocytosis; Erythrocytes; Folic Acid; Hemolysis; Humans; Lipoproteins; Mice; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Rabbits; Serum Albumin, Bovine; Static Electricity | 2020 |
An injectable thermosensitive hydrogel self-supported by nanoparticles of PEGylated amino-modified PCL for enhanced local tumor chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Female; Hydrogels; Injections; Mice, Inbred BALB C; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Polyesters; Polyethylene Glycols; Temperature | 2020 |
Multifunctional nanoparticles of paclitaxel and cyclodextrin-polypeptide conjugates with
Topics: Animals; Antineoplastic Agents; beta-Cyclodextrins; Cell Line; Cell Line, Tumor; Cell-Penetrating Peptides; Cyclodextrins; Drug Delivery Systems; HEK293 Cells; Humans; MCF-7 Cells; Mice; Multifunctional Nanoparticles; Neoplasms; Paclitaxel; Peptides | 2020 |
Design and evaluation of the anticancer activity of paclitaxel-loaded anisotropic-poly(lactic-co-glycolic acid) nanoparticles with PEGylated chitosan surface modifications.
Topics: Antineoplastic Agents; Chitosan; Drug Design; Drug Screening Assays, Antitumor; Humans; MCF-7 Cells; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols; Polylactic Acid-Polyglycolic Acid Copolymer | 2020 |
[Thermosensitive gel of polysaccharide from Ganoderma applanatum combined with paclitaxel for mice with 4T1 breast cancer].
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Ganoderma; Mice; Neoplasms; Paclitaxel; Poloxamer; Polysaccharides | 2020 |
Hyaluronic acid derivative-modified nano-structured lipid carrier for cancer targeting and therapy.
Topics: Amines; Animals; Drug Delivery Systems; Endocytosis; Female; Humans; Hyaluronic Acid; Lipids; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Paclitaxel | 2020 |
CPPF, A Novel Microtubule Targeting Anticancer Agent, Inhibits the Growth of a Wide Variety of Cancers.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colchicine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HeLa Cells; Hep G2 Cells; Humans; Jurkat Cells; K562 Cells; Male; MCF-7 Cells; Mice; Microtubules; Mitosis; Neoplasms; Paclitaxel; PC-3 Cells; U937 Cells; Xenograft Model Antitumor Assays; Zebrafish | 2020 |
Cancer cells undergoing epigenetic transition show short-term resistance and are transformed into cells with medium-term resistance by drug treatment.
Topics: Alkaline Phosphatase; Antibodies; Antineoplastic Agents; Cell Differentiation; Cell Line, Transformed; Cell Line, Tumor; Cellular Reprogramming; Cisplatin; Culture Media; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Neoplasms; Paclitaxel; Transcriptome | 2020 |
Inference on an heteroscedastic Gompertz tumor growth model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Death; Cell Proliferation; Computer Simulation; Female; Humans; Mathematical Concepts; Mice; Models, Biological; Neoplasms; Neoplasms, Experimental; Ovarian Neoplasms; Paclitaxel; Stochastic Processes | 2020 |
Redox responsive paclitaxel dimer for programmed drug release and selectively killing cancer cells.
Topics: Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Humans; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel; Polymers | 2020 |
Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Stress; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Immunogenic Cell Death; Immunotherapy; Mice; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Programmed Cell Death 1 Receptor; Tumor Microenvironment | 2020 |
Calculating degree based multiplicative topological indices of Hyaluronic Acid-Paclitaxel conjugates' molecular structure in cancer treatment.
Topics: Antineoplastic Agents; Humans; Hyaluronic Acid; Molecular Structure; Neoplasms; Paclitaxel | 2021 |
Acidity and Glutathione Dual-Responsive Polydopamine-Coated Organic-Inorganic Hybrid Hollow Mesoporous Silica Nanoparticles for Controlled Drug Delivery.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Drug Liberation; Female; Glutathione; Hydrogen-Ion Concentration; Indoles; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Paclitaxel; Polymers; Porosity; Silicon Dioxide; Xenograft Model Antitumor Assays | 2020 |
Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Female; HSP90 Heat-Shock Proteins; Humans; Kelch-Like ECH-Associated Protein 1; Lactams, Macrocyclic; Mice; Mice, Inbred BALB C; Mutation; Neoplasm Transplantation; Neoplasms; NF-E2-Related Factor 2; Oncogene Protein v-akt; Oxidation-Reduction; Paclitaxel | 2020 |
DPAGT1 Inhibitors of Capuramycin Analogues and Their Antimigratory Activities of Solid Tumors.
Topics: Aminoglycosides; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Drug Synergism; Enzyme Inhibitors; Humans; N-Acetylglucosaminyltransferases; Neoplasms; Paclitaxel; Snail Family Transcription Factors; Structure-Activity Relationship | 2020 |
Multifunctional composite nanoparticles based on hyaluronic acid-paclitaxel conjugates for enhanced cancer therapy.
Topics: Cell Line, Tumor; Drug Carriers; Drug Liberation; Humans; Hyaluronic Acid; Nanoparticles; Neoplasms; Paclitaxel | 2020 |
A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Topics: A549 Cells; Administration, Oral; Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colchicine; Crystallography, X-Ray; Humans; Male; Mice; Models, Molecular; Neoplasms; Paclitaxel; Protein Conformation; Tubulin; Tubulin Modulators; Xenograft Model Antitumor Assays | 2020 |
Programmable Delivery of Synergistic Cancer Drug Combinations Using Bicompartmental Nanoparticles.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Combinations; Drug Delivery Systems; Humans; Nanoparticles; Neoplasms; Paclitaxel; Tissue Distribution | 2020 |
Block copolymer [(L-GluA-5-BE)-
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Carriers; Drug Liberation; HEK293 Cells; HeLa Cells; Humans; Hydrogen-Ion Concentration; Nanostructures; Neoplasms; Paclitaxel; Porosity; Proteins; Rats | 2020 |
Protamine and BSA-dextran complex emulsion improves oral bioavailability and anti-tumor efficacy of paclitaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Dextrans; Drug Carriers; Gastrointestinal Tract; Male; Mice; Mice, Inbred ICR; Neoplasms; Paclitaxel; Protamines; Serum Albumin, Bovine; Treatment Outcome; Xenograft Model Antitumor Assays | 2020 |
Redox- and MMP-2-sensitive drug delivery nanoparticles based on gelatin and albumin for tumor targeted delivery of paclitaxel.
Topics: Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Gelatin; Humans; Matrix Metalloproteinase 2; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel; Tumor Microenvironment | 2020 |
Transient impact of paclitaxel on mouse fertility and protective effect of gonadotropin‑releasing hormone agonist.
Topics: Animals; Disease Models, Animal; Female; Fertility; Fertility Preservation; Gonadotropin-Releasing Hormone; Humans; Mice; Mice, Inbred ICR; Neoplasms; Ovarian Follicle; Ovulation Induction; Paclitaxel; Primary Ovarian Insufficiency | 2020 |
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Capecitabine; Carboplatin; Dexamethasone; Etoposide; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Oxaliplatin; Paclitaxel; Pre-Exposure Prophylaxis; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2020 |
Combination of Inhibitors of USP7 and PLK1 has a Strong Synergism against Paclitaxel Resistance.
Topics: A549 Cells; Cell Cycle Proteins; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Thiophenes; Ubiquitin-Specific Peptidase 7 | 2020 |
Metformin induced lactic acidosis impaired response of cancer cells towards paclitaxel and doxorubicin: Role of monocarboxylate transporter.
Topics: A549 Cells; Acidosis, Lactic; Animals; Antineoplastic Agents; Breast Neoplasms; Diabetes Mellitus, Type 2; Doxorubicin; Female; Humans; Hypoglycemic Agents; Lung Neoplasms; MCF-7 Cells; Metformin; Mice, Inbred NOD; Mice, SCID; Neoplasms; Paclitaxel | 2021 |
Depletion and Maturation of Myeloid-Derived Suppressor Cells in Murine Cancer Models.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Differentiation; Disease Models, Animal; Mice, Inbred C57BL; Mice, Transgenic; Myeloid-Derived Suppressor Cells; Neoplasms; Paclitaxel; Tretinoin | 2021 |
PAMAM G4.5 dendrimers for targeted delivery of ferulic acid and paclitaxel to overcome P-glycoprotein-mediated multidrug resistance.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Coumaric Acids; Dendrimers; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel | 2021 |
Macrophage-Membrane-Camouflaged Disintegrable and Excretable Nanoconstruct for Deep Tumor Penetration.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Membrane; Copper; Drug Carriers; Infrared Rays; Macrophages; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Neoplasms; Paclitaxel; RAW 264.7 Cells | 2020 |
Confidence intervals by constrained optimization-An algorithm and software package for practical identifiability analysis in systems biology.
Topics: Algorithms; Antineoplastic Agents, Phytogenic; Confidence Intervals; Dimerization; Kinetics; Likelihood Functions; Neoplasms; Paclitaxel; Software; STAT5 Transcription Factor; Systems Biology | 2020 |
Cationic polymer synergizing with chemotherapeutics and re-purposing antibiotics against cancer cells.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Neoplasms; Paclitaxel; Polymers | 2021 |
Identification and construction of a novel biomimetic delivery system of paclitaxel and its targeting therapy for cancer.
Topics: Biomimetics; Drug Delivery Systems; Humans; Molecular Targeted Therapy; Neoplasms; Paclitaxel | 2021 |
Population Pharmacokinetics of Docetaxel, Paclitaxel, Doxorubicin and Epirubicin in Pregnant Women with Cancer: A Study from the International Network of Cancer, Infertility and Pregnancy (INCIP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Infertility; Neoplasms; Paclitaxel; Pregnancy; Pregnant Women; Taxoids | 2021 |
A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technology: Development of targeted apoptosis initiators for cancer treatment.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Paclitaxel; PC-3 Cells; Tocopherols; Xenograft Model Antitumor Assays | 2021 |
Evaluation of Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel in Platinum-Refractory Metastatic Urothelial Cancer-Reply.
Topics: Albumins; Humans; Neoplasms; Paclitaxel; Platinum | 2021 |
Chromosomally unstable tumor cells specifically require KIF18A for proliferation.
Topics: Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Centrosome; Chromosomal Instability; Humans; Kinesins; Microtubules; Mitosis; Models, Biological; Neoplasms; Nocodazole; Paclitaxel; Spindle Apparatus | 2021 |
Engineering of Neutrophil Membrane Camouflaging Nanoparticles Realizes Targeted Drug Delivery for Amplified Antitumor Therapy.
Topics: Albumins; Animals; Cell Death; Cell Line, Tumor; Cell Membrane; Drug Delivery Systems; Endocytosis; Endothelial Cells; Humans; Immune Evasion; Inflammation; Mice; Nanoparticles; Nanotechnology; Neoplasms; Neutrophils; Paclitaxel; RAW 264.7 Cells; Tissue Distribution; TNF-Related Apoptosis-Inducing Ligand | 2021 |
Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP3A; Docetaxel; Female; Genotype; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Taxoids | 2021 |
Engineering of dendritic mesoporous silica nanoparticles for efficient delivery of water-insoluble paclitaxel in cancer therapy.
Topics: Drug Carriers; Drug Delivery Systems; Nanoparticles; Neoplasms; Paclitaxel; Porosity; Silicon Dioxide; Water | 2021 |
Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Polyesters; Polymers; Prodrugs; Taxoids | 2021 |
Co-Delivery of Paclitaxel and siRNA with pH-Responsive Polymeric Micelles for Synergistic Cancer Therapy.
Topics: Cell Line, Tumor; Drug Delivery Systems; Hydrogen-Ion Concentration; Micelles; Neoplasms; Paclitaxel; Polymers; RNA, Small Interfering | 2021 |
A Photopolymerized Semi-Interpenetrating Polymer Networks-Based Hydrogel Incorporated with Nanoparticle for Local Chemotherapy of Tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Drug Liberation; Humans; Hyaluronic Acid; Hydrogels; Mice; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols; Polylactic Acid-Polyglycolic Acid Copolymer; Xenograft Model Antitumor Assays | 2021 |
Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Female; Humans; Minnesota; Neoplasms; Paclitaxel | 2021 |
Quantitative imaging of intracellular nanoparticle exposure enables prediction of nanotherapeutic efficacy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Drug Carriers; Female; Fluorescent Dyes; Humans; Intravital Microscopy; Mice; Molecular Imaging; Molecular Probes; Nanoparticles; Neoplasms; Optical Imaging; Paclitaxel; Patient Selection; Reproducibility of Results; Theranostic Nanomedicine; Tissue Distribution; Tumor Microenvironment | 2021 |
Hypoxia-Sensitive Zwitterionic Vehicle for Tumor-Specific Drug Delivery through Antifouling-Based Stable Biotransport Alongside PDT-Sensitized Controlled Release.
Topics: Animals; Biofouling; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Hypoxia; Mice; Nanoparticles; Neoplasms; Paclitaxel; Photochemotherapy; Tumor Microenvironment | 2021 |
Biodegradable Flexible Electronic Device with Controlled Drug Release for Cancer Treatment.
Topics: Antineoplastic Agents, Phytogenic; Biocompatible Materials; Delayed-Action Preparations; Electronics; Humans; MCF-7 Cells; Neoplasms; Paclitaxel | 2021 |
Diagnostic and therapeutic nanoenzymes for enhanced chemotherapy and photodynamic therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Survival; Chlorophyllides; Contrast Media; Humans; Hydrogen Peroxide; Light; Liposomes; Magnetic Resonance Imaging; Manganese Compounds; Mice; Nanoparticles; Nanostructures; Neoplasms; Oxides; Oxygen; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Porphyrins; Theranostic Nanomedicine | 2021 |
An exploration of the impact of ethanol diluent on breath alcohol concentration in patients receiving paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breath Tests; Ethanol; Female; Humans; Ireland; Male; Middle Aged; Neoplasms; Paclitaxel; Prospective Studies | 2021 |
Cancer nanomedicine developed from total human serum: a novel approach for making personalized nanomedicine.
Topics: Animals; Cell Line, Tumor; Humans; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel; Serum; Xenograft Model Antitumor Assays | 2021 |
Evaluating the genetic basiss of anti-cancer property of Taxol in Saccharomyces cerevisiae model.
Topics: Antineoplastic Agents; DNA Damage; Humans; Models, Biological; Neoplasms; Oxidative Stress; Paclitaxel; Reactive Oxygen Species; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2021 |
A pH-Sensitive Polymeric Micellar System Based on Chitosan Derivative for Efficient Delivery of Paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Cell Line; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Drug Liberation; Humans; MCF-7 Cells; Micelles; Neoplasms; Paclitaxel; Particle Size; Polymers | 2021 |
The facile formation of hierarchical mesoporous silica nanocarriers for tumor-selective multimodal theranostics.
Topics: Animals; Cell Line, Tumor; Doxorubicin; Mice; Nanoparticles; Neoplasms; Paclitaxel; Precision Medicine; Silicon Dioxide | 2021 |
LDL mediated delivery of Paclitaxel and MRI imaging probes for personalized medicine applications.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Contrast Media; Drug Delivery Systems; Lipoproteins, LDL; Liver; Magnetic Resonance Imaging; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Muscles; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Precision Medicine | 2021 |
Singlet Oxygen-Responsive Polymeric Nanomedicine for Light-Controlled Drug Release and Image-Guided Photodynamic-Chemo Combination Therapy.
Topics: Acrylates; Animals; Antineoplastic Agents; Boron Compounds; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female; Humans; Mice; Nanoparticles; Neoplasms; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Polyesters; Polyethylene Glycols; Pyrroles; Singlet Oxygen | 2021 |
AIE-active polymeric micelles based on modified chitosan for bioimaging-guided targeted delivery and controlled release of paclitaxel.
Topics: Animals; Antineoplastic Agents; Carbohydrate Sequence; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Liberation; Female; Fluorescent Dyes; Humans; Mice; Micelles; Neoplasms; Paclitaxel | 2021 |
Drug resistance via radixin-mediated increase of P-glycoprotein membrane expression during SNAI1-induced epithelial-mesenchymal transition in HepG2 cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Genetic Vectors; Hep G2 Cells; Humans; Membrane Glycoproteins; Membrane Proteins; Microfilament Proteins; Neoplasms; Paclitaxel; Rhodamine 123; RNA, Messenger; RNA, Small Interfering; Snail Family Transcription Factors; Transfection | 2021 |
Enhanced antitumor efficacy of glutathione-responsive chitosan based nanoparticles through co-delivery of chemotherapeutics, genes, and immune agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Female; Glutathione; Humans; Interleukin-2; Mice; Nanoparticles; Neoplasms; Paclitaxel; RNA, Small Interfering; Survivin | 2021 |
Phase-change mesoporous Prussian blue nanoparticles for loading paclitaxel and chemo-photothermal therapy of cancer.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Ferrocyanides; Mice; Nanoparticles; Neoplasms; Paclitaxel; Phototherapy; Photothermal Therapy | 2021 |
A novel multi-functionalized multicellular nanodelivery system for non-small cell lung cancer photochemotherapy.
Topics: A549 Cells; Animals; Apoptosis; Biomimetics; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Carriers; Erythrocyte Membrane; Erythrocytes; Humans; Liposomes; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticle Drug Delivery System; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Photochemotherapy; Rats, Sprague-Dawley; RAW 264.7 Cells; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2021 |
Identification and in-silico characterization of taxadien-5α-ol-O-acetyltransferase (TDAT) gene in Corylus avellana L.
Topics: Acetyltransferases; Amino Acid Sequence; Biological Products; Corylus; Humans; Neoplasms; Paclitaxel; Phylogeny; Plants, Medicinal; Taxus | 2021 |
Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy.
Topics: Alopecia; Animals; Antineoplastic Agents, Phytogenic; Calcium; Cell Line, Tumor; Disease Models, Animal; Ganglia, Spinal; Humans; Macrophages; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Minoxidil; Neoplasms; Neurites; Neuroprotective Agents; Paclitaxel; Peripheral Nervous System Diseases; Sciatic Nerve | 2017 |
A Novel Galectin-1 Inhibitor Discovered through One-Bead Two-Compound Library Potentiates the Antitumor Effects of Paclitaxel
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Galectin 1; Humans; Mice; Neoplasms; Paclitaxel; Small Molecule Libraries; Xenograft Model Antitumor Assays | 2017 |
Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Cell Line, Tumor; Cholic Acid; Docetaxel; Drug Carriers; Humans; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Taxoids | 2017 |
Paclitaxel nanoparticle awakens immune system to fight against cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cells, Cultured; Click Chemistry; Drug Delivery Systems; Humans; Immune System; Macrophages; Melanoma, Experimental; Mice; Molecular Structure; Nanoparticles; Neoplasms; Paclitaxel; Phagocytosis | 2017 |
DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Topics: Acrylates; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caprylates; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Topoisomerase II Inhibitors; Tubulin; Tubulin Modulators | 2017 |
Nanoformulated water-soluble paclitaxel to enhance drug efficacy and reduce hemolysis side effect.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Carriers; Female; HeLa Cells; Hemolysis; Hexoses; Humans; Mice, Nude; Micelles; Neoplasms; Paclitaxel; Poloxamer; Solubility; Water | 2017 |
Biocompatibility and therapeutic evaluation of magnetic liposomes designed for self-controlled cancer hyperthermia and chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Liposomes; Magnetics; Magnetite Nanoparticles; Materials Testing; Mice; Neoplasms; Paclitaxel; Sarcoma, Experimental; Tissue Distribution | 2017 |
Enhanced tumor therapy via drug co-delivery and in situ vascular-promoting strategy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Capillary Permeability; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Endothelium-Dependent Relaxing Factors; Female; Humans; Mice; Mice, Inbred C57BL; Neoplasms; Neovascularization, Physiologic; Nitric Oxide; Paclitaxel | 2017 |
Nanomechanically Visualizing Drug-Cell Interaction at the Early Stage of Chemotherapy.
Topics: Antineoplastic Agents; Biomechanical Phenomena; Cytoskeleton; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Microtubules; Molecular Dynamics Simulation; Neoplasms; Paclitaxel | 2017 |
Fast-Clearable Nanocarriers Conducting Chemo/Photothermal Combination Therapy to Inhibit Recurrence of Malignant Tumors.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Drug Carriers; Drug Therapy, Combination; Mice; Nanoparticles; Neoplasms; Paclitaxel; Phototherapy; Silicon Dioxide | 2017 |
Antrodia cinnamomea sensitizes radio-/chemo-therapy of cancer stem-like cells by modulating microRNA expression.
Topics: Antineoplastic Agents; Antrodia; Cell Line, Tumor; Cell Proliferation; Cisplatin; Combined Modality Therapy; Epithelial-Mesenchymal Transition; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction | 2017 |
Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Female; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Physicians | 2017 |
MiR-4673 Modulates Paclitaxel-Induced Oxidative Stress and Loss of Mitochondrial Membrane Potential by Targeting 8-Oxoguanine-DNA Glycosylase-1.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; DNA Glycosylases; Gene Expression Regulation; Humans; Membrane Potential, Mitochondrial; MicroRNAs; Neoplasms; Oxidative Stress; Paclitaxel; Reactive Oxygen Species | 2017 |
Hypoxia-induced tumor cell resistance is overcome by synergistic GAPDH-siRNA and chemotherapy co-delivered by long-circulating and cationic-interior liposomes.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating); HeLa Cells; Humans; Hypoxia; Liposomes; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2017 |
Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Drug Synergism; Female; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Nitric Oxide; Nitroso Compounds; Paclitaxel; Pancreatic Neoplasms; Protein Multimerization; Serum Albumin, Human | 2017 |
Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fibroblasts; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2017 |
Studies of the precipitation pattern of paclitaxel in intravenous infusions and rat plasma using laser nephelometry.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Drug Carriers; Glycerol; Infusions, Intravenous; Lasers; Neoplasms; Nephelometry and Turbidimetry; Paclitaxel; Plasma; Rats; Rats, Wistar | 2018 |
Codelivery for Paclitaxel and Bcl-2 Conversion Gene by PHB-PDMAEMA Amphiphilic Cationic Copolymer for Effective Drug Resistant Cancer Therapy.
Topics: Cations; DNA; Drug Delivery Systems; Drug Resistance, Neoplasm; HEK293 Cells; Hep G2 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxybutyrates; Methacrylates; Neoplasms; Nylons; Paclitaxel; Plasmids; Polyesters; Prohibitins; Proto-Oncogene Proteins c-bcl-2; Surface-Active Agents; Transfection | 2017 |
A confidence building exercise in data and identifiability: Modeling cancer chemotherapy as a case study.
Topics: Algorithms; Antineoplastic Agents; Cell Cycle; Dose-Response Relationship, Drug; Humans; Models, Biological; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2017 |
Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Colorectal Neoplasms; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; ErbB Receptors; Gene Expression; Humans; Mitosis; Nanodiamonds; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2017 |
Tumor Microenvironment Responsive Nanogel for the Combinatorial Antitumor Effect of Chemotherapy and Immunotherapy.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents, Phytogenic; Chitosan; Drug Carriers; Drug Delivery Systems; Gels; Humans; Immunotherapy; Interleukin-2; Mice, Inbred C57BL; Neoplasms; Paclitaxel; Rats, Sprague-Dawley; Tumor Microenvironment | 2017 |
pH-sensitive and folic acid-targeted MPEG-PHIS/FA-PEG-VE mixed micelles for the delivery of PTX-VE and their antitumor activity.
Topics: alpha-Tocopherol; Animals; Antineoplastic Agents, Phytogenic; Drug Carriers; Drug Liberation; Dynamic Light Scattering; Female; Folic Acid; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Mice; Micelles; Microscopy, Electron, Transmission; Neoplasms; Paclitaxel; Particle Size; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2017 |
Ultrasound-induced mild hyperthermia improves the anticancer efficacy of both Taxol® and paclitaxel-loaded nanocapsules.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therapy; Female; Fluorocarbons; Hydrocarbons, Brominated; Hyperthermia, Induced; Mice, Nude; Nanocapsules; Neoplasms; Paclitaxel; Polyethylene Glycols; Polyglactin 910; Tissue Distribution; Treatment Outcome; Ultrasonic Therapy | 2017 |
Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Humans; Mice; Mice, Inbred BALB C; Micelles; Neoplasms; Oncolytic Viruses; Paclitaxel; Polymers; RAW 264.7 Cells; Tissue Distribution; Transduction, Genetic; Virus Replication | 2017 |
Distinct solubility and cytotoxicity regimes of paclitaxel-loaded cationic liposomes at low and high drug content revealed by kinetic phase behavior and cancer cell viability studies.
Topics: Cations; Cell Death; Cell Line, Tumor; Cell Survival; Crystallization; DNA; Humans; Kinetics; Liposomes; Neoplasms; Paclitaxel; Scattering, Small Angle; Solubility; Synchrotrons; X-Ray Diffraction | 2017 |
Enhanced tumor targeting effects of a novel paclitaxel-loaded polymer: PEG-PCCL-modified magnetic iron oxide nanoparticles.
Topics: Cell Line, Tumor; Drug Carriers; Ferric Compounds; Humans; Metal Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols; Polymers | 2017 |
Combination Cancer Therapy Using Chimeric Antigen Receptor-Engineered Natural Killer Cells as Drug Carriers.
Topics: Animals; Antigens, CD19; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cytotoxicity, Immunologic; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Gene Expression; Humans; Immunotherapy; Killer Cells, Natural; Liposomes; Mice; Mice, Knockout; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel; Receptor, ErbB-2; Receptors, Antigen; Recombinant Fusion Proteins; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Caveolae-Mediated Endocytosis Is Critical for Albumin Cellular Uptake and Response to Albumin-Bound Chemotherapy.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caveolae; Caveolin 1; Cell Line, Tumor; Endocytosis; Humans; Immunoblotting; Male; Mice, Nude; Microscopy, Confocal; Neoplasms; Paclitaxel; RNA Interference; Xenograft Model Antitumor Assays | 2017 |
Effect of high intensity focused ultrasound (HIFU) in conjunction with a nanomedicines-microbubble complex for enhanced drug delivery.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Cell Survival; Drug Delivery Systems; High-Intensity Focused Ultrasound Ablation; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Microbubbles; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel; Serum Albumin, Human; Tumor Burden | 2017 |
Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Humans; Lipids; Nanoparticles; Neoplasms; Paclitaxel; Polymers; Prodrugs | 2017 |
Modulating mitochondrial morphology enhances antitumor effect of 5-ALA-mediated photodynamic therapy both in vitro and in vivo.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Dynamins; Fluorouracil; GTP Phosphohydrolases; HeLa Cells; Humans; Immunohistochemistry; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mice, Nude; Microscopy, Fluorescence; Microtubule-Associated Proteins; Mitochondria; Mitochondrial Proteins; Neoplasms; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Plasmids; Rats; Reactive Oxygen Species; Survival Rate; Transplantation, Heterologous | 2017 |
Noncovalent interaction-assisted drug delivery system with highly efficient uptake and release of paclitaxel for anticancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Survival; Cell-Penetrating Peptides; Drug Delivery Systems; Drug Design; Drug Liberation; Endocytosis; Female; HeLa Cells; Heparin; Humans; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasms; Paclitaxel | 2017 |
Biodegradable zwitterionic sulfobetaine polymer and its conjugate with paclitaxel for sustained drug delivery.
Topics: A549 Cells; Betaine; Biodegradable Plastics; Delayed-Action Preparations; Humans; MCF-7 Cells; Neoplasms; Paclitaxel | 2017 |
Paclitaxel-mediated human aryl hydrocarbon receptor mRNA translation by an internal ribosomal entry site-dependent mechanism.
Topics: 5' Untranslated Regions; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Internal Ribosome Entry Sites; Neoplasms; Paclitaxel; Protein Biosynthesis; Receptors, Aryl Hydrocarbon; RNA, Messenger | 2017 |
Gene isoforms as expression-based biomarkers predictive of drug response in vitro.
Topics: Alternative Splicing; Antineoplastic Agents; Benzimidazoles; Biomarkers; Breast Neoplasms; Carrier Proteins; Cell Adhesion Molecules; Chemistry, Pharmaceutical; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Genome, Human; Humans; Integrin beta Chains; Lapatinib; Neoplasms; Paclitaxel; Pharmacogenetics; Protein Isoforms; Quinazolines; RNA-Binding Proteins; RNA, Messenger; Sequence Analysis, RNA; Transcriptome | 2017 |
Dual stimuli-responsive Fe
Topics: Acrylic Resins; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Ferrosoferric Oxide; Ferrous Compounds; Humans; Hydrogen-Ion Concentration; Magnetic Fields; Metallocenes; Micelles; Neoplasms; Oxidation-Reduction; Paclitaxel; Polymers | 2017 |
Delivery of paclitaxel using nanoparticles composed of poly(ethylene oxide)-b-poly(butylene oxide) (PEO-PBO).
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Epoxy Compounds; Hemolysis; Humans; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols; Rats, Sprague-Dawley; Tissue Distribution; Xenograft Model Antitumor Assays | 2018 |
Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel.
Topics: Albumins; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
Caspase-mediated cleavage of X-ray repair cross-complementing group 4 promotes apoptosis by enhancing nuclear translocation of caspase-activated DNase.
Topics: Animals; Apoptosis; Cell Nucleus; Deoxyribonucleases; DNA Fragmentation; DNA Repair; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; Mice; Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases; Serine-Arginine Splicing Factors; Signal Transduction; Staurosporine; Vincristine | 2018 |
Conjugation of paclitaxel to C-6 hexanediamine-modified hyaluronic acid for targeted drug delivery to enhance antitumor efficacy.
Topics: Acetamides; Apoptosis; Carbon-13 Magnetic Resonance Spectroscopy; Cell Death; Diamines; Drug Delivery Systems; Drug Liberation; Endocytosis; Flow Cytometry; Hep G2 Cells; Hexanes; Humans; Hyaluronic Acid; Neoplasms; Paclitaxel; Proton Magnetic Resonance Spectroscopy | 2018 |
Docetaxel promotes the generation of anti-tumorigenic human macrophages.
Topics: Antineoplastic Agents; Carcinogenesis; Cell Differentiation; Dendritic Cells; Docetaxel; Female; Humans; Immunity, Innate; Macrophages; Monocytes; Myeloid Cells; Neoplasms; Paclitaxel; T-Lymphocytes; Taxoids | 2018 |
Indocyanine green angiography findings of cystoid macular edema secondary to paclitaxel therapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Coloring Agents; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Indocyanine Green; Macula Lutea; Macular Edema; Male; Neoplasms; Paclitaxel; Tomography, Optical Coherence; Visual Acuity | 2018 |
A Novel Paclitaxel-Loaded Polymeric Micelle System with Favorable Biocompatibility and Superior Antitumor Activity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Hemolysis; Humans; Male; Mice, Nude; Micelles; Neoplasms; Paclitaxel; Particle Size; Polymers; Rats, Sprague-Dawley; Tumor Burden | 2018 |
Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Infusions, Intravenous; Isoflurophate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Light-Activatable Red Blood Cell Membrane-Camouflaged Dimeric Prodrug Nanoparticles for Synergistic Photodynamic/Chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Delayed-Action Preparations; Dimerization; Erythrocyte Membrane; Female; HeLa Cells; Humans; Light; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Photochemotherapy; Photosensitizing Agents; Prodrugs; Reactive Oxygen Species | 2018 |
CD44-Targeted Facile Enzymatic Activatable Chitosan Nanoparticles for Efficient Antitumor Therapy and Reversal of Multidrug Resistance.
Topics: alpha-Tocopherol; Animals; Chitosan; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hyaluronan Receptors; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Proteins; Neoplasms; NIH 3T3 Cells; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Development of biocompatible and VEGF-targeted paclitaxel nanodrugs on albumin and graphene oxide dual-carrier for photothermal-triggered drug delivery in vitro and in vivo.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Apoptosis; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Delivery Systems; Drug Liberation; Graphite; Humans; Hyperthermia, Induced; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Oxides; Paclitaxel; Phototherapy; Polyethylene Glycols; Vascular Endothelial Growth Factor A | 2018 |
Pro-apoptotic liposomes-nanobubble conjugate synergistic with paclitaxel: a platform for ultrasound responsive image-guided drug delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drug Compounding; Drug Delivery Systems; Humans; Liposomes; Mice, Inbred C57BL; Microbubbles; Neoplasms; Paclitaxel; Ultrasonography | 2018 |
Redox-responsive F127-folate/F127-disulfide bond-d-α-tocopheryl polyethylene glycol 1000 succinate/P123 mixed micelles loaded with paclitaxel for the reversal of multidrug resistance in tumors.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Disulfides; Drug Liberation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endocytosis; Folic Acid; Humans; Inhibitory Concentration 50; MCF-7 Cells; Micelles; Mitochondria; Neoplasms; Oxidation-Reduction; Paclitaxel; Poloxalene; Poloxamer; Reactive Oxygen Species; Vitamin E | 2018 |
MHI-148 Cyanine Dye Conjugated Chitosan Nanomicelle with NIR Light-Trigger Release Property as Cancer Targeting Theranostic Agent.
Topics: Animals; Carbocyanines; Cell Line; Chitosan; Coloring Agents; Coumarins; Humans; Hyperthermia, Induced; Light; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Phototherapy; Spectroscopy, Near-Infrared; Theranostic Nanomedicine; Thiazoles; Tissue Distribution | 2018 |
RNA-based micelles: A novel platform for paclitaxel loading and delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Cytokines; Drug Delivery Systems; Drug Liberation; Female; Humans; KB Cells; Mice; Mice, Nude; Micelles; Neoplasms; Paclitaxel; RAW 264.7 Cells; RNA | 2018 |
Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells.
Topics: Animals; Antimitotic Agents; Antineoplastic Agents; Apoptosis; Autocrine Communication; Caspase 8; Cell Cycle Checkpoints; Cell Line, Tumor; Ligands; M Phase Cell Cycle Checkpoints; Mice, Nude; Neoplasms; Oxazoles; Paclitaxel; Receptors, Tumor Necrosis Factor, Member 25; Recombinant Proteins; Tumor Necrosis Factor Ligand Superfamily Member 15 | 2018 |
TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; China; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Treatment Outcome | 2018 |
Light-Trigerred Cellular Epigenetic Molecule Release To Reverse Tumor Multidrug Resistance.
Topics: Antineoplastic Agents; Apoptosis; Delayed-Action Preparations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epigenesis, Genetic; HeLa Cells; Humans; MCF-7 Cells; Neoplasms; Paclitaxel; Ultraviolet Rays; Vorinostat | 2018 |
Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Models, Biological; Neoplasms; Neutropenia; Paclitaxel; Research Design; Treatment Outcome | 2018 |
Comparative Proteomics of Dying and Surviving Cancer Cells Improves the Identification of Drug Targets and Sheds Light on Cell Life/Death Decisions.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Fluorouracil; Humans; Methotrexate; Neoplasms; Paclitaxel; Proteome; Proteomics | 2018 |
Polymeric micelles: Theranostic co-delivery system for poorly water-soluble drugs and contrast agents.
Topics: Animals; Apoptosis; Cell Line, Tumor; Contrast Media; Drug Delivery Systems; Female; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Micelles; Neoplasms; Paclitaxel; Polymers; Solubility; Theranostic Nanomedicine; Water | 2018 |
CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; CD8-Positive T-Lymphocytes; CX3C Chemokine Receptor 1; Cytotoxins; Drug Therapy, Combination; Female; Granzymes; Humans; Immunotherapy; Male; Melanoma; Mice; Neoplasms; Paclitaxel; Perforin; Programmed Cell Death 1 Receptor | 2018 |
Paclitaxel-Loaded Polylactide/Polyethylene Glycol Fibers with Long-Term Antitumor Activity as a Potential Drug Carrier for Local Chemotherapy.
Topics: Antineoplastic Agents; Delayed-Action Preparations; Drug Carriers; Humans; MCF-7 Cells; Neoplasms; Paclitaxel; Polyesters; Polyethylene Glycols | 2018 |
Anticancer Profiling for Coumarins and Related
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Caco-2 Cells; Cell Proliferation; Cell Survival; Coumarins; Down-Regulation; Drug Synergism; Gene Expression Regulation, Neoplastic; HeLa Cells; Hep G2 Cells; Humans; In Vitro Techniques; Malvaceae; MCF-7 Cells; Molecular Structure; Naphthoquinones; Neoplasms; Paclitaxel; Plant Extracts | 2018 |
Metabolic cofactors NAD(P)H and FAD as potential indicators of cancer cell response to chemotherapy with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers; Flavin-Adenine Dinucleotide; Humans; Microscopy, Fluorescence, Multiphoton; NADP; Neoplasms; Oxidation-Reduction; Paclitaxel; Tumor Cells, Cultured | 2018 |
Effective treatment of the primary tumor and lymph node metastasis by polymeric micelles with variable particle sizes.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Lymphatic Metastasis; Mice, Inbred BALB C; Micelles; Neoplasms; Paclitaxel; Particle Size; Phosphatidylethanolamines; Polyethylene Glycols | 2018 |
Disulfide Bond-Driven Oxidation- and Reduction-Responsive Prodrug Nanoassemblies for Cancer Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Delayed-Action Preparations; Disulfides; Drug Liberation; Humans; Mice, Nude; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel; Prodrugs | 2018 |
Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Cycle Proteins; Cell Death; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; MCF-7 Cells; Mice; Mitosis; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2018 |
Ionic-Liquid-Based Paclitaxel Preparation: A New Potential Formulation for Cancer Treatment.
Topics: Antineoplastic Agents, Phytogenic; Drug Compounding; Drug Delivery Systems; Drug Hypersensitivity; Excipients; Glycerol; HeLa Cells; Humans; Ionic Liquids; Neoplasms; Paclitaxel; Solubility | 2018 |
Integration of genetic and functional genomics data to uncover chemotherapeutic induced cytotoxicity.
Topics: Black People; Capecitabine; Carboplatin; Cell Line; Cisplatin; Gene Expression Regulation, Neoplastic; Genetic Variation; Genome-Wide Association Study; Genome, Human; Humans; Molecular Sequence Annotation; Neoplasms; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; White People | 2019 |
Tumor environment differentiated "nanodepot" programmed for site-specific drug shuttling and combinative therapy on metastatic cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therapy; Drug Carriers; Female; Humans; Hyaluronoglucosaminidase; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Polyesters; Polyethyleneimine; Proteins; RNA Interference; RNA, Small Interfering; Tumor Microenvironment | 2018 |
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Evaluation, Preclinical; Folic Acid; Humans; Mice, Nude; Neoplasms; Oligopeptides; Paclitaxel; Pipecolic Acids; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Anticancer chemotherapy and radiotherapy trigger both non-cell-autonomous and cell-autonomous death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bystander Effect; Cell Death; Cell Line, Tumor; Cisplatin; Gamma Rays; HCT116 Cells; Humans; Jurkat Cells; MCF-7 Cells; Mice; Neoplasms; Oxaliplatin; Paclitaxel; Radiotherapy | 2018 |
Entropically driven controlled release of paclitaxel from poly(2-ethyl-2-oxazoline) coated maghemite nanostructures for magnetically guided cancer therapy.
Topics: Animals; Cisplatin; Doxorubicin; Drug Delivery Systems; Ferric Compounds; Humans; Nanostructures; Neoplasms; Paclitaxel; Polyamines; Polymers | 2018 |
Low-power and low-drug-dose photodynamic chemotherapy via the breakdown of tumor-targeted micelles by reactive oxygen species.
Topics: Animals; Antineoplastic Agents, Phytogenic; Delayed-Action Preparations; Drug Delivery Systems; Folic Acid; HeLa Cells; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasms; Paclitaxel; Photochemotherapy; Polyethylene Glycols; Porphyrins; Reactive Oxygen Species | 2018 |
Paclitaxel-Induced Ultrasmall Gallic Acid-Fe@BSA Self-Assembly with Enhanced MRI Performance and Tumor Accumulation for Cancer Theranostics.
Topics: Cell Line, Tumor; Ferric Compounds; Gallic Acid; Humans; Magnetic Resonance Imaging; Nanoparticles; Neoplasms; Paclitaxel; Theranostic Nanomedicine | 2018 |
Drug-Polymer Interaction, Pharmacokinetics and Antitumor Effect of PEG-PLA/Taxane Derivative TM-2 Micelles for Intravenous Drug Delivery.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Drug Carriers; Male; Mice; Micelles; Neoplasms; Paclitaxel; Polyethylene Glycols; Rats, Sprague-Dawley; Taxoids | 2018 |
Folate-receptor-targeted laser-activable poly(lactide-
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Liberation; Endocytosis; Female; Folate Receptors, GPI-Anchored; Folic Acid; Human Umbilical Vein Endothelial Cells; Humans; Hyperthermia, Induced; Indocyanine Green; Lactic Acid; Lasers; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Photoacoustic Techniques; Phototherapy; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Theranostic Nanomedicine; Tissue Distribution; Ultrasonography | 2018 |
Pro-Coagulant and Pro-Thrombotic Effects of Paclitaxel Mediated by Red Blood Cells.
Topics: Adolescent; Animals; Antineoplastic Agents; Cell-Derived Microparticles; Drug-Related Side Effects and Adverse Reactions; Erythrocytes; Human Umbilical Vein Endothelial Cells; Humans; Male; Neoplasms; Paclitaxel; Phosphatidylserines; Phospholipid Transfer Proteins; Rats; Rats, Sprague-Dawley; Thrombin; Thrombosis; Young Adult | 2018 |
Lipid insertion enables targeted functionalization of paclitaxel-loaded erythrocyte membrane nanosystem by tumor-penetrating bispecific recombinant protein.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Delivery Systems; ErbB Receptors; Erythrocyte Membrane; Erythrocytes; Fluorescence; Humans; Lipids; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Oligopeptides; Paclitaxel; Phosphatidylethanolamines; Polyethylene Glycols; Recombinant Proteins; Tissue Distribution | 2018 |
Crown ethers reverse P-glycoprotein-mediated multidrug resistance in cancer cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Membrane; Crown Ethers; Dogs; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Ion Transport; Madin Darby Canine Kidney Cells; Neoplasms; Paclitaxel; Potassium; Vincristine | 2018 |
Paclitaxel-induced formation of 3D nanocrystal superlattices within injectable protein-based hybrid nanoparticles.
Topics: Antineoplastic Agents, Phytogenic; Cell Survival; HeLa Cells; Humans; Injections; Magnetite Nanoparticles; MCF-7 Cells; Models, Molecular; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols; Serum Albumin, Human | 2018 |
Redox-responsive FRET-based polymer dot with BODIPY for fluorescence imaging-guided chemotherapy of tumor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Boron Compounds; Cell Line, Tumor; Dogs; Drug Carriers; Drug Liberation; Fluorescence Resonance Energy Transfer; Glutathione; Humans; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel; Polymers; Xenograft Model Antitumor Assays | 2018 |
Anti-EGFR lipid micellar nanoparticles co-encapsulating quantum dots and paclitaxel for tumor-targeted theranosis.
Topics: Animals; Antibodies, Immobilized; Antineoplastic Agents, Phytogenic; Aptamers, Nucleotide; Cell Line, Tumor; Drug Carriers; Drug Liberation; Drug Stability; ErbB Receptors; Humans; Mice; Micelles; Nanoparticles; Neoplasms; Optical Imaging; Paclitaxel; Quantum Dots; Theranostic Nanomedicine; Tissue Distribution; Transplantation, Heterologous | 2018 |
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells.
Topics: Adenosine Triphosphatases; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Lung Neoplasms; MAP Kinase Kinase Kinase 5; Mitoxantrone; Models, Molecular; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Kinase Inhibitors | 2019 |
Choosing the Best Chemotherapy Agent to Boost Immune Checkpoint Inhibition Activity.
Topics: Humans; Immunotherapy; Macrophages; Neoplasms; Paclitaxel; Toll-Like Receptor 4 | 2018 |
Hexa-functional tumour-seeking nano voyagers and annihilators for synergistic cancer theranostic applications.
Topics: Animals; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Chitosan; Drug Carriers; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; NIH 3T3 Cells; Paclitaxel; Theranostic Nanomedicine; Transplantation, Heterologous | 2018 |
Drug-Homogeneity Index in Mass-Spectrometry Imaging.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Humans; Mice; Models, Biological; Models, Theoretical; Neoplasms; Paclitaxel; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2018 |
Chemotherapy in pregnancy: exploratory study of the effects of paclitaxel on the expression of placental drug transporters.
Topics: Adult; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis | 2019 |
Risk Factors for Eye Disorders Caused by Paclitaxel: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Alkaline Phosphatase; Antineoplastic Agents, Phytogenic; Eye Diseases; Female; Hospitals; Humans; Logistic Models; Macular Edema; Male; Middle Aged; Nanoparticles; Neoplasms; Odds Ratio; Paclitaxel; Retrospective Studies; Risk Factors; Vision Disorders | 2018 |
pH-Sensitive morphological transitions in polymeric tadpole assemblies for programmed tumor therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Female; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Polymers | 2019 |
PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Peptides; Programmed Cell Death 1 Receptor; Regional Blood Flow; Survival Analysis; Tissue Distribution | 2018 |
pH and redox dual-responsive copolymer micelles with surface charge reversal for co-delivery of all-
Topics: A549 Cells; Adsorption; Animals; Antineoplastic Agents; Cell Death; Drug Delivery Systems; Drug Liberation; Drug Therapy, Combination; Humans; Hydrogen-Ion Concentration; Male; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel; Particle Size; Polymers; Serum Albumin, Bovine; Tretinoin | 2018 |
Development of drug-loaded protein nanoparticles displaying enzymatically-conjugated DNA aptamers for cancer cell targeting.
Topics: Antineoplastic Agents; Aptamers, Nucleotide; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Elastin; Female; Humans; MCF-7 Cells; Nanoparticles; Neoplasms; Paclitaxel | 2019 |
Past-in-the-Future. Peak detection improves targeted mass spectrometry imaging.
Topics: Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Neoplasms; Paclitaxel | 2018 |
Effect of the Folate Ligand Density on the Targeting Property of Folated-Conjugated Polymeric Nanoparticles.
Topics: Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Folic Acid; Humans; Nanoparticles; Neoplasms; Paclitaxel; Polyesters | 2019 |
Acetazolamide-Loaded pH-Responsive Nanoparticles Alleviating Tumor Acidosis to Enhance Chemotherapy Effects.
Topics: Acetazolamide; Acidosis; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Paclitaxel | 2019 |
Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure.
Topics: Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP2C8; Female; Genetic Association Studies; Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasms; Paclitaxel; Pharmacogenomic Variants; Phenotype | 2019 |
Transforming Weakness into Strength: Photothermal-Therapy-Induced Inflammation Enhanced Cytopharmaceutical Chemotherapy as a Combination Anticancer Treatment.
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Gold; Humans; Hyperthermia, Induced; Infrared Rays; Interleukin-8; Liver; Mice; Nanotubes; Neoplasms; Neutrophils; Optical Imaging; Paclitaxel; Phototherapy; Polyethylene Glycols; Tumor Necrosis Factor-alpha | 2019 |
Novel pH-sensitive zinc phthalocyanine assembled with albumin for tumor targeting and treatment.
Topics: Albumins; Amines; Animals; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Humans; Hydrogen-Ion Concentration; Indoles; Isoindoles; Male; Mice; Nanoparticles; Neoplasms; Organometallic Compounds; Paclitaxel; Reactive Oxygen Species; Solutions; Time Factors; Treatment Outcome; Zinc Compounds | 2018 |
Preparation and evaluation of carboxymethyl chitosan-rhein polymeric micelles with synergistic antitumor effect for oral delivery of paclitaxel.
Topics: Administration, Oral; Animals; Anthraquinones; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Liberation; Drug Synergism; Humans; Male; Mice, Inbred ICR; Micelles; Neoplasms; Paclitaxel; Verapamil | 2019 |
Design and synthesis of mixed micellar system for enhanced anticancer efficacy of Paclitaxel through its co-delivery with Naringin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Carriers; Drug Compounding; Drug Design; Drug Liberation; Drug Screening Assays, Antitumor; Drug Stability; Flavanones; Humans; MCF-7 Cells; Micelles; Neoplasms; Paclitaxel; Polymers | 2019 |
Extracellular vesicles enhance the targeted delivery of immunogenic oncolytic adenovirus and paclitaxel in immunocompetent mice.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Extracellular Vesicles; Lymphocytes, Tumor-Infiltrating; Male; Mice, Transgenic; Neoplasms; Oncolytic Viruses; Paclitaxel; Tissue Distribution | 2019 |
Biotin functionalized PEGylated poly(amidoamine) dendrimer conjugate for active targeting of paclitaxel in cancer.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Biotin; Cell Survival; Dendrimers; Drug Carriers; Humans; Neoplasms; Paclitaxel; Polyethylene Glycols; Spheroids, Cellular; Tumor Cells, Cultured | 2019 |
Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Disulfiram; Drug Carriers; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erythrocytes; Female; Hemolysis; Humans; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Rats, Sprague-Dawley; Tissue Distribution; Tumor Burden | 2019 |
A dual pH-sensitive liposomal system with charge-reversal and NO generation for overcoming multidrug resistance in cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Drug Resistance, Neoplasm; Humans; Hydrogen-Ion Concentration; Liposomes; Mice; Mice, Nude; Microscopy, Confocal; Neoplasms; Nitric Oxide; Paclitaxel; Polymers; Tissue Distribution; Transplantation, Heterologous | 2019 |
Bioprinting of 3D breast epithelial spheroids for human cancer models.
Topics: Bioprinting; Breast; Cell Line; Cell Survival; Coculture Techniques; Epithelial Cells; Female; Human Umbilical Vein Endothelial Cells; Humans; Models, Biological; Neoplasms; Paclitaxel; Spheroids, Cellular | 2019 |
Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Datasets as Topic; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Neoplasms; Netherlands; Paclitaxel; Prospective Studies; Retrospective Studies; Young Adult | 2019 |
Structure-Activity Relationships of Cytotoxic Lactones as Inhibitors and Mechanisms of Action.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Sesquiterpenes; Structural Homology, Protein; Structure-Activity Relationship; Topotecan; Tubulin; Tubulin Modulators | 2020 |
Transferrin-conjugated pH-sensitive platform for effective delivery of porous palladium nanoparticles and paclitaxel in cancer treatment.
Topics: Acrylic Resins; Animals; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Drug Delivery Systems; Endocytosis; Female; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Palladium; Polyethylene Glycols; Porosity; Tissue Distribution; Transferrin | 2019 |
Incorporation With Dendrimer-Like Biopolymer Leads to Improved Soluble Amount and In Vitro Anticancer Efficacy of Paclitaxel.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Biopolymers; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dendrimers; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Inhibitory Concentration 50; Neoplasms; Paclitaxel; PC-3 Cells; Pharmaceutical Vehicles | 2019 |
Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Molecular Docking Simulation; Neoplasms; Paclitaxel; Protein Binding; Up-Regulation | 2019 |
A CD44-Targeting Programmable Drug Delivery System for Enhancing and Sensitizing Chemotherapy to Drug-Resistant Cancer.
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Cell Line, Tumor; Cell Survival; Chondroitin Sulfates; Down-Regulation; Drug Carriers; Drug Resistance, Neoplasm; Humans; Hyaluronan Receptors; Hydrogels; Hydrophobic and Hydrophilic Interactions; Mice; Microscopy, Fluorescence; Nanoparticles; Neoplasms; Paclitaxel; Sunitinib; Transplantation, Heterologous | 2019 |
Alterations in the glycome after HDAC inhibition impact oncogenic potential in epigenetically plastic SW13 cells.
Topics: Antineoplastic Agents, Phytogenic; Biosynthetic Pathways; Cell Line, Tumor; Cell Plasticity; Cell Transformation, Neoplastic; Depsipeptides; Drug Resistance, Neoplasm; Epigenesis, Genetic; Glycosylation; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans; Neoplasms; Paclitaxel; Polysaccharides; Protein Processing, Post-Translational | 2019 |
Septin filament coalignment with microtubules depends on SEPT9_i1 and tubulin polyglutamylation, and is an early feature of acquired cell resistance to paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; CHO Cells; Cricetulus; Drug Resistance, Neoplasm; HeLa Cells; Humans; Kinesins; Microtubule-Associated Proteins; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Septins; Tubulin | 2019 |
Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy.
Topics: Adult; Aged; Antineoplastic Agents; Cancer Survivors; Cohort Studies; Exercise; Exercise Therapy; Female; Humans; Male; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life | 2019 |
Facile Engineering of Indomethacin-Induced Paclitaxel Nanocrystal Aggregates as Carrier-Free Nanomedicine with Improved Synergetic Antitumor Activity.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Humans; Immunotherapy; Indomethacin; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel | 2019 |
Preliminary results of identification and quantification of paclitaxel and its metabolites in human meconium from newborns with gestational chemotherapeutic exposure.
Topics: Adult; Chromatography, High Pressure Liquid; Chromatography, Liquid; Female; Follow-Up Studies; Humans; Infant, Newborn; Longitudinal Studies; Meconium; Neoplasms; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Registries; Tandem Mass Spectrometry | 2019 |
Combined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Movement; Drug Carriers; Female; Humans; Inhibitory Concentration 50; Male; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasms; Paclitaxel; Polyethylene Glycols; Stearic Acids; Tissue Distribution; Tumor Burden; Vitamin E; Whole Body Imaging | 2019 |
Dual-Responsive Size-Shrinking Nanocluster with Hierarchical Disassembly Capability for Improved Tumor Penetration and Therapeutic Efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Female; Humans; MCF-7 Cells; Mice; Mice, Nude; Micelles; Microscopy, Confocal; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Polymers; Survival Rate; Tissue Distribution; Transplantation, Heterologous | 2019 |
Synthesis of an Oxidation-Sensitive Polyphosphoester Bearing Thioether Group for Triggered Drug Release.
Topics: Cell Line, Tumor; Chlorophyllides; Delayed-Action Preparations; Drug Carriers; Humans; Hydrogen Peroxide; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols; Porphyrins | 2019 |
Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands.
Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-myb; Sesquiterpenes; Structure-Activity Relationship; Topotecan | 2020 |
A switchable NO-releasing nanomedicine for enhanced cancer therapy and inhibition of metastasis.
Topics: Animals; Cell Line, Tumor; Cell Survival; Glutathione; Half-Life; Humans; Hypothermia, Induced; Infrared Rays; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Nanomedicine; Nanoparticles; Neoplasms; Nitric Oxide; Paclitaxel; Photosensitizing Agents; Serum Albumin, Human; Singlet Oxygen | 2019 |
A photo-inducible protein-inorganic nanoparticle assembly for active targeted tumour theranostics.
Topics: Animals; Cell Line, Tumor; Cell Survival; Drug Carriers; Humans; Male; Mice; Mice, Inbred BALB C; Microscopy, Atomic Force; Muramidase; Nanoparticles; Neoplasms; Oligopeptides; Paclitaxel; Polyethylene Glycols; Quantum Dots; Theranostic Nanomedicine; Tissue Distribution; Transplantation, Heterologous; Ultraviolet Rays | 2019 |
A thermoresponsive nanocarrier for mitochondria-targeted drug delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Carriers; Drug Screening Assays, Antitumor; Humans; Mice; Mitochondria; Nanoparticles; Neoplasms; Paclitaxel; Structure-Activity Relationship; Temperature | 2019 |
The KEYNOTE-061 trial.
Topics: Antibodies, Monoclonal, Humanized; Esophagogastric Junction; Humans; Neoplasms; Paclitaxel | 2019 |
Design of diffusion-controlled drug delivery devices for controlled release of Paclitaxel.
Topics: Animals; Delayed-Action Preparations; Humans; Models, Biological; Models, Chemical; Neoplasms; Paclitaxel | 2019 |
An ATG5 knockout promotes paclitaxel resistance in v-Ha-ras-transformed NIH 3T3 cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Autophagy-Related Protein 5; Cell Cycle; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Gene Knockout Techniques; Genes, ras; Mice; Neoplasms; NIH 3T3 Cells; Paclitaxel; Tubulin Modulators | 2019 |
ROS-responsive targeting micelles for optical imaging-guided chemo-phototherapy of cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Survival; Drug Liberation; Endocytosis; Hep G2 Cells; Humans; Mice, Inbred C57BL; Micelles; Neoplasms; Optical Imaging; Paclitaxel; Phototherapy; Reactive Oxygen Species | 2019 |
Impact of Essential Medicine Stock Outs on Cancer Therapy Delivery in a Resource-Limited Setting.
Topics: Aged; Antineoplastic Agents; Botswana; Drugs, Essential; Female; Humans; Logistic Models; Male; Middle Aged; Neoplasms; Paclitaxel; Poverty; Retrospective Studies; Standard of Care; Strategic Stockpile; Treatment Outcome | 2019 |
Safety Evaluation of Paclitaxel-Eluting Biliary Metal Stent with Sodium Caprate in Porcine Biliary Tract.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Antineoplastic Agents, Phytogenic; Aspartate Aminotransferases; Cholestasis; Common Bile Duct; Decanoic Acids; Drug-Eluting Stents; Neoplasms; Paclitaxel; Self Expandable Metallic Stents; Serum Albumin; Sus scrofa; Swine | 2019 |
Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Australia; Female; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Oxaliplatin; Paclitaxel; Patient Reported Outcome Measures; Peripheral Nervous System Diseases; Surveys and Questionnaires | 2019 |
Redox-sensitive micelles based on retinoic acid modified chitosan conjugate for intracellular drug delivery and smart drug release in cancer therapy.
Topics: Antineoplastic Agents; Cell Survival; Chitosan; Cystamine; Drug Carriers; Drug Liberation; Hep G2 Cells; Humans; Micelles; Neoplasms; Oxidation-Reduction; Paclitaxel; Particle Size; Tretinoin | 2019 |
Polymersome nanoreactors with tumor pH-triggered selective membrane permeability for prodrug delivery, activation, and combined oxidation-chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Membrane Permeability; Drug Carriers; Female; Glucose Oxidase; Humans; Hydrogen Peroxide; Hydrogen-Ion Concentration; Mice, Inbred ICR; Neoplasms; Oxidation-Reduction; Paclitaxel; Polymers; Prodrugs | 2019 |
Hyperthermia Nanofiber Platform Synergized by Sustained Release of Paclitaxel to Improve Antitumor Efficiency.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Synergism; Female; Humans; Hyperthermia, Induced; Magnetite Nanoparticles; Mice; Mice, SCID; Nanofibers; Neoplasms; Paclitaxel; Polyesters; Xenograft Model Antitumor Assays | 2019 |
EPHB6 mutation induces cell adhesion-mediated paclitaxel resistance via EPHA2 and CDH11 expression.
Topics: Antineoplastic Agents, Phytogenic; Cadherins; Cell Line, Tumor; Drug Resistance, Neoplasm; Ephrin-A2; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Paclitaxel; Receptor, EphA2; Receptors, Eph Family | 2019 |
Spatial distribution of IL4 controls iNKT cell-DC crosstalk in tumors.
Topics: Animals; cdc42 GTP-Binding Protein; Dendritic Cells; Galactosylceramides; Humans; Immunological Synapses; Interleukin-4; Mice, Inbred C57BL; Microtubule-Organizing Center; Natural Killer T-Cells; Neoplasms; Paclitaxel; Receptors, Interleukin-4; Signal Transduction; STAT6 Transcription Factor; Th1 Cells; Th2 Cells | 2020 |
CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; G2 Phase; HeLa Cells; Humans; Microtubules; Mitosis; Molecular Docking Simulation; Neoplasms; Paclitaxel; Spindle Apparatus; Tubulin; Tubulin Modulators | 2020 |
Paclitaxel-Coated Balloons and Eluting Stents: Is There a Mortality Risk in Patients With Peripheral Artery Disease?
Topics: Antineoplastic Agents, Phytogenic; Consensus; Drug-Eluting Stents; Humans; Meta-Analysis as Topic; Neoplasms; Paclitaxel; Peripheral Arterial Disease; Proportional Hazards Models; Survival Analysis | 2019 |
Intracellular Trafficking Network and Autophagy of PHBHHx Nanoparticles and their Implications for Drug Delivery.
Topics: Adenine; Animals; Antineoplastic Agents, Phytogenic; Autophagy; Caveolins; Clathrin; Drug Carriers; Endocytosis; Endosomes; Exocytosis; Humans; MCF-7 Cells; Mice; Mice, SCID; Microscopy, Confocal; Nanoparticles; Neoplasms; Paclitaxel; Polyhydroxyalkanoates; Transplantation, Heterologous | 2019 |
The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death.
Topics: Animals; Apoptosis; bcl-X Protein; Cell Cycle Checkpoints; Cell Line, Tumor; DNA; Female; Humans; Interferon Regulatory Factor-3; Male; Mice; Mice, Inbred NOD; Mitosis; Neoplasms; Nucleosomes; Nucleotidyltransferases; Paclitaxel; Recombinant Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Survival Rate; Transcriptional Activation | 2019 |
PEG-derivatized birinapant as a nanomicellar carrier of paclitaxel delivery for cancer therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Survival; Coumarins; Dipeptides; Drug Carriers; Female; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Indoles; Mice; Mice, Inbred BALB C; Mice, SCID; Micelles; Neoplasms; Paclitaxel; Polyethylene Glycols; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
A Simple Glutathione-Responsive Turn-On Theranostic Nanoparticle for Dual-Modal Imaging and Chemo-Photothermal Combination Therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therapy; Fluorescent Dyes; Glutathione; Hyperthermia, Induced; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Optical Imaging; Paclitaxel; Photoacoustic Techniques; Phototherapy; Theranostic Nanomedicine | 2019 |
A tumor microenvironment model coupled with a mass spectrometry system to probe the metabolism of drug-loaded nanoparticles.
Topics: Antineoplastic Agents; Coculture Techniques; Drug Carriers; Equipment Design; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Microfluidic Analytical Techniques; Nanoparticles; Neoplasms; Paclitaxel; Reactive Oxygen Species; Spectrometry, Mass, Electrospray Ionization; Tumor Microenvironment | 2019 |
Chondroitin Sulfate-Linked Prodrug Nanoparticles Target the Golgi Apparatus for Cancer Metastasis Treatment.
Topics: Cell Line, Tumor; Chondroitin Sulfates; Drug Delivery Systems; Golgi Apparatus; Humans; Nanoparticles; Neoplasm Metastasis; Neoplasms; Paclitaxel; Prodrugs | 2019 |
NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calorimetry, Differential Scanning; Cell Line, Tumor; Cyclodextrins; Female; HeLa Cells; Humans; Imidazoles; Immunologic Factors; Immunotherapy; Isoindoles; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Neoplasms; Paclitaxel; Small Molecule Libraries; Solubility | 2019 |
Paclitaxel-loaded hydroxyapatite/collagen hybrid gels as drug delivery systems for metastatic cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Collagen; Drug Carriers; Durapatite; Gels; Humans; Neoplasms; Paclitaxel | 2013 |
Minimal "Self" peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles.
Topics: Animals; Antigens, Differentiation; Antineoplastic Agents; Autoantigens; Blood Circulation; CD47 Antigen; Diagnostic Imaging; Drug Delivery Systems; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Peptide Fragments; Phagocytes; Phagocytosis; Receptors, Immunologic; Signal Transduction | 2013 |
Transposon activation mutagenesis as a screening tool for identifying resistance to cancer therapeutics.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Line, Tumor; DNA Barcoding, Taxonomic; DNA Mutational Analysis; DNA Transposable Elements; Drug Resistance, Neoplasm; Humans; Mutagenesis, Insertional; Neoplasms; Paclitaxel; RNA, Messenger | 2013 |
Codelivery of mTERT siRNA and paclitaxel by chitosan-based nanoparticles promoted synergistic tumor suppression.
Topics: Absorption; Animals; Antineoplastic Agents; Caco-2 Cells; Carbocyanines; Carcinoma, Lewis Lung; Cell Death; Cell Proliferation; Chitosan; Drug Delivery Systems; Endocytosis; Flow Cytometry; Gene Silencing; Gene Transfer Techniques; Humans; Intracellular Space; Male; Mice; Nanoparticles; Neoplasms; Paclitaxel; Permeability; Quaternary Ammonium Compounds; RNA, Small Interfering; Telomerase; Tissue Distribution; Xenograft Model Antitumor Assays | 2013 |
Multifunctional nanoparticles based on a single-molecule modification for the treatment of drug-resistant cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Design; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorouracil; Humans; Hydrolysis; Models, Chemical; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols; Rhodamine 123; Vitamin E | 2013 |
Killed Bacillus subtilis spores expressing streptavidin: a novel carrier of drugs to target cancer cells.
Topics: Adsorption; Antibodies, Monoclonal, Humanized; Bacillus subtilis; Bacterial Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Carriers; Drug Delivery Systems; ErbB Receptors; HT29 Cells; Humans; Hydrogen-Ion Concentration; Neoplasms; Paclitaxel; Spores, Bacterial; Streptavidin | 2013 |
Dual anticancer drug/superparamagnetic iron oxide-loaded PLGA-based nanoparticles for cancer therapy and magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Survival; Doxorubicin; Lactic Acid; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Neoplasms; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Tumor Burden | 2013 |
Specific tumor delivery of paclitaxel using glycolipid-like polymer micelles containing gold nanospheres.
Topics: Ablation Techniques; Animals; Cell Death; Cell Line, Tumor; Chitosan; Diagnostic Imaging; Drug Delivery Systems; Endocytosis; Glycolipids; Gold; Humans; Light; Mice; Micelles; Nanospheres; Neoplasms; Oligosaccharides; Paclitaxel; Particle Size; Peptides; Polymers; Receptor, EphB4; Spectroscopy, Near-Infrared; Static Electricity; Stearic Acids; Temperature | 2013 |
Development of drug loaded nanoparticles for tumor targeting. Part 2: Enhancement of tumor penetration through receptor mediated transcytosis in 3D tumor models.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Carriers; Humans; Hyaluronan Receptors; Hyaluronic Acid; Microscopy, Confocal; Models, Biological; Nanoparticles; Neoplasms; Paclitaxel; Silicon Dioxide; Transcytosis | 2013 |
Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Docetaxel; Drug Monitoring; Female; Humans; Neoplasms; Paclitaxel; Pharmacogenetics; Precision Medicine; Taxoids | 2013 |
Synthesis and evaluation of star-shaped poly(ϵ-caprolactone)-poly(2-hydroxyethyl methacrylate) as potential anticancer drug delivery carriers.
Topics: Antineoplastic Agents, Phytogenic; Cell Survival; Drug Carriers; HeLa Cells; Humans; Micelles; Neoplasms; Paclitaxel; Polyesters; Polyhydroxyethyl Methacrylate; Polymerization | 2013 |
Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel.
Topics: Acetylation; alpha-Cyclodextrins; Animals; Apoptosis; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; Intracellular Space; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Toxicity Tests, Acute; Xenograft Model Antitumor Assays | 2013 |
Photo-crosslinked hyaluronic acid nanoparticles with improved stability for in vivo tumor-targeted drug delivery.
Topics: Animals; Cell Line, Tumor; Cell Survival; Cross-Linking Reagents; Drug Delivery Systems; Humans; Hyaluronic Acid; Light; Mice; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Tissue Distribution | 2013 |
In vivo investigation of hybrid Paclitaxel nanocrystals with dual fluorescent probes for cancer theranostics.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Cell Line, Tumor; Chemistry, Pharmaceutical; Female; Fluorescent Dyes; Humans; Matrix Metalloproteinases; Mice; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2014 |
Vitamin E reverses multidrug resistance in vitro and in vivo.
Topics: Adenosine Triphosphate; Animals; Antioxidants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Time Factors; Vitamin E; Xenograft Model Antitumor Assays | 2013 |
CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cytochrome P-450 CYP3A; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Genotype; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Polymorphism, Single Nucleotide; Sex Characteristics | 2013 |
PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
Topics: Adenosine Triphosphate; Affinity Labels; Allosteric Regulation; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line, Tumor; Colchicine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Hydrolysis; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyrimidines; Receptors, Fibroblast Growth Factor; Recombinant Proteins; Tubulin Modulators; Vincristine | 2013 |
Synthesis and biological evaluation of new paclitaxel analogs and discovery of potent antitumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Screening Assays, Antitumor; Halogenation; Humans; Models, Molecular; Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Taxus | 2013 |
Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lipids; MCF-7 Cells; Nanoparticles; Neoplasms; Paclitaxel; Structure-Activity Relationship; Tumor Cells, Cultured | 2013 |
Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Receptors, Eph Family | 2013 |
Surface charge-switchable polymeric magnetic nanoparticles for the controlled release of anticancer drug.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chemistry, Physical; Erythrocytes; Hot Temperature; Humans; Hydrogen-Ion Concentration; Lysine; Magnetics; Metal Nanoparticles; Microscopy, Electron, Transmission; Nanoparticles; Neoplasms; Oleic Acid; Paclitaxel; Polymers; Spectroscopy, Fourier Transform Infrared; Spectroscopy, Near-Infrared; Surface Properties; X-Ray Diffraction | 2013 |
Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Quinazolines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
[Comparison of a safety evaluation between paclitaxel injection NK and Taxol®].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel | 2013 |
Synthesis, isolation, stereostructure and cytotoxicity of paclitaxel analogs from cephalomannine.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Humans; Molecular Structure; Neoplasms; Paclitaxel; Phytotherapy; Plant Extracts; Structure-Activity Relationship; Taxoids | 2013 |
A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
Topics: Animals; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Delivery Systems; Endocytosis; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liposomes; Mice; Mice, Inbred BALB C; Neoplasms; Paclitaxel; Particle Size; Tumor Microenvironment | 2013 |
Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds.
Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Delivery Systems; Emulsions; Female; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Nanocapsules; Neoplasms; Paclitaxel; Receptor, ErbB-2; Trastuzumab | 2014 |
Targeting mitotic exit with hyperthermia or APC/C inhibition to increase paclitaxel efficacy.
Topics: Anaphase-Promoting Complex-Cyclosome; Antineoplastic Agents; Blotting, Western; Cyclin B; Humans; Hyperthermia, Induced; Mitosis; Neoplasms; Paclitaxel | 2013 |
Hot and toxic: hyperthermia and anti-mitotic drugs in cancer therapy.
Topics: Anaphase-Promoting Complex-Cyclosome; Antineoplastic Agents; Humans; Hyperthermia, Induced; Mitosis; Neoplasms; Paclitaxel | 2013 |
A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Female; Follow-Up Studies; Humans; Male; Membrane Transport Proteins; Middle Aged; Models, Statistical; Neoplasm Staging; Neoplasms; Paclitaxel; Pharmacogenetics; Polymorphism, Single Nucleotide; Prognosis; Young Adult | 2013 |
Characterization of novel MPS1 inhibitors with preclinical anticancer activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Cycle Proteins; Drug Synergism; Female; HeLa Cells; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Random Allocation; Transfection; Xenograft Model Antitumor Assays | 2013 |
A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Bridged-Ring Compounds; Caspase 8; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Fas Ligand Protein; fas Receptor; G2 Phase Cell Cycle Checkpoints; HeLa Cells; Humans; MCF-7 Cells; Microscopy, Fluorescence; Molecular Structure; Neoplasms; Paclitaxel; Polymerization; RNA Interference; Taxoids; Tubulin | 2013 |
MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; G2 Phase; Humans; Neoplasms; Paclitaxel; Sarcosine; Sulfonamides; Tubulin; Tubulin Modulators | 2013 |
Carrier-free functionalized multidrug nanorods for synergistic cancer therapy.
Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Carriers; Drug Synergism; Drug Therapy, Combination; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; KB Cells; MCF-7 Cells; Methotrexate; Mice; Mice, Inbred BALB C; Nanoparticles; Nanotubes; Neoplasms; Paclitaxel | 2013 |
Selective tissue distribution and long circulation endowed by paclitaxel loaded PEGylated poly(ε-caprolactone-co-L-lactide) micelles leading to improved anti-tumor effects and low systematic toxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Humans; Male; Mice; Micelles; Neoplasms; Paclitaxel; Polyesters; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2013 |
A novel polyethylene glycol mediated lipid nanoemulsion as drug delivery carrier for paclitaxel.
Topics: Animals; Cell Line, Tumor; Drug Carriers; Emulsions; Female; HeLa Cells; Humans; Inhibitory Concentration 50; Lipids; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Nanomedicine; Neoplasm Transplantation; Neoplasms; Paclitaxel; Polyethylene Glycols | 2014 |
Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.
Topics: Camptothecin; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drugs, Generic; Gemcitabine; Humans; India; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Poverty; Taxoids | 2013 |
Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cost-Benefit Analysis; Drug-Related Side Effects and Adverse Reactions; Female; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Nanoparticles; Neoplasms; Paclitaxel; Treatment Outcome | 2013 |
Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Mice; Neoplasms; Neuroblastoma; Osteosarcoma; Paclitaxel; Rhabdomyosarcoma; Xenograft Model Antitumor Assays | 2013 |
[Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy].
Topics: Antineoplastic Agents; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Pregabalin; Retrospective Studies | 2013 |
CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drug Delivery Systems; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Peptides | 2013 |
Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Delivery Systems; Humans; Matrix Metalloproteinase 2; Mice; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols; Prodrugs; Rats | 2013 |
Static magnetic fields increase tumor microvessel leakiness and improve antitumoral efficacy in combination with paclitaxel.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Disease Models, Animal; Endothelial Cells; Leukocytes; Magnetic Fields; Male; Mesocricetus; Microcirculation; Microscopy, Fluorescence; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Permeability | 2014 |
Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer.
Topics: Antineoplastic Agents; Cell Proliferation; Combined Modality Therapy; Drug Carriers; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Micelles; Neoplasms; Paclitaxel; Phospholipids; RNA, Small Interfering; Survivin; Tumor Cells, Cultured | 2014 |
Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Vincristine | 2014 |
Ultrabright and multicolorful fluorescence of amphiphilic polyethyleneimine polymer dots for efficiently combined imaging and therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Diagnostic Imaging; Drug Carriers; Drug Delivery Systems; Female; Heterografts; Humans; Hydrophobic and Hydrophilic Interactions; Materials Testing; Mice; Molecular Imaging; Neoplasms; Optical Imaging; Paclitaxel; Polyesters; Polyethyleneimine; Polymers; Surface-Active Agents; Tumor Burden | 2013 |
The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug Monitoring; Female; Mass Spectrometry; Mice; Microscopy; Neoplasms; Paclitaxel; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution; Tumor Burden | 2013 |
Supramolecular self-assembly forming a multifunctional synergistic system for targeted co-delivery of gene and drug.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DNA; Drug Delivery Systems; Endocytosis; Folic Acid; gamma-Cyclodextrins; Genetic Therapy; Humans; Models, Molecular; Neoplasms; Paclitaxel; Transfection; Tumor Suppressor Protein p53 | 2014 |
(18)F-alfatide II and (18)F-FDG dual-tracer dynamic PET for parametric, early prediction of tumor response to therapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Doxorubicin; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Neoplasms; Oligopeptides; Paclitaxel; Peptides, Cyclic; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors | 2014 |
Effect of coumarin derivative-mediated inhibition of P-glycoprotein on oral bioavailability and therapeutic efficacy of paclitaxel.
Topics: Administration, Oral; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cell Line, Tumor; Cell Survival; Coumarins; Daunorubicin; Humans; Male; Mice; Mice, Nude; Neoplasms; Paclitaxel; Rats; Rats, Sprague-Dawley; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Medium chain triglyceride (MCT) rich, paclitaxel loaded self nanoemulsifying preconcentrate (PSNP): a safe and efficacious alternative to Taxol.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Emulsifying Agents; Guinea Pigs; Humans; Mice; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Polymerization; Rats; Rats, Sprague-Dawley; Triglycerides; Xenograft Model Antitumor Assays | 2013 |
Combinations of TLR ligands: a promising approach in cancer immunotherapy.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Imidazoles; Immunomodulation; Immunotherapy; Ligands; Lymphocytes; Mice; Neoplasms; Paclitaxel; Poly I-C; Toll-Like Receptors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Folic Acid; HeLa Cells; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Nude; Neoplasms; Neoplasms, Experimental; Paclitaxel; Taxoids; Topotecan; Treatment Outcome; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2014 |
Novel thermo-sensitive hydrogel system with paclitaxel nanocrystals: High drug-loading, sustained drug release and extended local retention guaranteeing better efficacy and lower toxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Delayed-Action Preparations; Female; Humans; Hydrogels; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanoparticles; Neoplasms; Paclitaxel; Temperature; Treatment Outcome; Tumor Burden | 2014 |
Self-assembled hybrid nanoparticles for targeted co-delivery of two drugs into cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems; Humans; Lactic Acid; Nanoparticles; Neoplasms; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2014 |
Honokiol enhances paclitaxel efficacy in multi-drug resistant human cancer model through the induction of apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Ki-67 Antigen; Lignans; Mitochondria; Neoplasms; Paclitaxel; Receptors, Death Domain; Signal Transduction; STAT3 Transcription Factor | 2014 |
Enhanced antitumor efficacy by d-glucosamine-functionalized and paclitaxel-loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) polymer nanoparticles.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dioxanes; Drug Delivery Systems; Emulsions; Endocytosis; Glucosamine; Glucose Transport Proteins, Facilitative; Male; Mice; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Polyethylene Glycols; Polymers; Rats; Rats, Sprague-Dawley; Solvents | 2014 |
[Cancer, pain and treatment].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Humans; Neoplasms; Paclitaxel; Pain; Pain Management; Paraneoplastic Polyneuropathy; Peripheral Nervous System Diseases | 2014 |
Human mesenchymal stromal cells primed with paclitaxel, apart from displaying anti-tumor activity, maintain their immune regulatory functions in vitro.
Topics: Animals; Antineoplastic Agents; Humans; Mesenchymal Stem Cells; Neoplasms; Paclitaxel | 2014 |
A cell-based pharmacokinetics assay for evaluating tubulin-binding drugs.
Topics: Albumin-Bound Paclitaxel; Albumins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Evaluation; Drug Resistance, Neoplasm; Humans; Microtubules; Neoplasms; Paclitaxel; Polyglutamic Acid; Tubulin | 2014 |
Translymphatic chemotherapy targeting sentinel lymph nodes using a novel phospholipid polymer-Paclitaxel conjugate.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Inhibitory Concentration 50; Lymph Nodes; Lymphatic Metastasis; Male; Methacrylates; Neoplasms; Paclitaxel; Phosphorylcholine; Rats; Sentinel Lymph Node Biopsy | 2014 |
Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers; Cell Line, Tumor; DNA Damage; Fluorescent Antibody Technique; Humans; Microtubules; Mitosis; Neoplasms; Paclitaxel; RNA Interference; Single-Cell Analysis; Spindle Apparatus; Time-Lapse Imaging | 2014 |
Introduction: why a supplement on taxanes?
Topics: Antineoplastic Agents; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 2014 |
Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.
Topics: Adult; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
Biodistribution and pharmacokinetics in rats and antitumor effect in various types of tumor-bearing mice of novel self-assembled gelatin-oleic acid nanoparticles containing paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Drug Carriers; Drug Evaluation, Preclinical; Female; Gelatin; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Oleic Acid; Paclitaxel; Polymerization; Rats; Rats, Sprague-Dawley; Tissue Distribution; Tumor Cells, Cultured | 2014 |
Nanoparticle albumin-bound paclitaxel (nab-paclitaxel): extending its indications.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Neurotoxicity Syndromes; Paclitaxel | 2014 |
Rapid assessment of drug response in cancer cells using microwell array and molecular imaging.
Topics: 4-Chloro-7-nitrobenzofurazan; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Monitoring; Glucosamine; Humans; Molecular Imaging; Neoplasms; Paclitaxel; Tissue Array Analysis | 2014 |
Poly-cyclodextrin and poly-paclitaxel nano-assembly for anticancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cellulose; Cyclodextrins; Drug Carriers; Female; HeLa Cells; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Dynamics Simulation; Nanoparticles; Neoplasm Transplantation; Neoplasms; Paclitaxel; Polymers; Transplantation, Heterologous | 2014 |
Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy.
Topics: Adult; Antineoplastic Agents; Brazil; Cross-Sectional Studies; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Psychometrics; Severity of Illness Index; Surveys and Questionnaires; Taxoids | 2014 |
Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages--strategies for data mining in support of therapeutic studies.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Cluster Analysis; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Receptor Protein-Tyrosine Kinases; Receptors, Prostaglandin E, EP2 Subtype; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2014 |
B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; CHO Cells; Cricetulus; Female; Humans; Lymphocytes, Tumor-Infiltrating; Macrophages; Mice; Mice, Transgenic; Neoplasms; Organoplatinum Compounds; Paclitaxel; Phenotype; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
A synthetic manassantin a derivative inhibits hypoxia-inducible factor 1 and tumor growth.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lignans; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Transcription, Genetic; Xenograft Model Antitumor Assays | 2014 |
Amphiphilic carboxymethyl chitosan-quercetin conjugate with P-gp inhibitory properties for oral delivery of paclitaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Chitosan; Delayed-Action Preparations; Hep G2 Cells; Humans; Intestinal Absorption; Male; Mice; Micelles; Neoplasms; Paclitaxel; Quercetin; Rats; Rats, Sprague-Dawley; Solubility | 2014 |
Cytotoxic enhancement of hexapeptide-conjugated micelles in EGFR high-expressed cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Doxorubicin; Drug Carriers; ErbB Receptors; Humans; Lactic Acid; Micelles; Neoplasms; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2014 |
A novel approach to overcome multidrug resistance: utilization of P-gp mediated efflux of paclitaxel to attack neighboring vascular endothelial cells in tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Liposomes; Male; Mice, Inbred BALB C; Neoplasms; Paclitaxel; Polyethylene Glycols; Tumor Burden | 2014 |
Theranostic nanoemulsions: codelivery of hydrophobic drug and hydrophilic imaging probe for cancer therapy and imaging.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interactions; Mice, Nude; Nanomedicine; Neoplasms; Paclitaxel; Rhodamines; Vitamin E | 2014 |
Blocking anaplerotic entry of glutamine into the TCA cycle sensitizes K-Ras mutant cancer cells to cytotoxic drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Capecitabine; Cell Cycle Checkpoints; Cell Line, Tumor; Citric Acid Cycle; Cytotoxins; Deoxycytidine; Fluorouracil; Glutamine; Humans; Mutation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2015 |
Threaded macromolecules as a versatile framework for biomaterials.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cyclodextrins; Drug Carriers; Hydrogels; Macromolecular Substances; Mice; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols; Rotaxanes | 2014 |
Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Drug Delivery Systems; Exosomes; Humans; Mesenchymal Stem Cells; Mice; Neoplasms; Paclitaxel | 2014 |
Size-controlled biodegradable nanoparticles: preparation and size-dependent cellular uptake and tumor cell growth inhibition.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cell Division; Cell Line; Humans; Lactic Acid; Mice; Microscopy, Electron, Scanning; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2014 |
Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics.
Topics: Docetaxel; Doxorubicin; Epirubicin; Female; Humans; Neoplasms; Paclitaxel; Pregnancy; Taxoids | 2014 |
Enzymatic tumour tissue digestion coupled to SPE-UPLC-Tandem Mass Spectrometry as a tool to explore paclitaxel tumour penetration.
Topics: Animals; Antineoplastic Agents, Phytogenic; Calibration; Cattle; Chemistry, Pharmaceutical; Chromatography, Liquid; Humans; Microscopy, Fluorescence; Muscles; Neoplasm Transplantation; Neoplasms; Paclitaxel; Rats; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry | 2014 |
Prion-like nanofibrils of small molecules (PriSM) selectively inhibit cancer cells by impeding cytoskeleton dynamics.
Topics: Antineoplastic Agents; Apoptosis; Cytoskeleton; Endocytosis; Glioblastoma; HeLa Cells; Hep G2 Cells; Humans; MCF-7 Cells; Nanoparticles; Nanotechnology; Neoplasm Transplantation; Neoplasms; Nocodazole; Paclitaxel; Peptides; Prions; Protein Structure, Tertiary; tau Proteins; Tubulin | 2014 |
Sequencing of Charcot-Marie-Tooth disease genes in a toxic polyneuropathy.
Topics: Alleles; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Charcot-Marie-Tooth Disease; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Paclitaxel; Polyneuropathies; Prospective Studies; Rho Guanine Nucleotide Exchange Factors | 2014 |
Comparison of active, passive and magnetic targeting to tumors of multifunctional paclitaxel/SPIO-loaded nanoparticles for tumor imaging and therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Ferric Compounds; Lactic Acid; Magnetic Resonance Imaging; Magnetics; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Neoplasms; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Dendrimer-stabilized smart-nanoparticle (DSSN) platform for targeted delivery of hydrophobic antitumor therapeutics.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Chemistry, Pharmaceutical; Dendrimers; Dose-Response Relationship, Drug; Drug Carriers; Drug Stability; Hemolysis; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Inhibitory Concentration 50; Jurkat Cells; Kinetics; MCF-7 Cells; Microtubules; Nanoparticles; Nanotechnology; Neoplasms; Paclitaxel; Particle Size; Solubility; Surface Properties; Technology, Pharmaceutical; Tubulin Modulators | 2015 |
How Taxol/paclitaxel kills cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Cycle Checkpoints; Humans; Neoplasms; Paclitaxel | 2014 |
Paclitaxel loaded hyaluronic acid nanoparticles for targeted cancer therapy: in vitro and in vivo analysis.
Topics: Animals; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Humans; Hyaluronan Receptors; Hyaluronic Acid; Mice; Micelles; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Paclitaxel | 2015 |
Identification of 14-3-3β gene as a novel miR-152 target using a proteome-based approach.
Topics: 14-3-3 Proteins; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; HEK293 Cells; HLA-C Antigens; HLA-G Antigens; Humans; Mass Spectrometry; MicroRNAs; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Proteome; Proteomics; T-Lymphocytes | 2014 |
Low-dose paclitaxel improves the therapeutic efficacy of recombinant adenovirus encoding CCL21 chemokine against murine cancer.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chemokine CCL21; Cytokines; Cytotoxicity, Immunologic; Disease Models, Animal; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Melanoma, Experimental; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; Tumor Burden | 2014 |
Paclitaxel-loaded PEG-PE-based micellar nanopreparations targeted with tumor-specific landscape phage fusion protein enhance apoptosis and efficiently reduce tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Delivery Systems; Female; Humans; Mice; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Phosphatidylethanolamines; Polyethylene Glycols; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Mice; Models, Biological; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Transplantation, Heterologous | 2014 |
Chemosensitization of solid tumors by inhibition of Bcl-xL expression using DNAzyme.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Line, Tumor; Cell Survival; DNA, Catalytic; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2014 |
Lanreotide-conjugated PEG-DSPE micelles: an efficient nanocarrier targeting to somatostatin receptor positive tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cricetinae; Drug Carriers; Endocytosis; Fluorescent Dyes; Humans; Male; Micelles; Neoplasms; Paclitaxel; Peptides, Cyclic; Phosphatidylethanolamines; Polyethylene Glycols; Rats; Receptors, Somatostatin; Somatostatin; Spectrometry, Fluorescence; Xenograft Model Antitumor Assays | 2015 |
Extravascular red blood cells and hemoglobin promote tumor growth and therapeutic resistance as endogenous danger signals.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Erythrocytes; Hemoglobins; Hemorrhage; Inflammation; Interleukin-1beta; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Neovascularization, Pathologic; Oxidative Stress; Paclitaxel; Reactive Oxygen Species; Transcription Factor RelA; Tumor Microenvironment | 2015 |
Simultaneous delivery of therapeutic antagomirs with paclitaxel for the management of metastatic tumors by a pH-responsive anti-microbial peptide-mediated liposomal delivery system.
Topics: Animals; Antimicrobial Cationic Peptides; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Erythrocytes; Gene Silencing; Hemolysis; Hydrogen-Ion Concentration; Liposomes; Mice, Inbred BALB C; MicroRNAs; Neoplasms; Paclitaxel; Rats; Tissue Distribution; Tumor Burden; Wound Healing | 2015 |
Ultrasound contrast-enhanced imaging and in vitro antitumor effect of paclitaxel-poly(lactic-co-glycolic acid)-monomethoxypoly (ethylene glycol) nanocapsules with ultrasound-targeted microbubble destruction.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Contrast Media; Drug Carriers; Drug Delivery Systems; Flow Cytometry; Humans; Lactic Acid; Mice; Microbubbles; Microscopy, Fluorescence; Nanocapsules; Neoplasms; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Ultrasonography | 2015 |
Tumor-Targeting Multifunctional Rattle-Type Theranostic Nanoparticles for MRI/NIRF Bimodal Imaging and Delivery of Hydrophobic Drugs.
Topics: Animals; Carbocyanines; Cell Survival; Drug Carriers; Drug Delivery Systems; Ferric Compounds; Fluorescent Dyes; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanoparticles; Neoplasm Transplantation; Neoplasms; Paclitaxel; Phantoms, Imaging; Spectroscopy, Near-Infrared; Theranostic Nanomedicine; Transferrin | 2015 |
Preparation, pharmacokinetics, biodistribution, antitumor efficacy and safety of Lx2-32c-containing liposome.
Topics: Animals; Antineoplastic Agents; Liposomes; Male; Mice, Inbred C57BL; Neoplasms; Paclitaxel; Rats, Sprague-Dawley | 2014 |
Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody.
Topics: Amino Acid Chloromethyl Ketones; Animals; Carbocyanines; Cells, Cultured; Factor VIIa; Heterografts; Humans; Mice; Neoplasms; Optical Imaging; Paclitaxel; Thromboplastin | 2015 |
Port-a-Cath extravasation of vesicant cytotoxics: surgical options for a rare complication of cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Body Mass Index; Cisplatin; Device Removal; Dioxoles; Epirubicin; Equipment Failure; Extravasation of Diagnostic and Therapeutic Materials; Female; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Risk Factors; Surgical Flaps; Tetrahydroisoquinolines; Therapeutic Irrigation; Trabectedin; Vascular Access Devices; Young Adult | 2015 |
Shell-crosslinked hybrid nanoparticles for direct cytosolic delivery for tumor therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Line, Tumor; Cell Survival; Cytosol; Drug Carriers; Drug Liberation; Drug Stability; HeLa Cells; Humans; Lactoglobulins; Lecithins; Mice; Nanoparticles; Neoplasms; Paclitaxel; Tumor Burden | 2015 |
Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Genotype; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Genetic; tau Proteins | 2014 |
Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Topics: Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Movement; Cell Survival; Collagen; Coumarins; Drug Combinations; Drug Delivery Systems; Endocytosis; Female; Human Umbilical Vein Endothelial Cells; Humans; Intracellular Signaling Peptides and Proteins; Laminin; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Molecular Sequence Data; Nanomedicine; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Peptides; Proteoglycans; Rats, Sprague-Dawley; Subcutaneous Tissue; Thiazoles; Xenograft Model Antitumor Assays | 2015 |
Cancer cells mimic in vivo spatial-temporal cell-cycle phase distribution and chemosensitivity in 3-dimensional Gelfoam® histoculture but not 2-dimensional culture as visualized with real-time FUCCI imaging.
Topics: Animals; Cell Culture Techniques; Cell Cycle; Cell Death; Cell Line, Tumor; Cisplatin; Computer Systems; Female; Fluorescence; Gelatin Sponge, Absorbable; Humans; Mice, Nude; Molecular Imaging; Neoplasms; Paclitaxel; Time Factors; Ubiquitination | 2015 |
Paclitaxel-loaded micelles enhance transvascular permeability and retention of nanomedicines in tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Female; Liposomes; Male; Mice; Mice, Inbred BALB C; Micelles; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel; Permeability; Polymers; Time Factors; Tumor Microenvironment | 2015 |
Magnetoresponsive virus-mimetic nanocapsules with dual heat-triggered sequential-infected multiple drug-delivery approach for combinatorial tumor therapy.
Topics: Combined Modality Therapy; Doxorubicin; Drug Delivery Systems; HeLa Cells; Hot Temperature; Humans; Magnetic Phenomena; Nanocapsules; Neoplasms; Organ Specificity; Paclitaxel; Viruses | 2015 |
New thermosensitive nanoparticles prepared by biocompatible pegylated aliphatic polyester block copolymers for local cancer treatment.
Topics: Adipates; Antineoplastic Agents; Biocompatible Materials; Carcinoma; Drug Delivery Systems; Female; Fever; HeLa Cells; Hep G2 Cells; Hepatoblastoma; Hot Temperature; Humans; Liver Neoplasms; Nanocapsules; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Polypropylenes; Uterine Cervical Neoplasms | 2015 |
Programmed co-delivery of paclitaxel and doxorubicin boosted by camouflaging with erythrocyte membrane.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Chitosan; Doxorubicin; Drug Carriers; Erythrocyte Membrane; Humans; Hydrophobic and Hydrophilic Interactions; Magnetic Fields; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Oligopeptides; Paclitaxel; Polyethylene Glycols; Survival Rate; Tissue Distribution | 2015 |
Altered expression of platelet factor 4 and basic fibroblast growth factor correlates with the inhibition of tumor growth in mice.
Topics: Animals; Antibodies; Cell Line; Cell Movement; Cell Proliferation; Female; Fibroblast Growth Factor 2; Mice, Inbred C57BL; Neoplasms; Paclitaxel; Platelet Factor 4 | 2015 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
Checkpoint blockade immunotherapy for cancer comes of age.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Checkpoints; Clinical Trials as Topic; CTLA-4 Antigen; Humans; Immunotherapy; Ipilimumab; Molecular Targeted Therapy; Neoplasms; Nivolumab; Paclitaxel | 2015 |
Polymeric micelles and nanoemulsions as tumor-targeted drug carriers: Insight through intravital imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; Mice, Nude; Micelles; Microscopy; Nanoparticles; Neoplasms; Optical Imaging; Paclitaxel; Polymers | 2015 |
Somatostatin receptor-mediated specific delivery of paclitaxel prodrugs for efficient cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasms; Octreotide; Paclitaxel; Polyethylene Glycols; Prodrugs; Receptors, Somatostatin | 2015 |
Codelivery of paclitaxel and small interfering RNA by octadecyl quaternized carboxymethyl chitosan-modified cationic liposome for combined cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cations; Chitosan; Drug Carriers; Liposomes; Microscopy, Atomic Force; Microscopy, Electron, Transmission; Neoplasms; Paclitaxel; RNA, Small Interfering; Spectroscopy, Fourier Transform Infrared | 2015 |
In vitro and in vivo evaluation of APRPG-modified angiogenic vessel targeting micelles for anticancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Line; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Humans; Male; Mice; Micelles; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Polyethylene Glycols; Polyglactin 910; Tissue Distribution; Tumor Burden | 2015 |
Reversible lysine modification on proteins by using functionalized boronic acids.
Topics: Alkynes; Animals; Antineoplastic Agents, Phytogenic; Azides; Boronic Acids; Cell Line; Cell Line, Tumor; Folic Acid; Humans; Imines; Insulin; Lysine; Models, Molecular; Muramidase; Neoplasms; Paclitaxel; Polyethylene Glycols; Proteins | 2015 |
QnAs with Patrick Moore.
Topics: Cell Division; Herpesvirus 8, Human; Humans; Merkel cell polyomavirus; Mitosis; Neoplasms; Nocodazole; Oncogene Proteins; Oncogenic Viruses; Paclitaxel | 2015 |
Phase-change material filled hollow magnetic nanoparticles for cancer therapy and dual modal bioimaging.
Topics: Animals; Antineoplastic Agents; Cell Survival; Doxorubicin; Drug Carriers; Female; Hep G2 Cells; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, Nude; Microscopy, Atomic Force; Microscopy, Confocal; Neoplasms; Paclitaxel; Radiography; Survival Rate; Tissue Distribution; Transplantation, Heterologous | 2015 |
Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; MCF-7 Cells; MicroRNAs; Mutation; Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Ribonucleoside Diphosphate Reductase; Signal Transduction; Transfection; Tubulin | 2015 |
Drug delivery with nanospherical supramolecular cell penetrating peptide-taxol conjugates containing a high drug loading.
Topics: Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Cell-Penetrating Peptides; Drug Carriers; Hep G2 Cells; Humans; Molecular Sequence Data; Nanostructures; Neoplasms; Paclitaxel | 2015 |
Cancer cell surface induced peptide folding allows intracellular translocation of drug.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Humans; Mice, Nude; Neoplasms; Paclitaxel; Peptides; Protein Folding; Serum; Solubility | 2015 |
MRI-visible liposome nanovehicles for potential tumor-targeted delivery of multimodal therapies.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Contrast Media; Drug Carriers; Fluorescent Dyes; Heterocyclic Compounds; Humans; Liposomes; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Confocal; Nanostructures; Neoplasms; Oligopeptides; Organometallic Compounds; Paclitaxel; Polyethylene Glycols; Radiography; Transplantation, Heterologous | 2015 |
[Study of bioavailability of paclitaxel after sublingual administration].
Topics: Administration, Sublingual; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Chemistry, Pharmaceutical; Humans; Mice; Neoplasms; Paclitaxel | 2015 |
Ecdysteroids sensitize MDR and non-MDR cancer cell lines to doxorubicin, paclitaxel, and vincristine but tend to protect them from cisplatin.
Topics: Animals; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Ecdysteroids; Humans; MCF-7 Cells; Mice; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2015 |
Cancer Associated Fibroblast-Derived Hepatocyte Growth Factor Inhibits the Paclitaxel-Induced Apoptosis of Lung Cancer A549 Cells by Up-Regulating the PI3K/Akt and GRP78 Signaling on a Microfluidic Platform.
Topics: Animals; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Fibroblast Growth Factors; Fibroblasts; Heat-Shock Proteins; Humans; Microfluidics; Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Intracellular Self-Assembly of Taxol Nanoparticles for Overcoming Multidrug Resistance.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Benzothiazoles; Drug Resistance, Multiple; Drug Resistance, Neoplasm; HCT116 Cells; Humans; Mice, Nude; Nanoparticles; Neoplasms; Nitriles; Paclitaxel | 2015 |
Innovative use of the taxol binding peptide overcomes key challenges of stable and high drug loading in polymeric nanomicelles.
Topics: Amino Acid Sequence; Antineoplastic Agents; Binding Sites; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Humans; Micelles; Molecular Sequence Data; Neoplasms; Paclitaxel; Peptides; Polyethylene Glycols; Taxoids | 2015 |
Improved antitumor effect of paclitaxel administered in vivo as pH and glutathione-sensitive nanohydrogels.
Topics: Animals; Antineoplastic Agents, Phytogenic; Catalase; Female; Glutathione; Glutathione Disulfide; HeLa Cells; Humans; Hydrogels; Hydrogen-Ion Concentration; Kidney; Liver; Mice, Nude; Nanostructures; Neoplasms; Paclitaxel; Spleen; Superoxide Dismutase; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Disulfides; Drug Carriers; Erythrocytes; Hemolysis; Humans; Hydrolysis; Mice; Mice, Inbred BALB C; Mice, Nude; Nanostructures; Neoplasms; Paclitaxel; Particle Size; Polyethylene Glycols; Prodrugs; Tissue Distribution; Vitamin E | 2015 |
MYC Is a Major Determinant of Mitotic Cell Fate.
Topics: Animals; Antimitotic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Early Growth Response Protein 1; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mitochondrial Membrane Transport Proteins; Mitosis; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc | 2015 |
Matrices of a hydrophobically functionalized hyaluronic acid derivative for the locoregional tumour treatment.
Topics: Animals; Biocompatible Materials; Body Weight; Cell Death; HCT116 Cells; Humans; Hyaluronic Acid; Hydrolysis; Hydrophobic and Hydrophilic Interactions; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasms; Osmolar Concentration; Paclitaxel; Subcutaneous Tissue; Xenograft Model Antitumor Assays | 2015 |
Reversion of multidrug resistance by a pH-responsive cyclodextrin-derived nanomedicine in drug resistant cancer cells.
Topics: Acetylation; Adenosine Triphosphatases; alpha-Cyclodextrins; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cytoskeleton; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endocytosis; Energy Metabolism; Humans; Hydrogen-Ion Concentration; Membrane Potential, Mitochondrial; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel; Rhodamine 123 | 2015 |
A novel mitosis-associated lncRNA, MA-linc1, is required for cell cycle progression and sensitizes cancer cells to Paclitaxel.
Topics: Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Chromatin Immunoprecipitation; DNA-Binding Proteins; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Mitosis; Neoplasms; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Long Noncoding; RNA, Small Interfering; Transcription Factors; Transfection | 2015 |
Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Arginine; Cell Line, Tumor; Cell Survival; Chemical Phenomena; Drug Carriers; Female; Fluorescein-5-isothiocyanate; Folic Acid; Glutamic Acid; HEK293 Cells; Humans; Lethal Dose 50; Male; Mice; Mice, Nude; Molecular Weight; Neoplasms; Paclitaxel; Prodrugs; Solubility; Toxicity Tests, Acute; Xenograft Model Antitumor Assays | 2015 |
Targeted Mesoporous Iron Oxide Nanoparticles-Encapsulated Perfluorohexane and a Hydrophobic Drug for Deep Tumor Penetration and Therapy.
Topics: Antineoplastic Agents; Ferric Compounds; Fluorocarbons; Magnetics; Nanoparticles; Neoplasms; Paclitaxel; Temperature | 2015 |
Reversal of multidrug resistance by co-delivery of paclitaxel and lonidamine using a TPGS and hyaluronic acid dual-functionalized liposome for cancer treatment.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Hyaluronic Acid; Indazoles; Lipids; Liposomes; Male; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasms; Paclitaxel; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Vitamin E | 2015 |
Multifunctional theranostic contrast agent for photoacoustics- and ultrasound-based tumor diagnosis and ultrasound-stimulated local tumor therapy.
Topics: Acoustics; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Contrast Media; Female; Humans; Lasers; Mice, Inbred BALB C; Microbubbles; Nanoparticles; Neoplasms; Paclitaxel; Porphyrins; Serum Albumin; Theranostic Nanomedicine; Tumor Burden | 2015 |
Development of a validated LC-APCI-MS/MS method to study the plasma and tumor distribution of CHO-PTX intravenous lipid emulsion.
Topics: Animals; Atmospheric Pressure; Cholesterol; Chromatography, Liquid; Fat Emulsions, Intravenous; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Reproducibility of Results; Tandem Mass Spectrometry | 2016 |
Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Female; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Mice; Neoplasms; Paclitaxel; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Xenograft Model Antitumor Assays | 2016 |
Anti-Proliferative Effects of Hesa-A on Human Cancer Cells with Different Metastatic Potential.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Plant Preparations; Prostatic Neoplasms | 2015 |
Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Mice, Nude; Neoplasm Proteins; Neoplasms; Paclitaxel; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sulfones; Time Factors; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Thermosensitive Hydrogel System With Paclitaxel Liposomes Used in Localized Drug Delivery System for In Situ Treatment of Tumor: Better Antitumor Efficacy and Lower Toxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Delivery Systems; Drug Stability; Humans; Hydrogels; Liposomes; Male; Mice; Neoplasms; Paclitaxel; Particle Size; Sarcoma 180; Xenograft Model Antitumor Assays | 2016 |
Nanocomposite hydrogel incorporating gold nanorods and paclitaxel-loaded chitosan micelles for combination photothermal-chemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitosan; Combined Modality Therapy; Drug Carriers; Drug Stability; Gold; Hydrogels; Hyperthermia, Induced; Injections, Intralesional; Laser Therapy; Male; Mice; Micelles; Nanocomposites; Nanotubes; Neoplasms; Paclitaxel; Phototherapy; Xenograft Model Antitumor Assays | 2016 |
Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.
Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Diploidy; HCT116 Cells; Humans; Immunoblotting; M Phase Cell Cycle Checkpoints; Microscopy, Fluorescence; Mitosis; Morpholines; Neoplasms; Nocodazole; Paclitaxel; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Purines; RNA Interference; Tetraploidy; Time-Lapse Imaging; Tubulin Modulators | 2016 |
PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug.
Topics: Antineoplastic Agents; Dactinomycin; Daunorubicin; Doxorubicin; Fluorouracil; Gene Knockdown Techniques; HeLa Cells; Homeodomain Proteins; Humans; Neoplasms; Paclitaxel; Reactive Oxygen Species; Vinblastine; Vitamin K 3 | 2015 |
Altered Cell Cycle Arrest by Multifunctional Drug-Loaded Enzymatically-Triggered Nanoparticles.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Humans; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel | 2016 |
Biological evaluation of PEG modified nanosuspensions based on human serum albumin for tumor targeted delivery of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Erythrocytes; Hemolysis; Humans; Lethal Dose 50; Mice; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols; Rabbits; Serum Albumin; Suspensions; Tissue Distribution; Treatment Outcome | 2016 |
Two-Step Delivery: Exploiting the Partition Coefficient Concept to Increase Intratumoral Paclitaxel Concentrations In vivo Using Responsive Nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Female; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Mesothelioma; Mice; Nanoparticles; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2016 |
Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol.
Topics: Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Fluorouracil; Humans; Magnetic Field Therapy; Magnetic Fields; Mitosis; Neoplasms; Paclitaxel | 2016 |
Dual-functionalized liposomal delivery system for solid tumors based on RGD and a pH-responsive antimicrobial peptide.
Topics: Animals; Antimicrobial Cationic Peptides; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Humans; Hydrogen-Ion Concentration; Integrin alphaVbeta3; Liposomes; MCF-7 Cells; Mice; Mice, Inbred BALB C; Microscopy, Confocal; Neoplasms; Oligopeptides; Paclitaxel; Particle Size; Polyethylene Glycols; Tissue Distribution; Transplantation, Heterologous; Tumor Microenvironment | 2016 |
Profilin potentiates chemotherapeutic agents mediated cell death via suppression of NF-κB and upregulation of p53.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Doxorubicin; Enzyme Activation; HCT116 Cells; Humans; Neoplasms; NF-KappaB Inhibitor alpha; Paclitaxel; Poly(ADP-ribose) Polymerases; Profilins; Proto-Oncogene Proteins c-mdm2; RNA Interference; RNA, Small Interfering; Transcription Factor RelA; Transcriptional Activation; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation; Vinblastine | 2016 |
Imaging-guided photoacoustic drug release and synergistic chemo-photoacoustic therapy with paclitaxel-containing nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Female; Fluorocarbons; Folic Acid; Gold; HeLa Cells; Humans; Low-Level Light Therapy; Mice; Mice, Inbred BALB C; Nanoparticles; Nanotubes; Neoplasms; NIH 3T3 Cells; Paclitaxel; Photoacoustic Techniques; Volatilization | 2016 |
Enhanced Antitumor Activity of EGFP-EGF1-Conjugated Nanoparticles by a Multitargeting Strategy.
Topics: A549 Cells; Animals; Apoptosis; Cancer-Associated Fibroblasts; Drug Delivery Systems; Green Fluorescent Proteins; Humans; Macrophages; Mice; Mitochondrial Proteins; Nanoparticles; Neoplasms; Oncogene Proteins, Fusion; Paclitaxel; Peptide Elongation Factor G; Protein Binding; Stromal Cells | 2016 |
Impact of hydrogenation on physicochemical and biomedical properties of pH-sensitive PMAA-b-HTPB-b-PMAA triblock copolymer drug carriers.
Topics: Antineoplastic Agents, Phytogenic; Butadienes; Cell Line, Tumor; Delayed-Action Preparations; Drug Carriers; Elastomers; Humans; Hydrogen-Ion Concentration; Hydrogenation; Micelles; Neoplasms; Paclitaxel; Polymethacrylic Acids | 2016 |
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel.
Topics: Breast Neoplasms; Chromosome Segregation; Female; HCT116 Cells; HeLa Cells; Humans; M Phase Cell Cycle Checkpoints; Mad2 Proteins; MicroRNAs; Mitosis; Neoplasms; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Transfection | 2016 |
Paclitaxel-loaded phosphonated calixarene nanovesicles as a modular drug delivery platform.
Topics: A549 Cells; Antineoplastic Agents; Calixarenes; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Folic Acid; Humans; Hydrogen-Ion Concentration; Nanostructures; Neoplasms; Paclitaxel | 2016 |
Reporter nanoparticle that monitors its anticancer efficacy in real time.
Topics: Animals; Antineoplastic Agents; Apoptosis; B7-H1 Antigen; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Monitoring; Drug Resistance, Neoplasm; Esterases; Female; Fluorescent Dyes; Humans; Immunoglobulin G; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Microscopy, Fluorescence; Monitoring, Immunologic; Nanoparticles; Neoplasms; Oligopeptides; Paclitaxel; Polymers; Treatment Outcome; Tumor Burden | 2016 |
Tangeretin, a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function.
Topics: A549 Cells; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Caco-2 Cells; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flavones; G2 Phase Cell Cycle Checkpoints; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Neoplasms; Paclitaxel; Protein Binding; Protein Conformation; Structure-Activity Relationship; Taxoids; Time Factors | 2016 |
Self-Assembly of Porphyrin-Paclitaxel Conjugates Into Nanomedicines: Enhanced Cytotoxicity due to Endosomal Escape.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Endocytosis; Endosomes; HeLa Cells; Hep G2 Cells; Humans; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel; Porphyrins | 2016 |
Fibrin degradation by rtPA enhances the delivery of nanotherapeutics to A549 tumors in nude mice.
Topics: A549 Cells; Animals; Drug Delivery Systems; Fibrin; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Proteolysis; Recombinant Proteins; Tissue Plasminogen Activator; Tumor Microenvironment | 2016 |
Improving paclitaxel pharmacokinetics by using tumor-specific mesoporous silica nanoparticles with intraperitoneal delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Carriers; Humans; Mice; Nanoparticles; Neoplasms; Paclitaxel; Porosity; Silicon Dioxide | 2016 |
Tumor-specific cell-cycle decoy by Salmonella typhimurium A1-R combined with tumor-selective cell-cycle trap by methioninase overcome tumor intrinsic chemoresistance as visualized by FUCCI imaging.
Topics: Animals; Antineoplastic Agents; Carbon-Sulfur Lyases; Cell Cycle; Cisplatin; Drug Resistance, Neoplasm; Fluorescence; G2 Phase; HeLa Cells; Humans; Imaging, Three-Dimensional; Mice, Nude; Neoplasms; Paclitaxel; Recombinant Proteins; S Phase; Salmonella typhimurium; Ubiquitination | 2016 |
Filomicelles from aromatic diblock copolymers increase paclitaxel-induced tumor cell death and aneuploidy compared with aliphatic copolymers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Death; Cell Line, Tumor; Cell Survival; Drug Carriers; Humans; Hydrocarbons, Aromatic; Hydrophobic and Hydrophilic Interactions; Mice, SCID; Micelles; Neoplasms; Paclitaxel; Polyethylene Glycols; Polymers | 2016 |
Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Humans; Leucine; Microtubules; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasms; Paclitaxel; Point Mutation; Thermodynamics; Tubulin; Tubulin Modulators | 2016 |
Green design "bioinspired disassembly-reassembly strategy" applied for improved tumor-targeted anticancer drug delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Drug Compounding; Drug Delivery Systems; Erythrocytes; Female; Green Chemistry Technology; Hemolysis; Hep G2 Cells; Humans; Lipids; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Rabbits; Rats, Sprague-Dawley; Tumor Burden | 2016 |
Polaprezinc reduces paclitaxel-induced peripheral neuropathy in rats without affecting anti-tumor activity.
Topics: Analgesics; Animals; Antineoplastic Agents, Phytogenic; Carnosine; Cell Line, Tumor; Cell Survival; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Neoplasms; Organometallic Compounds; Paclitaxel; Peripheral Nervous System Diseases; Rats; Rats, Sprague-Dawley; Tumor Burden; Zinc Compounds | 2016 |
Protein Complexation and pH Dependent Release Using Boronic Acid Containing PEG-Polypeptide Copolymers.
Topics: A549 Cells; Animals; Antineoplastic Agents; Benzoquinones; Boronic Acids; Cell Proliferation; Cell Survival; Clone Cells; Drug Combinations; Female; Hydrogen-Ion Concentration; Immunohistochemistry; Ki-67 Antigen; Lactams, Macrocyclic; Mice, Nude; Micelles; Necrosis; Neoplasms; Paclitaxel; Peptides; Polyesters; Polyethylene Glycols; Polymers; Proteins; Proto-Oncogene Proteins c-akt; Sirolimus | 2017 |
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Topics: Albumins; Animals; Antibodies; Antigen-Presenting Cells; Carcinoma, Pancreatic Ductal; CD40 Antigens; CD8-Positive T-Lymphocytes; Clone Cells; Deoxycytidine; Gemcitabine; Immunity, Innate; Interferon-gamma; Lymphocyte Subsets; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Paclitaxel; Pancreatic Neoplasms; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2016 |
The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Drug Stability; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Phenylpropionates; Prodrugs; Propionates; Rats; Rats, Sprague-Dawley; Tumor Hypoxia; Tumor Microenvironment | 2016 |
Paclitaxel-Loaded TPGS-b-PCL Nanoparticles: In Vitro Cytotoxicity and Cellular Uptake in MCF-7 and MDA-MB-231 Cells versus mPEG-b-PCL Nanoparticles and Abraxane®.
Topics: Albumin-Bound Paclitaxel; Cytotoxins; Female; Humans; MCF-7 Cells; Nanoparticles; Neoplasms; Paclitaxel; Polyesters; Polyethylene Glycols; Vitamin E | 2016 |
Synthetic low-density lipoprotein (sLDL) selectively delivers paclitaxel to tumor with low systemic toxicity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Humans; Lipoproteins, LDL; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplasms; Paclitaxel; Particle Size; Xenograft Model Antitumor Assays | 2016 |
Impact of surfactant treatment of paclitaxel nanocrystals on biodistribution and tumor accumulation in tumor-bearing mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Poloxamer; Polyethylene Glycols; Propylene Glycols; Surface-Active Agents; Tissue Distribution | 2016 |
Influence of Chemotherapy on the Antioxidant Status of Human Skin.
Topics: Adult; Aged; Antineoplastic Agents; Antioxidants; Carotenoids; Docetaxel; Doxorubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Skin; Taxoids | 2016 |
Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel.
Topics: Chalcone; Drug Screening Assays, Antitumor; Humans; MCF-7 Cells; Mitosis; Neoplasms; Paclitaxel; Prenylation; Spindle Apparatus | 2016 |
Paclitaxel pre-medication: A comparison of two steroid pre-medication protocols.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Drug Hypersensitivity; Female; Glucocorticoids; Humans; Middle Aged; Neoplasms; Paclitaxel; Premedication; Retrospective Studies | 2017 |
Well-Defined Polymer-Paclitaxel Prodrugs by a Grafting-from-Drug Approach.
Topics: Cell Line, Tumor; Cell Survival; Humans; Hydrophobic and Hydrophilic Interactions; Neoplasms; Paclitaxel; Polymerization; Polymers; Prodrugs; Solubility | 2016 |
PHB-Based Gels as Delivery Agents of Chemotherapeutics for the Effective Shrinkage of Tumors.
Topics: 3-Hydroxybutyric Acid; Animals; Antineoplastic Agents; Cell Line; Doxorubicin; Drug Carriers; Drug Delivery Systems; Female; Gels; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Polyesters; Polyethylene Glycols; Polymers; Prohibitins; Temperature | 2016 |
Combined Tumor- and Neovascular-"Dual Targeting" Gene/Chemo-Therapy Suppresses Tumor Growth and Angiogenesis.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Mice; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel | 2016 |
Paclitaxel loaded magnetic nanocomposites with folate modified chitosan/carboxymethyl surface; a vehicle for imaging and targeted drug delivery.
Topics: Antineoplastic Agents, Phytogenic; Cell Survival; Chitosan; Drug Delivery Systems; Drug Liberation; Erythrocytes; Ferric Compounds; Folic Acid; Hemolysis; Humans; Magnetic Phenomena; MCF-7 Cells; Nanocomposites; Neoplasms; Nickel; Paclitaxel; Serum Albumin, Bovine | 2016 |
Self-Assembly of Amphiphilic Drug-Dye Conjugates into Nanoparticles for Imaging and Chemotherapy.
Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Cell Survival; Coloring Agents; Coordination Complexes; Humans; MCF-7 Cells; Microscopy, Confocal; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Platinum; Spectrophotometry, Ultraviolet | 2016 |
Evading P-glycoprotein mediated-efflux chemoresistance using Solid Lipid Nanoparticles.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Hyaluronan Receptors; Immunohistochemistry; Lipids; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Protein Binding; Software; Temperature | 2017 |
Structure-activity relationship study of novel 2-aminobenzofuran derivatives as P-glycoprotein inhibitors.
Topics: Amination; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Benzofurans; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Molecular Docking Simulation; Neoplasms; Paclitaxel; Structure-Activity Relationship; Vincristine | 2017 |
Supramolecular cyclodextrin nanocarriers for chemo- and gene therapy towards the effective treatment of drug resistant cancers.
Topics: Animals; Cyclodextrins; Drug Delivery Systems; Drug Resistance, Neoplasm; Folic Acid; Genetic Therapy; HeLa Cells; Hep G2 Cells; Humans; Mice; Molecular Structure; Nanoparticles; Neoplasms; Nuclear Receptor Subfamily 4, Group A, Member 1; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Transfection; Xenograft Model Antitumor Assays | 2016 |
Drug-induced co-assembly of albumin/catalase as smart nano-theranostics for deep intra-tumoral penetration, hypoxia relieve, and synergistic combination therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Catalase; Cell Line, Tumor; Chlorophyllides; Combined Modality Therapy; Female; Hydrogen Peroxide; Hypoxia; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Porphyrins; Radiation-Sensitizing Agents; Serum Albumin; Theranostic Nanomedicine; Tumor Microenvironment | 2017 |
3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chromatography, High Pressure Liquid; Female; Humans; Imaging, Three-Dimensional; Mesothelioma; Metal Nanoparticles; Mice; Mice, Nude; Neoplasms; Paclitaxel; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Titanium; Transplantation, Heterologous | 2016 |
Multifunctional gold-nanoparticles: A nanovectorization tool for the targeted delivery of novel chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cobalt; Coordination Complexes; Drug Carriers; ErbB Receptors; Fibroblasts; Gold; Humans; Male; Metal Nanoparticles; Mice; Mice, Inbred NOD; Mice, SCID; Nanoconjugates; Neoplasms; Paclitaxel; Polyethylene Glycols; Serum Albumin; Tumor Burden | 2017 |
Near-infrared mediated quantum dots and paclitaxel co-loaded nanostructured lipid carriers for cancer theragnostic.
Topics: Animals; Drug Carriers; Drug Delivery Systems; Emulsions; Female; Glycerides; Hep G2 Cells; Humans; Inhibitory Concentration 50; Lipids; Mice; Microscopy, Fluorescence; Nanostructures; Neoplasm Transplantation; Neoplasms; Oleic Acid; Optics and Photonics; Paclitaxel; Particle Size; Phosphatidylcholines; Quantum Dots; Spectroscopy, Near-Infrared; Temperature; Theranostic Nanomedicine | 2017 |
Paclitaxel-Paclitaxel Prodrug Nanoassembly as a Versatile Nanoplatform for Combinational Cancer Therapy.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Humans; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel; Prodrugs | 2016 |
Reply to Barroso-Sousa R et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Granulocyte Colony-Stimulating Factor; Granulocytes; Humans; Neoplasms; Paclitaxel; Retrospective Studies | 2017 |
Fingerprint changes among cancer patients treated with paclitaxel.
Topics: Case-Control Studies; Dermatoglyphics; Humans; Neoplasms; Paclitaxel | 2017 |
Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Female; Heterografts; Humans; Image Processing, Computer-Assisted; Male; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2016 |
Albumin-coated nanocrystals for carrier-free delivery of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line; Cell Line, Tumor; Male; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Paclitaxel; Serum Albumin; Tumor Burden | 2017 |
Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation.
Topics: Adenosine Triphosphate; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell-Derived Microparticles; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Gene Silencing; Glucose; Glycolysis; Humans; Interferon-alpha; Interferons; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-akt; RNA Interference; Secretory Vesicles; Signal Transduction; Taxoids; TNF-Related Apoptosis-Inducing Ligand | 2017 |
Advanced glycation end products (AGE) potentiates cell death in p53 negative cells via upregulaion of NF-kappa B and impairment of autophagy.
Topics: Antineoplastic Agents; Autophagy; Beclin-1; Endosomal Sorting Complexes Required for Transport; Glycation End Products, Advanced; HCT116 Cells; HeLa Cells; Hep G2 Cells; Humans; Nedd4 Ubiquitin Protein Ligases; Neoplasms; NF-kappa B; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Suppressor Protein p53; U937 Cells; Ubiquitin-Protein Ligases; Up-Regulation | 2017 |
Relay Drug Delivery for Amplifying Targeting Signal and Enhancing Anticancer Efficacy.
Topics: Animals; Antineoplastic Agents; Biomimetic Materials; Blood Vessels; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dextrans; Drug Delivery Systems; Human Umbilical Vein Endothelial Cells; Humans; Mice, Nude; Microtubules; Nanostructures; Neoplasm Transplantation; Neoplasms; Oligopeptides; Paclitaxel; Tumor Necrosis Factor-alpha | 2017 |
Thiazole-valine peptidomimetic (TTT-28) antagonizes multidrug resistance in vitro and in vivo by selectively inhibiting the efflux activity of ABCB1.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Heterografts; Humans; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Peptidomimetics; Thiazoles; Treatment Outcome; Valine | 2017 |
Extended pulsated drug release from PLGA-based minirods.
Topics: Antineoplastic Agents; Biocompatible Materials; Delayed-Action Preparations; Diffusion; Drug Carriers; Drug Liberation; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Lactic Acid; Microscopy, Electron, Scanning; Neoplasms; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Prodigiosin; Spectrophotometry, Ultraviolet; Temperature | 2017 |
PCL-based thermo-gelling polymers for in vivo delivery of chemotherapeutics to tumors.
Topics: Animals; Antineoplastic Agents; Chromatography, Gel; Doxorubicin; Drug Carriers; Gels; Hep G2 Cells; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Polyesters; Polyethylene Glycols; Polymers; Propylene Glycols; Spectroscopy, Fourier Transform Infrared; Transplantation, Heterologous | 2017 |
The BTK Inhibitor Ibrutinib (PCI-32765) Overcomes Paclitaxel Resistance in ABCB1- and ABCC10-Overexpressing Cells and Tumors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Male; Mice; Models, Molecular; Molecular Conformation; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Synthesis and Superpotent Anticancer Activity of Tubulysins Carrying Non-hydrolysable N-Substituents on Tubuvaline.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Mice; Microscopy, Fluorescence; Neoplasms; Paclitaxel; Structure-Activity Relationship; Transplantation, Heterologous; Tubulin; Tubulin Modulators; Valine; Vinblastine; Vinorelbine | 2017 |
Biodynamic imaging for phenotypic profiling of three-dimensional tissue culture.
Topics: Antineoplastic Agents, Phytogenic; Cell Culture Techniques; Drug Screening Assays, Antitumor; Holography; Neoplasms; Optical Imaging; Paclitaxel; Phenotype; Spheroids, Cellular; Tissue Culture Techniques | 2017 |
Pharmacogenomics of importance for paclitaxel chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Pharmacogenetics | 2008 |
p19(ras) amplifies p73beta-induced apoptosis through mitochondrial pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cytochromes c; DNA-Binding Proteins; Humans; Membrane Potential, Mitochondrial; Mitochondria; Neoplasms; Nuclear Proteins; Paclitaxel; Protein Transport; Proto-Oncogene Proteins p21(ras); Reactive Oxygen Species; Tumor Protein p73; Tumor Suppressor Proteins | 2008 |
Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin-biotin technology: Formulation development and in vitro anticancer activity.
Topics: Animals; Antineoplastic Agents; Avidin; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Carriers; Glioma; Humans; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Rats; Solubility; Technology, Pharmaceutical; Time Factors; Transferrin | 2008 |
Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
Topics: Animals; Antineoplastic Agents; Carbocyanines; Cell Line, Tumor; Contrast Media; Dendrimers; Diagnostic Imaging; Drug Carriers; Gonadotropin-Releasing Hormone; Humans; Liposomes; Mice; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Polymers; Receptors, LHRH; Xenograft Model Antitumor Assays | 2008 |
Retrospective review of cancer patients > or =80 years old treated with chemotherapy at a comprehensive cancer center.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Carboplatin; Combined Modality Therapy; Female; Gastrointestinal Neoplasms; Genital Neoplasms, Female; Head and Neck Neoplasms; Hematologic Neoplasms; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Thoracic Neoplasms; Treatment Outcome; Urogenital Neoplasms | 2008 |
Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatography, High Pressure Liquid; Colloids; Coumarins; Drug Carriers; Hematologic Neoplasms; Humans; Lactic Acid; Microscopy, Electron, Scanning; Microscopy, Fluorescence; Neoplasms; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2008 |
EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1.
Topics: Antineoplastic Agents; Benzylidene Compounds; Cell Hypoxia; Curcumin; Cytoskeleton; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Epothilones; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Microtubules; Mitosis; Neoplasms; Paclitaxel; Piperidones; Proteasome Endopeptidase Complex; Tumor Cells, Cultured; Von Hippel-Lindau Tumor Suppressor Protein | 2008 |
Inhibition of imatinib transport by uremic toxins during renal failure.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Benzamides; Biological Availability; Biological Transport; Humans; Imatinib Mesylate; Kidney Failure, Chronic; Liver Failure; Neoplasms; Organic Anion Transporters; Paclitaxel; Piperazines; Pyrimidines; Xenopus laevis | 2008 |
Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3.
Topics: Antineoplastic Agents; Caspase 3; Cell Death; Cell Line, Tumor; Doxorubicin; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; MicroRNAs; Neoplasms; Nucleic Acid Conformation; Paclitaxel; Reproducibility of Results; RNA, Messenger | 2008 |
Redefining the target again: chemotherapeutics as vascular disrupting agents?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Chemokine CXCL12; Drug Interactions; Drug Therapy, Combination; Endothelial Cells; Female; Humans; Mice; Neoplasms; Neoplasms, Experimental; Paclitaxel; Stem Cells; Vascular Endothelial Growth Factor A | 2008 |
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Drug Therapy, Combination; Endothelial Cells; Female; Gemcitabine; Humans; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Paclitaxel; Stem Cells; Tumor Burden; Vascular Endothelial Growth Factor A | 2008 |
Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Flow Cytometry; Gene Expression; Mice; Neoplasms; Oligodeoxyribonucleotides; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes, Regulatory; Toll-Like Receptor 9 | 2009 |
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Paclitaxel; Quinazolines; Transfection; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Drug Carriers; Drug Evaluation, Preclinical; Ethylene Oxide; Excipients; Flow Cytometry; Glycerol; HeLa Cells; Humans; Lactic Acid; Lactones; Male; Mice; Mice, Inbred Strains; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Surface-Active Agents; Survival Analysis | 2009 |
Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells.
Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Carcinoma; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Delivery Systems; Endocytosis; Glucose-6-Phosphate Isomerase; HCT116 Cells; HT29 Cells; Humans; Melanoma; Membrane Microdomains; Mice; Neoplasms; Paclitaxel; Receptors, Autocrine Motility Factor; Receptors, Cytokine; Ubiquitin-Protein Ligases | 2008 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
Characterizing heterogeneous cellular responses to perturbations.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Artifacts; Biomarkers, Tumor; Dexamethasone; DNA Replication; Dose-Response Relationship, Drug; Doxorubicin; Genetic Heterogeneity; Glucocorticoids; HeLa Cells; Humans; Hydroxamic Acids; Methotrexate; Microscopy, Fluorescence; Models, Biological; Neoplasms; Paclitaxel; Phenotype; Protein Synthesis Inhibitors; Tubulin Modulators | 2008 |
Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Mice; Neoplasms; Oligopeptides; Paclitaxel; Peptides; Polyethylene Glycols; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tissue Distribution; Triazoles | 2009 |
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Monitoring; Everolimus; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Prognosis; Protein Kinases; Sirolimus; Survival Rate; Tissue Distribution; TOR Serine-Threonine Kinases; Treatment Outcome | 2009 |
Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Collagen Type XI; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mimosine; Mitosis; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2009 |
Chromosomal instability determines taxane response.
Topics: Bridged-Ring Compounds; Cell Survival; Chromosomal Instability; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Microtubules; Neoplasms; Paclitaxel; Polymerase Chain Reaction; Prognosis; Taxoids | 2009 |
Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles.
Topics: Animals; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Drug Delivery Systems; Emulsions; Female; Humans; Mice; Microbubbles; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Phase Transition; Ultrasonics | 2009 |
Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carboxylesterase; Cell Proliferation; Cell Survival; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Dose-Response Relationship, Drug; Female; Genetic Vectors; Green Fluorescent Proteins; HeLa Cells; Herpesvirus 1, Human; Humans; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Prodrugs; Rabbits; Time Factors; Transfection; Vero Cells | 2010 |
Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Binding Sites; Cells, Cultured; DNA-Binding Proteins; Female; Humans; Mice; Mice, Nude; Mitochondria; Models, Molecular; Molecular Mimicry; Neoplasms; Nuclear Receptor Subfamily 4, Group A, Member 1; Paclitaxel; Peptide Fragments; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Receptors, Steroid; Tubulin; Tubulin Modulators | 2009 |
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan | 2010 |
FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Line; Cell Line, Tumor; Cytarabine; Docetaxel; Drug Therapy; Humans; Kidney; Neoplasms; Nuclear Proteins; Paclitaxel; Pancreatic Neoplasms; Phosphoprotein Phosphatases; Proto-Oncogene Proteins c-akt; Tacrolimus Binding Proteins; Taxoids | 2009 |
Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Deoxycytidine; Docetaxel; Fertility; Follicle Stimulating Hormone; Gemcitabine; Humans; Infertility, Male; Inhibins; Luteinizing Hormone; Male; Middle Aged; Neoplasms; Paclitaxel; Spermatogenesis; Taxoids; Testis; Ultrasonography; Young Adult | 2010 |
Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.
Topics: Animals; Antimitotic Agents; Apoptosis; Cdc20 Proteins; Cell Cycle Proteins; Cyclin B; Cyclin B1; Drug Resistance, Neoplasm; Enzyme Inhibitors; Genetic Therapy; HeLa Cells; Humans; Kinesins; Mice; Mitochondrial Membranes; Mitosis; Mutation; Neoplasms; Paclitaxel; Permeability; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Spindle Apparatus; Time Factors; Transfection | 2009 |
An intermittent live cell imaging screen for siRNA enhancers and suppressors of a kinesin-5 inhibitor.
Topics: Genome, Human; Green Fluorescent Proteins; HeLa Cells; Humans; Image Processing, Computer-Assisted; Kinesins; Models, Biological; Models, Statistical; Neoplasms; Nocodazole; Paclitaxel; RNA, Small Interfering; Spindle Apparatus; Time Factors; Tubulin Modulators | 2009 |
Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).
Topics: Antineoplastic Agents; Benzamides; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Models, Chemical; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Piperazines; Pyrimidines; Tetrazolium Salts; Thiazoles | 2009 |
Taxol induces paraptosis independent of both protein synthesis and MAPK pathway.
Topics: Antineoplastic Agents, Phytogenic; bcl-X Protein; Cell Death; Cell Size; Cell Survival; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Fluorescence Resonance Energy Transfer; Fluorescent Antibody Technique; Green Fluorescent Proteins; HeLa Cells; Humans; Luminescent Proteins; MAP Kinase Signaling System; Microscopy, Confocal; Mitochondrial Swelling; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Red Fluorescent Protein; Time Factors; Transfection; Vacuoles | 2010 |
Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.
Topics: Acetates; Animals; Anti-Asthmatic Agents; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Line; Chemotherapy, Adjuvant; Cyclopropanes; Dogs; Drug Resistance, Neoplasm; Drug Resistance, Viral; Fluoresceins; HIV Infections; HIV Protease Inhibitors; Indoles; Leukotriene Antagonists; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Phenylcarbamates; Propionates; Quinolines; Saquinavir; Sulfides; Sulfonamides; Time Factors; Tosyl Compounds | 2009 |
Inhibition of human gastric carcinoma cell growth in vitro and in vivo by cladosporol isolated from the paclitaxel-producing strain Alternaria alternata var. monosporus.
Topics: Alternaria; Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthalenes; Neoplasms; Paclitaxel; Plant Bark; Stomach Neoplasms; Taxus; Transplantation, Heterologous | 2009 |
Paclitaxel in cancer treatment: perspectives and prospects of its delivery challenges.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Neoplasms; Paclitaxel; Pharmaceutic Aids | 2009 |
Anti-HIF-1alpha antibody-conjugated pluronic triblock copolymers encapsulated with Paclitaxel for tumor targeting therapy.
Topics: Antineoplastic Agents, Phytogenic; Biocompatible Materials; Drug Carriers; Drug Delivery Systems; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Materials Testing; Micelles; Molecular Structure; Neoplasms; Paclitaxel; Particle Size; Poloxalene; Polymers | 2010 |
Spontaneous migration of cancer cells under conditions of mechanical confinement.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Humans; Microfluidics; Microscopy, Phase-Contrast; Microtubules; Neoplasms; Nocodazole; Paclitaxel | 2009 |
Paradoxical roles for antioxidants in tumor prevention and eradication.
Topics: Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Humans; Hydroquinones; Neoplasms; Oxidative Stress; Paclitaxel; Xenobiotics | 2010 |
Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.
Topics: Aldehydes; Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cell Movement; Cells, Cultured; Drug Carriers; Drug Delivery Systems; Female; Humans; Lactic Acid; Mice; Mice, Inbred BALB C; Molecular Structure; Nanoparticles; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Particle Size; Peptides; Polyesters; Polyethylene Glycols; Polymers | 2010 |
Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graft-carbon nanotubes for potent cancer therapeutics.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Humans; Nanotubes, Carbon; Neoplasms; Paclitaxel; Polyethylene Glycols | 2010 |
A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Endocytosis; Flow Cytometry; GPI-Linked Proteins; Humans; Kinetics; Membrane Glycoproteins; Mesothelin; Mice; Neoplasms; NIH 3T3 Cells; Paclitaxel; Receptor, ErbB-2 | 2010 |
The promise of paclitaxel-peptide conjugates for MMP-2-targeted drug delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Humans; Matrix Metalloproteinase 2; Neoplasms; Oligopeptides; Paclitaxel; Prodrugs | 2010 |
Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Membrane; Drug Resistance, Neoplasm; Glutathione Transferase; Humans; Immunoblotting; Male; Mice; Mice, Nude; Microscopy, Confocal; Mitochondria; Neoplasms; Paclitaxel; Prohibitins; Proteomics; Repressor Proteins; RNA Interference; Xenograft Model Antitumor Assays | 2010 |
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
Topics: Aged; Alleles; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Female; Genetic Association Studies; Haplotypes; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Paclitaxel; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Spain | 2011 |
LHRH-targeted nanoparticles for cancer therapeutics.
Topics: Acetylation; Animals; Dendrimers; Drug Delivery Systems; Gonadotropin-Releasing Hormone; Mice; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel; Surface Properties; Tissue Distribution; Xenograft Model Antitumor Assays | 2010 |
Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.
Topics: Animals; Antigens, CD; Antigens, Neoplasm; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Differentiation; Cell Line, Tumor; Chemotherapy, Adjuvant; Cyclophosphamide; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Drug Therapy, Combination; Granulocyte-Macrophage Colony-Stimulating Factor; Lymphocyte Activation; Mice; Mice, Transgenic; Neoplasm Transplantation; Neoplasms; Paclitaxel; Receptor, ErbB-2; Signal Transduction; Toll-Like Receptor 4; Tumor Burden | 2010 |
Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Survival; Complement Activation; Female; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Mice, Inbred C57BL; Micelles; Neoplasms; Oxazoles; Paclitaxel; Polymers; Solubility | 2010 |
Regulation of survivin by PI3K/Akt/p70S6K1 pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Chick Embryo; Chromones; Enzyme Inhibitors; Gene Knockdown Techniques; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Morpholines; Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; RNA, Small Interfering; Sirolimus; Survivin | 2010 |
Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.
Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Humans; Lymphocyte Depletion; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; T-Lymphocytes, Regulatory | 2010 |
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capillary Permeability; Doxorubicin; Humans; Liposomes; Mice; Neoplasms; Neuropilin-1; Oligopeptides; Paclitaxel; Permeability; Trastuzumab; Xenograft Model Antitumor Assays | 2010 |
Chemotherapeutic agents targeting the tubulin cytoskeleton modify LPS-induced cytokine secretion by dendritic cells and increase antigen presentation.
Topics: Antigen Presentation; Antineoplastic Agents; Cells, Cultured; Colchicine; Cytokines; Cytoskeleton; Dendritic Cells; Drug Interactions; Humans; Lipopolysaccharides; Lymphocyte Activation; Neoplasms; NF-kappa B; Paclitaxel; T-Lymphocytes; Tubulin | 2010 |
Multifunctional polymeric nanoparticles for combined chemotherapeutic and near-infrared photothermal cancer therapy in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line; Cell Survival; HeLa Cells; Humans; Mice; Mice, SCID; Nanoparticles; Neoplasms; Paclitaxel; Phototherapy; Spectroscopy, Near-Infrared; Temperature | 2010 |
Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities.
Topics: Biomarkers, Tumor; Cell Line, Transformed; Cell Line, Tumor; Drug Resistance, Neoplasm; Genetic Heterogeneity; Humans; Intracellular Signaling Peptides and Proteins; Microscopy, Fluorescence; Multivariate Analysis; Neoplasms; Paclitaxel; Signal Transduction; Systems Biology | 2010 |
Immunoglobulin E-mediated severe anaphylaxis to paclitaxel.
Topics: Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Asthma; Cisplatin; Deoxycytidine; Drug Hypersensitivity; Dyspnea; Epitopes; Female; Gemcitabine; Humans; Hypersensitivity, Immediate; Hypotension; Immunoglobulin E; Middle Aged; Neoplasms; Paclitaxel; Pulmonary Atelectasis; Remission Induction; Skin Tests | 2010 |
A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the intrinsic apoptotic pathway.
Topics: Abietanes; Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Proliferation; Cell Survival; Cytochromes c; Dose-Response Relationship, Drug; Doxorubicin; Female; HeLa Cells; Hep G2 Cells; HL-60 Cells; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Neoplasms; Paclitaxel; Phenanthrenes; Propyl Gallate; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Receptor, ErbB-2; Solubility; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Targeted cancer therapy with novel high drug-loading nanocrystals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carrier Proteins; Chemistry, Pharmaceutical; Drug Delivery Systems; Excipients; Female; Folate Receptors, GPI-Anchored; Glycerol; Hemolysis; Humans; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanoparticles; Neoplasm Transplantation; Neoplasms; Paclitaxel; Poloxamer; Receptors, Cell Surface; Surface-Active Agents | 2010 |
Evaluation of the novel gene Rabl3 in the regulation of proliferation and motility in human cancer cells.
Topics: Amino Acid Sequence; Base Sequence; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HeLa Cells; HL-60 Cells; HT29 Cells; Humans; K562 Cells; Molecular Sequence Data; Neoplasms; Paclitaxel; Phylogeny; rab GTP-Binding Proteins; RNA, Small Interfering; Transfection; Tumor Cells, Cultured | 2010 |
Phenylisoserine in the gas-phase and water: Ab initio studies on neutral and zwitterion conformers.
Topics: Acid-Base Equilibrium; Antineoplastic Agents; Drug Design; Gases; Humans; Hydrogen Bonding; Isomerism; Models, Molecular; Molecular Conformation; Neoplasms; Paclitaxel; Quantum Theory; Serine; Temperature; Thermodynamics; Water | 2011 |
[Investigation of factors associated with time change in breath alcohol concentration after paclitaxel administration].
Topics: Adult; Aged; Aged, 80 and over; Alcohols; Breath Tests; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Time Factors | 2010 |
Small compound inhibitors of basal glucose transport inhibit cell proliferation and induce apoptosis in cancer cells via glucose-deprivation-like mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Biological Transport; Blotting, Western; Caspase 3; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Glucose; Humans; Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerases; Tumor Suppressor Protein p53 | 2010 |
Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Butyrates; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Flow Cytometry; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imidazoles; Neoplasms; Nuclear Proteins; Paclitaxel; Peptides, Cyclic; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyridines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Protein p53; Vorinostat | 2012 |
Cationic polymer-mediated small interfering RNA delivery for P-glycoprotein down-regulation in tumor cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cations; Cell Line, Tumor; Down-Regulation; Doxorubicin; Drug Resistance, Multiple; Feasibility Studies; Gene Transfer Techniques; Humans; Lysine; Neoplasms; Paclitaxel; Polymers; RNA, Small Interfering | 2010 |
Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Death; Cell Line, Tumor; Combined Modality Therapy; HMGB1 Protein; Humans; Interferons; Mice; Mice, Nude; Neoplasms; Oncolytic Virotherapy; Oncolytic Viruses; Paclitaxel; Vaccinia virus | 2011 |
Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Drug Carriers; Humans; Male; Mice; Nanoparticles; Nanotechnology; Neoplasms; Paclitaxel; Phase Transition; Poloxamer; Polyethylene Glycols; Temperature; X-Ray Diffraction | 2010 |
Nanotechnology-based cancer therapeutics--promise and challenge--lessons learned through the NCI Alliance for Nanotechnology in Cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Blood-Brain Barrier; Drug Delivery Systems; Drug Resistance, Multiple; Humans; Mice; Nanomedicine; Nanoparticles; National Cancer Institute (U.S.); Neoplasms; Paclitaxel; RNA, Small Interfering; United States | 2011 |
Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Availability; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Intestinal Absorption; Intestinal Mucosa; Isonicotinic Acids; Male; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Permeability; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors; Tubulin Modulators; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
[Comparative studies of paclitaxel injection "SAWAI" and Taxol® Injection on pharmacokinetics in dogs and in vitro/vivo antitumor activities].
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Dogs; Female; Humans; Infusions, Intravenous; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2010 |
Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Topics: Adult; Animals; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; HCT116 Cells; HeLa Cells; Histones; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Organophosphates; Paclitaxel; Phosphorylation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Molecular simulations of Taxawallin I inside classical taxol binding site of β-tubulin.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Cell Line, Tumor; Hep G2 Cells; Humans; Molecular Dynamics Simulation; Molecular Structure; Neoplasms; Paclitaxel; Phytotherapy; Plant Bark; Plant Extracts; Protein Binding; Taxoids; Taxus; Tubulin | 2011 |
Bypassing multidrug resistance in cancer cells with biodegradable polymer capsules.
Topics: Antibiotics, Antineoplastic; Biocompatible Materials; Capsules; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Humans; Neoplasms; Paclitaxel; Polymers; Polymethacrylic Acids; Polyvinyls; Pyrrolidines | 2010 |
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.
Topics: Animals; Anti-Mullerian Hormone; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Chick Embryo; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Female; Fibrosarcoma; Head and Neck Neoplasms; Humans; Neoplasm Invasiveness; Neoplasms; Ovarian Neoplasms; Paclitaxel; Receptors, Peptide; Receptors, Transforming Growth Factor beta | 2011 |
The flavonoid quercetin transiently inhibits the activity of taxol and nocodazole through interference with the cell cycle.
Topics: Antineoplastic Agents, Phytogenic; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Food-Drug Interactions; G2 Phase; Humans; Microtubules; Neoplasms; Nocodazole; Osmolar Concentration; Paclitaxel; Quercetin; Time Factors; Tubulin; Tubulin Modulators; Tumor Suppressor Protein p53 | 2010 |
Antitumor activities of extracts and compounds from water decoctions of Taxus cuspidata.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chromatography, High Pressure Liquid; Female; Humans; Mice; Mice, Inbred Strains; Molecular Structure; Neoplasms; Paclitaxel; Phytotherapy; Plant Extracts; Plant Leaves; Taxus | 2010 |
Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison.
Topics: Biological Assay; Cell Death; Cell Survival; Dendrimers; Dextrans; Flow Cytometry; Folic Acid; Galactose; HeLa Cells; Hemolysis; Humans; Ligands; Neoplasms; Organ Specificity; Paclitaxel; Polypropylenes | 2011 |
pH-sensitive PEG-based micelles for tumor targeting.
Topics: Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cell Line, Tumor; Humans; Hydrogen-Ion Concentration; Micelles; Molecular Structure; Nanostructures; Neoplasms; Paclitaxel; Phospholipids; Polyethylene Glycols; Potentiometry; Sulfadimethoxine | 2011 |
Selective impairment of CD4+CD25+Foxp3+ regulatory T cells by paclitaxel is explained by Bcl-2/Bax mediated apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; CD4 Antigens; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Fluorescent Antibody Technique; Forkhead Transcription Factors; Interleukin-2 Receptor alpha Subunit; Mice; Mice, Inbred C57BL; Microscopy, Confocal; Neoplasm Transplantation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; T-Lymphocytes, Regulatory | 2011 |
Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-6; Janus Kinase 2; Lung Neoplasms; Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Tumor Cells, Cultured | 2010 |
Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers.
Topics: Antineoplastic Agents; beta Catenin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Neoplasms; Organoplatinum Compounds; Organoselenium Compounds; Oxaliplatin; Paclitaxel; RNA Interference; Taxoids; Topotecan | 2010 |
Free tubulin modulates mitochondrial membrane potential in cancer cells.
Topics: Adenosine Triphosphate; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Membrane; Colchicine; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic CMP; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Liver Neoplasms; Male; Membrane Potential, Mitochondrial; Membrane Potentials; Microtubules; Mitochondria, Liver; Neoplasms; Nocodazole; Paclitaxel; Rats; Rats, Sprague-Dawley; Rhodamines; Rotenone; Tubulin | 2010 |
HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Vorinostat | 2011 |
Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression.
Topics: Animals; Base Sequence; Cell Cycle Proteins; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Carriers; Drug Synergism; Female; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Polo-Like Kinase 1; Polymers; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA, Small Interfering; Time Factors; Xenograft Model Antitumor Assays | 2011 |
Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation.
Topics: Autophagy; Cell Line, Tumor; Chromatin; Chromatin Assembly and Disassembly; DNA Fragmentation; DNA Replication; Etoposide; Gamma Rays; Genome, Human; Homeodomain Proteins; Humans; Mitosis; Nanog Homeobox Protein; Neoplasms; Octamer Transcription Factor-3; Paclitaxel; Ploidies; Tumor Suppressor Protein p53 | 2011 |
Total synthesis and biological evaluation of a series of macrocyclic hybrids and analogues of the antimitotic natural products dictyostatin, discodermolide, and taxol.
Topics: Alkanes; Antimitotic Agents; Antineoplastic Agents; Carbamates; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Lactones; Macrolides; Neoplasms; Paclitaxel; Pyrones | 2011 |
Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Emulsions; Female; Fluorocarbons; Humans; Mice; Nanomedicine; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Ultrasonic Therapy; Ultrasonography | 2011 |
Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Case-Control Studies; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Haplotypes; Humans; Mutation, Missense; Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Proteins; RNA, Messenger; Software; Tubulin Modulators | 2011 |
Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cathepsin B; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Humans; Integrins; Mice; Mice, Inbred BALB C; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Paclitaxel; Polyglutamic Acid; Rats; Rats, Wistar | 2011 |
Falls in persons with chemotherapy-induced peripheral neuropathy.
Topics: Accidental Falls; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Docetaxel; Female; Humans; Logistic Models; Male; Middle Aged; Muscle Weakness; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Population Surveillance; Postural Balance; Prospective Studies; Risk Factors; Sensation Disorders; Severity of Illness Index; Surveys and Questionnaires; Taxoids | 2012 |
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Metformin; Mice; Mice, Nude; Neoplasms; Paclitaxel; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures.
Topics: Antineoplastic Agents; Cell Line, Tumor; Humans; Liposomes; Nanoparticles; Neoplasms; Paclitaxel; RNA, Small Interfering; Transfection | 2011 |
Development of an enzyme-linked immunosorbent assay system to determine the presence of antibodies specific for taxane structures.
Topics: Animals; Antibodies; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Cattle; Enzyme-Linked Immunosorbent Assay; Fungi; Humans; Hypersensitivity; Mice; Neoplasms; Paclitaxel; Phytotherapy; Risk Factors; Taxoids; Taxus | 2011 |
Decoration of polymeric micelles with cancer-specific peptide ligands for active targeting of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Lactones; Ligands; Materials Testing; Micelles; Molecular Structure; Neoplasms; Paclitaxel; Peptides; Polyesters; Polyethylene Glycols | 2011 |
Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7.
Topics: Animals; Cloning, Molecular; Humans; Interleukin-7; Iodine Radioisotopes; Mice; Neoplasms; Paclitaxel; Recombinant Fusion Proteins; Single-Chain Antibodies; Tissue Distribution | 2011 |
Development of a mouse model for assessing fatigue during chemotherapy.
Topics: Animals; Circadian Rhythm; Drug-Related Side Effects and Adverse Reactions; Fatigue; Female; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Models, Animal; Nanoparticles; Neoplasms; Neurologic Examination; Paclitaxel; Sleep | 2011 |
Antitumor efficacy, tumor distribution and blood pharmacokinetics of chitosan/glyceryl-monooleate nanostructures containing paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chitosan; Drug Delivery Systems; Female; Glycerides; Leukocyte Count; Mice; Mice, Inbred BALB C; Nanostructures; Neoplasms; Paclitaxel | 2011 |
Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxyglucose; Drug Synergism; Enzyme Activation; Humans; Hypoglycemic Agents; Male; Metformin; Mice; Mice, SCID; Neoplasms; Paclitaxel; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Polymeric micelles with water-insoluble drug as hydrophobic moiety for drug delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Drug Compounding; Drug Delivery Systems; Erythrocytes; Female; Hemolysis; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Mice, Nude; Micelles; Neoplasm Transplantation; Neoplasms; NIH 3T3 Cells; Paclitaxel; Polyesters; Rats; Solubility; Surface-Active Agents; Water | 2011 |
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; fas Receptor; Female; Histocompatibility Antigens Class I; Humans; Immunotherapy; Interleukin-18; Mice; Mice, Inbred C57BL; Neoplasms; Paclitaxel; T-Lymphocytes; Time Factors; Topotecan; Up-Regulation | 2011 |
A model of competing saturable kinetic processes with application to the pharmacokinetics of the anticancer drug paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Computer Simulation; Dose-Response Relationship, Drug; Drug Therapy, Computer-Assisted; Humans; Metabolic Clearance Rate; Models, Biological; Neoplasms; Paclitaxel; Treatment Outcome | 2011 |
Genetic variations of orosomucoid genes associated with serum alpha-1-acid glycoprotein level and the pharmacokinetics of paclitaxel in Japanese cancer patients.
Topics: 5' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Asian People; Exons; Female; Gene Dosage; Genetic Variation; Haplotypes; Hepatobiliary Elimination; Humans; Japan; Linkage Disequilibrium; Male; Middle Aged; Neoplasms; Orosomucoid; Paclitaxel; Pharmacogenetics; Phenotype | 2011 |
Amphiphilic multiarm star block copolymer-based multifunctional unimolecular micelles for cancer targeted drug delivery and MR imaging.
Topics: Animals; Cell Death; Cell Survival; Drug Delivery Systems; Folic Acid; Gadolinium; HeLa Cells; Humans; Hydrodynamics; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Methacrylates; Micelles; Microscopy, Atomic Force; Neoplasms; Organ Specificity; Paclitaxel; Polyethylene Glycols; Polymers; Rats; Rats, Sprague-Dawley; Surface-Active Agents; Time Factors | 2011 |
Scientist honored for work with paclitaxel: Interest in a unique chemical structure leads to drug that helps millions.
Topics: Antineoplastic Agents, Phytogenic; Awards and Prizes; History, 20th Century; History, 21st Century; Neoplasms; Paclitaxel; Pharmacology; Societies, Scientific; United States | 2011 |
Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cattle; Cell Line, Tumor; Drug Carriers; Female; Hemolysis; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Serum Albumin, Bovine; Sorafenib | 2011 |
Preparation and in vitro properties of redox-responsive polymeric nanoparticles for paclitaxel delivery.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Coumarins; Desiccation; Drug Carriers; Emulsions; Fluorescent Dyes; Glutathione; Humans; Microscopy, Electron, Scanning; Microscopy, Fluorescence; Nanoparticles; Neoplasms; Oxidation-Reduction; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Thiazoles | 2011 |
A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Biological Transport; Cell Proliferation; Cell Survival; Drug Carriers; Drug Resistance, Neoplasm; Female; Folic Acid; Folic Acid Transporters; Heparin; Humans; KB Cells; Mice; Microtubules; Nanoparticles; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2011 |
In vivo anti-tumor activity of polypeptide HM-3 modified by different polyethylene glycols (PEG).
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Half-Life; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Peptides; Polyethylene Glycols; Transplantation, Heterologous | 2011 |
Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel.
Topics: Cell Line, Tumor; Cytotoxins; Drug Resistance, Neoplasm; Humans; Microtubules; Neoplasms; Paclitaxel; RNA, Small Interfering; Tubulin Modulators | 2011 |
Human homolog of Drosophila expanded, hEx, functions as a putative tumor suppressor in human cancer cell lines independently of the Hippo pathway.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasms; Paclitaxel; Signal Transduction; Tumor Suppressor Proteins | 2012 |
Anticancer activity of chamaejasmine: effect on tubulin protein.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biflavonoids; Blotting, Western; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; Dogs; Female; Humans; Inhibitory Concentration 50; Models, Molecular; Neoplasms; Paclitaxel; Protein Binding; Thermodynamics; Tubulin; Vero Cells | 2011 |
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Administration Schedule; Humans; Killer Cells, Natural; Lymphocyte Activation; Neoplasms; Oncolytic Virotherapy; Paclitaxel; Reoviridae; Vascular Endothelial Growth Factor A; Virus Replication | 2011 |
Tumor-targeted polydiacetylene micelles for in vivo imaging and drug delivery.
Topics: Animals; Body Weight; Cell Death; Cell Line, Tumor; Diagnostic Imaging; Drug Delivery Systems; Humans; Injections, Intravenous; Mice; Micelles; Neoplasms; Paclitaxel; Polyacetylene Polymer; Polymers; Polyynes; Positron-Emission Tomography; Spectroscopy, Near-Infrared; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Precise evaluation of chemotherapy-induced peripheral neuropathy using the visual analogue scale: a quantitative and comparative analysis of neuropathy occurring with paclitaxel-carboplatin and docetaxel-carboplatin therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Pain Measurement; Peripheral Nervous System Diseases; Surveys and Questionnaires; Taxoids | 2012 |
Probenecid is a chemosensitizer in cancer cell lines.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; HeLa Cells; Humans; Microscopy, Fluorescence; Neoplasms; Paclitaxel; Probenecid; Tumor Stem Cell Assay | 2012 |
Synthesis of pheophorbide-a conjugates with anticancer drugs as potential cancer diagnostic and therapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Fluorescence; Fluorescent Dyes; HeLa Cells; Humans; Mice; Mice, Inbred C3H; Microscopy, Confocal; Molecular Conformation; Neoplasms; Paclitaxel; Spectrometry, Fluorescence; Stereoisomerism; Structure-Activity Relationship; Tissue Distribution; Tumor Cells, Cultured | 2011 |
Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors.
Topics: Amino Acid Sequence; Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Coumarins; Dioxanes; Drug Delivery Systems; Humans; Integrins; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Sequence Data; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Peptides; Polyethylene Glycols; Polymers; Rats; Rats, Sprague-Dawley; Spectroscopy, Fourier Transform Infrared; Subcellular Fractions; Thiazoles | 2011 |
Use of mathematical models to understand anticancer drug delivery and its effect on solid tumors.
Topics: Anticarcinogenic Agents; Cisplatin; Doxorubicin; Drug Delivery Systems; Humans; Models, Theoretical; Neoplasms; Paclitaxel | 2011 |
A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Docetaxel; Humans; Neoplasms; Paclitaxel; Ritonavir; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Taxoids | 2011 |
Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indazoles; Mice; Mice, Nude; Microscopy, Electron, Scanning; Nanoparticles; Neoplasms; Paclitaxel; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Facilitated intracellular delivery of peptide-guided nanoparticles in tumor tissues.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chitosan; Drug Carriers; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Neoplasms; Oligopeptides; Paclitaxel; Receptors, Interleukin-4; Tumor Burden | 2012 |
A paclitaxel-conjugated adenovirus vector for targeted drug delivery for tumor therapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Drug Carriers; Female; Humans; Mice; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Receptors, Virus | 2012 |
Selective N-alkylation of β-alanine facilitates the synthesis of a poly(amino acid)-based theranostic nanoagent.
Topics: Alkylation; Antineoplastic Agents, Phytogenic; beta-Alanine; Biopolymers; Cell Line, Tumor; Fluorescent Dyes; Folic Acid; Folic Acid Transporters; Humans; Hydrophobic and Hydrophilic Interactions; Light; Molecular Weight; Nanocapsules; Neoplasms; Paclitaxel; Particle Size; Peptides; Scattering, Radiation | 2011 |
A mechanistic study of tumor-targeted corrole toxicity.
Topics: Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Humans; Hydrogen-Ion Concentration; Immunotoxins; Microscopy, Confocal; Models, Biological; Neoplasms; Paclitaxel; Porphyrins | 2011 |
New anti-cancer characteristics of jatrophane diterpenes from Euphorbia dendroides.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Diterpenes; Drug Resistance, Multiple; Drug Synergism; Euphorbia; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Neoplasms; Paclitaxel; Plant Extracts; RNA, Messenger; Vascular Endothelial Growth Factors | 2011 |
Injectable self-assembled block copolymers for sustained gene and drug co-delivery: an in vitro study.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Delayed-Action Preparations; DNA; Drug Carriers; Drug Combinations; Genes, Reporter; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Luciferases; Microscopy, Electron, Scanning; Neoplasms; Paclitaxel; Poloxamer; Polyethylene Glycols; Transfection | 2012 |
Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles.
Topics: Antineoplastic Agents, Phytogenic; Cell Survival; Drug Carriers; Drug Delivery Systems; Endocytosis; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Intracellular Space; Ligands; Light; Magnetic Resonance Spectroscopy; Nanoparticles; Neoplasms; Paclitaxel; Peptides, Cyclic; Polymers; Scattering, Radiation; Solutions; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Subcellular Fractions; Time Factors; Transferrin | 2012 |
Design of multifunctional micelle for tumor-targeted intracellular drug release and fluorescent imaging.
Topics: Animals; Antineoplastic Agents; Drug Carriers; Fluoresceins; Fluorescence Resonance Energy Transfer; Hydrogen-Ion Concentration; Mice; Mice, Nude; Micelles; Microscopy, Confocal; Neoplasms; Paclitaxel; Quantum Dots | 2012 |
Enhancement of the targeting capabilities of the Paclitaxel-loaded pluronic nanoparticles with a glycol chitosan/heparin composite.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Cell Line, Tumor; Chitosan; Drug Carriers; Heparin; Male; Mice; Microscopy, Electron, Scanning; Nanoparticles; Neoplasm Transplantation; Neoplasms; Paclitaxel; Poloxamer; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Spectroscopy, Fourier Transform Infrared; Tissue Distribution | 2012 |
Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Female; Glycerol; Humans; Maximum Tolerated Dose; Mice; Mice, Nude; Nanospheres; Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Tyrosine; Xenograft Model Antitumor Assays | 2012 |
The efficiency of tumor-specific pH-responsive peptide-modified polymeric micelles containing paclitaxel.
Topics: Animals; Carbocyanines; Cell Line; Cell Proliferation; Female; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Micelles; Microscopy, Confocal; Microscopy, Electron, Transmission; Microvessels; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Particle Size; Peptides; Polymers; Tissue Distribution; Xenograft Model Antitumor Assays | 2012 |
Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Mesenchymal Stem Cells; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2011 |
Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apigenin; Apoptosis; Base Sequence; Blotting, Western; DNA Primers; Drug Synergism; Flow Cytometry; HeLa Cells; Humans; In Situ Nick-End Labeling; Neoplasms; Paclitaxel; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Superoxide Dismutase | 2011 |
Paclitaxel loaded nano-aggregates based on pH sensitive polyaspartamide amphiphilic graft copolymers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Hydrogen-Ion Concentration; Male; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Polymers; Tumor Burden | 2012 |
Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein.
Topics: Adenosine Triphosphatases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Crizotinib; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Rhodamine 123; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
[The role of nanotechnology in creating novel antitumor agents].
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Design; Female; Humans; Liposomes; Nanoparticles; Nanostructures; Nanotechnology; Neoplasms; Paclitaxel; Tamoxifen; Taxoids | 2011 |
Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Proliferation; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Neoplasms; Paclitaxel; Phenylurea Compounds; Quinolines; Signal Transduction; Transplantation, Heterologous; Tubulin Modulators; Tumor Microenvironment; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Y-Box-Binding Protein 1 | 2012 |
Well-defined, reversible boronate crosslinked nanocarriers for targeted drug delivery in response to acidic pH values and cis-diols.
Topics: Boronic Acids; Catechols; Cell Line, Tumor; Drug Carriers; Fluorescence Resonance Energy Transfer; Glucose; Humans; Hydrogen-Ion Concentration; Mannitol; Micelles; Nanoparticles; Neoplasms; Paclitaxel | 2012 |
Identification of a novel role of Septin 10 in paclitaxel-resistance in cancers through a functional genomics screen.
Topics: Antineoplastic Agents, Phytogenic; Benzimidazoles; Caspase 3; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Microtubule-Associated Proteins; Microtubules; Neoplasms; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Septins | 2012 |
MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Topics: Angiogenesis Inhibitors; Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Corrosion Casting; Dose-Response Relationship, Drug; Female; Fluorescence; HEK293 Cells; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Phosphorylation; Receptor, TIE-2; Retinal Neovascularization; Time Factors; Transfection; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2012 |
Transferrin coupled vesicular system for intracellular drug delivery for the treatment of cancer: development and characterization.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Dequalinium; Drug Carriers; Drug Compounding; Drug Stability; Female; Flow Cytometry; HeLa Cells; Humans; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Mitochondria; Neoplasms; Paclitaxel; Particle Size; Solubility; Surface Properties; Tissue Distribution; Transferrin; Xenograft Model Antitumor Assays | 2012 |
A translation inhibitor identified in a Drosophila screen enhances the effect of ionizing radiation and taxol in mammalian models of cancer.
Topics: Animals; Biological Products; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Drosophila melanogaster; Drug Screening Assays, Antitumor; Humans; Mice; Mutation; Neoplasms; Paclitaxel; Peptides, Cyclic; Protein Biosynthesis; Radiation, Ionizing; Xenograft Model Antitumor Assays | 2012 |
Conjugation of paclitaxel to iron oxide nanoparticles for tumor imaging and therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Contrast Media; Dextrans; Drug Carriers; HeLa Cells; Humans; Magnetite Nanoparticles; Mice; Mice, Inbred ICR; Models, Biological; Nanoconjugates; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2012 |
Direct and fast determination of paclitaxel, morphine and codeine in urine by micellar electrokinetic chromatography.
Topics: Analgesics, Opioid; Antineoplastic Agents, Phytogenic; Chromatography, Micellar Electrokinetic Capillary; Codeine; Humans; Morphine; Neoplasms; Paclitaxel; Sensitivity and Specificity; Time Factors | 2012 |
A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs.
Topics: Animals; Antineoplastic Agents, Phytogenic; Dog Diseases; Dogs; Dosage Forms; Female; Male; Neoplasms; Paclitaxel; Survival Analysis | 2013 |
Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cathepsin B; Cell Cycle; Cell Line, Tumor; Citrulline; Dipeptides; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Tumor Burden; Valine | 2012 |
[Support of hematological homeostasis during chemotherapy with taxanes].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caproates; Docetaxel; Female; Fever; Follow-Up Studies; Homeostasis; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Protective Agents; Severity of Illness Index; Stomach Neoplasms; Taxoids; Tongue Neoplasms | 2011 |
Inhibition of paclitaxel metabolism in vitro in human hepatocytes by Ginkgo biloba preparations.
Topics: Antineoplastic Agents, Phytogenic; Cognition Disorders; Dose-Response Relationship, Drug; Ginkgo biloba; Hepatocytes; Herb-Drug Interactions; Humans; Neoplasms; Paclitaxel; Plant Preparations | 2009 |
Mitochondria-specific nanocarriers for improving the proapoptotic activity of small molecules.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Chromatin; Drug Carriers; Female; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Mitochondria; Nanoparticles; Neoplasms; Paclitaxel; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 2012 |
Pharmacokinetics of a paclitaxel-loaded low molecular weight heparin-all-trans-retinoid acid conjugate ternary nanoparticulate drug delivery system.
Topics: Animals; Cell Line, Tumor; Drug Delivery Systems; Heparin, Low-Molecular-Weight; Humans; Mice; Microscopy, Atomic Force; Microscopy, Confocal; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Tissue Distribution; Treatment Outcome; Tretinoin; Tumor Burden; Whole Body Imaging | 2012 |
Effect of molecular weight of PGG-paclitaxel conjugates on in vitro and in vivo efficacy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Female; Humans; Lung; Lung Neoplasms; Mice; Mice, Nude; Molecular Weight; Neoplasms; Paclitaxel; Prodrugs; Proteins | 2012 |
Hydrotropic magnetic micelles for combined magnetic resonance imaging and cancer therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Contrast Media; Drug Carriers; Ferric Compounds; Magnetic Resonance Imaging; Magnetics; Mice; Mice, Nude; Micelles; Neoplasms; Paclitaxel | 2012 |
Nanoformulation of paclitaxel to enhance cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; HeLa Cells; Humans; Nanoparticles; Neoplasms; Paclitaxel; Poloxamer | 2013 |
A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Chromones; Dose-Response Relationship, Drug; Embryo, Nonmammalian; Humans; Morpholines; Neoplasms; Paclitaxel; Reproducibility of Results; Small Molecule Libraries; Xenograft Model Antitumor Assays; Zebrafish | 2012 |
Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Cell Line, Tumor; Drug Carriers; Female; Glycerol; Humans; Lethal Dose 50; Male; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasms; Paclitaxel; Phytotherapy; Plant Preparations; Povidone; Rats; Rats, Sprague-Dawley; Taxus; Tissue Distribution | 2012 |
Multifunctional drug delivery system for targeting tumor and its acidic microenvironment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line; Drug Delivery Systems; Folic Acid; Hydrogen-Ion Concentration; Mice; Mice, Nude; Nanoparticles; Neoplasms; Paclitaxel; Polyamines; Polyethylene Glycols; Polymethacrylic Acids; Rats; Rats, Sprague-Dawley | 2012 |
The inhibition of tumor growth and metastasis by self-assembled nanofibers of taxol.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Female; Hydrogel, Polyethylene Glycol Dimethacrylate; Hydrolysis; Male; Mice; Mice, Inbred C57BL; Nanofibers; Neoplasm Metastasis; Neoplasms; Paclitaxel | 2012 |
Sustained delivery of paclitaxel using thermogelling poly(PEG/PPG/PCL urethane)s for enhanced toxicity against cancer cells.
Topics: Animals; Cell Death; Chromatography, Gel; Delayed-Action Preparations; Gels; HeLa Cells; Humans; Magnetic Resonance Spectroscopy; Mice; Neoplasms; Paclitaxel; Phase Transition; Polyesters; Polyethylene Glycols; Propylene Glycol; Rheology; Spectroscopy, Fourier Transform Infrared; Temperature; Urethane | 2012 |
Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Paclitaxel; Retrospective Studies; Smoking; Taxoids; Young Adult | 2012 |
Core-shell nanocapsules stabilized by single-component polymer and nanoparticles for magneto-chemotherapy/hyperthermia with multiple drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Emulsions; Ferric Compounds; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Hyperthermia, Induced; Magnetic Fields; Mice; Nanocapsules; Nanoparticles; Neoplasms; Paclitaxel; Polymers; Transplantation, Heterologous | 2012 |
The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Female; Humans; Interferon-gamma; Interleukin-12; Mice; Mice, 129 Strain; Mice, Inbred BALB C; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Recombinant Fusion Proteins; Single-Chain Antibodies; Tissue Distribution; Treatment Outcome; Tumor Burden | 2012 |
A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cisplatin; Drug Delivery Systems; Humans; Inhibitory Concentration 50; Mice; Micelles; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Polymers; Prodrugs; Static Electricity; Tissue Distribution; Treatment Outcome | 2012 |
Structural insight into the mechanism of epothilone A bound to beta-tubulin and its mutants at Arg282Gln and Thr274Ile.
Topics: Antineoplastic Agents; Binding Sites; Catalytic Domain; Epothilones; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutant Proteins; Mutation; Neoplasms; Paclitaxel; Protein Binding; Protein Structure, Tertiary; Tubulin | 2012 |
An arginine derivative contained nanostructure lipid carriers with pH-sensitive membranolytic capability for lysosomolytic anti-cancer drug delivery.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arginine; Cell Line, Tumor; Cell Membrane; Cell Survival; Cells, Cultured; Drug Carriers; Erythrocytes; Hemolysis; Humans; Hydrogen-Ion Concentration; Lipids; Lysosomes; Male; Mice; Nanoparticles; Neoplasms; Paclitaxel; Rats; Serum Albumin, Bovine; Tissue Distribution | 2012 |
Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Freeze Drying; Humans; Inhibitory Concentration 50; Liposomes; Mice; Microscopy, Electron, Transmission; Neoplasms; Paclitaxel; Polymers; Rats; Rats, Sprague-Dawley | 2012 |
Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Biological Availability; Caco-2 Cells; Cell Line, Tumor; Colchicine; Docetaxel; Dogs; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasms; Paclitaxel; Polymerization; Rats; Rats, Sprague-Dawley; Taxoids; Tubulin; Tubulin Modulators | 2012 |
Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Topics: Aged; Algorithms; Antineoplastic Agents, Phytogenic; Computer Simulation; Drug Monitoring; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Paclitaxel | 2012 |
Electron paramagnetic resonance highlights that the oxygen effect contributes to the radiosensitizing effect of paclitaxel.
Topics: Animals; Antineoplastic Agents; Electron Spin Resonance Spectroscopy; In Situ Nick-End Labeling; Male; Mice; Micelles; Models, Biological; Neoplasms; Oxygen; Oxygen Consumption; Paclitaxel; Partial Pressure; Perfusion; Radiation-Sensitizing Agents; Staining and Labeling | 2012 |
Short-peptide-based molecular hydrogels: novel gelation strategies and applications for tissue engineering and drug delivery.
Topics: Animals; Biocompatible Materials; Cell Culture Techniques; Drug Carriers; Hydrogels; Hydrolysis; Hydrophobic and Hydrophilic Interactions; Mice; Nanofibers; Neoplasms; Paclitaxel; Peptides; Polyesters; Recombinant Proteins; Tissue Engineering | 2012 |
Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel(TM).
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Nanoparticles; Neoplasms; Paclitaxel | 2013 |
Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Caco-2 Cells; Cell Survival; Drug Carriers; Humans; Male; Nanoparticles; Neoplasms; Paclitaxel; Rats; Rats, Sprague-Dawley | 2012 |
Enhanced oral bioavailability and anti-tumour effect of paclitaxel by 20(s)-ginsenoside Rg3 in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Female; Ginsenosides; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasms; Paclitaxel; Permeability; Rats; Rats, Sprague-Dawley; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Preclinical combination therapy of thiarabine plus various clinical anticancer agents.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Camptothecin; Cell Line, Tumor; Cisplatin; Cyclophosphamide; Female; HT29 Cells; Humans; Irinotecan; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms; Paclitaxel; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Mathematical determination of cell population doubling times for multiple cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Division; Cell Line, Tumor; Computer Simulation; Humans; Models, Biological; Monte Carlo Method; Neoplasms; Paclitaxel | 2012 |
Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carboplatin; Combined Modality Therapy; Epidermal Growth Factor; Female; Humans; Immunotherapy, Active; Lymphocytes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Ovalbumin; Paclitaxel | 2013 |
Blood-pool multifunctional nanoparticles formed by temperature-induced phase transition for cancer-targeting therapy and molecular imaging.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Ethiodized Oil; Humans; Male; Mice; Mice, Inbred C3H; Molecular Imaging; Nanoparticles; Neoplasms; Paclitaxel; Phase Transition; Poloxamer; Polysorbates; Temperature; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Carboxymethylcellulose Sodium; Cell Line, Tumor; Delayed-Action Preparations; Docetaxel; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, SCID; Nanoparticles; Neoplasms; Paclitaxel; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
A micelle-shedding thermosensitive hydrogel as sustained release formulation.
Topics: Acrylamides; Acrylic Resins; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Delayed-Action Preparations; Female; Humans; Hydrogels; Mice; Mice, Nude; Micelles; Neoplasms; Paclitaxel; Polymers; Serum; Temperature; Tumor Burden; Water; Xenograft Model Antitumor Assays | 2012 |
A new model for determining the MTD during phase-I trials in pediatric oncology.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Humans; Infant; Maximum Tolerated Dose; Models, Statistical; Neoplasms; Paclitaxel | 2012 |
Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.
Topics: Algorithms; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cluster Analysis; Colchicine; Computational Biology; Cyclin-Dependent Kinases; Dasatinib; Databases, Genetic; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Pimozide; Purines; Pyrimidines; Terfenadine; Thiazoles; Tubulin Modulators; Verapamil | 2012 |
Mechanisms of antiproliferative drug release from bioresorbable porous structures.
Topics: Antineoplastic Agents; Biocompatible Materials; Drug-Eluting Stents; Farnesol; Humans; Models, Molecular; Neoplasms; Paclitaxel; Polyglactin 910; Porosity; Salicylates; Sirolimus; Solubility | 2013 |
Tumor suppression via paclitaxel-loaded drug carriers that target inflammation marker upregulated in tumor vasculature and macrophages.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; Inflammation; Intercellular Adhesion Molecule-1; Lymphocyte Function-Associated Antigen-1; Macrophages; Mice; Mice, SCID; Nanoparticles; Neoplasms; Paclitaxel; Protein Structure, Tertiary; Recombinant Proteins | 2013 |
Systems pharmacological analysis of paclitaxel-mediated tumor priming that enhances nanocarrier deposition and efficacy.
Topics: Algorithms; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Computer Simulation; Data Interpretation, Statistical; Drug Carriers; Drug Delivery Systems; Liposomes; Mice; Models, Statistical; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols | 2013 |
Mechanical and functional properties of epothilone-stabilized microtubules.
Topics: Animals; Cattle; Epothilones; Humans; Microtubules; Neoplasms; Paclitaxel; Protein Stability; tau Proteins; Tubulin Modulators | 2013 |
Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types.
Topics: Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Line, Tumor; DNA Damage; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Models, Biological; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Tumor Suppressor Protein p53 | 2012 |
Targeted delivery of paclitaxel to EphA2-expressing cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug Delivery Systems; Female; Gene Expression; Humans; Male; Mice; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Peptides; Receptor, EphA2; Transplantation, Homologous; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model.
Topics: Adult; Antineoplastic Agents; Docetaxel; Female; Humans; Maternal-Fetal Exchange; Neoplasms; Paclitaxel; Placenta; Pregnancy; Taxoids | 2012 |
pH-responsive lipid core micelles for tumour targeting.
Topics: Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Lipids; MCF-7 Cells; Micelles; Microscopy, Confocal; Neoplasms; Paclitaxel; Particle Size; Spectrometry, Fluorescence; Spectrometry, Mass, Electrospray Ionization | 2013 |
Lx2-32c, a novel taxane derivative, exerts anti-resistance activity by initiating intrinsic apoptosis pathway in vitro and inhibits the growth of resistant tumor in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; bcl-2-Associated X Protein; Bridged-Ring Compounds; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cytochromes c; DNA Fragmentation; Drug Resistance, Neoplasm; Fas Ligand Protein; fas Receptor; Female; Humans; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, Nude; Microtubules; Mitochondria; Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerases; Polymerization; Proto-Oncogene Proteins c-bcl-2; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel.
Topics: Animals; Antineoplastic Agents; Dioxanes; Female; Integrins; Mice; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Nanoparticles; Neoplasms; Paclitaxel; Polyethylene Glycols; Polymers | 2013 |
Elucidating mechanical transition effects of invading cancer cells with a subnucleus-scaled microfluidic serial dimensional modulation device.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial Cells; Female; Humans; Microfluidic Analytical Techniques; Microfluidics; Microtubules; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Paclitaxel | 2013 |
Carrier-free, functionalized pure drug nanorods as a novel cancer-targeted drug delivery platform.
Topics: Biocompatible Materials; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Endocytosis; Humans; Materials Testing; Microscopy, Confocal; Nanotubes; Neoplasms; Paclitaxel; Powders; Receptors, Cell Surface; Temperature; Time Factors; Water | 2013 |
Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Synergism; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Neoplasms; Paclitaxel; Praziquantel; Treatment Outcome; X-Linked Inhibitor of Apoptosis Protein | 2012 |
miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance.
Topics: Antineoplastic Agents, Phytogenic; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; bcl-2 Homologous Antagonist-Killer Protein; beta Catenin; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; MicroRNAs; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Paclitaxel; RNA, Neoplasm; Snail Family Transcription Factors; Transcription Factor 4; Transcription Factors; Wnt Proteins | 2013 |
Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Castor Oil; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Complement Activation; Complement Membrane Attack Complex; Complement System Proteins; Enzyme-Linked Immunosorbent Assay; Histamine; Humans; Hypersensitivity; Liposomes; Lung; Mice; Neoplasms; Paclitaxel | 2013 |
Anticancer agent shikonin is an incompetent inducer of cancer drug resistance.
Topics: Antineoplastic Agents; Cell Proliferation; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; MCF-7 Cells; Naphthoquinones; Neoplasms; Paclitaxel; Time Factors | 2013 |
Downregulation of the mitochondrial phosphatase PTPMT1 is sufficient to promote cancer cell death.
Topics: Adenosine Triphosphate; Cardiolipins; Cell Death; Gene Expression Regulation, Neoplastic; Gene Silencing; HeLa Cells; Humans; Mitochondria; Neoplasms; Paclitaxel; PTEN Phosphohydrolase | 2013 |
BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; HEK293 Cells; HL-60 Cells; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthalenes; Neoplasms; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2013 |
Gold nanorods carrying paclitaxel for photothermal-chemotherapy of cancer.
Topics: Cell Line, Tumor; Cell Membrane; Drug Carriers; Gold; Humans; Nanotubes; Neoplasms; Paclitaxel; Phototherapy | 2013 |
Nanoparticle mediated co-delivery of paclitaxel and a TLR-4 agonist results in tumor regression and enhanced immune response in the tumor microenvironment of a mouse model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Cytokines; Lactic Acid; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Toll-Like Receptor 4; Tumor Burden; Tumor Microenvironment | 2013 |
The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasms; Paclitaxel; Taxoids | 2002 |
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Female; Glycerol; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Surface-Active Agents | 2002 |
Characterization of nuclear betaII-tubulin in tumor cells: a possible novel target for taxol.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Nucleolus; Cell Nucleus; Colchicine; Dimerization; Dose-Response Relationship, Drug; Female; Fluorescent Dyes; Humans; Neoplasms; Nocodazole; Nucleolin; Paclitaxel; Phosphoproteins; Protein Isoforms; Rats; RNA-Binding Proteins; Tubulin; Tumor Cells, Cultured | 2002 |
Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs.
Topics: Antineoplastic Agents, Phytogenic; Cell Death; G2 Phase; Gene Expression Regulation, Neoplastic; Genes, p53; HL-60 Cells; Humans; Jurkat Cells; Microtubules; Neoplasms; Paclitaxel | 2002 |
Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Candidiasis; Cytomegalovirus Infections; Docetaxel; Fever; Herpesviridae Infections; Humans; Infections; Lung Diseases; Lymphopenia; Neoplasms; Paclitaxel; Pneumonia, Pneumocystis; Prospective Studies; T-Lymphocytopenia, Idiopathic CD4-Positive; Taxoids | 2002 |
Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Docetaxel; Epirubicin; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Leukocytes, Mononuclear; Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2002 |
An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.
Topics: 3T3 Cells; Animals; Carboplatin; Cytokines; Deoxycytidine; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Neoplasms; Paclitaxel; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
The possible correlation between activation of NF-kappaB/IkappaB pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; G2 Phase; Humans; I-kappa B Kinase; I-kappa B Proteins; MAP Kinase Kinase Kinase 1; Mitosis; Neoplasms; NF-kappa B; Paclitaxel; Protein Serine-Threonine Kinases; Tumor Cells, Cultured | 2002 |
Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Topics: Alu Elements; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Colonic Neoplasms; DNA, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, SCID; Neoplasms; Paclitaxel; Pancreatic Neoplasms; Piperazines; Polymerase Chain Reaction; Pyrimidines; Sensitivity and Specificity; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Weekly paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Administration Schedule; Humans; Neoplasms; Paclitaxel | 2002 |
Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.
Topics: Antineoplastic Agents; Drug Costs; Drug Therapy; Health Services Accessibility; Humans; Neoplasms; Ontario; Paclitaxel; Pharmaceutical Services; Program Development; Regional Medical Programs; State Government | 2002 |
Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target.
Topics: Antineoplastic Agents, Phytogenic; Body Surface Area; Clinical Trials as Topic; Humans; Neoplasms; Paclitaxel | 2003 |
Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Chemical; Neoplasms; Paclitaxel; Protein Binding; Time Factors | 2003 |
Polymer-conjugated paclitaxel as a radiosensitizing agent--a big step forward for combined modality therapy?
Topics: Antineoplastic Agents; Combined Modality Therapy; Humans; Neoplasm Metastasis; Neoplasms; Paclitaxel; Polyglutamic Acid; Radiation-Sensitizing Agents; Taxoids | 2003 |
Measurement of volumetric and vascular changes with dynamic contrast enhanced MRI for cancer therapy monitoring.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Docetaxel; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Paclitaxel; Radiography; Rats; Rats, Inbred F344; Taxoids; Time Factors; Treatment Outcome | 2002 |
Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Lineage; Combined Modality Therapy; Cyclophosphamide; Dendritic Cells; Epirubicin; Female; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Paclitaxel; Th2 Cells | 2003 |
Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Cisplatin; Cysteine; Disulfides; Glutathione; Half-Life; Humans; Infusions, Intravenous; Kinetics; Mesna; Neoplasms; Paclitaxel; Sulfhydryl Compounds | 2003 |
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
Topics: Agar; Animals; Antibodies, Monoclonal; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; NIH 3T3 Cells; Paclitaxel; Phosphorylation; Piperidines; Protein-Tyrosine Kinases; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Paclitaxel | 2003 |
Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Chromatography, Liquid; Docetaxel; Half-Life; Humans; Infusions, Intravenous; Mass Spectrometry; Models, Biological; Neoplasms; Paclitaxel; Reproducibility of Results; Specimen Handling; Taxoids; Time Factors | 2003 |
Paclitaxel increases p21 synthesis and accumulation of its AKT-phosphorylated form in the cytoplasm of cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytoplasm; Dose-Response Relationship, Drug; Humans; Neoplasms; Paclitaxel; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Spindle Apparatus; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2003 |
Paclitaxel pharmacokinetics, threshold models, and dosing strategies.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Paclitaxel | 2003 |
Paclitaxel pharmacokinetics, threshold models, and dosing strategies.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Paclitaxel | 2003 |
Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cells, Cultured; Endothelial Cells; Fibroblasts; Humans; Immunohistochemistry; Indoles; Metalloproteases; Neoplasm Invasiveness; Neoplasms; Oxindoles; Paclitaxel; Propionates; Protease Inhibitors; Pyrroles; Stromal Cells | 2003 |
Predictive cancer genomics--what do we need?
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Genomics; Humans; Neoadjuvant Therapy; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Sequence Analysis, DNA; Taxoids | 2003 |
Epidermal growth factor receptor blockade potentiates apoptosis mediated by Paclitaxel and leads to prolonged survival in a murine model of oral cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Death; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Head and Neck Neoplasms; Humans; In Situ Nick-End Labeling; Ligands; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Mouth Neoplasms; Neoplasms; Paclitaxel; Phosphorylation; Propidium; Pyrimidines; Pyrroles; Tongue; Tongue Neoplasms; Tyrosine | 2003 |
Inhibitory effects of docetaxel on expression of VEGF, bFGF and MMPs of LS174T cell.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Docetaxel; Endothelial Growth Factors; Fibroblast Growth Factor 2; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Multiple effects of paclitaxel are modulated by a high c-myc amplification level.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Compartmentation; Cell Division; Cell Nucleus; Colonic Neoplasms; Eukaryotic Cells; Gene Amplification; Gene Dosage; Genes, myc; Humans; Neoplasms; Paclitaxel; Phosphorylation; Tumor Cells, Cultured; Up-Regulation | 2003 |
Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Blood Proteins; Chemistry, Pharmaceutical; Docetaxel; Excipients; Female; Humans; Infusions, Intravenous; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Orosomucoid; Paclitaxel; Polysorbates; Taxoids | 2003 |
Improved chemical strategies for the targeted therapy of cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bridged-Ring Compounds; Doxorubicin; Drug Carriers; Drug Delivery Systems; Humans; Ligands; Mandelic Acids; Neoplasms; Oligopeptides; Paclitaxel; Taxoids | 2003 |
Design and total synthesis of a superior family of epothilone analogues, which eliminate xenograft tumors to a nonrelapsable state.
Topics: Animals; Antineoplastic Agents; Body Weight; Drug Screening Assays, Antitumor; Epothilones; Humans; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Neoplasms; Paclitaxel; Structure-Activity Relationship; Tumor Cells, Cultured | 2003 |
Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro.
Topics: Animals; Antibodies; Cadherins; Cell Cycle; Cell Line, Tumor; Drug Resistance; Etoposide; Fluorouracil; Humans; Mice; Neoplasms; Paclitaxel; Protein Kinase C; Protein Kinase C beta; Spheroids, Cellular; Vinblastine | 2004 |
Ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop.
Topics: Animals; Antineoplastic Agents; DNA-Binding Proteins; Ethylenes; Humans; Interleukin-10; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasms; Oligonucleotides, Antisense; Paclitaxel; Phosphorylation; STAT3 Transcription Factor; Trans-Activators | 2004 |
Effect of paclitaxel administration on P wave duration and dispersion.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Electrocardiography; Female; Heart; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel | 2004 |
Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Humans; Male; Middle Aged; Neoplasms; Nerve Fibers, Myelinated; Nociceptors; Paclitaxel; Pain; Pain Threshold; Psychomotor Performance; Sensation Disorders; Sensory Thresholds; Skin; Time Factors | 2004 |
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Neoplasms; Paclitaxel; Topotecan | 2004 |
Estimation of radiation-induced interphase cell death in cultures of human tumor material and in cell lines.
Topics: Cell Death; Humans; Interphase; Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2004 |
Chemotherapy-induced neuropathy: treatment by decompression of peripheral nerves.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carpal Tunnel Syndrome; Cisplatin; Decompression, Surgical; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand; Humans; Leg; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Nerve Compression Syndromes; Neuralgia; Ovarian Neoplasms; Paclitaxel; Pain Measurement; Paresthesia; Peripheral Nervous System Diseases; Treatment Outcome; Vincristine; Wrist | 2004 |
Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Hypoxia; Male; Neoplasms; Paclitaxel; Probability; Reference Values; Sensitivity and Specificity; Taxoids; Tumor Cells, Cultured | 2004 |
Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cells, Cultured; Coated Materials, Biocompatible; Drug Delivery Systems; Ethylene Glycols; Fibroblasts; Folic Acid; Humans; Materials Testing; Molecular Weight; Nanotubes; Neoplasms; Paclitaxel; Particle Size; Polyesters | 2005 |
In vivo measurement of microtubule dynamics using stable isotope labeling with heavy water. Effect of taxanes.
Topics: Animals; Antineoplastic Agents, Phytogenic; Deuterium Oxide; Dimerization; Humans; Mice; Mice, Nude; Microtubules; Neoplasms; Paclitaxel; Tubulin | 2004 |
Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Death; Cell Division; Cell Proliferation; Cells, Cultured; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Endothelium, Vascular; G2 Phase; Humans; Intracellular Membranes; Laminin; Membrane Potentials; Microcirculation; Microscopy, Fluorescence; Microtubules; Mitochondria; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Proteoglycans; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Time Factors | 2004 |
Peritonitis-induced antitumor activity of peritoneal macrophages from uremic patients.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Humans; Macrophages, Peritoneal; Neoplasms; Paclitaxel; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Suramin; Uremia | 2004 |
MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines.
Topics: Blotting, Northern; Cell Line, Tumor; Chromosomes, Human, Pair 7; Doxorubicin; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Male; Membrane Proteins; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Mitochondrial Proteins; Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phenotype; Recombinant Fusion Proteins; Transfection | 2004 |
Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.
Topics: Apoptosis; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Female; Gene Expression Profiling; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Ligands; Microscopy, Confocal; Neoplasm Metastasis; Neoplasms; Paclitaxel; Progesterone; Promoter Regions, Genetic; Protein Isoforms; Receptors, Estrogen; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors; Transcription, Genetic | 2005 |
Monitoring for potential adverse drug reactions in patients receiving chemotherapy.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Neoplasms; Paclitaxel; Pharmaceutical Services; United States | 2004 |
Synthesis and biological evaluation of a paclitaxel immunoconjugate.
Topics: Antibodies, Monoclonal; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Immunoconjugates; Immunotherapy; Molecular Structure; Neoplasms; Paclitaxel; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Succinic Acid | 2005 |
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Surface Area; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasms; Paclitaxel; Prospective Studies | 2004 |
Incorporating targeted treatments into standard regimens: whither the role of established doses?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Drug Therapy, Combination; Humans; Neoplasms; Paclitaxel; Phenylenediamines | 2004 |
Stable paclitaxel formulations in oily contrast medium.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Contrast Media; Doxorubicin; Drug Stability; Emulsions; Female; Iodized Oil; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasms; Oils; Paclitaxel; Solubility; Solvents | 2005 |
Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.
Topics: Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Survival; Centrosome; Drug Therapy, Combination; Enzyme Inhibitors; Flow Cytometry; Fluorescent Antibody Technique; HeLa Cells; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Immunoblotting; Kinetochores; Microtubules; Mitosis; Neoplasms; Nocodazole; Paclitaxel; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; Spindle Apparatus | 2005 |
Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Cell Line; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Microtubules; Neoplasms; Neovascularization, Pathologic; Paclitaxel | 2005 |
Sensitization for anticancer drug-induced apoptosis by betulinic Acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Betulinic Acid; Caspases; Cells, Cultured; Cisplatin; Complement Membrane Attack Complex; Complement System Proteins; Cytochromes c; Dactinomycin; Doxorubicin; Drug Synergism; Enzyme Activation; Etoposide; Fibroblasts; Glycoproteins; Humans; Membrane Potentials; Mitochondria; Mutation; Neoplasms; Paclitaxel; Pentacyclic Triterpenes; Proto-Oncogene Proteins c-bcl-2; Triterpenes; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2005 |
NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Peptide Fragments; Taxoids; Time Factors; Tissue Distribution; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays | 2005 |
PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors.
Topics: Androstadienes; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Glioma; Humans; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Molecular Structure; Molecular Weight; Neoplasm Transplantation; Neoplasms; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2005 |
Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids.
Topics: Antineoplastic Agents; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Doxorubicin; Flavonoids; Humans; Neoplasms; Paclitaxel; Piperidines; Pleural Effusion, Malignant; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Cells, Cultured | 2005 |
Effects of weekly paclitaxel or paclitaxel plus carboplatin on functionality and symptoms of geriatric patients with cancer as measured by a brief geriatric oncology module: a pilot experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Interviews as Topic; Male; Medical Oncology; Neoplasms; Paclitaxel; Pilot Projects; Quality of Life; Survival Rate | 2005 |
An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Carcinoma, Small Cell; Cell Line, Tumor; Cytochromes c; Disease Models, Animal; Drug Synergism; Humans; Lymphoma; Magnetic Resonance Spectroscopy; Mice; Mitochondria; Models, Molecular; Neoplasms; Nitrophenols; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Sulfonamides; Survival Rate | 2005 |
Divide and conquer: new generation of drugs targets mitosis.
Topics: Aneugens; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aurora Kinases; Cell Division; Enzyme Inhibitors; Humans; Kinesins; Mitosis; Neoplasms; Paclitaxel; Protein Serine-Threonine Kinases | 2005 |
Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Blotting, Western; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Etoposide; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Neoplasms; Paclitaxel; Phosphorus Radioisotopes; Phosphorylation; Piperazines; Precipitin Tests; Pyrimidines; RNA Helicases; RNA Interference; Stilbenes; Tumor Necrosis Factor-alpha | 2005 |
Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release.
Topics: Antineoplastic Agents, Phytogenic; Drug Carriers; Drug Therapy; Humans; Lactic Acid; Molecular Structure; Molecular Weight; Nanostructures; Neoplasms; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Polymers; Surface Properties; Vitamin E | 2006 |
Cancer cell adaptation to chemotherapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Camptothecin; Cell Line, Tumor; Cisplatin; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Irinotecan; Neoplasms; Paclitaxel; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Topotecan; Treatment Outcome; Up-Regulation | 2005 |
Induction of apoptotic cell death specifically in rat and human cancer cells by pancratistatin.
Topics: Amaryllidaceae Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Etoposide; Fibroblasts; Humans; Isoquinolines; Neoplasms; Paclitaxel; Rats | 2005 |
Pilot studies of the effect of zoledronic acid (Zometa) on tumor-derived cells ex vivo in the ATP-based tumor chemosensitivity assay.
Topics: Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Alendronate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspase 3; Caspase 7; Caspases; Cell Line, Tumor; Cell Survival; Cisplatin; Clodronic Acid; Diphosphonates; Energy Metabolism; Female; Humans; Imidazoles; Inhibitory Concentration 50; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Albumin-bound nanoparticle paclitaxel.
Topics: Albumin-Bound Paclitaxel; Albumins; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Nanostructures; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Polyethylene Glycols; Prodrugs | 2005 |
Therapeutic index, tubulin binders, and clinical medicine.
Topics: Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Paclitaxel; Tubulin | 2005 |
A cannabinoid pharmacotherapy for chemotherapy-evoked painful peripheral neuropathy.
Topics: Animals; Antineoplastic Agents; Cannabinoids; Humans; Neoplasms; Neuralgia; Paclitaxel; Peripheral Nervous System Diseases | 2005 |
Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epothilones; Female; Humans; Infusions, Intravenous; Male; Mice; Mice, Nude; Microtubules; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2005 |
The impact of paclitaxel or cisplatin-based chemotherapy on sympathetic skin response: a prospective study.
Topics: Adult; Case-Control Studies; Cisplatin; Electric Stimulation; Electromyography; Electrophysiology; Female; Galvanic Skin Response; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Prospective Studies; Sensitivity and Specificity; Skin; Sympathetic Nervous System | 2005 |
Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Drug Packaging; Drug Stability; Humans; Nanostructures; Neoplasms; Paclitaxel | 2005 |
Folate-conjugated methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Female; Fluorescent Dyes; Folic Acid; Humans; Kinetics; Micelles; Microscopy, Confocal; Neoplasms; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols | 2005 |
YM-231146, a novel orally bioavailable inhibitor of vascular endothelial growth factor receptor-2, is effective against paclitaxel resistant tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Mice; Mice, Nude; Morpholines; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Quinolines; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Disease Progression; Drug Therapy; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms; Neural Conduction; Paclitaxel; Peripheral Nervous System Diseases; Prospective Studies; Time Factors | 2005 |
A radioligand binding assay for antitubulin activity in tumor cells.
Topics: Benzamides; Binding, Competitive; Cell Death; Cell Line, Tumor; Drug Interactions; Drug Resistance, Multiple; Humans; Microtubules; Mitotic Index; Neoplasms; Paclitaxel; Radioligand Assay; Tubulin; Tubulin Modulators; Vinblastine | 2006 |
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fibrosarcoma; Gemcitabine; Lymphoma; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Tumor Necrosis Factor-alpha | 2006 |
Methionine dependence of tumours: a biochemical strategy for optimizing paclitaxel chemosensitivity in vitro.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Combinations; Drug Screening Assays, Antitumor; Humans; Methionine; Mice; Neoplasms; Paclitaxel; Rats; Vinblastine | 2006 |
The efficacy of Paclitaxel on solid tumour analysed by ATP bioluminescence assay and VEGF expression: a translational research study.
Topics: Adenosine Triphosphate; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; DNA, Neoplasm; Enzyme-Linked Immunosorbent Assay; Humans; Luminescent Measurements; Neoplasms; Paclitaxel; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2005 |
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Quinazolines; Thiazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2006 |
Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Docosahexaenoic Acids; Doxorubicin; Mice; Molecular Structure; Neoplasm Transplantation; Neoplasms; Paclitaxel | 2006 |
Cancer in the elderly population: the protection racket.
Topics: Age Factors; Aged; Antineoplastic Agents; Comorbidity; Humans; Neoplasms; Paclitaxel; Population Dynamics; Reproducibility of Results; Vulnerable Populations | 2006 |
Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors.
Topics: Angiostatins; Animals; Antineoplastic Agents; Cell Line, Tumor; Clonal Anergy; Cyclohexanes; Cyclophosphamide; Down-Regulation; Endostatins; Endothelial Cells; Endothelium; Humans; Intercellular Adhesion Molecule-1; Leukocytes; Mice; Neoplasms; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Peptides; Proteins; Sesquiterpenes; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2006 |
Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Biocompatible Materials; Delayed-Action Preparations; Drug Carriers; Humans; Nanostructures; Neoplasms; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Surface Properties | 2006 |
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors.
Topics: Age Factors; Antineoplastic Agents; Body Size; Female; Humans; Liver; Liver Function Tests; Male; Middle Aged; Models, Biological; Neoplasms; Paclitaxel; Population; Sex Factors | 2006 |
A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Capsules; Central Nervous System Diseases; Chemistry, Pharmaceutical; Cyclosporine; Female; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Polymers | 2007 |
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents, Phytogenic; Caspases; Cell Death; Cell Line, Tumor; Cisplatin; Drug Therapy; Enzyme Activation; Female; High-Temperature Requirement A Serine Peptidase 1; Humans; Male; Middle Aged; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Paclitaxel; RNA, Small Interfering; Serine Endopeptidases; Stomach Neoplasms | 2006 |
Profile of Susan Band Horwitz.
Topics: Animals; History, 20th Century; History, 21st Century; Humans; Neoplasms; Paclitaxel; Pharmacology; United States | 2006 |
Cytostatic activity of paclitaxel in coronary artery smooth muscle cells is mediated through transient mitotic arrest followed by permanent post-mitotic arrest: comparison with cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cells, Cultured; Coronary Restenosis; Coronary Vessels; G1 Phase; HL-60 Cells; Humans; Mitosis; Myocytes, Smooth Muscle; Neoplasms; Paclitaxel | 2006 |
Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents, Phytogenic; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA; Excipients; Female; Haplotypes; Humans; Japan; Male; Neoplasms; Paclitaxel; Polyethylene Glycols; Polymorphism, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA | 2006 |
Antivascular therapy of cancer metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Growth Substances; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Pyrimidines; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor | 2006 |
Application of ultrasound to selectively localize nanodroplets for targeted imaging and therapy.
Topics: Blood Vessels; Cell Culture Techniques; Cell Survival; Drug Delivery Systems; Feasibility Studies; Humans; Models, Biological; Models, Theoretical; Nanoparticles; Neoplasms; Paclitaxel; Photography; Tumor Cells, Cultured; Ultrasonic Therapy; Ultrasonics; Ultrasonography | 2006 |
[Analysis of antineoplastic drugs used in Cancer Center, Sun Yat-sen University, during the period of 1996-2005].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Drug Utilization Review; Gemcitabine; Humans; Neoplasms; Paclitaxel; Rituximab; Vinblastine; Vinorelbine | 2006 |
Naturally occurring resistance of bone marrow mononuclear and metastatic cancer cells to anticancer agents.
Topics: Antineoplastic Agents; Ascitic Fluid; Bone Marrow Cells; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Formazans; Humans; Inhibitory Concentration 50; Male; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Pleural Effusion, Malignant; Tetrazolium Salts | 2006 |
In vitro cell cultures obtained from different explants of Corylus avellana produce Taxol and taxanes.
Topics: Antineoplastic Agents, Phytogenic; Cell Culture Techniques; Cell Line, Tumor; Cells, Cultured; Corylus; Humans; Mitosis; Neoplasms; Paclitaxel; Plant Extracts; Taxoids | 2006 |
Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]Paclitaxel (FPAC).
Topics: Automation; Drug Resistance, Neoplasm; Fluorine Radioisotopes; Humans; Neoplasms; Paclitaxel; Quality Control; Radiochemistry; Radionuclide Imaging; Radiopharmaceuticals | 2007 |
Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Female; Fever; Humans; Liver Neoplasms; Necrosis; Neoplasms; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2007 |
Chk1 is required for spindle checkpoint function.
Topics: Animals; Aurora Kinase B; Aurora Kinases; Biopolymers; Catalysis; Cell Death; Checkpoint Kinase 1; Chickens; Chromosomal Instability; Chromosome Segregation; HCT116 Cells; Humans; Kinetochores; Microtubules; Neoplasms; Paclitaxel; Phosphorylation; Prometaphase; Protein Kinases; Protein Serine-Threonine Kinases; Protein Transport; Spindle Apparatus | 2007 |
VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases.
Topics: Animals; Antibodies; Antibody Formation; Cancer Vaccines; Cell Line, Tumor; Colorectal Neoplasms; Female; HT29 Cells; Humans; Immune Sera; Immunization; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Rhabdomyosarcoma; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
A generalised age- and phase-structured model of human tumour cell populations both unperturbed and exposed to a range of cancer therapies.
Topics: Algorithms; Camptothecin; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Kinetics; Models, Biological; Neoplasms; Paclitaxel; Time Factors | 2007 |
Tumor priming enhances delivery and efficacy of nanomedicines.
Topics: Animals; Antineoplastic Agents; Doxorubicin; Liposomes; Male; Mice; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasms; Paclitaxel | 2007 |
Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Mice; Mice, Inbred Strains; Neoplasms; Paclitaxel; S Phase; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk1-involved signaling pathways.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; G2 Phase; Humans; Neoplasms; Paclitaxel; Quinolones; Tubulin; Tubulin Modulators; Vincristine | 2007 |
Radiosensitization of paclitaxel, etanidazole and paclitaxel+etanidazole nanoparticles on hypoxic human tumor cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Dose-Response Relationship, Radiation; Etanidazole; HeLa Cells; Humans; Lactic Acid; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Nanotechnology; Neoplasms; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers | 2007 |
Encapsulation of paclitaxel in macromolecular nanoshells.
Topics: Cell Cycle; Cell Line, Tumor; Cytoskeleton; Drug Delivery Systems; Glycerol; Humans; Macromolecular Substances; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Nanoparticles; Neoplasms; Paclitaxel; Polymers; Solvents | 2007 |
CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Asian People; Base Sequence; Cytochrome P-450 CYP2C8; DNA Primers; Female; Genetic Variation; Genetics, Population; Haplotypes; Humans; Japan; Linkage Disequilibrium; Male; Middle Aged; Neoplasms; Paclitaxel; Pharmacogenetics | 2007 |
Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Cycle; Cell Line, Tumor; Cell Survival; Humans; Neoplasms; Paclitaxel; Phosphorylation; Prohibitins; Proto-Oncogene Proteins c-bcl-2 | 2007 |
In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Delivery Systems; Humans; Male; Materials Testing; Nanoparticles; Neoplasms; Paclitaxel; Particle Size; Polyesters; Polyethylene Glycols; Rats; Rats, Sprague-Dawley | 2007 |
Drug evaluation: CP-751871, a human antibody against type I insulin-like growth factor receptor for the potential treatment of cancer.
Topics: Antibodies; Carboplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Paclitaxel; Receptors, Somatomedin | 2007 |
Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biotransformation; Cell Division; Female; Half-Life; Humans; Models, Animal; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pharmacogenetics; Rats | 2007 |
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Nucleus; Colonic Neoplasms; Combined Modality Therapy; HMGB1 Protein; Humans; Immunotherapy; Killer Cells, Lymphokine-Activated; Melanoma; Melphalan; Microscopy, Confocal; Necrosis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2007 |
Multiparameter noninvasive assessment of treatment susceptibility, drug target inhibition and tumor response guides cancer treatment.
Topics: Animals; Annexins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Early Diagnosis; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Microscopy, Confocal; Microscopy, Fluorescence; Neoplasms; Paclitaxel; Predictive Value of Tests; Receptor, ErbB-2; Spectrometry, Fluorescence; Spectroscopy, Near-Infrared; Trastuzumab; Up-Regulation | 2007 |
Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines.
Topics: Aminoacridines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Cyclin B; Cyclin B1; Doxorubicin; Drug Therapy, Combination; G2 Phase; Humans; Immunoblotting; Immunoprecipitation; Neoplasms; Paclitaxel; Rhodamines; Tumor Cells, Cultured | 2007 |
Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Biological Transport; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Gefitinib; Glucose; Glucose Transporter Type 1; Humans; Neoplasms; Paclitaxel; Quinazolines | 2007 |
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.
Topics: Animals; Cell Line, Tumor; Drug Synergism; Extracellular Space; GPI-Linked Proteins; Humans; Immunotoxins; Membrane Glycoproteins; Mesothelin; Mice; Mice, Nude; Neoplasms; Paclitaxel; Receptors, Transferrin; Xenograft Model Antitumor Assays | 2007 |
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2008 |
Pattern analysis of microtubule-polymerizing and -depolymerizing agent combinations as cancer chemotherapies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Clinical Trials as Topic; Colchicine; Humans; Microtubules; Mitosis; Neoplasms; Paclitaxel; Phenotype; Rats; Rats, Inbred Strains; Tubulin Modulators | 2007 |
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Estradiol; Gefitinib; Humans; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Binding; Quinazolines | 2007 |
Chemical conjugation of muramyl dipeptide and paclitaxel to explore the combination of immunotherapy and chemotherapy for cancer.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Gene Expression Regulation; Humans; Immunotherapy; Interleukin-12; Macrophages, Peritoneal; Mice; Neoplasms; Paclitaxel; Tumor Necrosis Factor-alpha | 2008 |
Novel application of multicellular layers culture for in situ evaluation of cytotoxicity and penetration of paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Cell Proliferation; Cell Survival; Culture Techniques; Drug Evaluation, Preclinical; Fluoresceins; Fluorescent Dyes; Humans; Microscopy, Confocal; Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2008 |
Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Humans; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Nanoparticles; Neoplasms; Paclitaxel; Palmitates; Polyesters; Polyethylene Glycols; Receptor, ErbB-2; Sulfhydryl Compounds; Tissue Distribution; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2008 |
Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Allergic Agents; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Promethazine; Prospective Studies | 2008 |
Cordyceps sinensis health supplement enhances recovery from taxol-induced leukopenia.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Cordyceps; Dietary Supplements; Hematopoietic Stem Cells; Humans; Leukopenia; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Neoplasms; Osteoclasts; Paclitaxel; Stromal Cells | 2008 |
CSE1L/CAS, a microtubule-associated protein, inhibits taxol (paclitaxel)-induced apoptosis but enhances cancer cell apoptosis induced by various chemotherapeutic drugs.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cellular Apoptosis Susceptibility Protein; Doxorubicin; G2 Phase; Humans; Microtubule-Associated Proteins; Microtubules; Mitosis; Neoplasms; Paclitaxel; Protein Binding; Tubulin | 2008 |
Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies.
Topics: Antineoplastic Agents; Cell Cycle; Computer Simulation; Diffusion; Drug Resistance, Neoplasm; Energy Metabolism; Humans; Models, Biological; Molecular Weight; Neoplasms; Paclitaxel | 2008 |
Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.
Topics: Antimitotic Agents; Apoptosis; Caspases; Cell Cycle; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; HeLa Cells; HT29 Cells; Humans; Kinesins; Microtubules; Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2008 |
Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors.
Topics: Apoptosis; CD8 Antigens; Cell Death; Cell Line, Tumor; Collagen; Humans; Necrosis; Neoplasms; Oncolytic Virotherapy; Paclitaxel; Promoter Regions, Genetic; Simplexvirus; Spheroids, Cellular; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2008 |
[Action of taxol on human tumors transplanted in athymic mice].
Topics: Adult; Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Drug Evaluation, Preclinical; Female; Humans; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Neoplasms; Paclitaxel; Transplantation, Heterologous | 1983 |
Polymers help guide cancer drugs to tumor targets--and keep them there.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Carriers; Humans; Methacrylates; Neoplasms; Neoplasms, Experimental; Paclitaxel; Polymers | 1995 |
The Emerging Role of Paclitaxel in Cancer Chemotherapy. Proceedings of the Fox Chase Cancer Center Paclitaxel Investigators' Workshop. Boca Raton, Florida, February 23-27, 1994.
Topics: Clinical Trials as Topic; Humans; Neoplasms; Paclitaxel | 1995 |
In the clinic: where paclitaxel and docetaxel stand.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1995 |
The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Drug Synergism; Fluorometry; Glycerol; Humans; Kinetics; Neoplasms; Paclitaxel; Solvents; Tumor Cells, Cultured | 1995 |
Sixteenth Annual Interdisciplinary Cancer Research Workshop.
Topics: Animals; Biotransformation; Carcinogens; Cocarcinogenesis; Diet; Drug Resistance; Humans; Inflammation; Mice; Neoplasms; Paclitaxel; Rats; Risk Factors | 1994 |
p53 sweeps through cancer research.
Topics: Alzheimer Disease; Bunyaviridae Infections; Climate; Electric Conductivity; Genes, p53; Humans; Mutation; Myosins; Neoplasms; Orthohantavirus; Ozone; Paclitaxel; Research; Signal Transduction; Tuberculosis; Tumor Suppressor Protein p53 | 1993 |
Taxol researchers continue forging ahead.
Topics: Drug Synergism; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel | 1994 |
[Taxanes--a new generation of cytostatic drugs].
Topics: Bridged Bicyclo Compounds; Bridged-Ring Compounds; Humans; Neoplasm Staging; Neoplasms; Paclitaxel; Survival Rate; Taxoids | 1993 |
[Clinical experiences with dose finding and toxicity of taxol].
Topics: Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel | 1993 |
High-performance liquid chromatographic procedure for the quantitative determination of paclitaxel (Taxol) in human plasma.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Freezing; Half-Life; Humans; Neoplasms; Paclitaxel; Quality Control; Sensitivity and Specificity | 1993 |
[Taxanes--a new generation of cytostatic drugs].
Topics: Antineoplastic Agents, Phytogenic; Drug Approval; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel | 1993 |
Paclitaxel: a new antineoplastic agent.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Neoplasms; Paclitaxel | 1994 |
Docetaxel (Taxotere): a new anti-cancer drug with promising potential?
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1994 |
Pharmaceutical issues of paclitaxel.
Topics: Animals; Humans; Neoplasms; Paclitaxel | 1994 |
Estramustine: a novel radiation enhancer in human carcinoma cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Estramustine; Female; Flow Cytometry; Glioma; HeLa Cells; Humans; Male; Microtubules; Neoplasms; Paclitaxel; Prostatic Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Vinblastine | 1994 |
Drug watch providing essential information.
Topics: Buspirone; Humans; Lactation; Metronidazole; Neoplasms; Nicotine; Paclitaxel; Substance-Related Disorders; Vitamin K | 1994 |
[Taxol--cytostatic drug from the yew tree].
Topics: Animals; Humans; Microtubules; Mitosis; Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1993 |
Surprise! A fungus factory for taxol?
Topics: Drug Costs; Drug Industry; Humans; Mitosporic Fungi; Montana; Neoplasms; Paclitaxel; Patents as Topic | 1993 |
Report from the Second National Cancer Institute Workshop on Taxol and Taxus. 23-24 September 1992.
Topics: Animals; Humans; Neoplasms; Paclitaxel | 1993 |
Paclitaxel (taxol) Investigators' workshop. Proceedings of a Johns Hopkins Oncology Center Workshop. September 25, 1992.
Topics: Humans; Neoplasms; Paclitaxel | 1993 |
Nursing considerations in paclitaxel (Taxol) administration.
Topics: Alopecia; Drug Hypersensitivity; Drug Interactions; Drug Therapy; Extravasation of Diagnostic and Therapeutic Materials; Gastrointestinal Diseases; Heart Diseases; Humans; Injections, Intravenous; Mouth Mucosa; Neoplasms; Paclitaxel; Patient Care Planning; Stomatitis | 1993 |
Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein.
Topics: Albumins; Dialysis; Humans; In Vitro Techniques; Neoplasms; Orosomucoid; Paclitaxel; Plasma | 1993 |
Bristol-Myers Squibb involved in developing alternative sources of TAXOL.
Topics: Chemistry, Pharmaceutical; Humans; Neoplasms; Paclitaxel; Plants, Medicinal | 1993 |
Taxol reported to improve cancer treatment at ASCO meeting.
Topics: Female; Humans; Male; Neoplasms; Paclitaxel | 1993 |
Clinical trials referral resource. Clinical trials with Docetaxel (Taxotere).
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1993 |
Docetaxel: current status and future prospects.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Forecasting; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Taxoids | 1995 |
Diet and development of cancer.
Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Diet; Fruit; Humans; Neoplasms; Nutritional Sciences; Paclitaxel; Phytotherapy; Vegetables | 1995 |
Taxoids: new weapons against cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Microtubules; Molecular Structure; Neoplasms; Ovarian Neoplasms; Paclitaxel; Phytotherapy; Taxoids; Trees | 1996 |
Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1995 |
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pilot Projects; Remission Induction; Sarcoma; Thrombocytopenia | 1996 |
Chemotherapy enhancer passes first test.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials, Phase I as Topic; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Neoplasms; Paclitaxel | 1995 |
Use caution when managing paclitaxel and taxotere infiltrations.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Drug Eruptions; Humans; Infusions, Intravenous; Neoplasms; Nursing Assessment; Paclitaxel; Taxoids | 1996 |
Eighty-seventh annual meeting of the American Association for Cancer Research. Washington, D,C., 20-24 April 1996.
Topics: Aged; Antineoplastic Agents; Breast; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Female; Genes, p53; Genes, Tumor Suppressor; Humans; Hyperplasia; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Research; Survival Rate | 1996 |
Cancer treatments rationed by authority.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Costs; England; Health Care Rationing; Humans; Neoplasms; Paclitaxel; Taxoids | 1996 |
Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polysorbates; Surface-Active Agents; Taxoids | 1997 |
Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units.
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Screening Assays, Antitumor; Humans; Neoplasms; Neoplastic Stem Cells; Paclitaxel | 1997 |
Baseline apoptosis of tumor cells as a response predictor to chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cisplatin; Mice; Neoplasms; Neoplasms, Experimental; Paclitaxel; Tumor Suppressor Protein p53; Up-Regulation | 1997 |
Camptothecin and taxol: from discovery to clinic.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Chemistry, Analytic; Chemistry, Pharmaceutical; Clinical Trials as Topic; Countercurrent Distribution; Enzyme Inhibitors; History, 20th Century; Humans; Molecular Structure; Neoplasms; Paclitaxel; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tubulin Modulators; United States | 1996 |
Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Cell Cycle; Combined Modality Therapy; Disease Models, Animal; Drug Synergism; Female; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Male; Mammary Neoplasms, Animal; Mice; Microtubules; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Transduction, Genetic; Treatment Outcome; Tumor Cells, Cultured | 1998 |
Paclitaxel hypersensitivity reactions: a role for docetaxel substitution.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Hypersensitivity; Female; Glycerol; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 1998 |
Evaluation of the linearity of docetaxel pharmacokinetics.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Docetaxel; Humans; Neoplasms; Paclitaxel; Taxoids | 1998 |
Bcl-xL is phosphorylated in malignant cells following microtubule disruption.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; bcl-X Protein; Benzoquinones; Cell Count; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Humans; Lactams, Macrocyclic; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Phosphoprotein Phosphatases; Phosphorus Radioisotopes; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Quinones; Sodium Dodecyl Sulfate; Tubulin; Tumor Cells, Cultured | 1998 |
Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 1998 |
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Fluid Compartments; Cisplatin; Clinical Trials, Phase I as Topic; Doxorubicin; Drug Resistance, Multiple; Female; Glycerol; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Paclitaxel; Phenotype; Surface-Active Agents; Tissue Distribution | 1998 |
Proliferation indices as molecular pharmacodynamic endpoints in evaluation of anticancer drug effect in human solid tumors.
Topics: Antineoplastic Agents; Bromodeoxyuridine; Cell Division; DNA; Doxorubicin; Humans; Mitomycin; Neoplasms; Paclitaxel; Proliferating Cell Nuclear Antigen; Thymidine | 1998 |
Cancer treatment in Sweden--costs of drugs, inpatient and outpatient care from 1985 to 1996 and cost effectiveness of new drugs.
Topics: Ambulatory Care; Androgen Antagonists; Antineoplastic Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Filgrastim; Gemcitabine; Gonadotropin-Releasing Hormone; Granulocyte Colony-Stimulating Factor; Humans; Neoplasms; Paclitaxel; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Recombinant Proteins; Sweden | 1998 |
Glutamine treatment of paclitaxel-induced myalgias and arthralgias.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Arthralgia; Female; Glutamine; Humans; Male; Middle Aged; Muscles; Neoplasms; Paclitaxel; Pain | 1998 |
Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Doxorubicin; Humans; Neoplasm Metastasis; Neoplasms; Paclitaxel; Taxoids | 1998 |
Relationship between paclitaxel activity and pathobiology of human solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Humans; Immunohistochemistry; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Antimitotic drugs cause increased tumorigenicity of multidrug resistant cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Calcium-Calmodulin-Dependent Protein Kinases; CDC2-CDC28 Kinases; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Cyclins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Neoplasms; Oncogene Proteins v-raf; Paclitaxel; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Retroviridae Proteins, Oncogenic; Signal Transduction; Tumor Cells, Cultured; Vinblastine | 1999 |
Best supportive care.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Attitude of Health Personnel; Carcinoma, Non-Small-Cell Lung; Critical Illness; Humans; Lung Neoplasms; Neoplasms; Paclitaxel; Pain; Pain Management; Palliative Care; Terminology as Topic | 1998 |
On pushing the outer edge of the outer edge of paclitaxel's dosing envelope.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Humans; Neoplasms; Paclitaxel | 1999 |
Concurrent paclitaxel and radiation therapy in the treatment of solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Humans; Neoplasms; Paclitaxel; Radiation-Sensitizing Agents | 1999 |
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Topics: Alkyl and Aryl Transferases; Cell Survival; Cisplatin; Clone Cells; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Humans; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Piperidines; Pyridines; Sensitivity and Specificity; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Continual reassessment methods in phase I trials of the combination of two drugs in oncology.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Camptothecin; Clinical Trials, Phase I as Topic; Computer Simulation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Humans; Irinotecan; Likelihood Functions; Neoplasms; Neutropenia; Paclitaxel; Retrospective Studies; Taxoids | 1999 |
Determinants of paclitaxel penetration and accumulation in human solid tumor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Autoradiography; Culture Techniques; Diffusion; Female; Half-Life; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Mice; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pharyngeal Neoplasms; Tissue Distribution; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Dexamethasone-induced enhancement of resistance to ionizing radiation and chemotherapeutic agents in human tumor cells.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Female; Fibroblasts; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Tumor Cells, Cultured | 1999 |
Apoptosis as a predictor of paclitaxel-induced radiosensitization in human tumor cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Growth Inhibitors; HeLa Cells; HT29 Cells; Humans; Male; Neoplasms; Paclitaxel; Predictive Value of Tests; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1999 |
Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Paclitaxel; Rats; Rats, Nude; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Breast Neoplasms; Carbazoles; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Glucosides; Humans; Indoles; Leukemia P388; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Mice, Nude; Neoplasms; Paclitaxel; Prostatic Neoplasms; Time Factors | 1999 |
Taxing the taxanes: overused or undersold?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Synergism; Estramustine; Female; Humans; Neoplasms; Ovarian Neoplasms; Paclitaxel; Taxoids | 1999 |
Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel.
Topics: Acetone; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemical Precipitation; Chromatography, High Pressure Liquid; Docetaxel; Humans; Hydroxylation; Kinetics; Methanol; Methotrexate; Neoplasms; Paclitaxel; Rats; Rats, Wistar; Sensitivity and Specificity; Taxoids | 1999 |
Possible metabolic interaction between docetaxel and ifosfamide.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Ifosfamide; Liver; Microsomes; Neoplasms; Paclitaxel; Taxoids | 2000 |
High sensitivity ELISA determination of taxol in various human biological fluids.
Topics: Antineoplastic Agents, Phytogenic; Binding, Competitive; Calibration; Enzyme-Linked Immunosorbent Assay; Evaluation Studies as Topic; Feasibility Studies; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Neoplasms; Paclitaxel; Reproducibility of Results; Saliva; Sensitivity and Specificity | 1999 |
Cytochrome P-450 and other determinants of pharmacokinetics, toxicity, and efficacy in humans.
Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Humans; Neoplasms; Oxidoreductases, N-Demethylating; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; CCAAT-Enhancer-Binding Proteins; DNA-Binding Proteins; Female; Humans; Neoplasms; Paclitaxel; RNA, Messenger; Transcription Factor CHOP; Transcription Factors; Tumor Cells, Cultured | 2000 |
Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Cell Cycle; Cell Survival; Docetaxel; Drug Interactions; Enzyme Inhibitors; Humans; Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 2000 |
[Annual meeting of the American Association for Cancer Research].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Communication; Forecasting; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Medical Oncology; Mice; Neoplasms; Paclitaxel; Research; San Francisco; Societies, Medical | 2000 |
Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzazepines; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Daunorubicin; Docetaxel; Drug Resistance, Multiple; Feces; Half-Life; Humans; Intestinal Mucosa; Metabolic Clearance Rate; Mixed Function Oxygenases; Neoplasms; Paclitaxel; Quinolines; Taxoids; Tumor Cells, Cultured | 2000 |
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cyclosporine; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 2000 |
Docetaxel-induced lymphopenia in patients with solid tumors: a prospective phenotypic analysis.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Female; Humans; Immunophenotyping; Infections; Lymphocyte Count; Lymphocyte Subsets; Lymphocytes; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Neutrophils; Paclitaxel; Prospective Studies; Taxoids | 2000 |
Cellular immune profile of patients with advanced cancer before and after taxane treatment.
Topics: Aged; Antineoplastic Agents, Phytogenic; Cytokines; Cytotoxicity, Immunologic; Docetaxel; Female; Humans; Immunity, Cellular; Immunophenotyping; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Lymphocyte Activation; Lymphocyte Subsets; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2000 |
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cyclosporine; Drug Synergism; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel | 2000 |
Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Carboplatin; Cell Division; Cells, Cultured; Colony-Forming Units Assay; Cytokines; Flow Cytometry; Glutathione Transferase; Growth Substances; Hematopoietic Stem Cells; Humans; Megakaryocytes; Myeloid Progenitor Cells; Neoplasms; Paclitaxel; RNA, Messenger; Stromal Cells; Thrombopoietin; Verapamil | 2001 |
Hydrolyzable hydrophobic taxanes: synthesis and anti-cancer activities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged-Ring Compounds; Cell Cycle; DNA, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Humans; Mice; Mice, Nude; Molecular Structure; Neoplasms; Paclitaxel; Taxoids; Tubulin; Tumor Cells, Cultured | 2001 |
Selection with melphalan or paclitaxel (Taxol) yields variants with different patterns of multidrug resistance, integrin expression and in vitro invasiveness.
Topics: Antigens, CD; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blotting, Western; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Integrins; Melphalan; Membrane Glycoproteins; Neoplasm Invasiveness; Neoplasms; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Tetraspanin 29; Tumor Cells, Cultured | 2001 |
Highlights of the Eighth European Cancer Conference.
Topics: Amifostine; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Irinotecan; Neoplasms; Paclitaxel; Radiation Injuries; Radiation-Protective Agents; Taxoids; Vinblastine; Vinorelbine | 1995 |
Determinants of paclitaxel uptake, accumulation and retention in solid tumors.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Cell Membrane; Diffusion; Humans; Neoplasms; Paclitaxel; Tubulin; Tumor Cells, Cultured | 2001 |
Clinical significance of plasma nucleosome levels in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Humans; Leukocyte Count; Male; Mastectomy; Middle Aged; Neoplasms; Nucleosomes; Paclitaxel; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2001 |
Radiosensitization effect by combination with paclitaxel in vivo, including the effect on intratumor quiescent cells.
Topics: Animals; Apoptosis; Bromodeoxyuridine; Carcinoma, Squamous Cell; Cell Survival; Humans; Mice; Mice, Inbred C3H; Micronucleus Tests; Neoplasms; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Radiobiology; Radiotherapy Dosage; Time Factors; Tirapazamine; Triazines | 2001 |
Evaluating new treatments for advanced cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
What ever happened to...? Looking back 10 years.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Food; History, 20th Century; Humans; National Institutes of Health (U.S.); Neoplasms; Paclitaxel; Periodicals as Topic; Smoking; Tobacco Smoke Pollution; United States | 2001 |
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Interactions; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Radiation-Protective Agents; Radiation-Sensitizing Agents | 2001 |
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
Topics: Absorption; Administration, Oral; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Cyclosporine; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Neoplasms; Paclitaxel | 2001 |
Tumor targeting by conjugation of DHA to paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Docosahexaenoic Acids; Drug Delivery Systems; Lung Neoplasms; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2001 |
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Cyclosporine; Docetaxel; Drug Interactions; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
Cancer gene therapy using a survivin mutant adenovirus.
Topics: Adenoviruses, Human; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Chromosomal Proteins, Non-Histone; Cysteine Proteinase Inhibitors; Doxorubicin; Gene Expression; Genetic Therapy; Genetic Vectors; HeLa Cells; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; Microtubule-Associated Proteins; Mutagenesis, Site-Directed; Neoplasm Proteins; Neoplasms; Neoplasms, Experimental; Paclitaxel; Survivin; Tumor Cells, Cultured | 2001 |
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
Topics: Animals; Antineoplastic Agents; Biopsy; Carmustine; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Doxorubicin; Fenretinide; Guanine; Humans; Indoles; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Pyrroles; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2001 |
Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Body Weight; Cell Cycle; Cell Division; Docosahexaenoic Acids; Dogs; Dose-Response Relationship, Drug; Female; Flow Cytometry; Fluorescent Antibody Technique; HT29 Cells; Humans; Male; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubules; Muscle, Skeletal; Neoplasms; Neoplasms, Experimental; Paclitaxel; Rats; Time Factors; Tissue Distribution; Tumor Cells, Cultured | 2001 |
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies.
Topics: Blotting, Northern; Blotting, Western; Camptothecin; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cisplatin; Cyclin A; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Fluorouracil; Folic Acid Antagonists; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Protein Serine-Threonine Kinases; Quinazolines; RNA, Messenger; Tetracycline; Thiophenes; Thymidylate Synthase; Tumor Cells, Cultured | 2001 |
Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv.
Topics: Animals; Antineoplastic Agents, Phytogenic; DNA Primers; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Gene Targeting; Genetic Therapy; Genetic Vectors; Humans; Liposomes; Male; Mice; Mice, Nude; Neoplasms; Paclitaxel; Polymerase Chain Reaction; Receptors, Transferrin; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Technology evaluation: G-3139.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Dacarbazine; Docetaxel; Female; Genes, bcl-2; Genetic Therapy; Humans; Male; Mice; Mice, Inbred BALB C; National Institutes of Health (U.S.); Neoplasm Proteins; Neoplasms; Paclitaxel; Patents as Topic; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Safety; Structure-Activity Relationship; Taxoids; Thionucleotides; Treatment Outcome; United States | 1999 |
Targeted taxane therapy for cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Docosahexaenoic Acids; Humans; Neoplasms; Paclitaxel; Polyglutamic Acid; Prodrugs; Taxoids | 2002 |
Future treatment options with capecitabine in solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Forecasting; Humans; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Taxoids | 2002 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
Battle over generic taxol concludes, but controversy continues.
Topics: Clinical Trials as Topic; Drug Industry; Drugs, Generic; Humans; Legislation, Drug; National Institutes of Health (U.S.); Neoplasms; Paclitaxel; United States | 2002 |
New form of paclitaxel shows promise.
Topics: Antineoplastic Agents; Humans; Neoplasms; Paclitaxel; Polyglutamic Acid; Taxoids | 2001 |
New highly active taxoids from 9 beta-dihydrobaccatin-9,10-acetals.
Topics: Acetals; Antineoplastic Agents; Docetaxel; Drug Screening Assays, Antitumor; Humans; Neoplasms; Paclitaxel; Structure-Activity Relationship; Taxoids; Tumor Cells, Cultured | 2002 |
[The effect of L-Glutamine and Shakuyaku-Kanzo-to for paclitaxel-induced myalgia/arthralgia].
Topics: Antineoplastic Agents, Phytogenic; Arthralgia; Drug Administration Schedule; Drug Combinations; Drugs, Chinese Herbal; Female; Glutamine; Glycyrrhiza; Humans; Muscle, Skeletal; Neoplasms; Paclitaxel; Paeonia; Pain; Quality of Life | 2002 |
Feasibility and toxicity of weekly Paclitaxel-Carboplatin in 131 patients with pretreated and non-pretreated solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms; Paclitaxel; Palliative Care; Survival Rate | 2002 |
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Biological Availability; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Quinolines; Taxoids | 2002 |
Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.
Topics: Antineoplastic Agents, Phytogenic; Calibration; Docetaxel; Humans; Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Polysorbates; Reproducibility of Results; Sensitivity and Specificity; Taxoids | 2002 |
Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: results of a dose-escalation study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Dose-Response Relationship, Drug; Female; Glycerol; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pharmaceutical Vehicles; Surface-Active Agents | 2002 |
Localized delivery of paclitaxel in solid tumors from biodegradable chitin microparticle formulations.
Topics: Acetylglucosamine; Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Biodegradation, Environmental; Chitin; Drug Delivery Systems; Female; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Microspheres; Muramidase; Neoplasms; Neoplasms, Experimental; Paclitaxel; Poloxamer; Rats; Spectroscopy, Fourier Transform Infrared; Surface-Active Agents; Temperature; Time Factors; Tumor Cells, Cultured | 2002 |
Docetaxel: pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model.
Topics: Absorption; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Docetaxel; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Injections, Intravenous; Male; Models, Animal; Neoplasms; Paclitaxel; Rats; Rats, Sprague-Dawley; Taxoids; Tissue Distribution | 2002 |
Chemists vie to make a better taxol.
Topics: Alkaloids; Docetaxel; Drug Design; Neoplasms; Paclitaxel; Taxoids | 1992 |
Clinical trials referral resource. Clinical trials with all-trans-retinoic acid.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Humans; Neoplasms; Paclitaxel; Tretinoin | 1992 |
The promise of taxol.
Topics: Humans; Neoplasms; Paclitaxel | 1992 |
Effects of Taxotere on murine and human tumor cell lines.
Topics: Alkaloids; Animals; Cell Division; DNA; Docetaxel; Drug Resistance; Humans; Leukemia P388; Mice; Molecular Structure; Neoplasms; Paclitaxel; Protein Biosynthesis; RNA; Taxoids; Tumor Cells, Cultured | 1992 |
Whom do yew trust?
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Environment; Female; Humans; National Institutes of Health (U.S.); Neoplasms; Oregon; Ovarian Neoplasms; Paclitaxel; Trees; United States | 1991 |
Barking up the right tree.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Conservation of Natural Resources; Humans; National Institutes of Health (U.S.); Neoplasms; Oregon; Paclitaxel; Phytotherapy; Trees; United States; Washington | 1991 |
Cardiac disturbances during the administration of taxol.
Topics: Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Arrhythmias, Cardiac; Bradycardia; Electrocardiography; Female; Humans; Male; Microtubules; Middle Aged; Myocardial Infarction; Neoplasms; Paclitaxel; Tachycardia | 1991 |
A better way to make the medicine go down.
Topics: Acquired Immunodeficiency Syndrome; Alkaloids; Antibodies, Monoclonal; Antineoplastic Agents; Humans; Models, Biological; Neoplasms; Paclitaxel; Prodrugs | 1991 |
Phase I study of taxol using a 5-day intermittent schedule.
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents, Phytogenic; Bone Marrow; Dose-Response Relationship, Drug; Drug Evaluation; Female; Hematopoiesis; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Time Factors | 1986 |
High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial.
Topics: Alkaloids; Chromatography, High Pressure Liquid; Drug Evaluation; Half-Life; Humans; Kinetics; Metabolic Clearance Rate; Neoplasms; Paclitaxel; Quality Control; Software | 1987 |
Phase I clinical and pharmacokinetic study of taxol.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alkaloids; Alopecia; Cimetidine; Dexamethasone; Diphenhydramine; Drug Evaluation; Drug Interactions; Female; Half-Life; Humans; Kinetics; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Nervous System; Ovarian Neoplasms; Paclitaxel; Premedication; Stomach Neoplasms; Vomiting | 1987 |
Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cimetidine; Dexamethasone; Diphenhydramine; Drug Administration Schedule; Drug Evaluation; Drug Hypersensitivity; Humans; Infusions, Intravenous; Kinetics; Melanoma; Neoplasms; Nervous System Diseases; Neutropenia; Paclitaxel | 1987 |
Synthesis and structure-activity relationships of sinenxan A derivatives as multidrug resistance reversal agents.
Topics: Acetates; Calcium Channel Blockers; Diterpenes; Drug Resistance, Multiple; Humans; Neoplasms; Structure-Activity Relationship; Taxus; Tumor Cells, Cultured; Verapamil | 2010 |
Anticancer activity of an extract from needles and twigs of Taxus cuspidata and its synergistic effect as a cocktail with 5-fluorouracil.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Synergism; Fluorouracil; Humans; Male; Mice; Neoplasms; Plant Extracts; Rats; Rats, Sprague-Dawley; Taxus | 2011 |